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This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic 
Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA).  The 
original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised 
and republished as necessary. 
The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects 
information for the hazardous substance described therein.  Each peer-reviewed profile identifies and 
reviews the key literature that describes a hazardous substance’s toxicologic properties.  Other pertinent 
literature is also presented, but is described in less detail than the key studies.  The profile is not intended 
to be an exhaustive document; however, more comprehensive sources of specialty information are 
referenced. 
The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile 
begins with a public health statement that describes, in nontechnical language, a substance’s relevant 
toxicological properties.  Following the public health statement is information concerning levels of 
significant human exposure and, where known, significant health effects.  The adequacy of information to 
determine a substance’s health effects is described in a health effects summary.  Data needs that are of 
significance to protection of public health are identified by ATSDR and EPA. 
Each profile includes the following: 
(A) The examination, summary, and interpretation of available toxicologic information and 
epidemiologic evaluations on a hazardous substance to ascertain the levels of significant human 
exposure for the substance and the associated acute, subacute, and chronic health effects; 
(B) A determination of whether adequate information on the health effects of each substance 
is available or in the process of development to determine levels of exposure that present a 
significant risk to human health of acute, subacute, and chronic health effects; and 
(C) Where appropriate, identification of toxicologic testing needed to identify the types or 
levels of exposure that may present significant risk of adverse health effects in humans. 
The principal audiences for the toxicological profiles are health professionals at the Federal, State, and 
local levels; interested private sector organizations and groups; and members of the public.   
This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that has been 
peer-reviewed. Staff of the Centers for Disease Control and Prevention and other Federal scientists have 
also reviewed the profile.  In addition, this profile has been peer-reviewed by a nongovernmental panel 
and was made available for public review.  Final responsibility for the contents and views expressed in 
this toxicological profile resides with ATSDR. 
vi 
*Legislative Background 
The toxicological profiles are developed in response to the Superfund Amendments and Reauthorization 
Act (SARA) of 1986 (Public Law 99 499) which amended the Comprehensive Environmental Response, 
Compensation, and Liability Act of 1980 (CERCLA or Superfund).  This public law directed ATSDR to 
prepare toxicological profiles for hazardous substances most commonly found at facilities on the 
CERCLA National Priorities List and that pose the most significant potential threat to human health, as 
determined by ATSDR and the EPA.  The availability of the revised priority list of 275 hazardous 
substances was announced in the Federal Register on December 7, 2005 (70 FR 72840).  For prior 
versions of the list of substances, see Federal Register notices dated April 17, 1987 (52 FR 12866); 
October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17,1990 (55 FR 42067); 
October 17, 1991 (56 FR 52166); October 28, 1992 (57 FR 48801); February 28, 1994 (59 FR 9486); 
April 29, 1996 (61 FR 18744); November 17, 1997 (62 FR 61332); October 21, 1999 (64 FR 56792); 
October 25, 2001 (66 FR 54014), and November 7, 2003 (68 FR 63098). Section 104(i)(3) of CERCLA, 
as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on 
the list. 
vii VINYL CHLORIDE 
QUICK REFERENCE FOR HEALTH CARE PROVIDERS 
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous 
substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation 
of available toxicologic and epidemiologic information on a substance.  Health care providers treating 
patients potentially exposed to hazardous substances will find the following information helpful for fast 
answers to often-asked questions. 
Primary Chapters/Sections of Interest 
Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating 
patients about possible exposure to a hazardous substance.  It explains a substance’s relevant 
toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of 
the general health effects observed following exposure. 
Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, 
and assesses the significance of toxicity data to human health. 
Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by type 
of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length 
of exposure (acute, intermediate, and chronic).  In addition, both human and animal studies are 
reported in this section. 
NOTE: Not all health effects reported in this section are necessarily observed in the clinical 
setting. Please refer to the Public Health Statement to identify general health effects observed 
following exposure. 
Pediatrics: Four new sections have been added to each Toxicological Profile to address child health 
issues: 
Section 1.6 How Can (Chemical X) Affect Children? 
 
Section 1.7 How Can Families Reduce the Risk of Exposure to (Chemical X)? 
 
Section 3.7 Children’s Susceptibility 
 
Section 6.6 Exposures of Children 
 
Other Sections of Interest: 
Section 3.8 Biomarkers of Exposure and Effect 
Section 3.11 Methods for Reducing Toxic Effects 
ATSDR Information Center  
Phone: 1-888-42-ATSDR or (404) 498-0110 Fax: (770) 488-4178 
E-mail: atsdric@cdc.gov Internet: http://www.atsdr.cdc.gov 
The following additional material can be ordered through the ATSDR Information Center: 
Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an 
exposure history and how to conduct one are described, and an example of a thorough exposure 
history is provided.  Other case studies of interest include Reproductive and Developmental 
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Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide 
Toxicity; and numerous chemical-specific case studies. 
Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene 
(prehospital) and hospital medical management of patients exposed during a hazardous materials 
incident. Volumes I and II are planning guides to assist first responders and hospital emergency 
department personnel in planning for incidents that involve hazardous materials.  Volume III— 
Medical Management Guidelines for Acute Chemical Exposures—is a guide for health care 
professionals treating patients exposed to hazardous materials. 
Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances. 
Other Agencies and Organizations 
The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, 
injury, and disability related to the interactions between people and their environment outside the 
workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, 
GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015. 
The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational 
diseases and injuries, responds to requests for assistance by investigating problems of health and 
safety in the workplace, recommends standards to the Occupational Safety and Health 
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains 
professionals in occupational safety and health.  Contact: NIOSH, 200 Independence Avenue, 
SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, 
Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 
• Phone: 800-35-NIOSH. 
The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for 
biomedical research on the effects of chemical, physical, and biologic environmental agents on 
human health and well-being.  Contact:  NIEHS, PO Box 12233, 104 T.W. Alexander Drive, 
Research Triangle Park, NC 27709 • Phone: 919-541-3212. 
Referrals 
The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics 
in the United States to provide expertise in occupational and environmental issues.  Contact: 
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone:  202-347-4976 
• FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page:  http://www.aoec.org/. 
The American College of Occupational and Environmental Medicine (ACOEM) is an association of 
physicians and other health care providers specializing in the field of occupational and 
environmental medicine.  Contact: ACOEM, 25 Northwest Point Boulevard, Suite 700, 
Elk Grove Village, IL 60007-1030 • Phone:  847-818-1800 • FAX:  847-818-9266. 
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PEER REVIEW 
 
A peer review panel was assembled for the pre-public comment vinyl chloride.  The panel consisted of 
the following members:  
1.	 Finis L. Cavender, Ph.D., Consultant in Toxicology, Henderson, North Carolina; 
2. 	 Sam Kacew, Ph.D., Professor, Department of Cellular and Molecular Medicine, University of 
Ottawa, Ottawa, Ontario; and 
3.	 Andrew G. Salmon, Ph.D., Senior Toxicologist and Chief, Air Toxicology and Risk Assessment 
Unit, California Environmental Protection Agency, Lafayette, California. 
These experts collectively have knowledge of vinyl chloride's physical and chemical properties, 
toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and 
quantification of risk to humans.  All reviewers were selected in conformity with the conditions for peer 
review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, 
and Liability Act, as amended. 
Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer 
reviewers' comments and determined which comments will be included in the profile.  A listing of the 
peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their 
exclusion, exists as part of the administrative record for this compound.   
The citation of the peer review panel should not be understood to imply its approval of the profile's final 
content. The responsibility for the content of this profile lies with the ATSDR. 
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1 VINYL CHLORIDE 
1. PUBLIC HEALTH STATEMENT 

This public health statement tells you about vinyl chloride and the effects of exposure to it.   
The Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in 
the nation. These sites are then placed on the National Priorities List (NPL) and are targeted for 
long-term federal clean-up activities.  Vinyl chloride has been found in at least 616 of the 
1,662 current or former NPL sites.  Although the total number of NPL sites evaluated for this 
substance is not known, the possibility exists that the number of sites at which vinyl chloride is 
found could increase in the future as more sites are evaluated.  This information is important 
because these sites may be sources of exposure, and exposure to this substance can harm you. 
When a substance is released either from a large area, such as an industrial plant, or from a 
container, such as a drum or bottle, it enters the environment. Such a release does not always 
lead to exposure. You can be exposed to a substance only when you come in contact with it.  
You may be exposed by breathing, eating, or drinking the substance, or by skin contact. 
If you are exposed to vinyl chloride, many factors will determine whether you will be harmed.  
These factors include the dose (how much), the duration (how long), and how you come in 
contact with it. You must also consider any other chemicals you are exposed to and your age, 
sex, diet, family traits, lifestyle, and state of health. 
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1. PUBLIC HEALTH STATEMENT 
1.1 	 WHAT IS VINYL CHLORIDE? 
Vinyl chloride is known also as chloroethene, chloroethylene, ethylene monochloride, or 
monochloroethylene. At room temperature, it is a colorless gas, it burns easily, and it is not 
stable at high temperatures.  Vinyl chloride exists in liquid form if kept under high pressure or at 
low temperatures.  Vinyl chloride has a mild, sweet odor, which may become noticeable at 
3,000 parts vinyl chloride per million parts (ppm) of air.  However, the odor is of little value in 
preventing excess exposure. Most people begin to taste vinyl chloride in water at 3.4 ppm. 
Vinyl chloride is a manufactured substance that does not occur naturally; however, it can be 
formed in the environment when other manufactured substances, such as trichloroethylene, 
trichloroethane, and tetrachloroethylene, are broken down by certain microorganisms.  
Production of vinyl chloride in the United States grew at an average rate of about 7% from the 
early 1980s to the early 1990s, with current growth at about 3% annually.  Most of the vinyl 
chloride produced in the United States is used to make a polymer called polyvinyl chloride 
(PVC), which consists of long repeating units of vinyl chloride.  PVC is used to make a variety 
of plastic products including pipes, wire and cable coatings, and packaging materials.  Other uses 
include furniture and automobile upholstery, wall coverings, housewares, and automotive parts.  
At one time, vinyl chloride was used as a coolant, as a propellant in spray cans, and in some 
cosmetics.  However, since the mid-1970s, vinyl chloride mostly has been used in the 
manufacture of PVC.  Refer to Chapter 4 for more information about the chemical and physical 
properties of vinyl chloride.  For more information about the production and use of vinyl 
chloride, see Chapter 5. 
1.2 	 WHAT HAPPENS TO VINYL CHLORIDE WHEN IT ENTERS THE 
ENVIRONMENT? 
Most of the vinyl chloride that enters the environment comes from vinyl chloride manufacturing 
or processing plants, which release it into the air or into waste water.  EPA limits the amount that 
industries can release. Vinyl chloride also is a breakdown product of other synthetic chemicals.  
Vinyl chloride has entered the environment at hazardous waste sites as a result of improper 
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disposal or leakage from storage containers or spills, but some may result from the breakdown of 
other chemicals.  In addition, vinyl chloride has been found in tobacco smoke at very low levels. 
Liquid vinyl chloride evaporates easily.  Vinyl chloride in water or soil evaporates rapidly if it is 
near the surface.  Vinyl chloride in the air breaks down in a few days, resulting in the formation 
of several other chemicals including hydrochloric acid, formaldehyde, and carbon dioxide.   
Some vinyl chloride can dissolve in water.  Vinyl chloride can migrate to groundwater and can 
be in groundwater due to the breakdown of other chemicals.  Vinyl chloride is unlikely to build 
up in plants or animals that you might eat.  For more information about what happens to vinyl 
chloride in the environment, see Chapter 6. 
1.3 HOW MIGHT I BE EXPOSED TO VINYL CHLORIDE? 
Because vinyl chloride usually exists in a gaseous state, you are most likely to be exposed to it 
by breathing it. Vinyl chloride is not normally found in urban, suburban, or rural air in amounts 
that are detectable by the usual methods of analysis.  However, vinyl chloride has been found in 
the air near vinyl chloride manufacturing and processing plants, hazardous waste sites, and 
landfills. The amount of vinyl chloride in the air near these places ranges from trace amounts to 
over 1 ppm.  Levels as high as 44 ppm were found in the air at some landfills.  You can also be 
exposed to vinyl chloride in the air through tobacco smoke from cigarettes or cigars (both active 
smoking and second-hand smoke).  Levels of vinyl chloride in tobacco smoke are very low, 
usually around 5–30 nanograms per cigarette (a nanogram is 0.000000001 gram). 
You can be exposed to vinyl chloride by drinking water from contaminated wells.  Most drinking 
water supplies do not contain vinyl chloride. In a 1982 survey, vinyl chloride was found in 
fewer than 1% of the 945 groundwater supplies tested in the United States.  The concentrations 
in groundwater were up to 0.008 ppm. Other studies have reported vinyl chloride in 
groundwater at concentrations at or below 0.38 ppm.  At one time, the flow of water through 
PVC pipes added very low amounts of vinyl chloride to water.  For example, in one study of 
newly installed pipes, the drinking water had 0.001 ppm of vinyl chloride.  No current 
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information is available about the amount of vinyl chloride released from PVC pipes into water.  
In the past, vinyl chloride could get into food stored in materials containing PVC, but the U.S. 
government now regulates the amount of vinyl chloride in food packaging materials.  When less 
than about 1 ppm of vinyl chloride is trapped in PVC packaging, vinyl chloride in detectable 
amounts does not enter food by contact with these products. 
People who work at facilities that make vinyl chloride or PVC usually are exposed to higher 
levels than the general population. Work exposure occurs primarily from breathing air that 
contains vinyl chloride, but workers also are exposed when vinyl chloride contacts the skin or 
eyes. Based on studies using animals, it is possible that if vinyl chloride comes into contact with 
your skin or eyes, extremely small amounts could enter your body.   
Please refer to Chapter 6 for more information on ways that people are exposed to vinyl chloride. 
1.4 HOW CAN VINYL CHLORIDE ENTER AND LEAVE MY BODY? 
If vinyl chloride gas contacts your skin, tiny amounts may pass through the skin and enter your 
body. Vinyl chloride is more likely to enter your body when you breathe air or drink water 
containing it. This could occur near certain factories or hazardous waste sites or in the 
workplace. At low levels (<20 ppm), most of the vinyl chloride that you breathe or swallow 
enters your blood rapidly, then travels throughout your body.  When some portion of it reaches 
your liver, your liver changes it into several substances.  Most of these new substances also 
travel in your blood; once they reach your kidneys, they leave your body in your urine.  Most of 
the vinyl chloride is gone from your body a day after you breathe or swallow it.  The liver, 
however, makes some new substances that do not leave your body as rapidly.  A few of these 
new substances are more harmful than vinyl chloride because they react with chemicals inside 
your body and interfere with the way your body normally uses or responds to these chemicals.  
Some of these substances react in the liver and, depending on how much vinyl chloride you 
breathe in, may produce damage there.  Your body needs more time to get rid of these changed 
chemicals, but eventually removes them as well.  If you breathe or swallow more vinyl chloride 
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than your liver can chemically change, you will breathe out excess vinyl chloride.  Chapter 3 
contains more information about how vinyl chloride enters and leaves your body. 
1.5 HOW CAN VINYL CHLORIDE AFFECT MY HEALTH? 
Scientists use many tests to protect the public from harmful effects of toxic chemicals and to find 
ways to treat people who have been harmed. 
One way to learn whether a chemical will harm people is to determine how the body absorbs, 
uses, and releases the chemical.  For some chemicals, animal testing may be necessary.  Animal 
testing may also help identify health effects, such as cancer or birth defects.  Without laboratory 
animals, scientists would lose a basic method for getting information needed to make wise 
decisions that protect public health.  Scientists have the responsibility to treat research animals 
with care and compassion.  Scientists must comply with strict animal-care guidelines because 
laws today protect the welfare of research animals. 
If you breathe high levels of vinyl chloride, you will feel dizzy or sleepy.  These effects occur 
within 5 minutes if you are exposed to about 10,000 ppm of vinyl chloride.  You can easily smell 
vinyl chloride at this concentration.  It has a mild, sweet odor.  If you breathe still higher levels 
(25,000 ppm), you may pass out.  You can rapidly recover from these effects if you breathe fresh 
air. Some people get a headache when they breathe fresh air immediately after breathing very 
high levels of vinyl chloride. People who breathe extremely high levels of vinyl chloride can 
die. Studies in animals show that extremely high levels of vinyl chloride can damage the liver, 
lungs, and kidneys.  These levels also can damage the heart and prevent blood clotting.  The 
effects of ingesting vinyl chloride are unknown.  If you spill liquid vinyl chloride on your skin, it 
will numb the skin and produce redness and blisters. 
Some people who have breathed vinyl chloride for several years have changes in the structure of 
their livers.  People are more likely to develop these changes if they breathe high levels of vinyl 
chloride. Some people who have worked with vinyl chloride have nerve damage, and others 
develop an immune reaction. The lowest levels that produce liver changes, nerve damage, and 
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immune reaction in people are not known. Certain jobs related to PVC production expose 
workers to very high levels of vinyl chloride (i.e., pools of liquid vinyl chloride in vats or 
autoclaves). Some of these workers have problems with the blood flow in their hands.  Their 
fingers turn white and hurt when they go into the cold and may take a long time to recover when 
they go into a warm place.  In some of these people, changes have appeared on the skin of their 
hands and forearms.  Also, bones at the tips of their fingers have broken down.  Studies suggest 
that some people may be more sensitive to these effects than others. 
Some men who work with vinyl chloride have complained of a lack of sex drive.  Studies in 
animals showed that long-term exposure can damage the sperm and testes.  Some women who 
work with vinyl chloride have reported irregular menstrual periods.  Some have developed high 
blood pressure during pregnancy. 
Results from several studies have suggested that breathing air or drinking water containing 
moderate levels (100 ppm) of vinyl chloride might increase their risk for cancer.  However, the 
levels used in these studies were much higher than levels found in the ambient air and/or most 
drinking water supplies. Studies of workers who have breathed vinyl chloride over many years 
showed an increased risk for cancer of the liver.  Brain cancer, lung cancer, and some cancers of 
the blood also may be connected with breathing vinyl chloride over long periods.  Studies of 
long-term exposure in animals showed that cancer of the liver and mammary gland may increase 
at very low levels of vinyl chloride in the air (50 ppm).  Lab animals fed low levels of vinyl 
chloride each day (2 mg/kg/day) during their lifetime had an increased risk of getting liver 
cancer. 
The U.S. Department of Health and Human Services has determined that vinyl chloride is a 
known carcinogen. The International Agency for Research on Cancer has determined that vinyl 
chloride is carcinogenic to people, and EPA has determined that vinyl chloride is a human 
carcinogen. 
More information about the adverse health effects of vinyl chloride in humans and animals can 
be found in Chapters 2 and 3. 
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1.6 HOW CAN VINYL CHLORIDE AFFECT CHILDREN? 
 
This section discusses potential health effects in humans from exposures during the period from 
conception to maturity at 18 years of age.  
No studies are available that specifically address the effects of vinyl chloride in children.  Studies 
of women who live near vinyl chloride manufacturing plants did not show that vinyl chloride 
produces birth defects. Studies using pregnant animals showed that breathing high levels of 
vinyl chloride (5,000 ppm) can harm unborn baby animals.  Animal studies also show that vinyl 
chloride can produce more miscarriages early in pregnancy and decrease weight and delay 
skeletal development in fetuses.  These same very high levels of vinyl chloride also caused 
harmful effects in the pregnant animals.  Inhalation studies with animals have suggested that 
vinyl chloride might affect growth and development.  Animal studies also suggest that infants 
and young children might be more susceptible than adults to vinyl chloride-induced cancer. 
1.7 	 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO VINYL 
CHLORIDE? 
If your doctor finds that you have been exposed to substantial amounts of vinyl chloride, ask 
whether your children might also have been exposed.  Your doctor might need to ask your state 
health department to investigate. 
You can take some steps to limit your exposure to vinyl chloride.  Very low levels of vinyl 
chloride exist in the ambient air, but these levels are usually not high enough to be a cause of 
concern. If you live near a hazardous waste site, municipal landfill, or a chemical plant that 
produces vinyl chloride or PVC, you might be exposed to higher levels of this compound than 
the general public.  Vinyl chloride can leach from plastic PVC bottles or containers used to 
contain foods or beverages, but government agencies such as the Food and Drug Administration 
(FDA) have restricted the amount of vinyl chloride that can be present in these packages.  
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Tobacco smoke contains low levels of vinyl chloride, so limiting your family’s exposure to 
cigarette or cigar smoke may help reduce their exposure to vinyl chloride.   
People who work in facilities that manufacture or use vinyl chloride could be exposed to high 
levels of this chemical.  The Occupational Safety and Health Administration (OSHA) regulates 
these levels and employers must comply with these rules.  If you work in an industry that 
manufactures or uses vinyl chloride, strictly adhere to the rules provided by the safety officer and 
always use respirators when advised.   
1.8 	 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN 
EXPOSED TO VINYL CHLORIDE? 
The results of several tests can sometimes show if you have been exposed to vinyl chloride, 
depending on the amount of your exposure and how recently it happened.  However, scientists 
do not know whether these measurements can tell how much vinyl chloride you have been 
exposed to. These tests are not normally available at your doctor's office.  Vinyl chloride can be 
measured in your breath, but the test must be done shortly after exposure.  This test is not very 
helpful for measuring very low levels of the chemical.  The amount of the major breakdown 
product of vinyl chloride, thiodiglycolic acid, in the urine may give some information about 
exposure. However, this test must be done shortly after exposure and does not reliably indicate 
the level of exposure. Also, exposure to other chemicals can produce the same breakdown 
products in your urine. Vinyl chloride can bind to genetic material in your body.  The amount of 
this binding can be measured by sampling your blood and other tissues.  This measurement will 
give information about whether you have been exposed to vinyl chloride, but it is not sensitive 
enough to determine the effects on the genetic material resulting from exposure.  For more 
information, see Chapters 3 and 7. 
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1.9 	 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO 
PROTECT HUMAN HEALTH? 
The federal government develops regulations and recommendations to protect public health.  
Regulations can be enforced by law. The EPA, the Occupational Safety and Health 
Administration (OSHA), and the Food and Drug Administration (FDA) are some federal 
agencies that develop regulations for toxic substances.  Recommendations provide valuable 
guidelines to protect public health, but cannot be enforced by law.  The Agency for Toxic 
Substances and Disease Registry (ATSDR) and the National Institute for Occupational Safety 
and Health (NIOSH) are two federal organizations that develop recommendations for toxic 
substances. 
Regulations and recommendations can be expressed as “not-to-exceed” levels, that is, levels of a 
toxic substance in air, water, soil, or food that do not exceed a critical value that is usually based 
on levels that affect animals; they are then adjusted to levels that will help protect humans.  
Sometimes these not-to-exceed levels differ among federal organizations because they used 
different exposure times (an 8-hour workday or a 24-hour day), different animal studies, or other 
factors. 
Recommendations and regulations are also updated periodically as more information becomes 
available. For the most current information, check with the federal agency or organization that 
provides it. Some regulations and recommendations for vinyl chloride include the following: 
Vinyl chloride is regulated in drinking water, food, and air.  Because it is a hazardous substance, 
regulations on its disposal, packaging, and other forms of handling also exist.  EPA requires that 
the amount of vinyl chloride in drinking water not exceed 0.002 milligrams per liter (mg/L) of 
water (0.002 ppm).  Under the EPA's Ambient Water Quality Criteria for the protection of 
human health, a concentration of 0.025 micrograms per L (μg/L) of water (0.025 ppb) was 
established for protecting human health from water and organism ingestion and 2.4 micrograms 
per L (μg/L) of water (2.4 ppb) was determined for consumption of organisms only. 
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To limit intake of vinyl chloride through foods to levels considered safe, FDA regulates the vinyl 
chloride content of various plastics.  These include plastics that carry liquids and plastics that 
contact food. The limits for vinyl chloride content vary depending on the nature of the plastic 
and its use. 
EPA has established a reportable quantity for vinyl chloride.  If quantities of more than 1 pound 
(0.454 kilograms) are released to the environment, the National Response Center of the federal 
government must be told immediately. 
OSHA regulates levels of vinyl chloride in the workplace.  No employee may be exposed to 
vinyl chloride at levels greater than 1 ppm averaged over any 8-hour period or levels greater than 
5 ppm averaged over any period exceeding 15 minutes.  NIOSH recommends that the exposure 
limit (for a time-weighted average [TWA]) for vinyl chloride in air be the lowest reliably 
detectable concentration. Workers exposed to any measurable amount of it must wear special 
breathing equipment.  EPA sets emission standards for vinyl chloride and PVC plants.  The 
amount of vinyl chloride allowed to be emitted varies depending on the type of production and 
the discharge system used. 
Further regulations and guidelines that apply to vinyl chloride are presented in Chapter 8. 
1.10 WHERE CAN I GET MORE INFORMATION? 
If you have any more questions or concerns, please contact your community or state health or 
environmental quality department, or contact ATSDR at the address and phone number below. 
ATSDR can also tell you the location of occupational and environmental health clinics.  These 
clinics specialize in recognizing, evaluating, and treating illnesses that result from exposure to 
hazardous substances. 
Toxicological profiles also are available on-line at www.atsdr.cdc.gov and on CD-ROM.  You 
can request a copy of the ATSDR ToxProfiles™ CD-ROM by calling the toll-free information 
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and technical assistance number at 1-888-42ATSDR (1-888-422-8737), by e-mailing 
atsdric@cdc.gov, or by writing to: 
Agency for Toxic Substances and Disease Registry 
  Division of Toxicology and Environmental Medicine 
1600 Clifton Road NE 
  Mailstop F-32 
  Atlanta, GA 30333 
  Fax: 1-770-488-4178 
For-profit organizations may request copies of final Toxicological Profiles from 
National Technical Information Service (NTIS) 
5285 Port Royal Road 
  Springfield, VA 22161 
  Phone: 1-800-553-6847 or 1-703-605-6000 
  Web site: http://www.ntis.gov/ 
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2.1 	 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO VINYL CHLORIDE IN THE 
UNITED STATES 
Vinyl chloride is a one of the highest production volume chemicals in the world, with a current worldwide 
demand of roughly 16 billion pounds annually.  Approximately 98% of all vinyl chloride produced is 
used to manufacture polyvinyl chloride (PVC).  These PVC materials become end products in automotive 
parts, packaging products, pipes, construction materials, furniture, and a variety of other products.   
Most vinyl chloride released to the environment will eventually partition to air, where it is degraded by 
atmospheric oxidants such as hydroxyl radicals.  Very low levels of vinyl chloride are usually present in 
ambient air with concentrations typically around 1 μg/m3 (0.4 ppb) or less.  In areas in close proximity to 
vinyl chloride production facilities, higher airborne levels are often observed.  Elevated levels of vinyl 
chloride may also be found in the vicinity of hazardous waste sites and municipal landfills.  This may be 
due to the presence of vinyl chloride or the microbial degradation of other chlorinated solvents to form 
vinyl chloride.  Vinyl chloride is highly mobile in soil, and as a consequence, is occasionally detected in 
groundwater and drinking water in the United States at levels in the parts per billion (ppb) range, although 
the rapid rate of volatilization generally reduces the potential for vinyl chloride to leach substantially into 
groundwater.   
The general population is primarily exposed to vinyl chloride from inhalation of ambient air and the 
ingestion of foods or other items that may contain low levels of vinyl chloride that has leached from a 
PVC container. Vinyl chloride possesses high mobility in the plastic and can leach into the food, 
beverages, or water that is ultimately ingested by the consumer.  Dietary exposure to vinyl chloride from 
PVC packages used for food has been calculated by several agencies and, based upon estimated average 
intakes in the United Kingdom and the United States, an exposure of <0.0004 μg/kg/day was estimated 
for the late 1970s and early 1980s. People who smoke or work where vinyl chloride is produced or used 
may be exposed to higher levels of vinyl chloride. 
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2.2 SUMMARY OF HEALTH EFFECTS  
The effects of vinyl chloride exposure have been studied in humans and animals, with similar results 
being exhibited in all species.  Vinyl chloride exposure in humans is most likely to occur by inhalation or 
oral exposure routes. Effects from dermal exposures are unlikely, as vinyl chloride is not well absorbed 
across the skin.  Chronic-duration, occupational exposures to high levels of vinyl chloride have resulted in 
a specific suite of effects in humans, including narcotic effects, Raynaud’s phenomenon (blanching and 
numbness of fingers and discomfort experienced upon exposure to cold temperatures), acroosteolysis, 
scleroderma-like skin changes, hepatocellular alterations, and the development of hepatic angiosarcoma, a 
liver cancer that is quite rare in the general U.S. population.  Laboratory animal exposure to vinyl chloride 
has resulted in neurological, liver, and cancer effects as well as respiratory, reproductive, developmental, 
and lymphoreticular effects.  Though acute inhalation exposure of mice to vinyl chloride resulted in a 
developmental effect (on which the oral acute-duration Minimal Risk Level [MRL] is based), liver and 
neurological effects were observed consistently in vinyl chloride workers and several animal species 
across exposure durations, suggesting that these are the principal effects of vinyl chloride exposure.   
The liver is the most sensitive target organ for vinyl chloride toxicity for both intermediate- and chronic-
duration inhalation and chronic-duration oral exposures.  The sensitivity of the liver to acute-duration 
effects is difficult to assess, since studies of acute-duration exposures either reported liver effects from 
high exposures of ≥20,000 ppm or focused on reproductive and developmental effects.  The sensitivity of 
the liver to vinyl chloride exposure is consistent with the proposed mechanism of action in which 
metabolism of vinyl chloride via mixed function oxidases (MFO), specifically CYP2E1, results in the 
formation highly reactive metabolites.  These metabolites have been shown to bind to DNA and 
hepatocellular proteins. Thus, the prevalence of MFO activity in the liver and resulting production of 
reactive metabolites results in the observed sensitivity of the liver to cancer and noncancer effects.  
Occupational studies have identified a consistent group of liver effects resulting from vinyl chloride 
exposure, including hypertrophy, hyperplasia of hepatocytes and sinusoidal cells, portal fibrosis, 
sinusoidal dilation, and focal cellular degeneration. Animal studies demonstrate that the intensity of 
effects increased with increasing dose, ranging from cellular hypertrophy and sinusoidal compression, to 
vacuolization, hepatic hyperplasia, fibrosis, and necrosis.  Longer duration exposures resulted in 
manifestation of effects at lower doses.  In animal studies, the lowest observed adverse noncancer effects 
in the liver included liver cell polymorphisms and development of hepatic cysts resulting from chronic 
oral exposures of 2 mg/kg/day; centrilobular hypertrophy and fatty liver changes resulted from 
intermediate-duration inhalation exposures of 10 and 50 ppm, respectively.  In addition to noncancer 
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effects, the liver was sensitive to tumor development.  For intermediate- and chronic-duration inhalation 
and chronic-duration oral exposures, the development of liver angiosarcoma resulted from exposures as 
low as 50 ppm and 0.2 mg/kg/day, respectively.  The development of pre-neoplastic basophilic foci 
resulted from chronic oral exposures of 0.02 mg/kg/day.   
Neurological effects of vinyl chloride have been observed following inhalation exposures.  No data were 
available for neurological effects resulting from oral exposures.  Inhalation-related neurological effects in 
humans include dizziness, drowsiness and fatigue, headache, euphoria and irritability, nervousness and 
sleep disturbances, nausea, visual and hearing disturbances, and loss of consciousness.  Signs of 
pyramidal and cerebellar disturbances have also been observed.  Dizziness has been reported by 
volunteers acutely exposed to 8,000 ppm, while nausea and subsequent headache resulted from exposures 
of 20,000 ppm.  Peripheral neurological effects have been reported, including parasthesia, tingling or 
warmth in the extremities, numbness or pain in the fingers, and depressed reflexes.  A variety of effects in 
animals from acute-duration inhalation exposures include ataxia, decreased coordination, twitching, 
tremors, and unconsciousness.  Chronic-duration exposures resulted in damaged nerve tissue, including 
degeneration of brain tissue and fibrosis of peripheral nerve endings.  
Human studies of reproductive and developmental effects from vinyl chloride exposure resulted in 
equivocal results. Studies examining parental employment and/or residential proximity to vinyl chloride 
facilities and birth defects reported links to fetal loss and defects of the central nervous system, alimentary 
tract, genitalia, and incidence of club foot. Other studies found no such association or suggested that 
inappropriate or inadequate study designs and statistical methodology were employed.  In animals, a few 
studies have identified reproductive and developmental effects.  Decreased testicular weight, reduced 
male fertility, and spermatogenic epithelial necrosis resulted from intermediate-duration inhalation 
exposures of 100–500 ppm, but were not observed in rats exposed to up to 1,100 ppm.  Gestational 
exposures of 2,500 ppm resulted in ureter dilation in rat offspring, while delayed ossification was 
observed following 500 ppm exposures in mice.  This exposure also resulted in 17% maternal mortality.  
A no-observed-adverse-effect level (NOAEL) of 50 ppm was associated with delayed ossification in mice 
and is the basis for the acute-duration inhalation MRL. 
The Department of Health and Human Services has determined vinyl chloride to be a known human 
carcinogen. The International Agency for Research on Cancer (IARC) has concluded that sufficient 
evidence for carcinogenicity in humans and animals exists and has placed vinyl chloride in 
carcinogenicity category 1 (i.e., carcinogenic to humans).  Similarly, EPA concluded that vinyl chloride is 
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a known human carcinogen by the inhalation route of exposure, based on human epidemiological data.  
By analogy, vinyl chloride is considered a known human carcinogen by the oral route because of positive 
animal bioassay data as well as pharmacokinetic data allowing dose extrapolation across routes.  By 
inference, EPA considers vinyl chloride highly likely to be carcinogenic by the dermal route because it 
acts systemically.  EPA derived an inhalation unit risk of 8.8x10-6 per μg/m3 for continuous lifetime 
exposure from birth based on the incidence of liver tumors observed in rats exposed to vinyl chloride via 
inhalation. An inhalation unit risk of 4.4x10-6 per μg/m3 for continuous lifetime exposure during 
adulthood was also estimated by EPA.  An oral slope factor for continuous lifetime exposure from birth 
was estimated by EPA to be 1.5 per mg/kg/day based on the incidence of liver tumors in rats.  An oral 
slope factor of 7.5x10-1 per mg/kg/day for continuous lifetime exposure during adulthood was also 
estimated by EPA. 
Noncancerous hepatotoxicity and carcinogenicity of vinyl chloride are discussed in greater detail below.  
The Reader is referred to Section 3.2, Discussion of Health Effects by Route of Exposure, for additional 
information on other effects. 
Noncancerous Hepatic Effects. The liver appears to be the most sensitive target organ of vinyl 
chloride toxicity.  Liver effects serve as the basis for the intermediate-duration inhalation MRL and the 
chronic-duration oral MRL (see Section 2.3).  Changes in the liver have been observed in workers 
exposed to unknown levels of vinyl chloride via inhalation.  The characteristic pattern of changes detected 
by peritoneoscopy and confirmed in several studies include hypertrophy and hyperplasia of hepatocytes 
and sinusoidal cells; sinusoidal dilation associated with damage to the cells lining the sinusoids and/or 
sinusoidal occlusion associated with crowding due to cellular hypertrophy and hyperplasia; focal areas of 
hepatocellular degeneration due to disruption of hepatic circulation; and fibrosis of portal tracts, septa, 
and periportal and intralobular perisinusoidal regions.  In fact, the extent of hepatic fibrosis appears to 
represent the primary difference between effects observed in animals and humans, as reticulin and 
collagen deposition in human liver tissue was greater than that observed in animals.  Species differences 
in fibrosis may also have been impacted by co-exposure to ethanol via alcohol consumption.  Case studies 
suggest that portal fibrosis and portal hypertension contributed to worker mortality.  Further, liver 
cirrhosis was implicated in increased mortality in an IARC update of a multi-center cohort of workers 
exposed to moderate to high concentrations of vinyl chloride and in a cohort of workers from five PVC 
production sites in Taiwan.  Though the critical confounding factor of alcohol consumption by workers at 
these sites was not considered, an analysis of another large cohort of vinyl chloride workers suggested 
that vinyl chloride exposure was an independent risk factor for liver cirrhosis, which exhibited a 
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synergistic interaction with alcohol consumption.  Regardless of species differences, it is possible that the 
development of fibrosis resulted via an immune-mediated mechanism rather than cytotoxicity, as 
structural changes occurring in the livers of humans and animals were not generally accompanied by 
changes in serum hepatic enzyme activities.  The lack of change in serum biochemistry may have been 
due to the limited scope of the necrotic changes.  
These findings in epidemiology studies are supported by studies in animals.  The animal data indicate a 
progression of effects across doses and durations.  Acute- and intermediate-duration effects seen in the 
livers of animals that inhaled 50,000–300,000 ppm of vinyl chloride included fatty liver changes, 
hepatocellular hypertrophy, vacuolization, sinusoidal compression, and liver congestion.  Centrilobular 
degeneration and necrosis resulted from intermediate-duration exposure of 50–200 ppm.  Centrilobular 
hypertrophy occurred in rats following an intermediate-duration inhalation of 10 ppm.  The dose-related 
progression of effect intensity from the minimally adverse increase in size of centrilobular hepatocytes to 
degeneration and necrosis is consistent with the appearance of highly reactive metabolites due to focused 
MFO metabolism of vinyl chloride in the liver (see discussion below).  Low-level intermediate- and 
chronic-duration inhalation exposures of 50 ppm also resulted in the development of hepatic 
angiosarcoma, though it is not known if carcinogenicity was preceded by or independent of a progression 
of non-cancer effects. Chronic oral exposures resulted in areas of cellular alteration, polymorphism, and 
necrosis in the livers of rats given 2 mg/kg/day vinyl chloride in the diet, while the appearance of 
basophilic foci, considered a pre-neoplastic lesion, occurred following exposures of 0.02 mg/kg/day.   
Though the mechanism of toxicity for liver effects of vinyl chloride is not well understood, the parent 
compound is metabolized to the reactive metabolites 2-chloroethylene oxide and, subsequently, 
2-chloroacetaldehyde via MFOs, whose activity is primarily concentrated in the liver.  The presence of 
the reactive 2-chloroacetaldehyde likely results in protein adduction, which can interfere with normal 
cellular function, resulting in cytotoxicity. This is consistent with the progression of effects from 
hypertrophy to fatty changes, hyperplasia, and necrosis.  The effects of hepatic fibrosis may be a 
secondary effect of the initiation of immune responses to cytotoxicity.  This is consistent with enhanced 
collagen deposition observed in workers, which is believed to be an immune-mediated response. 
Cancer.    The development of cancer in humans as a result of vinyl chloride exposure has been 
demonstrated in a number of studies of workers in the vinyl chloride production industry.  The strongest 
evidence comes from the cluster of reports of greater than expected incidences of liver angiosarcoma.  
Though no exposure data were available for these workers, there is a convincing association between 
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vinyl chloride exposure and the development of liver angiosarcoma, as this type of liver cancer is 
considered to be very rare in humans (25–30 cases/year in the United States).  The latency period for the 
development of hepatic angiosarcoma appears to be quite lengthy, as angiosarcoma continues to occur in 
workers employed prior to 1960; workers diagnosed after 1975 showed a latency of 27–47 years. 
Other types of cancer that have shown a significant increase in incidence among vinyl chloride workers 
include hepatocellular carcinoma and cholangiocellular carcinoma, cancer of the lung and respiratory 
tract, the lymphatic/hematopoietic system, and the brain and central nervous system.  However, 
uncertainty exists in the association of vinyl chloride exposure and some soft tissue tumors.  A meta­
analysis of data for over 22,000 workers suggested no excess cancer risk for soft tissue sarcoma, brain, 
lymphoid, and hematopoietic system cancers.  More recent follow-up studies have failed to find a 
significant association between vinyl chloride exposure and respiratory tract and brain cancer.    
Studies in several animal species support the conclusion that vinyl chloride is carcinogenic.  In rats, 
chronic exposure to 5–5,000 ppm vinyl chloride vapors resulted in significant incidence of mammary 
gland carcinomas, Zymbal’s gland carcinomas, nephroblastoma, and liver angiosarcoma.  Intermediate- 
and chronic-duration exposures of 50–2,500 ppm vinyl chloride resulted in significant incidence of liver 
angiosarcoma, carcinoma, and angioma, lung adenoma, mammary gland carcinoma, adipose tissue 
hemangiosarcoma, and hemangiosarcoma of the subcutis and peritoneum in mice.  With the exception of 
liver angiosarcomas, which have been observed in all species (including humans), there is little 
consistency in tumor types across species.  Chronic-duration oral administration of 2–6 mg/kg/day of 
vinyl chloride resulted in the development of neoplastic liver nodules, hepatocellular carcinoma, and lung 
and liver angiosarcoma in rats. 
Studies in rats, mice, and hamsters provide evidence that exposure early in life increases the risk of 
hemangiosarcoma in liver, skin, and spleen, stomach angiosarcoma, and mammary gland carcinoma, as 
compared to the risk associated with exposure after 12 months of age.  Due to the latency period for vinyl 
chloride-induced cancer, exposure of animals early in life may have increased the likelihood of 
developing tumors and affect the type of tumor that develops.   
The metabolism of vinyl chloride to the highly reactive metabolites, the observance of DNA adduction in 
mechanistic studies, and the observed carcinogenicity resulting from a single, high level inhalation 
exposure in animals, suggest that the primary mechanism of vinyl chloride carcinogenicity involves direct 
DNA interactions rather than secondary responses to cytotoxicity.  The mutation profile of DNA adducts 
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formed by the reactive metabolites of vinyl chloride, 2-chloroethylene oxide and 2-chloroacetaldehyde, 
includes the four cyclic etheno-adducts 1,N6-ethenoadenine, 3,N4-ethenocytosine, 3,N2-ethenoguanine, 
and 1,N2-ethenoguanine.  These adducts produce base-pair transitions during transcription and DNA 
crosslinks. Such mutations have resulted in the mutation of ras oncogenes, as observed in hepatic 
angiosarcoma tumors of workers exposed to high levels of vinyl chloride.  Further, mutations in the 
p53 tumor suppressor gene, which has been associated with a variety of tumor types, have been identified 
in vinyl chloride workers.  Mutations in p53 of vinyl chloride-exposed rats were similar to those reported 
in humans.   
2.3 MINIMAL RISK LEVELS (MRLs) 
Estimates of exposure levels posing minimal risk to humans (MRLs) have been made for vinyl chloride.  
An MRL is defined as an estimate of daily human exposure to a substance that is likely to be without an 
appreciable risk of adverse effects (noncarcinogenic) over a specified duration of exposure.  MRLs are 
derived when reliable and sufficient data exist to identify the target organ(s) of effect or the most sensitive 
health effect(s) for a specific duration within a given route of exposure.  MRLs are based on 
noncancerous health effects only and do not consider carcinogenic effects.  MRLs can be derived for 
acute, intermediate, and chronic duration exposures for inhalation and oral routes.  Appropriate 
methodology does not exist to develop MRLs for dermal exposure. 
Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1990), 
uncertainties are associated with these techniques.  Furthermore, ATSDR acknowledges additional 
uncertainties inherent in the application of the procedures to derive less than lifetime MRLs.  As an 
example, acute inhalation MRLs may not be protective for health effects that are delayed in development 
or are acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic 
bronchitis. As these kinds of health effects data become available and methods to assess levels of 
significant human exposure improve, these MRLs will be revised. 
Inhalation MRLs 
Epidemiological and case studies in humans did not provide sufficient data regarding exposure levels and 
durations and their correlation with hepatic, neurological, immunological, and carcinogenic effects.  
Therefore, animal studies were used for the derivation of inhalation MRLs.   
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•	 An MRL of 0.5 ppm has been derived for acute-duration inhalation exposure (≤14 days) to vinyl 
chloride. 
A number of studies in animals identified acute-duration lowest-observed-adverse-effect levels 
(LOAELs) for frank narcosis and severe lung, liver, and kidney damage following exposures of 5,000– 
400,000 ppm of vinyl chloride.  Exposure of pregnant rats to 2,500 ppm 7 hours/day over gestational 
days 6–15 resulted in ureter dilation in the offspring (John et al. 1977, 1981).  In the same study, pregnant 
mice exposed to 500 ppm for the same duration exhibited delayed ossification in the fetuses.  A NOAEL 
of 50 ppm was identified for mice.   
The study of John et al. (1977, 1981) study serves as the principal study for the derivation of an acute-
duration inhalation MRL based on the NOAEL of 50 ppm for delayed ossification.  In this study, groups 
of 19–26 pregnant CF-1 mice were exposed to 0, 50, or 500 ppm vinyl chloride for 7 hours/day on 
gestational days 6–15 (John et al. 1977, 1981).  No adverse maternal or fetal effects were noted at 
50 ppm, with the exception of an increase in crown-rump length that was not observed at 500 ppm.  At 
the LOAEL of 500 ppm, delayed ossification was observed.  A significant increase in fetal resorptions 
and reduced litter size at 500 ppm was considered to have been within historical control limits.  There was 
frank maternal toxicity at 500 ppm (17% death).   
The duration-adjusted NOAEL (NOAELADJ) was calculated as follows: 
NOAELADJ = 50 ppm x 7 hours / 24 hours = 15 ppm 
The human equivalent concentration (NOAELHEC) for an extrarespiratory effect produced by a 
category 3 gas, such as vinyl chloride, was calculated by multiplying the NOAELADJ by the ratio of the 
blood:gas partition coefficients in animals and humans ([Hb/g]A / [Hb/g]H). Since the partition coefficient in 
mice is greater than that in humans, a default value of 1 is used for the ratio, resulting in a NOAELHEC of 
15 ppm.  The acute-duration inhalation MRL of 0.5 ppm was derived by dividing the NOAELHEC of 
15 ppm by an uncertainty factor of 30 (3 for species extrapolation with dosimetric adjustment and 10 for 
human variability).  
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•	 An MRL of 0.03 ppm has been derived for intermediate-duration inhalation exposure (15– 
364 days) to vinyl chloride. 
Reduced male fertility, decreased tested weight, and spermatogenic epithelial necrosis was observed in 
male rats exposed from 11 weeks to 10 months to 100–500 ppm vinyl chloride (Bi et al. 1985; Short et al. 
1977; Sokal et al. 1980).  Decreased white blood cell counts resulted from exposure of rats to 20,000 ppm 
for 3 months (Lester et al. 1963), while increased lymphocyte proliferation resulted in mice exposed to 
10 ppm for up to 8 weeks (Sharma and Gehring 1979).  Exposures of 10–1,000 ppm resulted in increases 
and decreases in various relative and absolute organ weights (Sharma and Gehring 1979), including the 
liver (Bi et al. 1985; Sokal et al. 1980; Torkelson et al. 1961).  Adverse histopathological changes in the 
liver of rats and mice exposed to 2,000–3,000 ppm have been observed in several other intermediate-
duration inhalation studies (Lester et al. 1963; Schaffner 1978; Sokal et al. 1980; Torkleson et al. 1961; 
Wisniewska-Knypl et al. 1980).  Centrilobular degeneration and necrosis was observed in rabbits exposed 
to 200 ppm for 6 months (Torkleson et al. 1961).  Fatty liver changes were also observed in two studies of 
rats exposed to 50 ppm for 10 months (Sokal et al. 1980; Wisniewska-Knypl et al. 1980).  The lowest 
observed effect level was 10 ppm, which resulted in centrilobular hypertrophy in F1 female rats exposed 
for 19 weeks (Thornton et al. 2002).   
While effects were observed in both mice and rats exposed to 10 ppm, the rat study provided data for 
centrilobular hypertrophy in F1 offspring, a minimally adverse effect in a sensitive subpopulation 
(offspring) of the target organ (liver) that is sensitive to both inhalation and oral exposures.  Further, the 
rat study provided data for a longer exposure period than the mouse study.  Therefore, the study of 
Thornton et al. (2002) was chosen as the principal study for derivation of the intermediate-duration 
inhalation MRL, providing a critical effect level of 10 ppm as the LOAEL for centrilobular hypertrophy.  
In the Thornton et al. (2002) study, groups of 30 male and female Sprague-Dawley rats were exposed to 
0, 10, 100, or 1,100 ppm vinyl chloride, 6 hours/day for 10 weeks prior to mating and during a 3-week 
mating period.  F0 females were exposed during gestation and lactation.  Absolute and relative mean liver 
weights were significantly increased at all exposure levels in F0 males and in 100 and 1,100 ppm F1 
males. Slight centrilobular hypertrophy resulted in 1,100-ppm male and female F0 and F1 rats, 100 ppm 
male and female F0 and F1 rats, and in the 10 ppm F0 and F1 female rats.  The incidence rate for 
centrilobular hypertrophy in the F1 females was statistically significant.   
An intermediate-duration inhalation MRL of 0.03 ppm was derived for vinyl chloride, based on a 
benchmark concentration of 5 ppm derived from the concentration-response data for hepatic centrilobular 
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hypertrophy in female Sprague-Dawley rats (Thornton et al. 2002).  Using the Benchmark Dose Software 
(BMDS version 1.3.2), incidence data were fit to eight dichotomous models to derive the lower 
95% confidence limit (LEC10) of a 10% extra risk for hepatic centrilobular hypertrophy, which was 
selected as the benchmark response for the point of departure.  Several models provided equivalent 
goodness-of-fit statistics. Therefore, the LEC10 value of 5 ppm, derived from the simplest model 
(Weibull), was selected as the point of departure for calculating an intermediate-duration inhalation MRL 
(see Appendix A for more detailed information on the application of Benchmark Dose Modeling in 
deriving the intermediate-duration inhalation MRL for vinyl chloride).  The LEC10 of 5 ppm was 
duration-adjusted for intermittent exposure as follows: 
LEC10ADJ = 5 ppm x 6 hours / 24 hours = 1 ppm. 
The human equivalent concentration (LEC10HEC) was calculated using EPA (1994g) methodology for an 
extrarespiratory effect produced by a category 3 gas by multiplying the LEC10ADJ by the ratio of the 
blood:gas partition coefficients in animals and humans ([Hb/g]A / [Hb/g]H). The partition coefficient in rats 
is greater than that in humans.  Therefore, a default value of 1 is used for the ratio, resulting in a LEC10HEC 
of 1 ppm.  The intermediate-duration inhalation MRL of 0.03 ppm was derived by dividing the LEC10HEC 
of 1 ppm in rats by an uncertainty factor of 30 (3 for species extrapolation with a dosimetric adjustment 
and 10 for human variability).   
In the absence of exposure level data, the human data base did not provide a suitable LOAEL or NOAEL 
for derivation of a chronic-duration inhalation MRL.  A NOAEL (10 ppm) and a LOAEL (100 ppm) were 
identified for testicular effects (increases in the number of degenerative seminiferous tubule changes) in a 
chronic-duration inhalation study (Bi et al. 1985).  However, the results of the Thornton et al. (2002) 
study suggest that liver effects would occur at lower concentrations (10 ppm) than the reported testicular 
effects. Though several other chronic-duration studies did report carcinogenicity in rats chronically 
exposed to 5–250 ppm vinyl chloride (Drew et al. 1983; Lee et al. 1977a, 1978; Maltoni et al. 1981), they 
did not report the incidence of noncancerous or precancerous histopathological lesions in the any tissue.  
Therefore, no chronic-duration inhalation MRL was derived for vinyl chloride.   
Oral MRLs 
No studies of human adverse effects resulting from oral exposure to vinyl chloride were available.  
Therefore, animal studies were used for the derivation of MRLs.  No acute- or intermediate-duration oral 
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MRLs were derived for vinyl chloride because of an absence of data on the effects of oral exposure to 
vinyl chloride for these duration categories.   
•	 An MRL of 0.003 mg/kg/day has been derived for chronic-duration oral exposure (≥365 days) to 
vinyl chloride. 
Chronic gavage doses of 30 mg/kg/day vinyl chloride in rats resulted in increased collagen deposition and 
skin thickness (Knight and Gibbons 1987).  Decreased blood clotting time was observed in rats given 
17 mg/kg/day (Feron et al. 1981).  Doses of 6 mg/kg/day in female rats resulted in extensive hepatic 
necrosis and 100% early mortality (Feron et al. 1981).  A number of effects were observed in rats given 
1.7–1.8 mg/kg/day, including hepatocellular alterations (Feron et al. 1981), liver cell polymorphisms, and 
increased mortality (Til et al. 1983, 1991).  The LOAEL of 1.7 mg/kg/day for liver cell polymorphism in 
both sexes and hepatic cysts in female rats was the lowest identified LOAEL and was associated with the 
lowest identified NOAEL for any chronic effect of 0.17 mg/kg/day.  Liver cell polymorphism is not 
considered a precursor to carcinogenicity (Afzelius and Schoental 1967; Schoental and Magee 1957, 
1959) and represents an effect to the target organ that is sensitive to both inhalation and oral exposures of 
vinyl chloride.  For these reasons, the study of Til et al. (1983, 1991) was chosen as the critical study and 
the NOAEL of 0.17 mg/kg/day was chosen as the critical effect level for derivation of the chronic-
duration oral MRL. 
In the study of Til et al. (1983, 1991), groups of 50 or 100 male and female Wistar rats were administered 
vinyl chloride in the daily diet at 0, 0.46, 4.6, or 46 ppm for 149 weeks.  Using measurements of 
evaporative loss of vinyl chloride from the diet, the study authors calculated the average oral intake of the 
combined sexes during the daily feeding periods to be 0, 0.018, 0.17, and 1.7 mg/kg/day for the 0, 0.49, 
4.49, and 44.1ppm groups, respectively.  Types and incidences of neoplastic and nonneoplastic liver 
lesions were determined at the end of the study.  A LOAEL of 1.7 mg/kg/day was identified for 
significantly increased incidences of liver cell polymorphism in male and female rats and increased 
incidence of hepatic cysts in female rats.  The NOAEL for nonneoplastic liver effects is 0.17 mg/kg/day. 
Other histopathologic lesions, described as hepatic foci of cellular alteration, were observed at all dose 
levels in female rats and in high-dose male rats, but were not used to derive an MRL because they are 
considered to be preneoplastic lesions.   
This MRL of 0.003 mg/kg/day was based on a NOAEL of 0.17 mg/kg/day for noncancerous liver effects 
(i.e., liver cell polymorphism) in female Wistar rats (Til et al. 1983, 1991) and application of the 
physiologically based pharmacokinetic (PBPK) model (Clewell et al. 2001; EPA 2000). Source code and 
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parameter values for running the rat and human models in Advance Continuous Simulation Language 
(ACSL) were transcribed from Appendix C of EPA (2000).  Exposures in the Til et al. (1983, 1991) rat 
dietary exposure study were simulated in rats as 4-hour oral exposures with the NOAEL dose for liver 
effects of 0.17 mg/kg/day.  The total amount of vinyl chloride metabolized in 24 hours per liter of liver 
volume was the rat internal dose metric used to determine the human oral dose that would result in an 
equivalent human internal dose.  One kilogram of liver was assumed to have an approximate volume of 
1 L. The human model was run iteratively, until the model converged with the internal dose estimate for 
the rat (3.16 mg/L liver).  The human dose was assumed to be uniformly distributed over a 24-hour 
period. The resulting human oral dose of 0.09 mg/kg/day, associated with the rat NOAEL of 
0.17 mg/kg/day (Til et al. 1983, 1991), served as the basis for the chronic-duration oral MRL for vinyl 
chloride. The chronic-duration oral MRL of 0.003 mg/kg/day was derived by dividing the PBPK-
modeled equivalent human NOAEL of 0.09 mg/kg/day for liver cell polymorphisms by an uncertainty 
factor of 30 (3 for species extrapolation with a dosimetric adjustment and 10 for human variability).  
More detailed information regarding the application of the PBPK model in deriving the chronic-duration 
oral MRL for vinyl chloride is provided in Appendix A. 
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3.1 INTRODUCTION 
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective on the toxicology of vinyl chloride.  It 
contains descriptions and evaluations of toxicological studies and epidemiological investigations and 
provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health. 
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile. 
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE  
To help public health professionals and others address the needs of persons living or working near 
hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, 
oral, and dermal) and then by adverse health effect (death, systemic, immunological, neurological, 
reproductive, developmental, genotoxic, and carcinogenic effects).  These data are discussed in terms of 
three exposure periods: acute (14 days or less), intermediate (15–364 days), and chronic (365 days or 
more). 
Levels of significant exposure for each route and duration are presented in tables and illustrated in 
figures. The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest-
observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies. 
LOAELs have been classified into "less serious" or "serious" effects.  "Serious" effects are those that 
evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress 
or death). "Less serious" effects are those that are not expected to produce significant dysfunction or 
death, or those whose significance to the organism is not entirely clear.  ATSDR acknowledges that a 
considerable amount of judgment may be required in establishing whether an end point should be 
classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be 
insufficient data to decide whether the effect is indicative of significant dysfunction.  However, the 
Agency has established guidelines and policies that are used to classify these end points.  ATSDR 
believes that there is sufficient merit in this approach to warrant an attempt at distinguishing between 
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"less serious" and "serious" effects.  The distinction between "less serious" effects and "serious" effects is 
considered to be important because it helps the users of the profiles to identify levels of exposure at which 
major health effects start to appear.  LOAELs or NOAELs should also help in determining whether or not 
the effects vary with dose and/or duration, and place into perspective the possible significance of these 
adverse effects to human health.   
The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and 
figures may differ depending on the user's perspective.  Public health officials and others concerned with 
appropriate actions to take at hazardous waste sites may want information on levels of exposure 
associated with more subtle effects in humans or animals (LOAELs) or exposure levels below which no 
adverse effects (NOAELs) have been observed.  Estimates of levels posing minimal risk to humans 
(Minimal Risk Levels or MRLs) may be of interest to health professionals and citizens alike. 
Levels of exposure associated with carcinogenic effects (Cancer Effect Levels, CELs) of vinyl chloride 
are indicated in Tables 3-1 and 3-2 and Figures 3-1 and 3-2.  Because cancer effects could occur at lower 
exposure levels, Figures 3-1 and 3-2 also shows a range for the upper bound of estimated excess risks, 
ranging from a risk of 1 in 10,000 to 1 in 10,000,000 (10-4 to 10-7), as developed by EPA. 
Estimates of exposure levels posing minimal risk to humans (MRLs) have been made for vinyl chloride.  
An MRL is defined as an estimate of daily human exposure to a substance that is likely to be without an 
appreciable risk of adverse effects (noncarcinogenic) over a specified duration of exposure.  MRLs are 
derived when reliable and sufficient data exist to identify the target organ(s) of effect or the most sensitive 
health effect(s) for a specific duration within a given route of exposure.  MRLs are based on 
noncancerous health effects only and do not consider carcinogenic effects.  MRLs can be derived for 
acute, intermediate, and chronic duration exposures for inhalation and oral routes.  Appropriate 
methodology does not exist to develop MRLs for dermal exposure. 
Although methods have been established to derive MRLs (Barnes and Dourson 1988; EPA 1990), 
uncertainties are associated with these techniques.  Furthermore, ATSDR acknowledges additional 
uncertainties inherent in the application of the procedures to derive less than lifetime MRLs.  As an 
example, acute inhalation MRLs may not be protective for health effects that are delayed in development 
or are acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic 
bronchitis. As these kinds of health effects data become available and methods to assess levels of 
significant human exposure improve, these MRLs will be revised.  It should be noted that MRLs are also 
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not protective in the case of altered health status caused by exposure to cigarette smoking or excessive 
alcohol consumption (i.e., altered lung and liver function). 
A User's Guide has been provided at the end of this profile (see Appendix B).  This guide should aid in 
the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs. 
3.2.1 Inhalation Exposure 
3.2.1.1 Death 
A report by Danziger (1960) described the deaths of two vinyl chloride workers.  In one case, a worker 
exposed to high concentrations of vinyl chloride emitted from an open valve was found dead.  In another 
case, a worker responsible for cleaning a polymerization tank was found dead in the tank.  Autopsies 
performed on these men showed congestion of the internal organs, particularly the lungs and kidneys, and 
failure of the blood to clot.  Circumstances surrounding the deaths suggested that the deaths were due to 
breathing very high levels of vinyl chloride.   
No increase in mortality was observed in 1,100 workers exposed to vinyl chloride compared to the same 
number of controls in a 7-year prospective cohort study of (Laplanche et al. 1992).  At the time of the 
study interview, 36% of the 1,100 workers were currently being exposed to vinyl chloride, and 64% had 
been exposed in the past (Laplanche et al. 1987, 1992). 
Brief exposures to concentrations of vinyl chloride ranging from 100,000 to 400,000 ppm have been 
shown to be fatal in experimental animals such as rats (Lester et al. 1963; Mastromatteo et al. 1960; 
Prodan et al. 1975), guinea pigs (Mastromatteo et al. 1960; Patty et al. 1930; Prodan et al. 1975), mice 
(Mastromatteo et al. 1960; Prodan et al. 1975), and rabbits (Prodan et al. 1975).  At these concentrations, 
deaths occurred within 30–60 minutes.  Male mice exposed to 30,000 ppm vinyl chloride 6 hours/day for 
5 days, in a dominant lethal study showed an increased mortality rate (Anderson et al. 1976).  An 
increased mortality rate was also observed at much lower concentrations in maternal mice in a 
developmental toxicity study (John et al. 1977, 1981).  In this study, maternal mice had an increased 
incidence of deaths following exposure to 500 ppm for 10 days during gestation. 
Decreased longevity was observed in intermediate-duration studies (Adkins et al. 1986; Drew et al. 1983; 
Feron et al. 1979a; Hong et al. 1981; Lee et al. 1978) and chronic-duration studies (Drew et al. 1983; 
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Feron et al. 1979a; Viola 1970). A treatment-related increase in the mortality rate was observed in mice 
exposed to 500 ppm of vinyl chloride for 6 hours/day, 5 days/week, for 6 months (Adkins et al. 1986).  In 
mice and rats maintained for 12 months following a 6-month, 6 hour/day, 5 day/week exposure regime, 
decreased longevity was observed at concentrations as low as 50 ppm; however, statistical analyses of the 
data were not available to verify the significance of the decrease (Hong et al. 1981).  Substantial increases 
in the mortality rate of mice and rats exposed to 250 ppm vinyl chloride for 12 months were observed by 
Lee et al. (1977a, 1978). In addition, small increases in mortality of mice and rats during the 12-month 
exposure period were observed at 50 ppm in these reports; however, the statistical significance of these 
increases was not reported. 
The influence of the age on survival of female animals exposed to vinyl chloride was examined by Drew 
et al. (1983).  In female hamsters exposed to 200 ppm, two strains of female mice exposed to 50 ppm, and 
female rats exposed to 100 ppm for 12 months, a higher death rate was observed when 2-month-old 
animals were exposed than when 8- or 14-month-old animals were exposed.  Similar trends were 
observed when hamsters and mice were exposed to these concentrations for 6 months.  The treatment-
related deaths in this study may be due to the induction of vinyl chloride-induced carcinogenesis.  These 
results demonstrate the importance of the latency period for cancer and associated mortality.  Animals 
that were exposed at a younger age had a longer post-exposure period for the development of tumors.  It 
is difficult to assess the sensitivity of younger animals to cancer mortality in this study because the same 
exposure concentrations were used for each age group.  These results do not necessarily indicate that 
young people are more susceptible to the lethal effects of vinyl chloride, since animals that were exposed 
later in life may have died of age-related causes prior to the expression of the lethal effects.  This study 
was limited in that only one dose of vinyl chloride was tested in each species. 
All reliable LOAEL values for death in each species and duration category are recorded in Table 3-1 and 
plotted in Figure 3-1. 
3.2.1.2 Systemic Effects  
The highest NOAEL values and all reliable LOAEL values for each study with a systemic end point in 
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500 F (5/29 died) John et al. 1977, 1981 
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1, 5 d 
6 hr/d Hepatic 50000 M 
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100000 M (hepatocellular 
vacuolization, increased 
AKT and SDH) 
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Jaeger et al. 1974 
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Species Frequency NOAEL Less Serious Serious Reference 
Figure (Strain) (Route) System (ppm) (ppm) (ppm) Chemical Form 
17 Gn Pig 
(NS) 
30 min Resp 100000 (slight pulmonary 
hyperemia) 






300000 (fatty degeneration) 
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Mastromatteo et al. 1960 
Lester et al. 1963 
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500 Hehir et al. 1981 
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1 hr 5000 50000 (ataxia) 
30 min 100000 (narcosis) 
30 min 100000 (tremor, loss of 
consciousness) 
up to 8 hr 10000 25000 (narcosis) 
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2500 F (ureter dilation) 
4 hr/d 
Gd 6-19 1100 
Reference 
Chemical Form 
Hehir et al. 1981 
Mastromatteo et al. 1960 
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Patty et al. 1930 
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Species Frequency NOAEL Less Serious Serious
 Reference 
Figure (Strain) (Route) System (ppm) (ppm) (ppm)










































Cardio 10 M 100 M 
Renal 100 M 3000 M 
(delayed ossification) John et al. 1977, 1981 
(delayed ossification) John et al. 1977, 1981 
5000	 (CEL: bronchioalveolar 
adenoma) 
Hehir et al. 1981 
50 (17/26 died) Hong et al. 1981 
500 M (37/70 died) 
500 F (23/70 died) 
Adkins et al. 1986 
50 (15/16 died) Hong et al. 1981 
(increased relative heart 
weight) 
Bi et al. 1985 
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(increased relative heart Bi et al. 1985 
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(increased relative liver 
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relative liver weight) 
(thin coats, scaly tails) 
(decreased white blood Lester et al. 1963 
cells) 
(moderate hepatocellular 













































Species Frequency NOAEL Less Serious Serious Reference 
Figure (Strain) (Route) System (ppm) (ppm) (ppm) Chemical Form 
Rat 	 10 mo 
(Wistar) 	 5 d/wk 
Musc/skel 20000 M Sokal et al. 1980 
5 hr/d 
Hepatic 50 M (fatty changes) 
Renal 50 M 500 M (increased kidney weight) 
Bd Wt 50 M (10% decrease in body 
weight) 
Rat 	 16 wk (M) c 
(Sprague- 19 wk (F) 
Hepatic 10 F (centrilobular hypertrophy Thornton et al. 2002 
Dawley) 2 gen 
in F1 female rats) 
4 hr/d 
Bd Wt 	 1100 
Rat 	 6 mo Hemato 200 Torkelson et al. 1961 




Hepatic 100 	 (increased relative liver 
weight) 
Renal 200 
Bd Wt 200 
Rat 	 10 mo 
(Wistar) 	 5 d/wk 



































Table 3-1 Levels of Significant Exposure to Vinyl Chloride - Inhalation (continued) 
a











































Resp 2500 M (proliferation and 
hypertrophy of bronchial 
epithelium; 
hypersecretion of mucin; 
hyperplasia of alveolar 
epithelium) 






Hepatic 100 200 (centrilobular 
degeneration and 
necrosis) 
Torkelson et al. 1961 
Renal 200 












































Species Frequency NOAEL Less Serious Serious Reference 
Figure (Strain) (Route) System (ppm) (ppm) (ppm) Chemical Form 
Immuno/ Lymphoret 
51 Rat 3 mo 
6 d/wk 100 M 3000 M (increased spleen 	 Bi et al. 1985 (Wistar) 	
6 hr/d weight) 
Rat 	 6 mo 
(Wistar) 	 6 d/wk 
10 M (increased spleen Bi et al. 1985 
6 hr/d weight) 
Rat 	 10 mo 
(Wistar) 	 5 d/wk 
50 M (increased spleen Sokal et al. 1980 






10 M (increased spontaneous 
lymphocyte proliferation) 
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Hehir et al. 1981 












































Less Serious Serious Reference 
(ppm) (ppm) Chemical Form 
58	 Rat 10 mo 
(Wistar) 5 d/wk 
5 hr/d 





59 Rat 6 mo 
(Fischer- 344) 5 d/wk 
6 hr/d 












60	 Rat 33 d 
(Sprague- 6 d/wk 
Dawley) 8 hr/d 
61 Rat 6 or 10 mo 






























































Table 3-1 Levels of Significant Exposure to Vinyl Chloride - Inhalation	 (continued) 
a

















Frequency NOAEL Less Serious 	 Serious Reference 
(Route) 
System (ppm) (ppm) 	 (ppm) Chemical Form 
16 wk (M) 


















1100 F (CEL: foci of Thornton et al. 2002 
hepatocellular alterations 
considered to be 
pre-neoplastic) 
50 	 (CEL: pulmonary Adkins et al. 1986 
adenoma) 
50 F (CEL: hemangiosarcoma Drew et al. 1983 
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a Numbers correspond to entries in Figure 3-1. 
b Used to derive an acute-duration inhalation Minimal Risk Level (MRL) of 0.5 ppm. A NOAEL was adjusted for intermittent exposure and converted to a Human Equivalent 
Concentration (HEC) before applying uncertainty factors. The MRL was obtained by dividing the NOAEL-HEC by an uncertainty factor of 30 (3 for extrapolation from animals to 
humans using a dosimetric adjustment, and 10 for human variability). 
c Used to derive an intermediate-duration inhalation MRL of 0.03 ppm. LEC10 converted to an HEC and adjusted for intermittent exposure before applying uncertainty factors. The 
MRL was obtained by dividing the LEC10-HEC by an uncertainty factor of 30 (3 for extrapolation from animals to humans using a dosimetric adjustment, and 10 for human variability). 
AKT = alpha-ketoglutarate transaminase; B - both; Bd Wt = body weight; Cardio = cardiovascular; CEL = cancer effect level; d = day(s); derm = dermal; Endocr = endocrine; F = 
Female; Gd = gestational day; Gn pig = guinea pig; hemato = hematological; hr = hour(s); Immuno = immunological; LOAEL = lowest-observed-adverse-effect level; M = male; min = 
minute(s); mo = month(s); Musc/skel = musculoskeletal; NOAEL = no-observed-adverse-effect level; NS = not specified; Resp = respiratory; SDH = sorbitol dehydrogenase; wk = 










































Figure 3-1 Levels of Significant Exposure to Vinyl Chloride - Inhalation 






















17g 17g1r 12r7g 17g 16m 
5m 10h9g 12r16m 12r17g2r 
100000 8g 17g 16m 12r 11r 12r 16m6m 











































Figure 3-1 Levels of Significant Exposure to Vinyl Chloride - Inhalation (continued) 
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*Doses represent the lowest dose tested per study that produced a tumorigenic 
response and do not imply the existence of a threshold for the cancer endpoint. 0.1 
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Figure 3-1 Levels of Significant Exposure to Vinyl Chloride - Inhalation (continued) 
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Respiratory Effects.    Limited information is available on the acute adverse effects from inhalation of 
vinyl chloride by humans.  Autopsy findings from a man who died after being overcome by vinyl chloride 
revealed the irritating nature of a high-level inhalation exposure.  The lungs were found to be intensely 
hyperemic, and some desquamation of the alveolar epithelium had occurred (Danziger 1960). Reports 
regarding respiratory effects in workers who are occupationally exposed to vinyl chloride are 
contradictory.  Several epidemiologic studies found no increased incidence of respiratory disease among 
vinyl chloride workers (Gamble et al. 1976; Laplanche et al. 1987, 1992; NIOSH 1977).  However, 
adverse respiratory effects were reported in several epidemiologic surveys and case reports, with these 
effects including increased incidence of emphysema (Suciu et al. 1975; Wong et al. 1991), decreased 
respiratory volume and vital capacity, respiratory insufficiency (Suciu et al. 1975), decreased respiratory 
oxygen and carbon dioxide transfer (Lloyd et al. 1984), pulmonary fibrosis of the linear type (Suciu et al. 
1975), abnormal chest x-rays (Lilis et al. 1975, 1976), and dyspnea (Walker 1976).  Interpretation of 
many of these results is confounded by the inclusion of smokers among those exposed to vinyl chloride 
and the concurrent exposure of many vinyl chloride workers to PVC resin dust, which is known to 
produce respiratory lesions (Mastrangelo et al. 1979). 
Brief inhalation of high concentrations of vinyl chloride produced respiratory inflammation in a variety of 
animals.  A 30-minute exposure of guinea pigs, mice, and rats to 100,000 ppm of vinyl chloride produced 
hyperemia in all three species (Mastromatteo et al. 1960).  Exposure to higher concentrations 
(200,000 ppm and 300,000 ppm) produced increased congestion, edema, and at the highest 
concentrations, pulmonary hemorrhages in all three species (Mastromatteo et al. 1960).  Tracheal 
epithelium was also absent in one guinea pig exposed to 400,000 ppm for 30 minutes (Mastromatteo et al. 
1960).  Edema and congestion of the lungs of rats were also observed following a 2-hour exposure to 
150,000 ppm (Lester et al. 1963). 
Histopathologic examination of mice exposed to 2,500 ppm vinyl chloride 5 hours/day, 5 days/week for 
5–6 months revealed proliferation and hypertrophy of the bronchiolar epithelium, hyperplasia of the 
alveolar epithelium, hypersecretion of mucin (Suzuki 1978, 1980, 1981), increased endoplasmic 
reticulum and free ribosomes in Clara cells, and mobilization of alveolar macrophages (Suzuki 1980).  
These changes were observed irrespective of the recovery period (2 or 37 days), indicating that they were 
not readily reversible.  However, these studies were limited by the small number of animals tested and the 
absence of a statistical analysis. 
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Chronic exposure of rats to 5,000 ppm 7 hours/day, 5 days/week for 12 months produced hyperplasia of 
the olfactory epithelium, increased cellularity of the interalveolar septa of the lungs, and an increased 
incidence of pulmonary hemorrhage (Feron and Kroes 1979).  Interstitial pneumonia and hemorrhagic 
lungs were observed in rats exposed to 30,000 ppm of vinyl chloride 4 hours/day, 5 days/week for 
12 months (Viola et al. 1971).  However, neither of these studies reported the statistical significance of 
these findings. 
Cardiovascular Effects.    Occupational exposure to vinyl chloride has been associated with the 
development of Raynaud's phenomenon, a condition in which the fingers blanch and become numb with 
discomfort upon exposure to the cold.  It has also been reported in a worker exposed once to a vinyl 
chloride leak (Ostlere et al. 1992).  Although only a small percentage of vinyl chloride workers develop 
Raynaud's phenomenon (Laplanche et al. 1987, 1992; Lilis et al. 1975; Marsteller et al. 1975; Suciu et al. 
1963, 1975; Veltman et al. 1975; Walker 1976), the incidence is significantly higher than in unexposed 
workers (Laplanche et al. 1987, 1992).  Investigation of the peripheral circulation of workers afflicted 
with Raynaud's phenomenon has revealed thickening of the walls of the digital arteries (Harris and 
Adams 1967), narrowing of the arterial lumen (Veltman et al. 1975), vascular occlusions (Walker 1976), 
arterial occlusions (Preston et al. 1976; Veltman et al. 1975), tortuosity (Preston et al. 1976), 
hypervascularity (Preston et al. 1976), inflammatory infiltration of the arterioles (Magnavita et al. 1986), 
deposition of immune products along the vascular endothelium (Ward 1976), vasomotor impairment 
(Suciu et al. 1963), and impaired capillary microcirculation (Magnavita et al. 1986; Maricq et al. 1976).  
Three reports indicate that upon removal from exposure, Raynaud's phenomenon gradually disappears 
(Freudiger et al. 1988; Suciu et al. 1963, 1975).  For further discussion of Raynaud's phenomenon, see 
Immunological/Lymphoreticular Effects (Section 3.2.1.3). 
Splenomegaly, with evidence of portal hypertension (dilated peritoneal veins and esophageal varices), has 
been reported by investigators studying the effects of vinyl chloride exposure (Marsteller et al. 1975).  In 
addition, hypertension among vinyl chloride workers (NIOSH 1977; Suciu et al. 1975) and significantly 
increased mortality rate due to cardiovascular and cerebrovascular disease (Byren et al. 1976) have been 
reported. An association between vinyl chloride exposure and arterial hypertension was observed in an 
occupational worker study.  Conclusive evidence was not provided for an association of vinyl chloride 
with coronary heart disease (Kotseva 1996). 
Investigators studying the anesthetic properties of vinyl chloride in dogs have observed that doses 
producing anesthesia (100,000 ppm, Oster et al. 1947; 150,000–900,000 ppm, Carr et al. 1949) also 
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produced cardiac arrhythmias.  Arrhythmias were characterized by intermittent tachycardia, 
extraventricular systoles, vagal beats, ventricular fibrillation, and atrioventricular block.  However, the 
statistical significance of these effects was not reported.  At high concentrations (>30,000 ppm), vinyl 
chloride was been shown to sensitize the heart to epinephrine, resulting in cardiac arrhythmias in dogs 
(Clark and Tinston 1973). No histopathological changes in the heart were noted in guinea pigs exposed to 
400,000 ppm of vinyl chloride for 30 minutes (Mastromatteo et al. 1960). 
A study by Bi et al. (1985) demonstrated an increase in the relative heart weight at concentrations of vinyl 
chloride as low as 10 ppm when administered to male rats 6 hours/day, 6 days/week for 6 months.  Heart 
weight was also increased after 3 months in rats exposed to 100 ppm under this regimen (Bi et al. 1985).  
Chronic exposure of rats to 5,000 ppm vinyl chloride 7 hours/day, 5 days/week for 1 year resulted in 
increases in areas of myodegeneration in the heart and thickening of the walls of arteries (Feron and 
Kroes 1979).  However, the statistical significance of this effect was not reported.  Exposure of rats to 
30,000 ppm of vinyl chloride 4 hours/day, 5 days/week for 1 year also produced thickening of the walls of 
small arterial vessels.  The thickening was characterized by a proliferation of the endothelium.  In some 
vessels, the thickening was severe enough to cause blockage of the lumen (Viola 1970). 
Gastrointestinal Effects.    Approximately 32% of the vinyl chloride workers examined by Lilis et al. 
(1975) reported a history of "gastritis, ulcers (gastric and duodenal), and upper gastrointestinal bleeding."  
Because these subjects were not compared to workers who had not been exposed to vinyl chloride, the 
significance of these findings is unknown. Other symptoms reported by vinyl chloride workers included 
nausea, abdominal distension, and heartburn. Loss of appetite and nausea have been reported in 
Singapore workers exposed to 1–21 ppm vinyl chloride (Ho et al. 1991).  However, these workers were 
selected on the basis of liver dysfunction. 
No studies were located regarding gastrointestinal effects in animals following inhalation exposure to 
vinyl chloride. 
Hematological Effects.    Blood tests performed at autopsy of two workers whose deaths were 
believed to be due to exposure to extremely high levels of vinyl chloride revealed that blood clotting did 
not occur (Danziger 1960).  Slight-to-severe thrombocytopenia in workers occupationally exposed to 
vinyl chloride was reported in several studies (Marsteller et al. 1975; Micu et al. 1985; Veltman et al. 
1975), but Lilis et al. (1975) found no increased incidence of thrombocytopenia in vinyl chloride workers.  
A prospective study of female workers exposed to vinyl chloride at levels ranging from 0.2 to 130.7 ppm 
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showed that the exposed workers had a significantly lower number of platelets than the nonexposed 
controls during the early part of their pregnancies (weeks 8–10) but that this effect abated by the end of 
the pregnancy (34–38 weeks) following a period free from exposure (Bao et al. 1988).  Splenomegaly was 
reported in a number of studies (Ho et al. 1991; Marsteller et al. 1975; Popper and Thomas 1975; Suciu et 
al. 1963; Veltman et al. 1975).  Thrombocytopenia was found in patients who both did and did not present 
with splenomegaly (Veltman et al. 1975).  Increased levels of two plasma proteins (α1- and α2-globulin) 
were reported in studies examining the effects of occupational exposure to vinyl chloride (Harris and 
Adams 1967; Suciu et al. 1975). 
A brief (30-minute) exposure of guinea pigs to 400,000 ppm vinyl chloride resulted in a failure of the 
blood to clot in the animals that died during the exposure (Mastromatteo et al. 1960).  Mice that were 
exposed to 5,000 ppm (4 hours/day for 6 days) or 10,000 ppm (4 hours/day for 5 days) showed an 
increased emergence of basophilic stippled erythrocytes (Kudo et al. 1990).  This effect was also noted in 
mice that were exposed for 10 weeks to 50 ppm intermittently (4 hours/day for 4–5 days/week,) or to 30– 
40 ppm continuously for 62 days (Kudo et al. 1990).  Exposure of dogs and rats to 200 ppm for 
7 hours/day, 5 days/week, for 6 months had no effect on hematologic values (Torkelson et al. 1961).  
Also, an 8-week exposure of mice to 1,000 ppm for 6 hours/day, 5 days/week had no effect on 
erythrocyte or leukocyte counts (Sharma and Gehring 1979).  Exposure of rats to either 50,000 ppm for 
8 hours/day for 19 consecutive days or 20,000 ppm for 8 hours/day, 5 days/week for 92 days resulted in a 
decrease in white blood cells (Lester et al. 1963).  Exposure of rats to 5,000 ppm vinyl chloride for 
7 hours/day, 5 days/week for 1 year produced increased hematopoiesis in the spleen (Feron and Kroes 
1979). The statistical significance of these results was not reported.  Blood clotting time was decreased in 
rats exposed to 5,000 ppm for7 hours/day for 1 year, but the statistical significance of these effects was 
not reported (Feron et al. 1979a). 
Musculoskeletal Effects.    Acroosteolysis, or resorption of the terminal phalanges of the finger, was 
observed in a small percentage of workers occupationally exposed to vinyl chloride (Dinman et al. 1971; 
Lilis et al. 1975; Marsteller et al. 1975; Sakabe 1975; Veltman et al. 1975; Wilson et al. 1967).  Bone 
lesions were most often confined to the terminal phalanges of the fingers, but in a few cases the bones of 
the toes (Harris and Adams 1967), feet (Preston et al. 1976), sacroiliac joint (Harris and Adams 1967), 
and arms, legs, pelvis, and mandible (Preston et al. 1976) were also involved.  Development of 
acroosteolysis was most often preceded by Raynaud's phenomenon (Dinman et al. 1971; Freudiger et al. 
1988; Harris and Adams 1967; Magnavita et al. 1986; Markowitz et al. 1972; Preston et al. 1976; Sakabe 
1975; Veltman et al. 1975; Wilson et al. 1967).  In two reports, bone resorption was observed to progress 
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despite discontinuation of exposure (Markowitz et al. 1972; Preston et al. 1976).  However, in two other 
reports, improvement was observed after exposure ceased (Veltman et al. 1975; Wilson et al. 1967).  Joint 
pain was also reported by Lilis et al. (1975). 
Although Sokal et al. (1980) found no alterations in the bones of male rats exposed to 20,000 ppm for 
5 hours/day, 5 days/week for 10 months, Viola (1970) observed skeletal changes (i.e., osteochondroma) 
in the bones of rats exposed to 30,000 ppm for 4 hours/day, 5 days/week for 12 months.  The statistical 
significance of these effects was not reported and only one exposure level was tested. 
Hepatic Effects.    Throughout the early years of the use of vinyl chloride, only a minimal degree of 
functional hepatic abnormalities were detected in workers.  However, when it became apparent in the 
early 1970s that angiosarcoma of the liver was associated with long-term vinyl chloride exposure, an 
intensive effort was initiated by a number of investigators to characterize the hepatic effects of vinyl 
chloride. These studies revealed characteristic hepatic lesions produced by vinyl chloride exposure (Berk 
et al. 1975; Falk et al. 1974; Gedigke et al. 1975; Ho et al. 1991; Jones and Smith 1982; Lilis et al. 1975; 
Liss et al. 1985; Marsteller et al. 1975; NIOSH 1977; Popper and Thomas 1975; Suciu et al. 1975; 
Tamburro et al. 1984; Vihko et al. 1984).  The incidence and severity of the effects correlated well with 
the duration of exposure (Gedigke et al. 1975; Lilis et al. 1975; NIOSH 1977).  
Routine, noninvasive techniques revealed hepatomegaly in a limited number of workers (14–37%) (Ho et 
al. 1991; Lilis et al. 1975; Marsteller et al. 1975; NIOSH 1977; Suciu et al. 1963, 1975).  However, when 
peritoneoscopy was performed or biopsies were obtained from exposed workers, Marsteller et al. (1975) 
found a much higher prevalence of hepatic abnormalities.  Only 37% of the workers studied by Marsteller 
et al. (1975) were diagnosed with hepatomegaly, but peritoneoscopy revealed a 50% incidence of granular 
changes in the liver surface and an 86% incidence of capsular fibrosis with increased numbers of capsular 
vessels. Histopathological examination of the biopsied tissue from these workers revealed an 80% 
incidence of collagenization of the sinusoidal walls, a 90% incidence of proliferation of cells lining the 
sinusoids, a 30% incidence of septal fibrosis, and degeneration of hepatocytes (incidence not specified).  
A number of other investigators observed similar changes in liver tissues obtained from workers exposed 
to vinyl chloride (Falk et al. 1974; Gedigke et al. 1975; Popper and Thomas 1975; Tamburro et al. 1984).  
Based on these observations, a profile of vinyl chloride-induced liver damage was compiled and includes 
the following features:  hypertrophy and hyperplasia of hepatocytes, activation and hyperplasia of 
sinusoidal lining cells, fibrosis of the portal tracts and the septa and intralobular perisinusoidal regions, 
sinusoidal dilation, and focal areas of hepatocellular degeneration.  This pattern of changes was observed 
54 VINYL CHLORIDE 
3. HEALTH EFFECTS 
to be highly unusual and was similar to the hepatic changes produced by arsenic (Gedigke et al. 1975).  In 
addition, the degenerative changes in hepatocytes appeared to be less severe when biopsy material was 
obtained from workers who had not been exposed to vinyl chloride recently.  However, sinusoidal 
changes were not influenced by the length of time since the last exposure (Gedigke et al. 1975). 
One possible reason that the hepatotoxic effects of vinyl chloride went undetected for many years was the 
lack of sensitivity of standard biochemical liver function tests to detect the liver injury produced by vinyl 
chloride (Berk et al. 1975; Marsteller et al. 1975; Tamburro et al. 1984; Vihko et al. 1984).  For example, 
the values obtained in several standard biochemical liver function tests (activities of serum alkaline 
phosphatase, aspartate aminotransferase, alanine aminotransferase, gamma-glutamyltransferase) from 
workers with biopsy evidence of vinyl chloride-associated liver damage were not significantly higher than 
those from unexposed controls (Liss et al. 1985).  Gamma-glutamyltransferase levels were significantly 
higher in workers exposed to vinyl chloride at TWA exposure concentrations of >10 ppm compared to 
workers exposed to lower exposure concentrations (Du et al. 1995).  Workers exposed to lower levels of 
vinyl chloride had gamma-glutamyltransferase levels that were within the normal range (Hensyl 1990).  
Abnormal liver function (i.e., increased alkaline phosphatase, alanine aminotransferase, or 
gamma-glutamyltransferase) was demonstrated in workers exposed to high concentrations of vinyl 
chloride (1–20 ppm) (Ho et al. 1991; Lilis et al.1975) and workers who experienced a combined exposure 
to vinyl chloride and ethylene dichloride (Cheng et al. 1999).  In the mixed exposure situation, altered 
liver function may be related to the effect of each component or the interactive effect of the mixture.  
Serum bile acids (Berk et al. 1975; Liss et al. 1985) and/or indocyanine green clearance (Liss et al. 1985; 
Tamburro et al. 1984) correlated with liver injury.  Furthermore, investigators have shown that levels of 
chenodeoxycholic acid (a serum bile acid) in asymptomatic vinyl chloride workers were elevated when 
compared to the 95% interval of values from a healthy reference population (Vihko et al. 1984).  The 
serum hyaluronic acid concentration was demonstrated to be elevated in workers with angiosarcoma of 
the liver, while other liver function tests were normal (McClain et al. 2002).   
A recent IARC update of a multi-center cohort study demonstrated an increase in mortality from liver 
cirrhosis in workers exposed to moderate to high concentrations of vinyl chloride (Ward et al. 2001). 
Morbidity associated with liver cirrhosis was also reported to be elevated among vinyl chloride workers 
(Du and Wang 1998). Alcohol intake was not evaluated as a critical confounding factor in these studies.  
Mastrangelo et al (2004) evaluated the possible interaction between alcohol consumption, hepatitis 
infection, and liver cirrhosis in a large cohort of vinyl chloride workers.  Vinyl chloride was suggested to 
be an independent risk factor for liver cirrhosis with a synergistic interaction described for alcohol 
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consumption and an additive interaction observed for hepatitis infection.  Liver ultrasonography 
illustrated an increase in the incidence of periportal fibrosis in vinyl chloride workers (Maroni et al. 
2003). Portal fibrosis and portal hypertension were considered to contribute to mortality in several cases 
(Lee et al. 1996; Lelbach 1996).   
Brief exposure of animals to extremely high concentrations of vinyl chloride has been shown to produce 
hepatic damage.  For example, acute exposure (30 minutes) of guinea pigs and mice to 300,000 ppm of 
vinyl chloride produced liver congestion or severe fatty degeneration while 200,000 ppm caused fatty 
infiltration in rats (Mastromatteo et al. 1960).  Exposure to 100,000 ppm for 6 hours produced 
centrilobular vacuolization and increased alanine serum α-ketoglutarate transaminase activity in rats 
(Jaeger et al. 1974).  However, exposure of rats to 50,000 ppm for 6 hours produced no observable effects 
on the liver (Reynolds et al. 1975a, 1975b).  In contrast, a single-concentration study in which pregnant 
rats were continuously exposed to 1,500 ppm for 7–9 days during either the first or second trimester of 
pregnancy resulted in an increase in the liver-to-body-weight ratio (Ungvary et al. 1978).  Interestingly, a 
single 1-hour exposure of mice to 500, 5,000, or 50,000 ppm of vinyl chloride, followed by an 18-month 
observation period, resulted in an increased incidence of hepatocellular hypertrophy in these animals at 
terminal sacrifice (Hehir et al. 1981).  The hypertrophy was not dose dependent; thus, the significance of 
this effect is uncertain. 
In studies with longer durations of exposure, lower concentrations of vinyl chloride have produced 
hepatic toxicity. Symptoms of hepatotoxicity that have been observed in rats have included 
hepatocellular degeneration (Sokal et al. 1980; Torkelson et al. 1961; Wisniewska-Knypl et al. 1980), 
swelling of hepatocytes with compression of sinusoids (Lester et al. 1963), dilation of the rough 
endoplasmic reticulum (Du et al. 1979), proliferation (Sokal et al. 1980) or hypertrophy (Thornton et al. 
2002; Wisniewska-Knypl et al. 1980) of smooth endoplasmic reticulum, changes in metabolic enzyme 
activities (Du et al. 1979; Wisniewska-Knypl et al. 1980), proliferation of reticulocytes (Sokal et al. 
1980), and an increased liver-to-body-weight ratio (Bi et al. 1985; Lester et al. 1963; Sokal et al. 1980; 
Thornton et al. 2002; Torkelson et al. 1961).  For example, exposure of rats to 500 ppm for 7 hours/day, 
5 days/week for 4.5 months resulted in an increase in liver-to-body-weight ratio and granular 
degeneration (Torkelson et al. 1961). An increased liver-to-body-weight ratio was also found in rats 
exposed to 100 ppm vinyl chloride for 7 hours/day, 5 days/week for 6 months (Torkelson et al. 1961).  
Relative liver weight was decreased in mice exposed to 1,000 ppm vinyl chloride for 6 hours/day, 
5 days/week for 8 weeks (Sharma and Gehring 1979).  The liver-to-body-weight ratio was shown to be 
increased in male rats exposed to 3,000 ppm, but not 100 ppm, vinyl chloride for 6 hours/day, 
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5 days/week for 12 months (Bi et al. 1985).  Significantly increased liver-to-body-weight ratio was also 
observed in rats exposed to concentrations of vinyl chloride as low as 10 ppm for 6 hours/day, 
6 days/week for 6 months (Bi et al. 1985).  Exposure of rats to 500 ppm for 5 hours/day, 5 days/week for 
10 months produced swelling of hepatocytes and proliferation of reticuloendothelial cells, increased liver 
weight, and cellular degeneration; at 50 ppm, small lipid droplets and proliferation of smooth 
endoplasmic reticulum were noted (Sokal et al. 1980). Histopathological examination of rats exposed to 
either 50,000 ppm vinyl chloride for 8 hours/day for 19 consecutive days or 20,000 ppm vinyl chloride 
for 8 hours/day, 5 days/week, for 92 days showed hepatocellular hypertrophy, vacuolization, and 
sinusoidal compression (Lester et al. 1963).  Mice exposed to 2,500 ppm vinyl chloride 5 hours/day, 
5 days/week for up to 6 months showed histopathological changes in the liver that included hyperplasia of 
hepatocytes and activated sinusoidal cells (Schaffner 1978).  Centrilobular necrosis and degeneration 
were noted in rabbits exposed to 200 ppm vinyl chloride 7 hours/day, 5 days/week for 6 months but not at 
100 ppm vinyl chloride in this regimen (Torkelson et al. 1961).  Also, exposure of rats to 50 ppm for 
5 hours/day, 5 days/week for 10 months produced fatty degeneration and proliferation of the smooth 
endoplasmic reticulum (Wisniewska-Knypl et al. 1980).  Liver effects were observed in a 2-generation 
reproductive toxicity study where rats were exposed to 0, 10, 100, or 1,100 ppm vinyl chloride 
(6 hours/day for a 10-week premating period and a 3-week mating period) (Thornton et al. 2002).  
Absolute and relative mean liver weights were significantly increased at all exposure levels in F0 males 
and in 100- and 1,100-ppm F1 males.  Centrilobular hypertrophy, considered to be a minimal adverse 
effect, was noted in the livers of all 1,100-ppm male and female F0 and F1 rats, most 100-ppm male and 
female F0 and F1 rats, and in 2/30 and 6/30 of the 10-ppm F0 male and F1 female rats, respectively.  
Centrilobular hypertrophy was not noted in the 30 female rats of the control group.  Histopathological 
alterations occurring at 100 and 1,100 ppm included centrilobular hypertrophy and acidophilic, 
basophilic, and clear cell foci.  Based on this study, an intermediate-duration MRL of 0.03 ppm was 
derived from a benchmark dose of 5 ppm as described in the footnote in Table 3-1. 
The NOAELs for liver effects in a number of species following a 6-month exposure to vinyl chloride 
indicated that mice and rats were the most sensitive (NOAEL=50 ppm), rabbits were the next most 
sensitive (NOAEL=100 ppm), and dogs and guinea pigs were the least sensitive (NOAEL>200 ppm) 
(Torkelson et al. 1961). 
Popper et al. (1981) compared histopathological findings from sections of liver from mice and rats 
exposed by Maltoni and LeFemine (1975) with the liver biopsy material obtained from vinyl chloride 
workers. Hyperplasia and hypertrophy of hepatocytes and/or sinusoidal cells, with areas of sinusoidal 
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dilation, were observed in both humans and rodents. The major difference between the species was the 
greater degree of fibrosis, seen as reticulin deposition and collagen formation, in the livers of humans.  
Also, inflammatory cells were present in the livers of humans but not rodents. 
Renal Effects.    No studies were located regarding renal effects in humans after inhalation exposure to 
vinyl chloride. 
Acute exposure of mice and rats to 300,000 ppm of vinyl chloride for 30 minutes resulted in kidney 
congestion (Mastromatteo et al. 1960).  Also, the kidneys of one mouse out of five exposed to either 
100,000 or 200,000 ppm of vinyl chloride for 30 minutes showed degenerative changes (Mastromatteo et 
al. 1960).  Exposure of rats to 50,000 ppm for 8 hours/day for 19 consecutive days or 20,000 ppm for 
8 hours/day, 5 days/week for 92 days produced no adverse effects on the kidneys (Lester et al. 1963).  
However, exposures of male rats to 3,000 ppm for 6 hours/day, 6 days/week, for 3 months produced an 
increase in the kidneys-to-body-weight ratio (Bi et al. 1985).  After a 6-month observation period, there 
was also an increased kidneys-to-body-weight ratio noted in the male rats exposed to 100 ppm vinyl 
chloride for 6 hours/day, 6 days/week for 12 months; no effect was noted at 10 ppm (Bi et al. 1985). 
Relative kidney weights were increased in male rats exposed to 500 ppm vinyl chloride for 5 hours/day, 
5 days/week, for 10 months, although no histopathological changes in the kidney were noted (Sokal et al. 
1980).  No changes in kidney weights were reported when mice were exposed to 1,000 ppm vinyl 
chloride 6 hours/day, 5 days/week for 8 weeks (Sharma and Gehring 1979).  Urinalysis values were 
within normal limits in rats and rabbits exposed to 200 ppm vinyl chloride for up to 7 hours/day, 
5 days/week, for 6 months (Torkelson et al. 1961).  One year of exposure to 5,000 ppm vinyl chloride for 
7 hours/day, 5 days/week produced an increase in the kidneys-to-body-weight ratio (Feron et al. 1979a) 
and tubular nephrosis in rats (Feron and Kroes 1979).  However, the statistical significance of these 
findings was not reported in the study. 
Endocrine Effects.    A study of workers exposed to vinyl chloride in PVC manufacturing plants 
reported that most workers who presented with scleroderma were shown to have thyroid insufficiency 
(Suciu et al. 1963). 
No histopathological effects on the adrenals were reported in guinea pigs exposed to 400,000 ppm for 
30 minutes (Mastromatteo et al. 1960).  Rats exposed to 30,000 ppm vinyl chloride 4 hours/day, 
5 days/week for 12 months were found to have colloid goiter and markedly increased numbers of 
perifollicular cells (Viola 1970). 
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Dermal Effects.    Occupational exposure to vinyl chloride was observed to produce scleroderma-like 
skin changes on the hands of a small percentage of exposed workers (Freudiger et al. 1988; Lilis et al. 
1975; Marsteller et al. 1975; Suciu et al. 1963, 1975; Veltman et al. 1975; Walker 1976).  The skin 
changes were characterized by a thickening of the skin (Lilis et al. 1975; Markowitz et al. 1972; Ostlere et 
al. 1992; Preston et al. 1976; Veltman et al. 1975; Walker 1976), decreased elasticity (Lilis et al. 1975), 
and edema (Lilis et al. 1975; Suciu et al. 1975) and were almost exclusively observed in exposed 
individuals who also suffered from Raynaud's phenomenon.  Skin biopsies revealed increased collagen 
bundles in the subepidermal layer of the skin (Harris and Adams 1967; Markowitz et al. 1972; Ostlere et 
al. 1992; Veltman et al. 1975).  Biochemical analyses by Jayson et al. (1976) demonstrated that a high 
rate of collagen synthesis was taking place in the affected skin.  Most often the skin changes were 
confined to the hands and wrists, but Jayson et al. (1976) reported scleroderma-like skin changes on the 
hands, arms, chest, and face of one afflicted worker. 
Skin changes were observed in rats exposed to 30,000 ppm for 12 months (Viola 1970).  The skin of the 
paws of the exposed rats showed areas of hyperkeratosis, thickening of the epidermis, edema, collagen 
dissociation, and fragmentation of the elastic reticulum.  Interpretation of these results is limited by the 
absence of a statistical analysis and insufficient information on the treatment of control animals.  Lester et 
al. (1963) reported that male rats exposed to 50,000 ppm vinyl chloride 8 hours/day for 19 days had thin 
coats and scaly tails, while females exposed to the same concentration showed no effects.  For further 
information regarding scleroderma-like responses to vinyl chloride exposure, see Immunological and 
Lymphoreticular Effects (Section 3.2.1.3). 
Ocular Effects.    Ocular effects that have been reported after inhalation exposure are believed to have 
resulted from direct contact of the vinyl chloride gas with the eyes and are discussed under Dermal 
Exposure (Section 3.2.3.2).  No studies were located regarding ocular effects in humans that were related 
solely to the inhalation of vinyl chloride.  No histopathological changes were noted in the eyes of guinea 
pigs exposed to 400,000 ppm vinyl chloride for 30 minutes (Mastromatteo et al. 1960). 
Body Weight Effects.    Several studies have reported that workers intoxicated by vinyl chloride 
experienced anorexia (Suciu et al. 1963, 1975). 
No effects on body weight were noted in ICR mice exposed to either 10,000 ppm vinyl chloride 
4 hours/day for 5 days or to 5,000 ppm vinyl chloride 4 hours/day for 6 days (Kudo et al. 1990).  No 
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consistent or dose-related differences in body weight were noted between control rats and rats exposed to 
up to 50,000 ppm for 1 hour or rats exposed to 500 ppm 5 days/week, for 2 weeks (Hehir et al. 1981).  
However, statistical analysis was not performed.  No changes in body weight gain were noted in rats or 
rabbits exposed to 200 ppm vinyl chloride 7 hours/day, 5 days/week for 6 months (Torkelson et al. 1961) 
or in mice exposed to 1,000 ppm vinyl chloride 6 hours/day, 5 days/week for 8 weeks (Sharma and 
Gehring 1979).  Significant decreases were found in the body weight of rats exposed to 100 ppm vinyl 
chloride 6 hours/day, 6 days/week for 12 months; these changes were not observed at 10 ppm (Bi et al. 
1985).  Significant decreases were also noted in mean body weights of rats exposed to 5,000 ppm vinyl 
chloride 7 hours/day, 5 days/week for 4–52 weeks but these data were not quantified (Feron et al. 1979a).  
This study was limited since only one concentration was tested.  Body weight was decreased 10% in male 
rats exposed to 50 ppm vinyl chloride 5 hours/day, 5 days/week for 10 months (Sokal et al. 1980).  
Maternal body weight gain was significantly decreased in mice exposed to 500 ppm for 7 hours/day 
during gestation days (Gd) 6–15 (John et al. 1977). 
3.2.1.3 Immunological and Lymphoreticular Effects  
A number of studies have examined the immunologic profiles of workers occupationally exposed to vinyl 
chloride. Male workers exposed to vinyl chloride for an average of 8 years, with concentrations ranging 
from 1 to 300 ppm during sampling periods, were found to have significantly increased percentages of 
lymphocytes compared to controls (Fucic et al. 1995, 1997, 1998).  Additionally, 75 out of these 
100 workers showed disturbances of mitotic activity in these cells.  A statistically significant increase in 
circulating immune complexes in workers exposed to vinyl chloride was observed when compared to 
levels in unexposed workers (Bogdanikowa and Zawilska 1984).  The increase in circulating immune 
complexes was greatest in women and in those with duties involving exposure to relatively higher levels 
of vinyl chloride.  Compared to controls, immunoglobulin G (IgG) levels were significantly increased in 
women exposed to the high levels of vinyl chloride in the same study. 
Studies of workers who have developed "vinyl chloride disease," a syndrome consisting of Raynaud's 
phenomenon, acroosteolysis, joint and muscle pain, enhanced collagen deposition, stiffness of the hands, 
and scleroderma-like skin changes, indicate that this disease may have an immunologic basis.  Sera 
obtained from patients with varying degrees of severity of symptoms of vinyl chloride disease 
demonstrate a close correlation between the disease severity and the extent of the immunologic 
abnormality (Grainger et al. 1980; Langauer-Lewowicka et al. 1976; Ward 1976), although these 
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symptoms have been reported without immunological findings (Black et al. 1986; Ostlere et al. 1992).  
The most frequent immunologic finding in workers with vinyl chloride disease is an increase in 
circulating immune complexes or cryoglobulinemia.  In workers with the most severe clinical signs, there 
also are an increased incidence of B-cell proliferation, hyperimmunoglobulinemia (Ward 1976), 
cryoglobulinemia (Grainger et al. 1980), and complement activation (Grainger et al. 1980; Ward 1976).  
Evidence of a structurally altered IgG has been obtained, and it has been proposed that vinyl chloride (or 
a metabolite) binds to IgG (Grainger et al. 1980).   
Based on the similarity of vinyl chloride disease and systemic sclerosis, which may be a genetically 
linked autoimmune disease, Black et al. (1983, 1986) examined the human lymphocyte antigen (HLA) 
phenotypes of patients with vinyl chloride disease. Many autoimmune diseases show statistically 
significant associations with certain HLA alleles. These authors found that when compared to unexposed 
controls or asymptomatic controls, workers with vinyl chloride disease had a significantly greater 
incidence of possessing the HLA-DR5 allele.  Furthermore, among those with the disease, the severity of 
the symptoms was significantly related to the possession of the HLA-DR3 and B8 alleles.  These authors 
concluded that susceptibility was increased in the presence of HLA-DR5 or a gene in linkage 
disequilibrium with it, and progression was favored by HLA-DR3 and B8 phenotypes.  Immune system 
dysfunction has also been linked to a case of polymyositis (i.e., muscle fiber necrosis and atrophy) in an 
exposed worker, with involvement of antibodies to histidyl-t-RNA synthetase (Jo-1) (Serratrice et al. 
2001). 
Splenomegaly was reported in a number of studies (Ho et al. 1991; Marsteller et al. 1975; Popper and 
Thomas 1975; Suciu et al. 1963; Veltman et al. 1975).  No histopathological changes were noted in the 
spleen or lymph nodes of guinea pigs exposed to 400,000 ppm vinyl chloride for 30 minutes 
(Mastromatteo et al. 1960).  An increase in the relative spleen weight was observed in rats exposed to 
50 ppm for 5 hours/day, 5 days/week for 10 months (Sokal et al. 1980).  Although no dose response was 
evident, increased relative spleen weight was also reported by Bi et al. (1985) when rats were exposed to 
either 10 ppm for 6 hours/day, 6 days/week for 6 months or 3,000 ppm for 6 hours/day, 6 days/week for 
3 months.  This effect was not observed at 100 ppm in the 3-month study (Bi et al. 1985). 
The immunologic effects of vinyl chloride have been examined in mice (Sharma and Gehring 1979). 
Lymphocytes isolated from the spleens of mice exposed to concentrations as low as 10 ppm vinyl 
chloride 6 hours/day, 5 days/week for 4 weeks had increased spontaneous and lectin-stimulated 
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transformation.  This increase was not observed when lymphocytes from unexposed mice were cultured 
in the presence of vinyl chloride. 
The highest NOAEL value and all reliable LOAEL values for immunological effects in guinea pigs, mice, 
and rats exposed in acute- and intermediate-duration studies are recorded in Table 3-1 and plotted in 
Figure 3-1.  For further information on Raynaud's phenomenon and scleroderma-like responses to vinyl 
chloride, see Cardiovascular and Dermal Effects (Section 3.2.1.2). 
3.2.1.4 Neurological Effects 
Vinyl chloride was once considered for use as an inhalation anesthetic (ACGIH 2003).  Investigators 
studying the effects of vinyl chloride exposure frequently report central nervous system symptoms that 
are consistent with the anesthetic properties of vinyl chloride.  The most commonly reported central 
nervous system effects are ataxia or dizziness (Ho et al. 1991; Langauer-Lewowicka et al. 1983; Lilis et 
al. 1975; Marsteller et al. 1975; Spirtas et al. 1975; Suciu et al. 1963, 1975; Veltman et al. 1975), 
drowsiness or fatigue (Langauer-Lewowicka et al. 1983; Spirtas et al. 1975; Suciu et al. 1963, 1975; 
Walker 1976), loss of consciousness (NIOSH 1977), and/or headache (Langauer-Lewowicka et al. 1983; 
Lilis et al. 1975; Marsteller et al. 1975; NIOSH 1977; Spirtas et al. 1975; Suciu et al. 1963, 1975; 
Veltman et al. 1975).  Other central nervous system effects that have been reported by vinyl chloride 
workers include euphoria and irritability (Suciu et al. 1963, 1975), visual and/or hearing disturbances 
(Marsteller et al. 1975), nausea (Marsteller et al. 1975; Spirtas et al. 1975), memory loss (Langauer-
Lewowicka et al. 1983; Suciu et al. 1963, 1975), and nervousness and sleep disturbances (Langauer-
Lewowicka et al. 1983; Suciu et al. 1963).  Central nervous system tests revealed pyramidal signs and 
cerebellar disturbances in some exposed subjects (Langauer-Lewowicka et al. 1983); however, reliable 
estimates of exposure levels producing these effects were not available. 
Exposure of volunteers to known levels of vinyl chloride has provided some indication of the levels of 
vinyl chloride associated with the effects noted above.  Volunteers exposed to 25,000 ppm vinyl chloride 
for 3 minutes, in a single-exposure study, reported experiencing dizziness, disorientation, and burning 
sensations in the feet during exposure (Patty et al. 1930).  Recovery from these effects was rapid upon 
termination of exposure, but the subjects developed headaches.  Exposure of volunteers to concentrations 
of vinyl chloride ranging from 4,000 to 20,000 ppm for 5 minutes twice a day in periods separated by 
6 hours on 3 consecutive days was studied by Lester et al. (1963).  No effects were noted at 4,000 ppm.  
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However, at 8,000 ppm one of six subjects reported feeling dizzy.  The incidence of dizziness increased at 
higher concentrations. Nausea was experienced at higher concentrations, and recovery from all effects 
was rapid upon termination of exposure.  Headaches developed following exposure to 20,000 ppm. 
Indications of an exposure-related peripheral neuropathy have been observed in a number of the 
occupational studies.  A peripheral neuropathy, most severe in hands and feet, was diagnosed in 70% of 
the vinyl chloride workers examined in a study by Perticoni et al. (1986).  The peripheral neuropathy was 
manifested as denervation-related fasciculations and fibrillations and increased duration and amplitude of 
motor unit potentials (indicating collateral sprouting).  Similar effects were observed by Magnavita et al. 
(1986) in a case study of a vinyl chloride worker.  Other peripheral nervous system symptoms have been 
reported by a number of investigators studying the effects of occupational exposure to vinyl chloride.  
The symptom most frequently reported was tingling (paresthesia) in the extremities (Lilis et al. 1975; 
Sakabe 1975; Spirtas et al. 1975; Suciu et al. 1963, 1975; Veltman et al. 1975; Walker 1976).  Additional 
peripheral nervous system symptoms included numbness in the fingers (Lilis et al. 1975; Sakabe 1975), 
weakness (Langauer-Lewowicka et al. 1983; Suciu et al. 1963, 1975), depressed reflexes (NIOSH 1977), 
warmth in the extremities (Suciu et al. 1963, 1975), and pain in the fingers (Sakabe 1975).  It is unclear 
whether some of these symptoms are associated with tissue anoxia due to vascular insufficiency, or 
whether they represent the direct toxic effects of vinyl chloride on peripheral nerves. 
Acute exposure of a number of species to high levels of vinyl chloride has provided additional 
information on the characteristics of the central nervous system effects that are produced.  Exposure of 
guinea pigs to 10,000 ppm for 8 hours (Patty et al. 1930) was observed to be without effects.  Exposure to 
25,000 ppm resulted in ataxia, which developed into unconsciousness during the 8-hour exposure.  As the 
concentration was increased, the development of unconsciousness was more rapid.  At 100,000 ppm, 
Mastromatteo et al. (1960) observed the development of unconsciousness within 30 minutes.  Mice 
experienced similar signs at approximately equivalent exposure levels.  At 5,000 ppm, vinyl chloride was 
without effect during a 1-hour exposure.  Exposure to 50,000 ppm produced ataxia and twitching (Hehir 
et al. 1981), and at 100,000 ppm for 30 minutes, unconsciousness was produced, proceeded by increased 
motor activity, incoordination, twitching, and tremors (Mastromatteo et al. 1960).  Similar effects in rats 
were observed by Lester et al. (1963), Jaeger et al. (1974), and Mastromatteo et al. (1960).  In contrast, in 
two reports using rats, exposure to 50,000 ppm for either 1 or 6 hours was without effect (Hehir et al. 
1981; Jaeger et al. 1974).  No effects were noted in rats exposed to 500 ppm vinyl chloride for 2 weeks 
(1 hour/day, 5 days/week) or in rats exposed to 50 ppm for 20 weeks (1 hour/day, 5 days/week) (Hehir et 
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al. 1981).  In addition, tolerance developed to the intoxicating effects of exposure to 50,000 ppm vinyl 
chloride after five or six 8-hour exposures (Lester et al. 1963). 
Chronic exposure of rats to high levels of vinyl chloride has produced damage to nervous tissue.  Rats 
exposed to 30,000 ppm for 4 hours/day, 5 days/week for 12 months in a single-concentration study were 
soporific during exposures (Viola 1970; Viola et al. 1971).  Following 10 months of exposure, the rats 
had decreased responses to external stimuli and disturbed equilibrium.  Histopathological examination 
revealed diffuse degeneration of gray and white matter.  Cerebellar degeneration in the Purkinje cell layer 
was pronounced.  Also, peripheral nerve endings were surrounded and infiltrated with fibrous tissue 
(Viola 1970; Viola et al. 1971).  Nonneoplastic lesions in the brain were not noted in rats exposed to 
5,000 ppm for 7 hours/day, 5 days/week for 12 months in a single-concentration study by Feron and 
Kroes (1979). 
The highest NOAEL values and all reliable LOAEL values for neurological effects in each species from 
acute- or intermediate-duration studies are recorded in Table 3-1 and plotted in Figure 3-1. 
3.2.1.5 Reproductive Effects  
A number of case reports of workers occupationally exposed to vinyl chloride suggest that sexual 
performance may be affected by vinyl chloride.  However, these studies are limited by the lack of 
quantification of exposure levels and possible concomitant exposures to other chemicals.  Sexual 
impotence was reported by 24% of the workers examined by Suciu et al. (1975).  Approximately 20% of 
the workers examined by Veltman et al. (1975) complained of potency troubles.  A loss of libido in 35% 
and impotence and decreased androgen secretion in 8% of workers exposed at least once to very high 
levels of vinyl chloride were also reported by Walker (1976). 
In retrospective and prospective studies by Bao et al. (1988), increased incidence and severity of elevated 
blood pressure and edema during pregnancy (preeclampsia) were found in female workers exposed to 
vinyl chloride when compared to unexposed workers.  Company records indicated that exposure levels 
ranged from 3.9 to 89.3 ppm during the retrospective study and from 0.2 to 130.7 ppm during the 
prospective study.  More detailed information regarding the exposure levels was not presented. 
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A 2-generation reproductive toxicity study was conducted in rats exposed to vinyl chloride via inhalation 
(Thornton et al. 2002).  Male and female Sprague-Dawley rats were exposed to 0, 10, 100, or 1,100 ppm 
vinyl chloride 6 hours/day for a 10-week premating period and a 3-week mating period.  No adverse 
effects were noted in reproductive capability over the two generations at any dose.  No effects were seen 
in body weight, feed consumption, ability to reproduce, gestation index or length, or pre- and 
postweaning developmental landmarks.  Sperm counts, motility, and morphology were also unaffected by 
vinyl chloride exposure.  Changes in liver weights and/or histopathological alterations were seen in F0 and 
F1 generation male and female rats.  For further information regarding the liver toxicity of vinyl chloride, 
see Section 3.2.1.2. 
Two dominant lethal studies examined the reproductive performance of exposed male rats.  A brief 
exposure (5 days, 6 hours/day) of mice to concentrations of vinyl chloride as high as 30,000 ppm had no 
effect on male fertility or pre- or postimplantation loss (Anderson et al. 1976).  In contrast, exposure of 
male rats to concentrations as low as 250 ppm for 6 hours/day, 5 days/week for 11 weeks produced a 
decrease in the ratio of pregnant to mated females, indicating a decrease in male fertility; this effect was 
not observed at 50 ppm (Short et al. 1977).  These results are supported by two studies using rats in which 
adverse effects of vinyl chloride on the testes were observed (Bi et al. 1985; Sokal et al. 1980).  Exposure 
of rats to 100 ppm for 6 hours/day, 6 days/week for 12 months produced a significant increase in the 
incidence of damage to the seminiferous tubules and depletion of spermatocytes (Bi et al. 1985).  At the 
6-month interim sacrifice, a significant decrease in testicular weight was also observed at 100 ppm.  No 
effect on male reproductive organs was observed in this study at 10 ppm.  Several methodological 
limitations have been identified for this study. Temperature and humidity conditions in the inhalation 
chambers were not maintained within the normal range.  Inhalation chamber volume and air flow were 
also not held constant across dose groups.  A significant increase in damage to the spermatogenic 
epithelium and disorders of spermatogenesis were found with exposure to 500 ppm vinyl chloride for 
5 hours/day, 5 days/week for 10 months, but was not observed after exposure to 50 ppm vinyl chloride 
(Sokal et al. 1980).  Temperature and relative humidity values were not reported for this study.  No 
significant change in testicular weight was found in rats exposed to 500 ppm for 7 hours/day, 5 days/week 
for 4.5 months or in dogs, rabbits, or guinea pigs exposed to 200 ppm for 7 hours/day, 5 days/week for 
6 months (Torkelson et al. 1961).  However, the quality of this study is limited because of the small 
number of animals tested.  Exposures involved up to 10 rats or guinea pigs of each gender, three rabbits 
of each sex, and one dog of each sex.  No histopathological data on the testes of these animals were 
presented. 
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The highest NOAEL values and all reliable LOAEL values for reproductive effects in each species and 
duration category are recorded in Table 3-1 and plotted in Figure 3-1. 
3.2.1.6 Developmental Effects 
Although evidence has been presented indicating that members of communities with nearby vinyl 
chloride polymerization facilities have significantly greater incidences of some forms of developmental 
toxicity, these studies failed to demonstrate a statistically significant correlation between the 
developmental toxicity and either parental occupation or proximity to the facility (Edmonds et al. 1978; 
Infante 1976; Rosenman et al. 1989; Theriault et al. 1983). 
The pregnancy outcome of wives of workers employed at a vinyl chloride polymerization facility was 
compared to the pregnancy outcome of wives of a control group made up of unexposed rubber workers 
and PVC fabricators believed to be exposed to "very low" levels of vinyl chloride (Infante et al. 1976a, 
1976b). Pregnancy outcomes were determined based on the responses given by fathers on a 
questionnaire. Infante et al. (1976a, 1976b) and NIOSH (1977) reported a significant excess of fetal loss 
in the group whose husbands had been exposed to vinyl chloride.  The greatest difference occurred in 
wives of men under 30 years of age, where fetal loss was 5.3% for controls and 20.0% for exposed 
workers. However, this study has been severely criticized based on the conduct of the study and method 
of statistical analysis used (Hatch et al. 1981; Stallones 1987).  Furthermore, Hatch et al. (1981) and 
Stallones (1987) concluded that the study failed to demonstrate an association of parental exposure to 
vinyl chloride with increased fetal loss. 
Additional work by Infante (1976) and Infante et al. (1976b) examined the occurrence of congenital 
malformations among populations exposed to emissions from PVC polymerization facilities.  A 
statistically significant increase in birth defects was observed in three cities in which polymerization 
facilities were located when compared to statewide and countywide averages.  The greatest increases 
were noted in malformations of the central nervous system, upper alimentary tract, and genital organs and 
in the incidence of club foot. However, this study has also been criticized based on the conduct and 
analyses used (Hatch et al. 1981; Stallones 1987).  These authors concluded that the study failed to 
demonstrate an association between exposure to emissions and the prevalence of birth defects.  
Furthermore, another study that examined the incidence of malformations in one of the cities studied by 
Infante (1976) concluded that, although the city had statistically increased incidences of congenital 
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malformations, no correlation existed with parental proximity to the polymerization plant or with parental 
employment at the plant (Edmonds et al. 1975).  In fact, more parents of control infants worked at the 
plant or lived closer to the plant than parents of infants with central nervous system malformations. 
Additional studies have also examined the prevalence of congenital malformations in populations exposed 
to emissions from polymerization facilities (Edmonds et al. 1978; Rosenman et al. 1989; Theriault et al. 
1983).  The incidence of central nervous system defects in a West Virginia county with a polymerization 
plant was compared to incidences in other regions in the United States with no known exposure to vinyl 
chloride (Edmonds et al. 1978).  Although the rate of central nervous system defects in the West Virginia 
county exceeded that in control areas, no correlation was noted between the increased central nervous 
system defects and parental occupation or potential exposure based on proximity to the plant or prevailing 
wind patterns. 
A significantly greater prevalence of birth defects was found in residents of a town with a polymerization 
facility than in three matched towns without potential for exposure to vinyl chloride (Theriault et al. 
1983).  The most commonly reported defects included those of the musculoskeletal, alimentary, 
urogenital, and central nervous systems.  The incidences were observed to fluctuate with seasonal changes 
in emissions.  However, no correlations were found between the presence of defects and proximity of the 
residence to the plant or parental occupation.  Also, other industrial emissions could not be eliminated as 
potential sources of the increased incidence of congenital malformations observed and additional 
confounding factors such as nutritional status, smoking, and alcohol and other drug use were not 
eliminated. 
No significant increases in birth defects were observed in a community with two polymerization facilities, 
but odds ratios for central nervous system defects were found to correlate with the amount of emissions 
from the individual facilities and with the distance of the residences of affected parents from the facilities 
(Rosenman et al. 1989).  However, this study was limited by the small sample size. 
Pregnancy outcomes of mothers occupationally exposed to vinyl chloride for >1 year were compared to 
those of pregnant workers not exposed to vinyl chloride in retrospective and prospective studies (Bao et 
al. 1988).  Company records indicated that exposure levels ranged from 3.9 to 89.3 ppm during the 
retrospective study and from 0.2 to 130.7 ppm during the prospective study.  More detailed information 
regarding the exposure levels was not presented.  The study authors concluded that exposure to vinyl 
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chloride did not correlate with changes in sex ratio, birth weight or height, perinatal mortality, or the 
incidence of congenital abnormalities. 
A number of inhalation studies have examined the effects of vinyl chloride exposure on pregnancy 
outcome in animals.  Results of these studies indicate that vinyl chloride produces adverse developmental 
effects at concentrations that are also toxic to maternal animals.  John et al. (1977, 1981) exposed rats and 
rabbits to 0, 500, or 2,500 ppm and mice to 0, 50, or 500 ppm throughout the period of organogenesis.  
Separate control groups were used for each of the mice exposure concentrations.  Mice were most 
sensitive to the effects of vinyl chloride.  In mice exposed to 500 ppm, maternal toxicity was evidenced 
by decreased food consumption, decreased body weight gain, and increased mortality rate (John et al. 
1977, 1981).  Delayed ossification was noted in fetuses at 500 ppm.  The only significant fetal effect 
observed at 50 ppm was an increase in crown-rump length. The biological significance of this effect is 
unknown. Based on this NOAEL of 50 ppm, an acute-duration MRL of 0.5 ppm was calculated as 
described in the footnote in Table 3-1. In rats, 500 ppm produced decreased maternal weight gain and 
fetal weight, increased crown-rump length, and vertebral lumbar spurs.  Increasing the exposure level to 
2,500 ppm was not associated with a dose-dependent increase in these effects.  The only effects observed 
at 2,500 ppm were decreased maternal food consumption and, in fetuses, an increased incidence of dilated 
ureters. In rabbits exposed to 500 ppm, maternal animals had decreased food consumption, and fetal 
animals had delayed ossification.  These effects were not observed in rabbits at 2,500 ppm.  However, the 
number of animals that were tested at 2,500 ppm was much lower than at 500 ppm (5 versus 20); thus, no 
conclusions may be drawn as to the dose response of these effects. 
An embryo-fetal developmental toxicity study was conducted in rats exposed to vinyl chloride via 
inhalation (Thornton et al. 2002).  Female Sprague-Dawley rats were exposed to 0, 10, 100, or 1,100 ppm 
vinyl chloride 6 hours/day on Gd 6–19. No adverse effects were noted in embryo-fetal developmental 
parameters including uterine implantation, fetal gender distribution, fetal body weight, and fetal 
malformations and variations. Vinyl chloride produced a decrease in maternal body weight gain at all 
exposure levels; however, no changes were observed in feed consumption, clinical signs, or postmortem 
gross findings.  Maternal liver and kidney weights were increased relative to total body weight.   
Exposure of rats to either 0 or 1,500 ppm of vinyl chloride during the first, second, or third trimester of 
pregnancy was examined (Ungvary et al. 1978).  In maternal animals, an increased liver-to-body weight 
ratio was observed in those exposed during the first and second trimesters, but no histopathologic 
alterations were found.  A significant increase in resorptions was observed in animals exposed during the 
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first trimester of pregnancy.  Two central nervous system malformations (microphthalmia and 
anophthalmia) were observed in exposed fetuses but not in controls, but the incidence of these 
malformations did not reach statistical significance.  This study is limited in that only a single 
concentration of vinyl chloride was tested, precluding conclusions as to the dose-response relationship of 
the effects observed. 
The effects of exposure of rats to vinyl chloride throughout gestation were examined by Mirkova et al. 
(1978) and Sal'nikova and Kotsovskaya (1980).  An unspecified number of pregnant rats were exposed to 
0, 1.9, or 13.9 ppm for 4 hours/day for the 21 days of gestation.  Fetuses were examined for abnormalities 
just prior to the end of gestation, and offspring were examined at 6 months postparturition (Sal'nikova and 
Kotsovskaya 1980).  At 13.9 ppm, a decrease in maternal erythrocyte count was observed.  At 1.9 and 
13.9 ppm, fetuses had an increased incidence of hemorrhages, and at 13.9 ppm, increased edema.  
However, the affected organs were not specified.  Rats examined at 6 months, following in utero 
exposure to 1.9 ppm, were found to have decreased hemoglobin and leukocytes and decreased organ 
weights (males:  liver, kidneys, spleen; females:  lung, liver).  In addition to these effects, exposure to 
13.9 ppm in utero resulted in an increased hexanol sleep time and a decreased ability of the rats to orient 
themselves.   
Continuous exposure of an unspecified number of rats throughout gestation to 2.4 ppm of vinyl chloride 
resulted in decreased fetal weight and increased early postimplantation loss, hematomas, and 
hydrocephaly with intracerebral hematoma.  Weanling rats had hepatotoxic effects including decreased 
bile enzyme activity, decreased bile secretion, and decreased cholic acid content,.  No histological data on 
the livers of pups, or information regarding maternal health, or statistical analyses of the data were 
presented (Mirkova et al. 1978). Also, both this study and the report by Sal'nikova and Kotsovskaya 
(1980) failed to provide information on the number of animals in each test group. 
The developmental toxicity of vinyl chloride was examined using a whole embryo culture system (Zhao 
et al. 1996). Vinyl chloride induced embryo growth retardation, but was not shown to be teratogenic in 
the rat in vitro whole embryo culture system. 
The highest NOAEL value and all reliable LOAEL values for developmental effects in mice, rats, and/or 
rabbits in acute-duration studies are recorded in Table 3-1 and plotted in Figure 3-1.   
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3.2.1.7 Cancer 
A recent review pooled the analyses of worker cohorts from 56 vinyl chloride plants in North America 
and Europe (Bosetti et al. 2003).  This analysis includes over 22,000 workers and represents the most 
comprehensive data on occupational risks of vinyl chloride exposure.  An elevated risk of liver cancer 
mortality was observed.  While differences between the two cohorts were observed for excess soft tissue 
sarcoma and brain cancer, no significant excess for these effects were seen in the pooled data.  Deaths 
from lung and laryngeal cancer were lower than expected, and no excess cancer risk was observed for 
lymphoid and hematopoietic system cancers.  The most compelling evidence for the carcinogenic 
potential of vinyl chloride in humans comes from the cluster of reports of greater than expected 
incidences of angiosarcoma of the liver in workers occupationally exposed to vinyl chloride (Byren et al. 
1976; Creech and Johnson 1974; Forman et al. 1985; Fox and Collier 1977; Infante et al. 1976b; Jones et 
al. 1988; Laplanche et al. 1992; Lee et al. 1996; Monson et al. 1975; Pirastu et al. 1990; Rinsky et al. 
1988; Simonato et al. 1991; Teta et al. 1990; Theriault and Allard 1981; Waxweiler et al. 1976; Weber et 
al. 1981; Wong et al. 1991; Wu et al. 1989).  Angiosarcoma of the liver is considered to be a very rare 
type of cancer (25–30 cases/year in the United States) (Heath et al. 1975).  However, approximately 
30 years after the introduction of vinyl chloride for use in the industrial production of PVC, it became 
apparent that workers exposed to high levels of vinyl chloride had an unusually high incidence of this 
type of tumor.  Investigators identified an increased likelihood of developing hepatic angiosarcoma 
among those exposed to the highest levels of vinyl chloride and those exposed to vinyl chloride for the 
longest duration (Fortwengler et al. 1999; Fox and Collier 1977; Infante et al. 1976b; Jones et al. 1988; 
Rinsky et al. 1988; Weber et al. 1981; Wong et al. 1991; Wu et al. 1989).  Angiosarcoma of the liver was 
not found in residents living in the vicinity of vinyl chloride sites, unless they were also exposed to high 
concentrations of vinyl chloride in the workplace (Elliott and Kleinschmidt 1997).  Based on this 
information, vinyl chloride is considered to be a carcinogen in humans (EPA 1994c; IARC 1987). 
Histopathological examination of liver tissue from humans with hepatic angiosarcoma has led to the 
hypothesis that angiosarcoma develops as a result of hyperplastic changes in sinusoidal cells.  Areas of 
transition to angiosarcoma contained greatly increased numbers of sinusoidal cells with greatly expanded 
sinusoidal spaces. Also, hepatic cells were replaced by fibrous tissue forming trabeculae.  These areas 
also showed infiltration of angiosarcoma cells.  In fully developed angiosarcoma, multiple areas with 
nodules of angiosarcoma cells were noted, the centers of which exhibited hemorrhagic necrosis (Popper et 
al. 1981).  A recent case report suggests that vinyl chloride can also produce malignant hemangio­
pericytoma in the liver, which is a vascular tumor similar to angiosarcoma (Hozo et al. 1997, 2000).   
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Other liver tumors, including hepatocellular carcinoma and cholangiocellular carcinoma, have also been 
associated with occupational exposure to vinyl chloride (Cheng et al. 1999; Du and Wang 1998; Lelbach 
1996; Saurin et al. 1997; Ward et al. 2001; Weihrauch et al. 2000; Wong et al. 2002a, 2003a).  A meta­
analysis of eight independent studies confirms an increased risk of hepatocellular carcinoma for 
occupational workers exposed to vinyl chloride (Boffetta et al. 2003).  The risk of developing liver cancer 
appears elevated in those with a history of Hepatitis B viral infection (Du and Wang 1998; Wong et al. 
2003a). Mastrangelo et al (2004) evaluated the possible interaction between alcohol consumption, 
hepatitis infection and hepatocellular carcinoma in a large cohort of vinyl chloride workers.  Vinyl 
chloride was suggested to be an independent risk factor for hepatocellular carcinoma with a synergistic 
interaction described for alcohol consumption and an additive interaction observed for hepatitis infection.  
Lewis (2003) reports the continuing occurrence of angiosarcoma of the liver in retirees from a PVC 
production plant in Louisville, Kentucky.  This ongoing incidence is reported primarily for those workers 
employed prior to 1960, suggesting that those exposed to the highest concentrations of vinyl chloride 
remain at risk for developing cancer for the remainder of their lives.  The reported latency period for 
workers diagnosed prior to 1975 was 12–28 years, while those diagnosed after 1975 showed a latency of 
27–47 years.      
Other cancers that have shown a statistically significant increase in mortality rate among vinyl chloride 
workers, in at least some studies, include cancer of the brain and central nervous system, the lung and 
respiratory tract, connective and other soft tissues, and the lymphatic/hematopoietic system.  With regard 
to cancer of the brain and central nervous system, Cooper (1981), Waxweiler et al. (1976), and Wong et 
al. (1991) reported statistically significant increases; Monson et al. (1975) reported an increase in central 
nervous system cancer mortality in a proportional mortality study; Byren et al. (1976), Simonato et al. 
(1991), and Tabershaw and Gaffey (1974) reported increases that were not statistically significant; and 
Fox and Collier (1977), Jones et al. (1988), Thomas et al. (1987), and Wu et al. (1989) found no increase 
in cancer of the central nervous system among workers occupationally exposed to vinyl chloride.  It 
should be noted that the Cooper (1981), Tabershaw and Gaffey (1974), and Wong et al. (1991) studies 
were all based on the same cohort from a Chemical Manufacturers Association (CMA) study (Wong and 
Whorton 1993).  Workers in the studies by Waxweiler et al. (1976) and Wu et al. (1989) were also 
employed at the same plants used for the CMA study (Wong and Whorton 1993).  At least one analysis of 
epidemiological studies exposed certain weaknesses in the data that support a causal link between vinyl 
chloride and brain cancer (Doll 1988). 
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Follow up mortality studies at polymer production plants indicate that liver cancer mortality remained 
elevated while brain cancer mortality was markedly reduced (as compared to earlier studies).  It should be 
noted that increased brain cancer incidence was not  associated with vinyl chloride exposure in these later 
studies (Lewis 2001; Lewis and Rempala 2003; Lewis et al. 2003; Mundt et al. 2000).  In a meta-analysis 
of eight independent studies, no statistically significant increase in brain cancer mortality was observed 
(Boffetta et al. 2003). An IARC update of a European multi-center cohort study was also negative for 
brain cancer (Ward et al. 2001). 
An association between respiratory tract cancer and vinyl chloride exposure has not been consistently 
observed. A significant increase in cancer of the respiratory tract was reported by Belli et al. (1987), 
Infante et al. (1976b), and Waxweiler et al. (1976), and also by Monson et al. (1975) in a proportional 
mortality study.  Although smoking history was not considered in these studies, Waxweiler et al. (1976) 
noted that the types of respiratory tract cancer most frequently recorded were large-cell undifferentiated 
carcinoma or adenocarcinoma, which are two lung cancer types not usually associated with smoking, but 
may be due to concomitant exposure.  Increased risk of lung cancer was also associated with exposure to 
high concentrations of polyvinyl chloride dust particles (Mastrangelo et al. 2002).  Respiratory tract 
cancer was not reported as elevated in studies by Buffler et al. (1979), Cheng et al. (1999), Cooper 
(1981), Fox and Collier (1977), Jones et al. (1988), Mundt et al. (2000), Scelo et al. (2004), Simonato et 
al. (1991), Wong et al. (1991, 2002a), and Wu et al. (1989).  Similarly, a meta-analysis of eight 
independent studies (Boffetta et al. 2003) and an IARC update of a multi-center cohort study did not 
demonstrate excess mortality from lung cancer (Ward et al. 2001). 
A significant increase in cancers of connective and other soft tissues was observed in a recent follow up 
mortality study (Mundt et al. 2000) and in a meta-analysis of eight independent studies (Boffetta et al. 
2003).  Rhomberg (1998) also suggests that vinyl chloride can induce soft tissue sarcoma outside of the 
liver; however, an IARC update of a multi-center cohort study was negative for soft tissue sarcoma (Ward 
et al. 2001). A meta-analysis of five occupational exposure studies additionally suggests a weak 
association between vinyl chloride exposure and pancreatic cancer (Ojajarvi et al. 2001). 
A statistically significant increase in cancers of the lymphatic/hematopoietic system was reported by 
Rinsky et al. (1988), Smulevich et al. (1988), Weber et al. (1981), and Wong et al. (2002a).  Monson et al. 
(1975) also reported an increase in their proportional mortality study.  However, no statistically 
significant increase in these types of cancer was reported by Infante et al. (1976b), Jones et al. (1988), 
Mundt et al. (2000), or Wong et al. (1991).  In a meta-analysis of eight independent studies, the mortality 
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data for cancers of the lymphatic/hematopoietic system were highly variable.  A strong association was 
not observed between vinyl chloride exposure and lymphatic/hematopoietic system cancers; however, a 
negative conclusion was considered premature (Boffetta et al. 2003). 
An increased incidence of malignant melanoma among vinyl chloride workers has been reported (Heldaas 
et al. 1984, 1987), but the significance of this finding has been disputed (ten Berge 1987).  A follow up to 
the original Heldaas (1984, 1987) studies reported only one additional case of melanoma between 1985 
and 1993, weakening the proposed association between vinyl chloride exposure and the development of 
malignant melanoma (Langard et al. 2000). 
Few studies directly address the incidence of cancer in women occupationally exposed to vinyl chloride.  
However, one study found that women employed in the production of vinyl chloride and PVC had a 
significantly greater chance of developing leukemia or lymphomas (Smulevich et al. 1988). Furthermore, 
the subgroup of women who were exposed to the highest levels of vinyl chloride had increased incidences 
of stomach cancer and the highest incidences of leukemia and lymphoma.  No significant increase in any 
type of cancer was observed in exposed males in this report, irrespective of the level of exposure. 
The human epidemiology data demonstrate a clear association between vinyl chloride exposure and liver 
cancer (i.e., angiosarcoma and hepatocellular carcinoma).  Although other cancers have been previously 
reported for vinyl chloride workers (i.e., respiratory tract cancer, brain cancer), recent follow-up studies 
do not demonstrate a consistent association between vinyl chloride exposure and tumor formation in these 
organ systems (Boffetta et al. 2003; Lewis 2001; Lewis and Rempala 2003; Lewis et al. 2003; Mundt et 
al. 2000; Ward et al. 2001). 
Studies in several animal species support the conclusion that vinyl chloride is carcinogenic.  A large 
series of experiments was performed by Maltoni et al. (1981) using rats (Sprague-Dawley and Wistar), 
mice, and hamsters.  All animals were chamber exposed; controls were chamber exposed to air only.  The 
test material was >99.9% pure.  A complete gross and histopathological examination of every animal was 
performed. However, extremely limited histopathological data were presented and cancer incidences 
were presented only in summary tables.  Also, survival of control animals was poor in some of the 
experiments.  Furthermore, statistical analyses, where present, appear to be based on a compilation of data 
from several individual studies.  In one group of studies, Maltoni et al. (1981) exposed Sprague-Dawley 
rats to vinyl chloride for 52 weeks at concentrations ranging from 1 to 30,000 ppm.  Animals were 
examined at the time of their spontaneous death.  Statistically significant increases were noted in the 
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incidence of mammary gland carcinomas, Zymbal gland carcinomas, nephroblastoma, and liver 
angiosarcoma.  Exposure of Swiss mice to 50 ppm vinyl chloride for 4 hours/day, 5 days/week for 
30 weeks also appeared to increase the incidence of liver angiosarcoma and angioma (Maltoni et al. 
1981).  Maltoni et al. (1981) also reported that decreasing the duration of exposure decreased the 
incidence of vinyl chloride-related tumors (nephroblastomas, liver angiosarcomas, Zymbal gland 
carcinomas, and to some extent, neuroblastomas), but statistics were not presented to support these 
conclusions. 
Some variation in the target organs that developed tumors was observed when different species were 
exposed to vinyl chloride (Maltoni et al. 1981).  Whereas angiosarcomas of the liver were reported to 
occur in rats, mice, and hamsters, mammary gland carcinomas were found only in rats and mice; Zymbal 
gland carcinomas, neuroblastomas, and nephroblastomas were found only in rats; lung tumors were found 
only in mice; and melanomas, acoustical duct epithelial tumors, and leukemias were found only in 
hamsters. 
Other inhalation experiments support the carcinogenicity of vinyl chloride.  Rats and mice exposed to 0, 
50, 250, or 1,000 ppm for 6 hours/day, 5 days/week for 6 months (Hong et al. 1981) or up to 12 months 
(Lee et al. 1977a, 1978) had a significantly increased incidence of hemangiosarcoma of the liver at 
≥250 ppm.  Increases in bronchio-alveolar adenoma of the lung and mammary gland tumors 
(adenocarcinomas, squamous and anaplastic cell carcinomas) were also observed in mice at ≥50 ppm, 
although it is unclear whether the increases in these tumor types are statistically significant (Lee et al. 
1977a, 1978).  Mice exposed to 50 or 500 ppm vinyl chloride for 6 hours/day, 5 days/week for 6 months 
or 1 year had an increased incidence of lung adenoma, as well as hemangiosarcoma of fat tissue in 
various organs (Holmberg et al. 1976). Only one liver hemangiosarcoma was noted.  Male rats exposed 
to concentrations as low as 100 ppm for 6 hours/day, 6 days/week, for 12 months had significantly 
increased incidence of cancer, including angiosarcoma of the liver and lung, when sacrificed at 18 months 
(Bi et al. 1985).  Rats exposed to 30,000 ppm vinyl chloride 4 hours/day, 5 days/week, for 12 months had 
an increased incidence of epidermoid carcinoma of the skin, adenocarcinoma of the lungs, and 
osteochondroma in the bones (Viola et al. 1971), and rats exposed to 5,000 ppm for 52 weeks had primary 
tumors in the brain, lung, Zymbal gland, and nasal cavity (Feron and Kroes 1979).  However, these 
studies (Feron and Kroes 1979; Viola et al. 1971) are limited by the absence of statistical analysis of the 
data. A concentration-dependent increase in tumor formation (alveologenic adenomas of the lung, 
angiosarcomas of the liver, and adenosquamous carcinoma of the mammary gland) was observed in mice 
exposed to 0, 50, 200, or 2,500 ppm vinyl chloride in a study performed for the Manufacturing Chemists 
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Association (Keplinger et al. 1975).  However, no statistics were presented to support these conclusions.  
Furthermore, an audit of data performed for the Manufacturing Chemists Association (CMA 1979) 
indicated that mishandling of the tissues precluded making statements regarding the relationship of 
tumors other than angiosarcoma of the liver to vinyl chloride exposure.  Female mice exposed to 50 ppm 
vinyl chloride showed increased incidence of hemangiosarcoma of the subcutis and peritoneum as well as 
tumors of the lung and mammary gland (Drew et al. 1983), i.e., hemangiosarcoma of the skin, spleen, or 
liver and mammary gland carcinomas. 
In a preliminary study with a limited number of animals, alveogenic lung tumors developed in 26 of 
27 mice exposed to 2,500 or 6,000 ppm for 5–6 months (Suzuki 1978).  A concentration-related increase 
in the incidence of alveogenic tumors was observed in a study in which a greater number of mice were 
exposed to 0–600 ppm for 4 weeks and then observed for up to 40 weeks postexposure (Suzuki 1983).  
The lowest concentration at which multiple foci tumors were observed was 100 ppm (Suzuki 1983.)  A 
significant increase in the incidence of pulmonary adenomas was reported in mice exposed to 50 ppm, 
6 hours/day, 5 days/week for 6 months (Adkins et al. 1986).  An increase in bronchio-alveolar adenoma 
was observed in a lifespan study in mice that were exposed to 50 ppm for 100 1-hour exposures, 500 ppm 
for 10 1-hour exposures, or 5,000 ppm for a single 1-hour exposure (Hehir et al. 1981).  The statistical 
significance of these observations was not reported. 
Some data suggest that exposure of animals early in their lives may increase the likelihood of developing 
tumors due to the latency period for vinyl chloride-induced cancer (Drew et al. 1983).  Early life exposure 
may also affect the type of tumor that develops (Maltoni et al. 1981).  When hamsters, mice, and rats 
were exposed to vinyl chloride for periods of 6–24 months starting at various times after weaning, the 
incidence of tumors such as hemangiosarcoma of the liver, skin, and spleen, and angiosarcoma of the 
stomach was greater when animals were exposed for 12 months immediately after weaning than if 
animals were held for 12 months and then exposed for the next 12 months (Drew et al. 1983).  Mammary 
gland carcinoma was also significantly increased when 2- or 8-month-old hamsters, but not 14- or 
20-month-old hamsters, were exposed to 200 ppm vinyl chloride for 6 months (Drew et al. 1983).  
Fibroadenoma of the mammary gland was also increased in female rats exposed to 100 ppm of vinyl 
chloride for 6 hours/day, 5 days/week, over 6–24 months (Drew et al. 1983).  Also, when pregnant rats 
were exposed to 6,000 ppm vinyl chloride from gestation day 12 through 18, the incidence of mammary 
gland carcinomas, Zymbal gland carcinomas, and forestomach epithelial tumors was reported to be 
greater in transplacentally exposed animals than in maternal animals (Maltoni et al. 1981).  At 
10,000 ppm in this study, nephroblastomas were increased in transplacentally exposed animals compared 
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to maternal animals (Maltoni et al. 1981).  No control group was used, however, and no statistics were 
presented to support the conclusions.  Maltoni and Cotti (1988) also exposed pregnant rats to 2,500 ppm 
vinyl chloride starting on Gd 12 and continued to expose both maternal animals and offspring for a total 
of 76 weeks. Hepatocarcinoma, hepatic angiosarcoma, and neuroblastoma were increased in treated 
animals compared to controls.  The incidence of hepatocarcinoma was reported to be much higher in 
offspring than in maternal animals.  In contrast, the incidence and latency period of neuroblastomas and 
hepatic angiosarcomas was similar between offspring and parents.  However, no statistics were presented 
to support these conclusions. 
Many of the tumors that were observed in the Drew et al. (1983) and Maltoni et al. (1981) studies were 
also observed in a study performed by Froment et al. (1994).  In this study, Sprague-Dawley pups were 
exposed to 500 ppm vinyl chloride 8 hours/day, 6 days/week, on postpartum days 3–28.  After weaning, 
22 animals/gender were exposed for an additional 2 weeks, for a total exposure duration of 33 days.  Rats 
were observed daily until death or development of tumors, and the surviving rats were sacrificed at 
19 months.  All livers from exposed animals that appeared normal at gross examination were found to 
contain multiple nodular hyperplastic foci of hepatocytes.  Liver tumors that were found in exposed 
animals included angiosarcomas, hepatocellar carcinomas, and benign cholangiomas.  Other tumors found 
included pulmonary angiosarcoma (probably metastatic), nephroblastoma, abdominal angiomyoma, 
leukemia, Zymbal gland carcinoma, pituitary adenoma, mammary carcinoma, and mammary fibroma.  
Tumor incidence was not reported in control animals.  Only one concentration (500 ppm) of vinyl 
chloride was used because the purpose of the study was to examine the genotoxicity of vinyl chloride in 
liver tumors produced by exposure. 
In general, the available evidence from inhalation studies in animals supports the finding in humans; that 
vinyl chloride is a carcinogen by this route of exposure.  Based on these and other findings, the National 
Toxicology Program of the Department of Health and Human Services has determined vinyl chloride to 
be a known human carcinogen (DHHS 2002).  In addition, IARC has concluded that sufficient evidence 
for carcinogenicity in humans and animals exists and has placed vinyl chloride in carcinogenicity 
category 1 (i.e., carcinogenic to humans) (IARC 1987).  EPA also has concluded that sufficient evidence 
of carcinogenicity exists in humans and animals and has classified vinyl chloride according to its 1986 
classification scheme as a Group A or known human carcinogen (EPA 1994c).  EPA’s current weight-of­
evidence characterization for vinyl chloride concludes that vinyl chloride is a known human carcinogen 
by the inhalation route of exposure, based on human epidemiological data.  By analogy, vinyl chloride is 
carcinogenic by the oral route because of positive animal bioassay data as well as pharmacokinetic data 
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allowing dose extrapolation across routes.  Vinyl chloride is also considered highly likely to be 
carcinogenic by the dermal route because it is well absorbed and acts systemically (EPA 2000); however, 
animal data suggest that dermal absorption of vinyl chloride gas is not likely to be significant (Hefner et 
al. 1975a). Because the epidemiological evidence does not provide sufficient exposure and incidence data 
to quantify risk based solely on human data, EPA cancer potency factors for inhalation and oral exposure 
have been calculated based on animal studies.  An inhalation unit risk of 8.8x10-6 per ug/m3 for 
continuous lifetime exposure from birth was estimated by EPA (2000) based on the incidence of liver 
tumors observed in rats in the inhalation study by Maltoni et al. (1981).  An inhalation unit risk of 
4.4x10-6 per ug/m3.for continuous lifetime exposure during adulthood was also estimated by EPA (2000). 
Air concentrations associated with excess cancer risks of 10-4, 10-5, 10-6, and 10-7 are 9.0x10-3, 9.0x10-4, 
9.0x10-5, and 9.0x10-6 ppm, respectively, and are plotted in Figure 3-1.  These risks were calculated using 
physiologically based pharmacokinetic (PBPK) modeling, which is discussed in further detail in 
Section 3.4. The lowest concentrations tested that produced a tumorigenic response CEL for each species 
and duration category are recorded in Table 3-1 and plotted in Figure 3-1. 
3.2.2 Oral Exposure  
All dosages of vinyl chloride administered in the diet are reported as mg/kg (body weight)/day unless 
otherwise specified. 
3.2.2.1 Death 
No studies were located regarding lethal effects in humans following oral exposure to vinyl chloride. 
No studies were located regarding acute or intermediate lethal effects of vinyl chloride in animals.  
However, decreased longevity has been observed in rats as a result of chronic ingestion of vinyl chloride.  
Significant increases in mortality were observed by Feron et al. (1981) when Wistar rats were allowed to 
consume vinyl chloride doses as low as 5.6 mg/kg/day in the diet for 4 hours/day over a 2-year period.  
Also, the effects of consumption of vinyl chloride during a lifespan study in Wistar rats lasting almost 
3 years (149 weeks) were examined by Til et al. (1983, 1991).  These authors found a decreased survival 
rate at a vinyl chloride dosage of 1.7 mg/kg/day.  In both of these studies, vinyl chloride was administered 
by incorporating PVC resin that was high in vinyl chloride content into the diet.  In the Til et al. (1991) 
study, the diets of the control animals contained 1% PVC powder that did not contain residual vinyl 
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chloride. Vaporization of vinyl chloride from the diets was limited by presenting feed containing the 
vinyl chloride to the rats for only a 4-hour period. 
All reliable LOAEL values for death in rats following chronic exposure are recorded in Table 3-2 and 
plotted in Figure 3-2. 
3.2.2.2 Systemic Effects  
The highest NOAEL values and all reliable LOAEL values for hematological, hepatic, dermal, and body 
weight effects in rats following chronic oral exposure are recorded in Table 3-2 and plotted in Figure 3-2. 
No studies were located regarding adverse respiratory, cardiovascular, gastrointestinal, musculoskeletal, 
renal, endocrine, or ocular effects in humans or animals following oral exposure to vinyl chloride. 
Hematological Effects.    No studies were located regarding adverse hematological effects in humans 
after oral exposure to vinyl chloride. 
Rats fed 17 mg/kg/day for 2 years showed decreased clotting time of the blood, which was not observed 
at 5.6 mg/kg/day (Feron et al. 1981).  No changes in thrombocyte count or prothrombin times were noted 
in Wistar rats fed diets containing low concentrations of vinyl chloride in PVC resin (1.7 mg/kg/day) for 
149 weeks (Til et al. 1983, 1991). 
Hepatic Effects.    No studies were located regarding adverse hepatic effects in humans after oral 
exposure to vinyl chloride. 
Chronic exposure of rats to vinyl chloride in their feed for 149 weeks produced an increase in the 
incidence of several types of microscopic liver lesions in male and female rats.  Neoplastic and 
preneoplastic lesions in the liver included several types of foci of cellular alteration (i.e., clear-cell, 
basophilic, eosinophilic, or mixed), neoplastic nodules, hepatocellular carcinoma, and angiosarcoma.  
Other liver lesions associated with vinyl chloride exposure included liver-cell polymorphism and hepatic 
cysts.  The high-dose group in male and female rats (1.7 mg/kg/day) represents a LOAEL for noncancer 
liver effects in this study (i.e, liver cell polymorphism, hepatic cysts) (Til et al. 1983, 1991).  The human 



























































Hemato 5.6 17 (decreased clotting time) Feron et al. 1981 
Hepatic 1.8 (cellular alteration) 17 M extensive necrosis 
b 
5.6 F (extensive necrosis) 
Rat 2 yr Dermal 30 (increased skin Knight and Gibbons 1987
(Wistar) 1 x/d thickness, collagen)
(GO) 
Rat 149 wk 
(Wistar) 4 hr/d 
Hemato 1.7 Til et al. 1983, 1991 
(F) 
c 
Hepatic 0.17 F 1.7 F (liver cell polymorphism) 



























Table 3-2 Levels of Significant Exposure to Vinyl Chloride - Oral	 (continued) 
a













Frequency NOAEL Less Serious 	 Serious Reference 
(Route) 











5.6 M (CEL: angiosarcoma of 	 Feron et al. 1981 
lung; neoplastic nodules 
of liver, hepatic 
angiosarcoma) 
b 




50 M (CEL: liver Maltoni et al. 1981 
angiosarcoma) 
b 
16.65 F (CEL: liver 
angiosarcoma) 

































Species Frequency NOAEL Less Serious Serious Reference 






1.7 M (CEL: hepatocellular 
carcinoma) 
Til et al. 1983, 1991 
1.7 F (CEL: neoplastic nodules 
of liver) 
b 
0.018 F (CEL: basophilic foci 
considered to be 
pre-neoplastic lesions) 
1.7 (CEL: hepatic 
angiosarcoma) 
a Numbers correspond to entries in Figure 3-2. 
b Differences in levels of health effects and cancer effects between male and females are not indicated in Figure 3-2. Where such differences exist, only the levels of effect for the 
most sensitive gender are presented. 
c Used to derive an chronic-duration Minimal Risk Level (MRL) of 0.002 mg/kg/day; dose divided by an uncertainty factor of 100 (10 for extrapolation from animals to humans and 10 
for human variability). 
B - both; Bd Wt = body weight; CEL = cancer effect level; d = day(s); derm = dermal; (F) = feed; F = Female; (GO) = gavage in oil; hemato = hematological; hr = hour(s); LOAEL = 









































Figure 3-2 Levels of Significant Exposure to Vinyl Chloride - Oral 














































*Doses represent the lowest dose tested per study that produced a tumorigenic 
response and do not imply the existence of a threshold for the cancer endpoint. 10-7 1E-7 
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for a chronic oral MRL of 0.003 mg/kg/day.  Chronic oral exposure of rats fed vinyl chloride daily during 
a 4-hour period for 2 years also resulted in areas of hepatocellular alteration at concentrations as low as 
1.8 mg/kg/day (Feron et al. 1981).  In this study, areas of necrosis were observed in the liver of female 
rats fed 5.6 mg/kg/day and male rats fed 17 mg/kg/day (Feron et al. 1981).  Increased incidence of hepatic 
cysts were found in female rats fed 1.7 mg/kg/day and clear or basophilic areas of cellular alteration were 
found in male rats fed 1.7 mg/kg/day in the Til et al. (1983, 1991) studies. 
Dermal Effects.    No studies were located regarding adverse dermal effects in humans after oral 
exposure to vinyl chloride. 
Daily administration of 30 mg/kg of vinyl chloride to rats by gavage for 2 years produced increased 
thickness, moisture content, and collagen content of the skin.  Newly synthesized intermolecular and 
intramolecular collagen crosslinks were also significantly increased (Knight and Gibbons 1987). 
Body Weight Effects.    No studies were located regarding adverse body weight effects in humans 
after oral exposure to vinyl chloride. 
No changes in body weight were noted in Wistar rats fed 1.7 mg/kg/day vinyl chloride mixed with PVC 
powder in the diet for 149 weeks (Til et al. 1983, 1991). 
No studies were located regarding the following health effects in humans or animals after oral exposure to 
vinyl chloride: 
3.2.2.3 Immunological and Lymphoreticular Effects  
3.2.2.4 Neurological Effects 
3.2.2.5 Reproductive Effects  
3.2.2.6 Developmental Effects 
3.2.2.7 Cancer 
No studies were located regarding cancer in humans following oral exposure to vinyl chloride. 
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Four studies were located that examined the carcinogenic potential of vinyl chloride in animals when 
administered by the oral route.  In two of these studies in Wistar rats, conducted for 149 weeks, vinyl 
chloride was added to the diet by incorporating PVC powder containing a high level of the monomer 
(Feron et al. 1981; Til et al. 1983, 1991).  To limit volatilization of vinyl chloride from the diet, the rats 
were allowed access to the diet for only 4 hours/day.  The actual intake of vinyl chloride in these reports 
was calculated by taking into consideration both the food consumption and the rate of vinyl chloride 
evaporation. Statistically significant increases in hepatic angiosarcoma of the liver were observed in the 
2-year study by Feron et al. (1981) at 5.6 mg/kg/day in males and 17 mg/kg/day in females.  In the same 
study, statistically significant increases in neoplastic nodules of the liver were also observed at a 
concentration of 5.6 mg/kg/day in males but as low as 1.8 mg/kg/day in females (Feron et al. 1981).  
Also, in the 149-week study by Til et al. (1983, 1991), statistically significant increases in hepatocellular 
carcinoma were observed in males at 1.7 mg/kg/day and hepatic neoplastic nodules in females at 
1.7 mg/kg/day.  A few animals exposed to 1.7 mg/kg/day in this study developed hepatic angiosarcoma.  
An increased incidence of Zymbal gland tumors was also observed in the study by Feron et al. (1981).  
Although the increase was not statistically significant, the tumors were considered to be treatment related 
based on the historical rarity of this type of tumor. 
Two studies were located in which vinyl chloride was administered to Sprague-Dawley rats by gavage for 
52 weeks. In one of these studies, a statistically significant increase in the incidence of hepatic 
angiosarcomas was observed at doses as low as 16.65 mg/kg/day in females and 50 mg/kg/day in males.  
Zymbal gland tumors at 16.65 and 50 mg/kg/day, even though not statistically significant, were 
considered to be treatment related because of the rarity of this type of tumor (Maltoni et al. 1981).  Lower 
doses of vinyl chloride were also tested in a similar study in which hepatic angiosarcomas were observed 
at doses as low as 0.3 mg/kg/day and Zymbal gland tumors at 1 mg/kg/day.  Although neither of these 
findings reached statistical significance, the tumors were considered to be treatment related because of the 
historically rare observation of these tumor types in the colony (Maltoni et al. 1981). 
Based on the evidence of carcinogenicity in animals after oral exposure, it would be prudent to consider 
the potential for carcinogenic effects in humans by this route as well.  The National Toxicology Program 
of the Department of Health and Human Services has determined vinyl chloride to be a known human 
carcinogen (DHHS 2002). In addition, IARC has concluded that sufficient evidence for carcinogenicity 
in humans and animals exists and has placed vinyl chloride in carcinogenicity category 1 (i.e., 
carcinogenic to humans) (IARC 1987).  EPA also has concluded that sufficient evidence of 
carcinogenicity exists in humans and animals and has classified vinyl chloride according to its 1986 
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classification scheme as a Group A or known human carcinogen (EPA 1994c).  EPA’s current weight-of­
evidence characterization for vinyl chloride concludes that vinyl chloride is a known human carcinogen 
by the inhalation route of exposure, based on human epidemiological data.  By analogy, vinyl chloride is 
considered carcinogenic by the oral route because of positive animal bioassay data as well as 
pharmacokinetic data allowing dose extrapolation across routes.  By inference, vinyl chloride is also 
considered highly likely to be carcinogenic by the dermal route because it acts systemically (EPA 2000). 
Because the epidemiological evidence does not provide sufficient exposure and incidence data to quantify 
risk based solely on human data, EPA cancer potency factors for inhalation and oral exposure have been 
calculated based on animal studies.  An oral slope factor for continuous lifetime exposure from birth was 
estimated by EPA (2000) to be 1.5 per mg/kg/day based on the incidence of liver tumors in rats in the 
study by Feron et al. (1981).  An oral slope factor of 7.5x10-1 per mg/kg/day for continuous lifetime 
exposure during adulthood was also estimated by EPA (2000).  Oral doses associated with excess cancer 
risks of 10-4, 10-5, and 10-6 are 1.33x10-4, 1.33x10-5, 1.33x10-6, and 1.33x10-7 mg/kg/day, respectively, and 
are plotted in Figure 3-2.  These risks were calculated using PBPK modeling, which is discussed in 
further detail in Section 3.4. The lowest doses tested that produced a tumorigenic response (CEL) in rats 
chronically exposed to vinyl chloride by the oral route are recorded in Table 3-2 and plotted in Figure 3-2. 
3.2.3 Dermal Exposure  
Dermal exposure to vinyl chloride may occur by skin contact with either gaseous or liquid vinyl chloride.  
Negligible amounts of gaseous vinyl chloride are absorbed through the skin (see also Section 3.4 
regarding absorption by the dermal route).  However, dermal exposure can also occur by direct contact of 
gaseous vinyl chloride with the eyes.  Only studies that specifically relate to dermal contact of liquid vinyl 
chloride or adverse ocular effects occurring with inhalation exposure to gaseous vinyl chloride are 
discussed below. 
3.2.3.1 Death 
No studies were located regarding lethal effects in humans or animals after dermal exposure to vinyl 
chloride. 
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3.2.3.2 Systemic Effects  
No studies were located regarding adverse respiratory, cardiovascular, gastrointestinal, hematological, 
musculoskeletal, hepatic, renal, or endocrine effects in humans or animals after dermal exposure to vinyl 
chloride. 
Dermal Effects.    Vinyl chloride exists as a liquid when stored under pressure.  However, when it is 
released from pressurized containers, it rapidly vaporizes into gas.  Thus, the adverse dermal effects 
observed after exposure to vinyl chloride are not unique to vinyl chloride but can be expected as a result 
of a rapidly evaporating liquid on the skin.  The effects are due to tissue freezing rather than direct 
toxicity of vinyl chloride.  A man who had liquid vinyl chloride sprayed on his hands developed second 
degree burns. At first, the man reported that his hands felt numb.  Within a short period, the hands had 
developed marked erythema and edema (Harris 1953). 
No studies were located regarding adverse dermal effects in animals after dermal exposure to vinyl 
chloride. 
Ocular Effects.    Local burns on the conjunctiva and cornea were observed in a man who died after 
exposure to an unknown quantity of vinyl chloride escaping from an open valve (Danziger 1960). 
No adverse ocular effects were noted in guinea pigs exposed for 30 minutes to up to 400,000 ppm vinyl 
chloride in inhalation chambers (Mastromatteo et al. 1960). 
3.2.3.3 Immunological and Lymphoreticular Effects  
No studies were located regarding adverse immunological and lymphoreticular effects in humans or 
animals following dermal exposure to vinyl chloride. 
3.2.3.4 Neurological Effects 
A man who had liquid vinyl chloride sprayed on his hands initially reported that his hands felt numb 
(Harris 1953). 
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No studies were located regarding adverse neurological effects in animals after dermal exposure to vinyl 
chloride. 
No studies were located regarding the following adverse health effects in humans or animals after dermal 
exposure to vinyl chloride: 
3.2.3.5 Reproductive Effects  
3.2.3.6 Developmental Effects 
3.2.3.7 Cancer 
3.3 GENOTOXICITY  
Vinyl chloride has been shown to be mutagenic and clastogenic in both in vivo and in vitro test systems.  
Tables 3-3 and 3-4 list the key in vivo and in vitro genotoxicity studies for vinyl chloride. 
Genotoxicity studies of vinyl chloride in humans include a large number of assays for chromosomal 
aberrations in the cultured lymphocytes of occupationally exposed workers.  Studies completed through 
the mid-1980s generally found a statistically significant increase in the frequency of chromosomal 
aberrations, usually of the chromatid type (i.e., affecting only one of the two strands formed upon 
deoxyribonuclei c acid [DNA] replication), but also including some chromosomal-type defects such as 
inversions, rings, and translocations, which affect the entire chromosome (Anderson et al. 1981; 
Anderson 1999, 2000; Fleig et al. 1978; Fucic et al. 1990; Heath et al. 1977).  An increase in 
chromosomal aberrations was also observed following an accidental environmental exposure to vinyl 
chloride (Becker et al. 2001; Huttner and Nikolova 1998; Huttner et al. 1998, 1999).  Workers exposed to 
vinyl chloride for an average of 15 years were shown to have elevated levels of micronuclei and 
chromosomal aberrations when compared to the unexposed controls (Garaj-Vrhovac et al. 1990).  An 
increase in chromosome aberrations and micronuclei was correlated with the air concentration of vinyl 
chloride at a plastics plant and the excretion of thiodyglycolic acid in the urine of exposed workers 
(Vaglenov et al. 1999).  Micronuclei counts were also increased in a group of 52 workers exposed to vinyl 
chloride levels of 1.3–16.7 ppm compared to those of controls, but these increases were not observed in 
workers exposed to 0.3–7.3 ppm (Sinues et al. 1991).  Micronuclei were also increased in lymphocytes 
from 19 workers exposed to 50 ppm vinyl chloride for approximately 15 years (Fucic et al. 1990).  
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Table 3-3. Genotoxicity of Vinyl Chloride In Vivo 
Species (test system) End point Results Reference 
Mouse Dominant lethal – Anderson et al. 1976 
Micronuclei + Richardson et al. 1983 
Rat Dominant lethal – Short et al. 1977 
– Anderson et al. 1976 
– Purchase et al. 1975 
 Chromosomal aberration + Anderson and Richardson 1981 
Hamster Chromosomal aberration + Fleig et al. 1978 
Human lymphocyte Sister chromatid exchange – Hansteen et al. 1978 
+ Kucerova et al. 1979 
+ Sinués et al. 1991 
+ Fucic et al. 1990a 
+ Fucic et al. 1992 
+ Fucic et al. 1995 
+ Fucic et al. 1996a 
+ Fucic et al. 1996b 
+ Zhao et al. 1994 
DNA damage + Awara et al. 1998 
+ Du et al. 1995 
Micronuclei + Fucic et al. 1990a 
+ Garaj-Vrhovac et al. 1990 
+ Sinués et al. 1991 
+ Vaglenov et al. 1999 
Chromosomal aberration + Hansteen et al. 1978 
+ Heath et al. 1977 
+ Kucerova et al. 1979 
_ Picciano et al. 1977 
+ Purchase et al. 1978 
+ Ducatman et al. 1975 
+ Anderson 1980, 1981 
+ Fleig et al. 1978 
+ Fucic et al. 1990a, 1990b 
+ Fucic et al. 1995 
+ Fucic et al. 1996a 
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Table 3-3. Genotoxicity of Vinyl Chloride In Vivo 
Species (test system) End point Results Reference 
+ Fucic et al. 1996b 
Human lymphocyte (cont.) Chromosomal aberration + Funes-Cravioto et al. 1975 
+ Hrivnak et al. 1990 
+ Garaj-Vrhovac et al. 1990 
+ Anderson, 1999 
+ Becker et al. 2001 
+ Huttner et al. 1998 
+ Huttner et al. 1999 
+ Huttner and Nikolova 1998 
+ Fucic et al. 1992 
+ Vaglenov et al. 1999 
Rat DNA alkylation + Laib et al. 1989 
+ Green and Hathway 1978 
+ Gwinner et al. 1983 
+ Singer et al. 1987 
+ Bolt et al. 1986 
+ Ciroussel et al. 1990 
+ Eberle et al. 1989 
Mouse DNA alkylation + Osterman-Golkar et al. 1977 
DNA damage + Walles et al. 1988 
Rat DNA adduct + Fedtke et al. 1990 
+ Ciroussel et al. 1990 
+ Swenberg et al. 1992 
+ Bolt et al. 1986 
+ Morinello et al. 2002a, 2002b 
+ Eberle et al. 1989 
– = negative result; + = positive result; DNA = deoxyribonucleic acid 
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Table 3-4. Genotoxicity of Vinyl Chloride In Vitro 
Result 
Without 
Species (test system) End point With activation activation Reference 
Salmonella typhimurium Reverse mutation 	 + – Rannug et al. 1974 
+ + Bartsch et al. 1975, 
1976 
+ + Andrews et al. 1976 
+ + Simmon et al. 1977 
Not tested – Elmore et al. 1976 
+ + Poncelet et al. 1980 
+ + De Meester et al. 1980 
+ + Victorin and Stahlberg 
1988a 
+ 	 Not tested McCann et al. 1975 
+ + Rannug et al. 1976 
TA100, TA1535 Base-pair substitution + + duPont 1992a, 1992b 
+ Not tested Malaveille et al. 1975 
TA98, TA1537, TA1538 Frameshift mutation – – 
Escherichia coli Not applicable + Jacobsen et al. 1989 
Saccharomyces Not tested – Shahin 1976 
cerevisiae 
Gene conversion + Not tested Loprieno et al. 1976 
Schizosaccharomyces Forward mutation + – Loprieno et al. 1977 
pombe 
+ Not tested Loprieno et al. 1976 
D7RAD yeast Gene conversion + _ Ekardt et al. 1981 
Chinese hamster ovary Not applicable + Huberman et al. 1975 
cells 
+ 	 Not tested Drevon et al. 1978 
+ – duPont 1992c 
Bacillus subtilis Rec-repair Not tested – Elmore et al. 1976 
Rat liver microsomes RNA alkylation Not applicable + Laib and Bolt 1977 
QT6 (avian cells) Inhibition of DNA Not applicable + Kandala et al. 1990 
synthesis 
– = negative result; + = positive result; DNA = deoxyribonucleic acid; RNA = ribonucleic acid 
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Increased sister chromatid exchanges have also been reported in occupationally exposed workers (Fucic 
et al. 1990, 1992, 1995; Kucerova et al. 1979; Sinues et al. 1991; Zhao et al. 1996).  Sister chromatid 
exchange frequencies were significantly increased compared to those of the controls at 0.003–7.3 ppm 
vinyl chloride (Sinues et al. 1991).  A positive correlation between frequency of chromosomal aberrations 
and length of exposure and history of exposure to excursion levels (up to 2,000 ppm) was reported by 
Purchase et al. (1978), who examined a cohort of 57 vinyl chloride workers, 19 on-site controls, and five 
off-site controls. The exposures for this cohort ranged from 1,000 ppm between 1945 and 1955 to 5 ppm 
since 1975. These authors also reported an effect on chromosomal aberrations from smoking.  Smoking 
and the presence of an aldehyde dehydrogenase 2 genotype was associated with an increase in the 
frequency of sister chromatid exchange in vinyl chloride workers (Wong et al. 1998).  DNA damage in 
lymphocytes of plastic industry workers was also demonstrated by a single-cell gel electrophoresis 
technique. A correlation was observed between the severity of DNA damage and the duration of 
exposure (Awara et al. 1998).  DNA single strand breaks present in human lymphocytes from exposed 
workers were quickly repaired following cessation of exposure (Du et al. 1995).  Induction of single-
strand breaks in liver DNA was also observed in mice after inhalation of vinyl chloride (Walles et al. 
1988). 
The reversibility of chromosome damage has been reported for several populations of workers following 
a cessation or reduction of exposure to vinyl chloride.  The increase of chromosome aberrations observed 
in workers exposed to 50 ppm returned to normal within 42 months after exposure levels had been 
reduced to <5 ppm (Anderson et al. 1980).  Another study demonstrated a statistically significant increase 
in aberrations in workers exposed to concentrations of approximately 25 ppm.  Following a reduction in 
exposure to 1 ppm, vinyl chloride chromosomal aberrations had returned to control values (Hansteen et 
al. 1978).  A 9-year follow-up study of an occupationally exposed population demonstrated a decrease in 
chromosome aberrations and sister chromatid exchange frequencies over time, corresponding to a 
decrease in vinyl chloride air concentrations at the plant (Fucic et al. 1996a, 1996b).   
The reversibility of clastogenic effects was not seen in another study of 12 current and 3 retired plastics 
industry workers who had been exposed to vinyl chloride while employed for 1.5–35 years (Fucic et al. 
1992).  Sister chromatid exchange frequencies were significantly higher in workers exposed to 
concentrations up to 2,000 ppm than in the controls.  These findings showed no significant decrease in 
sister chromatid exchange frequencies from 8 days to 10 years after exposure (Fucic et al. 1992).   
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Other papers on human subjects have focused on specific mechanisms involved in the clastogenic effects 
of vinyl chloride.  A cohort of 67 workers exposed to approximately 5 ppm for an average of 15 years 
was reported to have a nonrandom distribution of chromatid and bichromatid breaks (Fucic et al. 1990b).  
The most frequently affected areas of the genome were the terminal segments of the A, B, and C group 
chromosomes, suggesting that vinyl chloride or its metabolites interact more frequently with specific sites 
along the chromosome than would be expected.  The study authors presented no correlation with 
particular fragile sites (gene sequences more prone to breakage than normal) or oncogene locations 
known to occur at these terminal segments.  The implication is that the carcinogenicity of vinyl chloride 
could be at least partially explained by its nonrandom interaction with particular genes.  These workers 
were also periodically exposed to 2,000 ppm for short periods.  No specific information was given as to 
the frequency or duration of these events. 
Male workers (n=20) who had been employed for 2–14 years at a vinyl chloride polymerization plant 
exposed to concentrations of vinyl chloride of 1 ppm (with occasional peaks of 300 ppm) underwent 
cytogenetic testing (Fucic et al. 1995).  The test results were compared to those from 20 unexposed 
control men.  Exposed individuals had higher percentages of chromosome aberrations, primarily 
chromatid breaks. Sister chromatid exchange frequencies were also increased in exposed workers (4– 
22 per cell) compared to controls (4–7 per cell).  Significant changes in mitotic activity were noted among 
exposed workers; values for second mitosis were lower than controls and values for third mitosis were 
higher than controls (Fucic et al. 1995, 1997).  Chromosome aberrations were not increased in workers 
exposed to <5 ppm vinyl chloride; however, the average exposure duration for this study was <1 year 
(Picciano et al. 1977). 
Genetic polymorphisms of metabolic and DNA repair genes have been associated with the sister 
chromatid exchange frequency in exposed workers (Wong et al. 2003b).  Metabolic genotypes for 
CYP2E1, aldehyde dehydrogenase 2 (ALDH2) and the DNA repair genotype for x-ray repair cross 
complementing group1 (XRCC1) were associated with an increased risk of DNA damage in humans. 
Animal studies of rats and mice exposed via inhalation to vinyl chloride have concentrated on identifying 
the direct effects of vinyl chloride and its metabolites on DNA.  Vinyl chloride is metabolized by mixed 
function oxidases (MFO) to form an epoxide intermediate, 2-chloroethylene oxide, which spontaneously 
rearranges to form 2-chloroacetaldehyde.  Reactive metabolites of vinyl chloride can be transported 
intercellularly from parenchymal cells to the nonparenchymal cells (Kuchenmeister et al. 1996).  Many 
studies have characterized the mutation profile associated with DNA adducts formed by the reactive 
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metabolites of vinyl chloride (Akasaka et al. 1997; Chiang et al. 1997; Dosanjh et al. 1994; Guichard et 
al. 1996; Matsuda et al. 1995; Pandya and Moriya 1996; Zhang et al. 1995; Zielinski and Hergenhahn 
2000;).  Four primary mutagenic DNA adducts are formed by the reactive metabolites of vinyl chloride.  
These are cyclic etheno-adducts that include 1,N6-ethenoadenine, 3,N4-ethenocytosine, N2,3-etheno­
guanine, and 1,N2-ethenoguanine. These adducts can induce base-pair (i.e., purine-to-purine or 
pyrimidine-to-pyrimidine exchange) transitions during transcription (Cullinan et al. 1997; Oesch and 
Doerjer, 1982; Pandya and Moriya 1996; Singer et al. 1987, 1996). 1,N6-Ethenoadenine adducts have 
been demonstrated to trap topoisomerase I, affecting DNA replication and transcription (Pourquier et al. 
1998). DNA crosslinks can also be formed because chloracetaldehyde is bifunctional (Singer 1994).  The 
adduct 7-(2’-oxoethyl)guanine is also extensively formed in mammalian liver (Laib et al. 1981); however, 
it is quickly recognized and removed by DNA repair mechanisms.  Etheno-adducts are less abundant, but 
more persistent because they are poorly repaired (Brandt-Rauf et al. 2000b; Whysner et al. 1996). 
The identification of the etheno-nucleosides has been reported following inhalation exposure to vinyl 
chloride in rats (Bolt et al. 1986; Ciroussel et al. 1990; Eberle et al. 1989; Fedtke et al. 1990; Morinello et 
al. 2002a, 2002b; Swenberg et al. 1992).  Immature rats exposed in vivo formed 6 times more of this 
nucleoside adduct, which correlated with the age-related sensitivity to carcinogenesis in these animals 
(Ciroussel et al. 1990).  This age-related sensitivity to DNA adduct formation was also noted in an 
inhalation study of lactating rats and their 10-day-old pups exposed 4 hours/day, for 5 days to 600 ppm of 
vinyl chloride (Fedtke et al. 1990).  Concentrations of two adducts found in the liver of the pups were 
4-fold higher than those found in the liver of the dams.  Increased alkylation of liver DNA and increased 
cell proliferation were reported by Laib et al. (1989) following exposure to 600 ppm vinyl chloride for 
6 hours. Young rats were apparently more susceptible to the effects of vinyl chloride, but only three male 
adults and two female adults were used for comparison.  The concentration of ethenoguanine adducts was 
2–3-fold greater in weanling rats as compared to adult rats exposed at the same dose for the time period 
(0, 10, 100, or 1,100 ppm, 6 hours/day for 5 days) (Morinello et al. 2002a).  Rats exposed to 2,000 ppm 
vinyl chloride for 8 hours/day, 5 days/week, for 3 weeks beginning at 7 days of age demonstrated 
hepatocellular ATPase-deficient foci and alkylation of liver DNA (Gwinner et al. 1983).  A study in rats 
exposed to 1,100 ppm vinyl chloride for 6 hours/day, 5 days/week for 1 or 4 weeks demonstrated that 
ethenoguanine adducts are not formed in the adult rat brain (Morinello et al. 2002b).  This differential 
induction of DNA adducts (brain vs. liver) may relate to the direct effect of reactive intermediates at the 
site of metabolite generation.  
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The role of etheno-adducts in the carcinogenesis of vinyl chloride has been recently reviewed (Albertini 
et al. 2003; Barbin 1998, 1999, 2000; Kielhorn et al. 2000; Laib 1986; Nivard and Vogel 1999; Whysner 
et al. 1996). Both 2-chloroethylene oxide and 2-chloroacetaldehyde can react with DNA nucleotide 
bases; however, 2-chloroethylene oxide is a more potent mutagen and may be the ultimate carcinogenic 
metabolite of vinyl chloride (Chiang et al. 1997).  Etheno-adducts generate mainly base pair substitution 
mutations.  Mutations in specific genes (i.e., ras oncogenes, p53 tumor suppressor gene) have been 
identified in vinyl chloride-induced liver tumors in rats and humans and are discussed in further detail 
below. Exocylic DNA adducts are excised from the DNA by glycosylase enzymes that contribute to 
genetic stability (Laval and Saparbaev 2001).  The four primary cyclic adducts formed in DNA by the 
vinyl chloride metabolite chloroacetaldehyde are released by human glycosylase enzymes (Dosanjh et al. 
1994; Singer and Hang 1999).  The expression of the DNA repair enzyme N-methylpurine-
DNA-glycosylase was shown to be deficient in nonparenchymal cells of the rat liver, which are the target 
cells for vinyl chloride-induced angiosarcoma (Holt et al. 2000; Swenberg et al. 1999).  However, there 
was no difference observed in the formation of ethenoguanine adducts in hepatocytes and 
nonparenchymal cells immediately following vinyl chloride exposure (Morinello et al. 2002a).  Together, 
these data suggest that cellular differences in DNA repair capacity may play a role in vinyl chloride-
induced carcinogenesis. It is important to note that endogenously formed etheno-adducts are also present 
in humans and laboratory animals due to a reaction between DNA and lipid peroxidation by-products.  
This background incidence of etheno-adducts should be taken into account when evaluating exposure to 
chemicals like vinyl chloride (Albertini et al. 2003; Bartsch and Nair 2000; Gonzalez-Reche et al. 2002; 
Swenberg et al. 2000; Watson et al. 1999; Yang et al. 2000; Zielinski and Hergenhahn 2001). 
It has been suggested that members of the ras gene family, including Ha-ras, Ki-ras, and N-ras, are 
responsible for the control of cell proliferation and differentiation (Froment et al. 1994).  DNA adducts 
formed by vinyl chloride metabolites can produce point mutations in these genes.  Mutations of the 
Ki-ras-2 gene has been found in hepatic angiosarcomas of workers exposed to high levels of vinyl 
chloride; this specific gene was shown to be activated by a GC-AT transition at codons 12 and 13 
(Brandt-Rauf et al. 1995; Marion et al. 1991; Weihrauch et al. 2002).  Similar mutations of Ki-ras-2 have 
been found in hepatocellular carcinomas of workers exposed to vinyl chloride (Weihrauch et al. 2001a, 
2001b).  Hypermethylation of the p16 gene was also associated with Ki-ras-2 mutation in hepatocellular 
carcinomas from exposed workers (Weinhrauch 2001b).   
Mutation of the Ki-ras-2 gene results in the expression of a mutant p21 protein.  This mutant oncoprotein 
was detected in serum samples taken from vinyl chloride workers with angiosarcoma of the liver (DeVivo 
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et al. 1994; Marion 1998).  Mutant p21 protein was also detected in the serum or plasma of exposed 
workers without liver tumors and a relationship between the frequency of the mutant protein in serum and 
the intensity of vinyl chloride exposure was demonstrated in several studies (Brandt-Rauf et al. 1995; 
DeVivo et al. 1994; Li et al. 1998; Luo et al. 1998, 2003; Marion 1998). 
Rat liver tumors induced by exposure to 500 ppm vinyl chloride were examined for mutations of the 
Ha-ras, Ki-ras, and N-ras genes (Boivin-Angele et al. 2000; Froment et al. 1994; Marion and Boivin-
Angele 1999).  In contrast with the studies in humans, Ki-ras gene mutation does not occur in rats or mice 
with angiosarcoma of the liver induced by vinyl chloride exposure.  Rats with hepatocellular carcinoma 
demonstrated a AT–TA transversion of base 2 of codon 61 of the Ha-ras gene.  This mutation was not 
detected in rodent angiosarcoma of the liver suggesting that there might be cell-specific factors that affect 
the ras gene. Other mutations in codons 13 and 36 of the N-ras A gene were found in two out of five of 
the liver angiosarcomas examined (Froment et al. 1994).  These studies suggest differing molecular 
mechanisms of carcinogenesis in humans and rodents. 
The p53 tumor suppressor gene is mutated in a variety of human cancers (Staib et al. 2003; Trivers et al. 
1995).  A study was performed to examine the p53 tumor suppressor genes and the murine double min­
2 (MDM2) proto-oncogenes from tumors of five vinyl chloride workers; four with angiosarcoma of the 
liver and one with hepatocellular carcinoma (Hollstein et al. 1994).  The p53 tumor suppressor gene was 
being tested for mutation, while the MDM2 proto-oncogene was being tested for amplification.  No 
amplification of the MDM2 gene was detected; however, adenosine-to-thymidine missense mutations 
were found in exons 5–8 (codons 249 and 255) of the p53 gene in two of the angiosarcoma cases.  In 
another study, tumors (angiosarcoma of the liver) from three of six vinyl chloride workers also had 
adenosine-to-thymidine missense mutations in the p53 gene (codons 249, 255, and 179) (Trivers et al. 
1995). Data from a study of angiosarcoma of the liver resulting from endogenous or unknown sources 
(i.e., no vinyl chloride exposure) indicated that p53 mutations were uncommon, providing support for the 
specificity of p53 mutations with vinyl chloride exposure in cases of angiosarcoma of the liver (Soini et 
al. 1995).  The p53 gene mutation pattern in rat liver tumors (angiosarcoma and hepatocellular carcinoma) 
was shown to be similar to that observed in human tumors from vinyl chloride-exposed workers (Barbin 
et al. 1997; Marion and Boivin-Angele 1999).  Mutations of the p53 gene were found in hepatocellular 
carcinomas from workers exposed to vinyl chloride; however, no correlation with vinyl chloride exposure 
occurred and the mutation pattern was thought to reflect endogenous mechanisms rather that chemical 
mutagenesis (Weihrauch et al. 2000).  A p53 mutation at codon 179 was detected in myofibroblast-type 
cells isolated from a liver tumor in an exposed worker (Boivin et al. 1997).  Ki-ras mutations were not 
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observed in these cells.  Vinyl chloride mutations of the p53 gene produce conformational effects in the 
expressed p53 protein that affect its function (Chen et al. 1999).  
Mutant p53 protein and/or anti-p53 antibodies have been detected in the serum and plasma of vinyl 
chloride-exposed workers (Luo et al. 1999; Marion 1998; Smith et al. 1998; Trivers et al. 1995).  A 
relationship between the frequency of the mutant protein or p53 antibodies in serum/plasma and the 
intensity of vinyl chloride exposure was demonstrated in these studies.  Polymorphisms of the genes for 
vinyl chloride metabolism (CYP2E1) and DNA repair (x-ray cross-complementing group 1) are 
associated with a greater risk of p53 gene mutation and over-expression of p53 mutant protein (Li et al. 
2003; Wong et al. 2002b). 
Rat studies suggest that gap junctional intercellular communication mediated by connexin 37 is disturbed 
in angiosarcoma of the liver; however, mutation of the connexin 37 gene is considered rare (Saito et al. 
1997).  The incidence of hypoxanthine-guanine-phosphoribosyl-transferase (HPRT) mutants was not 
consistently elevated in workers exposed to vinyl chloride (Huttner and Holzapfel 1996; Liber et al. 
1999).  HPRT mutants were also not increased in humans accidentally exposed to vinyl chloride (Becker 
et al. 2001). 
Vinyl chloride has not been shown to be positive for dominant lethal effects in rats exposed to up to 
30,000 ppm, for 6 hours/day for 5 days (Anderson et al. 1976; Purchase et al. 1975; Short et al. 1977).  
The studies showed no evidence of pre- or postimplantation loss among the untreated females mated to 
the exposed males.  These results indicate that no germinal mutations were produced by these acute 
exposures. Vinyl chloride induces somatic and sex-linked recessive lethal mutations in Drosophila, but 
does not induce dominant lethal mutations (Ballering et al. 1996; Giri 1995; Magnusson and Ramel et al. 
1978). 
Vinyl chloride is mutagenic in S. typhimurium (Andrews et al. 1976; Bartsch et al. 1975, 1976; de 
Meester et al. 1980; Elmore et al. 1976; Malaveille et al. 1975; Poncelet et al. 1980; Simmon et al. 1977), 
but only in strains reverted by base-pair substitution by alkylating agents rather than by frameshift 
mutations (Bartsch et al. 1976; duPont 1992a, 1992b).  Metabolic activation is necessary for any 
mutagenic activity in this system (Rannug et al. 1974) or for a maximal response (Simmon et al. 1977).  
In addition, vinyl chloride is mutagenic in the gaseous phase, but not when it is dissolved in water 
(Poncelet et al. 1980).  The negative findings for vinyl chloride dissolved in water are most likely due to 
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methodological problems associated with rapid evaporation and therefore do not reflect a lack of 
mutagenic potential.   
Concentrations of vinyl chloride tested in vitro range from 0.275% (Shahin 1976) to 40% (duPont 1992a). 
Shahin (1976) reported negative results for 0.275 and 0.55% vinyl chloride in Saccharomyces cerevisiae. 
In S. typhimurium, a doubling of revertants has been reported to occur at about 5% vinyl chloride 
(Victorin and Stahlberg 1988a). Vinyl chloride was found to be mutagenic in Chinese hamster ovary 
cells and yeast (Drevon et al. 1978; duPont 1992c; Eckardt et al. 1981; Loprieno et al. 1976).  A 5-hour 
exposure to 4,600 ppm vinyl chloride did not cause mutatgenicity in the mammalian spot test (Peter and 
Ungvary 1980).  Workers exposed to vinyl chloride have been shown to have increased chromosomal 
aberrations, micronucleic counts, and sister chromatid exchange frequencies (Anderson et al. 1980; Fucic 
et al. 1992, 1995, 1997; Garaj-Vrhovac et al. 1990; Kucerova et al. 1979; Sinues et al. 1991; Zhao et al. 
1996). 
There is evidence that in S. typhimurium, E. coli, and B. subtilis, it is the oxidation of vinyl chloride to the 
reactive intermediates 2-chloroethylene oxide and 2-chloroacetaldehyde that is responsible for the 
mutagenicity of vinyl chloride (Bartsch et al. 1976, 1979; Hussain and Osterman-Golkar, 1976; Jacobsen 
et al. 1989; Laumbach et al. 1977; McCann et al. 1975; Rannug et al. 1976).  The S-9 fraction from 
surgically obtained human liver specimens was shown to metabolize vinyl chloride to electrophiles that 
were mutagenic to S. typhimurium TA1530 (Sabadie et al. 1980).  Mutagenicity assays were performed 
by exposing the plates containing S. typhimurium and 150 μL human S-9 fraction to a gaseous mixture of 
20% vinyl chloride in air for 4 hours.  Vinyl chloride was removed after the exposure.  The vinyl chloride 
concentration in the aqueous phase of the plates was 4x10-3 M. Incubation was continued for an 
additional 48 hours.  When compared with the number of revertants per plate resulting from identically 
prepared S-9 fractions from female strain BD IV rats, human S-9 fractions induced mutations (and 
presumably metabolism to a reactive electrophile) to an average 84% of the extent mediated by rat S-9.  
However, a 9-fold individual variation was observed. 
Chloroacetaldehyde appears to be less genotoxic in yeast and Chinese hamster V79 cells than 
2-chloroethylene oxide (Huberman et al. 1975; Loprieno et al. 1977) and has been shown to inhibit DNA 
synthesis in avian cells (Kandala et al. 1990).  However, 2-chloroacetaldehyde has been shown to react 
directly with single-stranded DNA, which then produced base changes and subsequent reversion in E. coli 
when the DNA was inserted via phage (Jacobsen et al. 1989).  Recent data have also shown 
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2-chloroacetaldehyde to be mutagenic in human fibroblast cells using shuttle vectors (Matsuda et al. 
1995). 
3.4 TOXICOKINETICS 
Vinyl chloride is volatile and exposure occurs largely by inhalation.  Studies in humans and animals have 
shown that vinyl chloride is readily absorbed through the lungs (Krajewski et al. 1980; Withey, 1976).  
Animal studies demonstrate that vinyl chloride is rapidly and almost completely absorbed from the 
gastrointestinal tract after oral exposure (Watanabe et al. 1976a; Withey 1976).  A single study in 
monkeys, suggests that dermal absorption of vinyl chloride gas is not likely to be significant (Hefner et al. 
1975a). No studies were located that reported the absorption of vinyl chloride in humans after oral or 
dermal exposure.   
Animal studies indicate that the distribution of vinyl chloride is rapid and widespread; however, storage in 
the body is limited because of rapid metabolism and excretion.  Metabolites of vinyl chloride have been 
found in the liver, kidney, spleen, skin, and brain, but tissue concentrations do not increase following 
repeated exposure (Bolt et al. 1976a; Butcher et al. 1977; Duprat et al., 1977; Watanabe 1978a, 1976b).  
Vinyl chloride has been shown to cross the placenta after inhalation exposure (Ungvary et al. 1978).  No 
studies were located that reported tissue distribution after inhalation, oral, or dermal exposure to vinyl 
chloride in humans or after dermal exposure in animals.  Vinyl chloride distribution may be affected by 
differences in gender, age, and nutritional status.   
Vinyl chloride metabolism in humans is attributed to the cytochrome P-450 monooxygenases in the liver 
(Ivanetich et al. 1977; Sabadie et al. 1980; Salmon 1976).  The proposed metabolic pathways for vinyl 
chloride are shown in Figure 3-3.  Data obtained in rats indicate that metabolic pathways are consistent 
for both inhalation and oral exposure (Bartsch et al., 1976, 1979; Green and Hathway 1975, 1977; 
Hathway 1977; Watanabe and Gehring 1976; Watanabe et al. 1976a).  Metabolism occurs via the 
oxidation of vinyl chloride by mixed function oxidases (MFO) to form an epoxide intermediate, 
2-chloroethylene oxide, which spontaneously rearranges to form 2-chloroacetaldehyde.  Intermediates are 
detoxified primarily via glutathione conjugation and conjugates are excreted in urine as substituted 
cysteine derivatives.  Metabolism has been shown to follow Michaelis-Menten kinetics in rats, with 
enzyme saturation near 100 ppm in air or between 1 and 100 mg/kg/day for a single gavage dose (Hefner 
et al. 1975b; Watanabe et al. 1976a).  Macromolecular binding has been attributed to the reactive 
intermediate 2-chloroethylene oxide, which binds to DNA and RNA (ribonucleic acid), and its reaction  
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Figure 3-3. Proposed Metabolic Pathways for Vinyl Chloride* 
Omixed function oxidase
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thiodiglycolic acid (thiodiacetic acid)** 
*Derived from Bolt et al. (1980); Cogliano and Parker (1992); Hefner et al. (1975b); Park et al. (1993); and Plugge 
and Safe (1977). 
**Excreted in urine. 
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product, 2-chloroacetaldehyde, which binds to protein molecules (Barbin et al., 1975; Guengerich and 
Watanabe 1979; Guengerich et al. 1979, 1981; Kappus et al. 1976; Watanabe et al. 1978a, 1978b).  No 
studies were located regarding vinyl chloride metabolism in humans after oral or dermal exposure or in 
animals after dermal exposure.  It should be noted that the toxicokinetics of vinyl chloride could be 
affected by compromised liver function or exposure to alcohol and other drugs and chemicals. 
Animal studies have demonstrated that the primary route of excretion is dose-dependent (Watanabe and 
Gehring 1976; Watanabe et al. 1978a, 1976b).  Vinyl chloride metabolites are excreted primarily in the 
urine following oral or inhalation exposure to low doses.  At higher doses where metabolic saturation has 
been exceeded, vinyl chloride is exhaled as the parent compound.  This was also demonstrated in humans 
exposed by inhalation, where exhalation of vinyl chloride was a minor pathway of elimination at low 
concentrations (Krajewski et al. 1980). No studies were located regarding excretion in humans after oral 
or dermal exposure to vinyl chloride.  After dermal exposure in monkeys, most of the little vinyl chloride 
absorbed was excreted in exhaled air (Hefner et al. 1975a). 
3.4.1 Absorption 
3.4.1.1 Inhalation Exposure 
Inhalation absorption of vinyl chloride is rapid in humans.  Young adult male volunteers were exposed to 
vinyl chloride concentrations of 2.9, 5.1, 11.7, or 23.5 ppm by gas mask for 6 hours (Krajewski et 
al. 1980).  Retention was estimated by measuring the difference between inhaled and exhaled 
concentrations. An average retention of 42% was estimated.  Although the results varied among the 
individuals tested, the percentage retained was independent of the concentration inhaled.  Since retention 
did not change with increasing vinyl chloride concentrations, it appears that saturation of the major 
pathway of overall metabolism did not occur in this exposure regimen. 
Animal data demonstrate that the inhalation absorption of vinyl chloride occurs readily and rapidly. 
PBPK models that have been developed to provide quantitative estimates of uptake are discussed in 
Section 3.4.5.  Peak blood levels occurred at 30 minutes in rats exposed (head only) to 7,000 ppm 
(Withey 1976).  On removal from the vinyl chloride atmosphere, blood levels fell rapidly.  After 2 hours, 
concentrations were barely detectable.   
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3.4.1.2 Oral Exposure  
No studies were located regarding absorption in humans after oral exposure to vinyl chloride. 
Several studies in rats indicate that vinyl chloride is rapidly and virtually completely absorbed from the 
gastrointestinal tract. Peak blood levels of vinyl chloride were observed within 10–20 minutes after 
dosing in rats administered single oral doses (44–92 mg/kg) of vinyl chloride in aqueous solution (Withey 
1976).  Peak blood levels varied from 6 to >40 μg/mL.  Data from another study in which rats were 
administered single gavage doses of 0.05, 1, and 100 mg/kg vinyl chloride labelled with radioactive 
carbon (14C-vinyl chloride) (in corn oil) suggested that almost complete absorption of vinyl chloride 
occurred (Watanabe et al. 1976a). The fraction of the administered dose recovered in the feces, roughly 
indicative of the proportion unabsorbed, ranged from 0.47 to 2.39%; total recovery ranged from 82.3 to 
91.3%.  Loss of radioactivity might be attributed either to experimental error or to incomplete sampling of 
the carcass.  Fecal excretion was measured in rats fed 0, 1.8, 5.6, and 17.0 mg/kg/day of vinyl chloride 
monomer (from powdered PVC containing a high level of the monomer) (Feron et al. 1981).  Fecal 
excretion accounted for 8, 10, and 17% of the vinyl chloride present in the low-, middle-, and high-dose 
groups, respectively.  The investigators hypothesized that the vinyl chloride recovered from the feces was 
encapsulated by PVC and was not available to the rats for absorption, and that absorption of available 
vinyl chloride was virtually complete. 
3.4.1.3 Dermal Exposure  
No studies were located regarding absorption in humans after dermal exposure to vinyl chloride. 
Animal data suggest that dermal absorption of vinyl chloride gas is not likely to be significant.  Dermal 
absorption was measured in two rhesus monkeys that received full body (except head) exposure to vinyl 
chloride gas. It was estimated that 0.031 and 0.023% of the total available vinyl chloride was absorbed at 
800 and 7,000 ppm, respectively, after a 2–2.5-hour exposure (Hefner et al. 1975a).  The investigators 
concluded that, after short-term exposure to high concentrations, dermal absorption was far less 
significant than inhalation absorption.  No information is available regarding dermal absorption of vinyl 
chloride from liquid or solid mediums. 
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3.4.2 Distribution 
Representative vinyl chloride partition coefficients for humans, rats, mice, and hamsters can be found in 
Table 3-5. These partition coefficients were obtained for use in PBPK models.  They were estimated 
using a vial equilibration technique (Air Force 1990b).  Further details about how the values were 
obtained, including the number of experiments completed and whether the errors shown are standard 
deviations or standard errors, were not provided.  In general, concentrations of vinyl chloride found in fat 
are higher than would be found in other tissues.  Partition coefficients for vinyl chloride range from 10 to 
20 (fat/air) and from 1 to 3 (muscle/air, blood/air, and liver/air).  In animal studies, females have shown 
greater partitioning from air to fat than males. 
Tissue/blood partition coefficients in male Sprague-Dawley rats, measured using a vial equilibration 
method, have been reported as 10±3 for fat/blood, 0.4±0.2 for muscle/blood, 0.7±0.3 for liver/blood, and 
0.7±0.4 for kidney/blood (Barton et al. 1995). 
3.4.2.1 Inhalation Exposure 
No studies were located regarding tissue distribution in humans after inhalation of vinyl chloride. 
Data from rat studies suggest that the distribution of inhaled vinyl chloride is rapid and widespread, but 
storage of vinyl chloride in the body is limited by rapid metabolism and excretion.  In rats exposed to 
14C-vinyl chloride and pretreated with 6-nitro-1,2,3-benzothiadiazole to block metabolism of vinyl 
chloride by microsomal cytochrome P-450 oxidation pathways, the highest levels of radiolabel were 
located in the fat, with lesser amounts in the blood, liver, kidney, muscle, and spleen.  When metabolism 
was not blocked, the highest levels of radiolabelled metabolites were located in the liver and kidney 
(Buchter et al. 1977).  Immediately after a 5-hour exposure to 14C-vinyl chloride at 50 ppm, tissue levels 
of 14C-activity, expressed as the percentage incorporated per gram of tissue, were highest in the kidney 
(2.13%) and liver (1.86%), with lower levels in the spleen (0.73%) and brain (0.17%) (Bolt et al. 1976a).  
Radioactivity in tissue was measured in rats 72 hours after exposure to 10 or 1,000 ppm 14C-vinyl 
chloride for 6 hours.  In order of decreasing concentration for rats exposed to 10 ppm, 14C-labeled 
compounds (expressed as percentage), present as nonvolatile metabolites, were measured in the liver 
(0.14), kidney (0.08), skin (0.07), lung (0.07), muscle (0.05), carcass (0.05), plasma (0.05), and fat (0.03).  
For rats exposed to 1,000 ppm, radiolabel (expressed as percentage) was measured in the liver (0.15), skin  
102 VINYL CHLORIDE 
3. HEALTH EFFECTS 











































M 2.4±0.5 – – – 






























Humanc NA NR 1.16 – – – 
aAir Force 1990b; values determined using vial equilibration method. 
bBarton et al. 1995 
cEPA 1987g 
– = no data; F = female; M = male; NA = not applicable; NR = not reported 
103 VINYL CHLORIDE 
3. HEALTH EFFECTS 
(0.12), kidney (0.06), carcass (0.05), lung (0.05), muscle (0.04), fat (not detected), and plasma (not 
detected) (Watanabe et al. 1976b).  There was no difference in the routes or rate of excretion between 
repeated-dose versus single-dose exposure of rats to 5,000 ppm of 14C-vinyl chloride (Watanabe et 
al. 1978a). The concentration of radiolabel detected in tissues 72 hours after exposure revealed no 
statistically significant difference between rats exposed once or repeatedly to vinyl chloride.  Percentages 
of radioactivity after 72 hours measured in tissues are as follows (for single and repeated doses, 
respectively):  liver (0.12 and 0.16), kidney (0.06 and 0.07), skin (0.05 and 0.08), carcass (0.03 and 0.04), 
and fat (not detected and not detected). 
Placental transfer of vinyl chloride can occur rapidly in rats.  Female rats exposed to approximately 0, 
2,000, 7,000, or 13,000 ppm vinyl chloride for 2.5 hours on Gd 18 showed high concentrations of vinyl 
chloride in maternal and fetal blood and amniotic fluid (Ungvary et al. 1978).  Vinyl chloride 
concentrations in maternal blood were 19.02, 32.40, and 48.43 μg/mL, respectively, while fetal blood 
concentrations were 12.80, 22.67, and 30.52 μg/mL, respectively.  Vinyl chloride concentrations in 
amniotic fluid were 0, 4.27, 4.93, and 13.50 μg/mL, at 2,000, 7,000, and 13,000 ppm vinyl chloride, 
respectively (Ungvary et al. 1978). 
3.4.2.2 Oral Exposure  
No studies were located regarding tissue distribution in humans after oral exposure to vinyl chloride. 
The level of 14C-nonvolatile metabolites was measured in tissues of rats 72 hours after single gavage 
doses (0.05–100 mg/kg) of 14C-vinyl chloride in corn oil (Watanabe et al. 1976a).  The highest levels of 
radioactivity for each dose level occurred in the liver.  These levels were 2–5 times higher than in the 
other tissues examined (skin, plasma, muscle, lung, fat, and carcass). 
3.4.2.3 Dermal Exposure  
No studies were located regarding tissue distribution for humans or animals after dermal exposure to 
vinyl chloride. 
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3.4.3 Metabolism 
3.4.3.1 Inhalation Exposure 
Metabolism can be quantitatively estimated from gas uptake experiments in which, after initial absorption 
of vinyl chloride, continued absorption is largely attributed to metabolism.  Krajewski et al. (1980) 
exposed young men to vinyl chloride at concentrations of 2.9, 5.1, 11.7, and 23.5 ppm by gas mask for 
6 hours. Retention was independent of the inhaled concentration and did not change with increasing vinyl 
chloride concentrations, suggesting that saturation of the major metabolic pathway did not occur over this 
exposure range. 
The major metabolic pathway of vinyl chloride involves oxidation by mixed-function oxidases to form a 
highly reactive epoxide intermediate, 2-chloroethylene oxide, which spontaneously rearranges to form 
2-chloroacetaldehyde (Guengerich et al. 1979, 1981; Gwinner et al. 1983; Laib 1982).  These 
intermediates are detoxified mainly through conjugation with glutathione catalyzed by glutathione 
S-transferase. The conjugated products are excreted in urine as substituted cysteine derivatives and 
include thiodiglycolic acid, S-formylmethylcysteine, and N-acetyl-S-(2-hydroxyethyl) cysteine (Bolt et al. 
1980; Hefner et al. 1975b).  Urinary metabolites identified in rats exposed by inhalation include polar 
compounds at low exposure concentrations (Hefner et al. 1975b; Watanabe et al. 1976b) and 
2-chloroacetic acid at high exposure concentrations (Hefner et al. 1975b). 
Early work on the metabolism of vinyl chloride in animals indicated that metabolism is a dose-dependent, 
saturable process. Rats were exposed to vinyl chloride in a closed chamber at concentrations of about 50– 
1,000 ppm for 52.5–356.3 minutes (Hefner et al. 1975b).  Additional rats pretreated with ethanol (to 
inhibit alcohol dehydrogenase activity) or SKF 525-A (to inhibit microsomal oxidase activity) were 
similarly exposed.  Metabolism, estimated by measuring the rate of disappearance of vinyl chloride from 
the closed system, followed first-order kinetics with a half-life of 86 minutes at <100 ppm.  At >220 ppm, 
metabolism was slowed to a half-life of 261 minutes, suggesting saturation of the pathway predominant at 
100 ppm.  Pretreatment with ethanol depressed the rate of metabolism by approximately 83% at 
<100 ppm but by approximately 47% at >1,000 ppm.  Pretreatment with SKF 525-A, however, had no 
effect at <100 ppm but depressed metabolism by 19% at >1,000 ppm.  The study authors postulated 
alternative pathways for vinyl chloride metabolism. They suggested that at low concentrations sequential 
oxidation to 2-chloroethanol, 2-chloroacetaldehyde, and 2-chloroacetic acid involving alcohol 
dehydrogenase (inhibited by pretreatment with ethanol) appeared to be the predominant pathway.  Little 
2-chloroacetic acid was formed, however, possibly because 2-chloroacetaldehyde conjugated rapidly with 
105 VINYL CHLORIDE 
3. HEALTH EFFECTS 
ubiquitous sulfhydryl groups.  The authors further speculated that when the alcohol dehydrogenase 
pathway became saturated, 2-chloroethanol could be oxidized by catalase in the presence of hydrogen 
peroxide (H2O2) to a peroxide, which could undergo subsequent dehydration to form 2-chloro­
acetaldehyde.  However, it appears that the only support for this proposed metabolism of vinyl chloride 
by alcohol dehydrogenase comes from studies demonstrating metabolic inhibition by alcohol.  This is not 
recognized as a direct pathway for metabolism of vinyl chloride in modern PBPK modeling studies.  It is 
possible that ethanol exerts its effects by inhibiting specific P-450 enzymes involved in the metabolic 
activation of vinyl chloride.  
Isolated rat liver cells converted 14C-vinyl chloride into nonvolatile metabolites (Hultmark et al. 1979).  
Using this in vitro technique, it was determined that metabolism was NADPH-dependent, located in the 
microsomal fraction of the liver, and probably involved an MFO.  Pretreatment with 6-nitro-1,2,3-benzo­
thiadiazole, an inhibitor of some microsomal cytochrome P-450 oxidation pathways, was sufficient to 
totally block the metabolism of vinyl chloride in rats exposed to 0.45 ppm in a closed system for 5 hours 
(Bolt et al. 1977). This observation suggests that metabolism of vinyl chloride proceeds primarily 
through an MFO pathway with likely production of an epoxide intermediate. 
Inhalation exposure to high concentrations of vinyl chloride has also been associated with a reduction in 
the liver nonprotein sulfhydryl concentration in the rat (Barton et al. 1995).  These results are consistent 
with conjugation of the metabolites of vinyl chloride with limited reserves of glutathione and/or cysteine 
(Bolt et al. 1976b; Hefner et al. 1975b; Jedrychowski et al. 1984; Watanabe et al. 1978b). 
Saturation of metabolic pathways was observed in rats and monkeys that were exposed in a closed system 
to 14C-vinyl chloride (Bolt et al. 1977; Buchter et al. 1980; Filser and Bolt 1979).  In Wistar rats, 
metabolic saturation was determined to occur at approximately 250 ppm, and a metabolic rate (Vmax) of 
110 μmol/hour/kg was estimated (Bolt et al. 1977; Filser and Bolt 1979).  Kinetic constants of 
58 μmol/hour/kg for Vmax and 1 μM for the Km in male Sprague-Dawley rats have also been reported 
(Barton et al. 1995).  In an experiment using rhesus monkeys, metabolic saturation occurred at 200 ppm, 
with a Vmax of 50 μmol/hour/kg (Buchter et al. 1980).  The Vmax of 50 μmol/hour/kg that was estimated 
using rhesus monkeys was suggested as a closer approximation of metabolism in humans than the value 
of 110 μmol/hour/kg estimated for rats by Filser and Bolt (1979). 
Kinetic constants for vinyl chloride metabolism have also been derived from in vitro studies in rat liver 
microsomes (El Ghissassi et al. 1998).  Vinyl chloride metabolism to reactive species followed Michaelis­
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Menton kinetics with a Km of 7.42 μM and a Vmax of 4,674 pmol/mg protein/minute.  Inhibitor studies 
using chemical and immunological inhibitors demonstrate that vinyl chloride is metabolized primarily by 
CYP2E1. 
Several investigators have observed the binding of nonvolatile metabolites of 14C-vinyl chloride to liver 
macromolecules in vitro and in rats exposed by inhalation (Guengerich and Watanabe 1979; Guengerich 
et al. 1979, 1981; Kappus et al. 1976; Watanabe et al. 1978a, 1978b).  In single-exposure experiments at 
different concentrations, the extent of macromolecular binding increased proportionately to the amount of 
vinyl chloride metabolized and disproportionately to the exposure concentration (Watanabe et al. 1978b).  
The extent of macromolecular binding was increased by repeated exposure to vinyl chloride (Watanabe et 
al. 1978a) and by pretreatment with phenobarbital (Guengerich and Watanabe 1979).  Macromolecular 
binding has been attributed to the reactive intermediate 2-chloroethylene oxide, which has been shown to 
bind to DNA and RNA, and to its rearrangement product, 2-chloroacetaldehyde, which has been shown to 
bind to protein molecules (Guengerich and Watanabe 1979; Guengerich et al. 1979, 1981; Kappus et al. 
1976; Watanabe et al. 1978a, 1978b). 
3.4.3.2 Oral Exposure  
No studies were located regarding metabolism in humans after oral exposure to vinyl chloride.  
Urinary metabolites identified from rats ingesting 14C-vinyl chloride are consistent with the metabolic 
pathways postulated for inhalation exposure, in particular with the formation of 2-chloroethylene oxide 
and 2-chloroacetaldehyde.  Metabolites identified include N-acetyl-S-(2-hydroxyethyl)cysteine, 
2-chloroacetic acid, and thiodiglycolic acid (Green and Hathway 1975, 1977; Watanabe and Gehring 
1976; Watanabe et al. 1976a).  Metabolic saturation appears to occur with a single gavage dose of 
between 1 and 100 mg/kg/day (Watanabe et al. 1976a). 
3.4.3.3 Dermal Exposure  
No studies were located regarding metabolism in humans or animals after dermal exposure to vinyl 
chloride. 
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3.4.4 Elimination and Excretion 
3.4.4.1 Inhalation Exposure 
Human data suggest that exhalation of unmetabolized vinyl chloride is not an important pathway of 
elimination at low exposure concentrations.  The mean concentration in expired air for humans exposed 
for 6 hours to air containing 2.9–23.5 ppm ranged from 0.21 to 1.11 ppm, representing from 7.23 to 
4.73% of the inhaled amounts, respectively (Krajewski et al. 1980). 
Animal studies indicate that the importance of exhalation of vinyl chloride as a major route of excretion 
varies with the exposure concentration. The mode of excretion of vinyl chloride and its metabolites 
following inhalation exposure of animals to different concentrations reflects the saturation of metabolic 
pathways.  The cumulative excretion of radioactivity over a 72-hour postexposure period was measured in 
rats exposed to 10–1,000 ppm (Watanabe and Gehring 1976; Watanabe et al. 1976b) or 5,000 ppm 
(Watanabe et al. 1978a) 14C-vinyl chloride for 6 hours.  Radioactivity expired as carbon dioxide or vinyl 
chloride, excreted in the urine and feces, and retained in the carcass was expressed as a percentage of the 
total radioactivity recovered.  The results suggest that metabolism was nearly complete at 10 ppm because 
less than 2% of the recovered radioactivity occurred as unchanged parent compound.  The predominant 
route for excretion of radioactive metabolites was through the urine, accounting for about 70% of the 
recovered radioactivity.  Metabolism became saturated at 1,000 ppm, since unchanged vinyl chloride 
increased to 12.3% and urinary radioactivity decreased to 56.3%.  At 5,000 ppm, more than half the 
recovered radioactivity appeared as unchanged vinyl chloride in expired air, and urinary excretion 
accounted for about 27% of the recovered activity. Generally, there was little change in the proportion of 
recovered radioactivity excreted in the feces or exhaled as carbon dioxide.  The percentage of the 
radioactivity retained in the carcass and tissues appeared to be somewhat decreased at 5,000 ppm 
compared with 10 and 1,000 ppm, suggesting preferential retention of metabolites rather than unchanged 
vinyl chloride.  It should be noted that the trend of a greater percentage of vinyl chloride being exhaled at 
higher concentrations in animals is the opposite of what was observed in humans in Krajewski et al. 
(1980).  In humans, a higher percentage of unmetabolized vinyl chloride was found in expired air at lower 
concentrations (Krajewski et al. 1980). However, it is possible that a reversal of this trend would occur in 
humans if concentrations were increased to those used in the animal studies or to concentrations closer to 
the Km for human metabolism. 
Pulmonary excretion of unaltered vinyl chloride in rats followed first-order kinetics regardless of 
exposure concentrations, with half-lives of 20.4, 22.4, and 30 minutes following 6-hour exposures at 10, 
108 VINYL CHLORIDE 
3. HEALTH EFFECTS 
1,000, and 5,000 ppm, respectively.  The urinary excretion of radioactivity was biphasic, with the second 
or slow phase accounting for less than 3% of the total urinary excretion.  Estimated half-lives for the rapid 
(first-order) phase were 4.6, 4.1, and 4.5 hours, at 10, 1,000, and 5,000 ppm, respectively. Urinary 
metabolites included N-acetyl-S- (2-hydroxyethyl)cysteine, thiodiglycolic acid, and possibly 
S-(2-hydroxyethyl)cysteine (Watanabe et al. 1976b).  Identification of these metabolites of vinyl chloride 
in the urine indicates that vinyl chloride is transformed in the body to a reactive metabolite, which is then 
detoxified by reaction with glutathione (GSH, gamma-glutamylcysteinylglycine).  Subsequently the 
glutamic acid and glycine moieties of the tripeptide are cleaved, and the cysteine conjugate of the reactive 
metabolite of vinyl chloride is either acetylated or further oxidized and excreted.  Thiodiglycolic acid is 
the major metabolite of vinyl chloride detected in the urine of exposed workers (Cheng et al. 2001).  
Urinary thiodiglycolic acid levels were correlated with vinyl chloride levels in air at concentrations 
>5 ppm. 
3.4.4.2 Oral Exposure  
No studies were located regarding excretion in humans after oral exposure to vinyl chloride. 
Single oral doses of 14C-vinyl chloride (0.05, 0.25, 1.0, 20, 100, and 450 mg/kg) were administered to 
rats, and the excretion of radioactivity was monitored over a 72-hour period (Green and Hathway 1975; 
Watanabe and Gehring 1976; Watanabe et al. 1976a).  A striking increase in exhalation of unchanged 
vinyl chloride and compensatory decreases in urinary and fecal excretion of radioactivity and exhalation 
of carbon dioxide were observed at >20 mg/kg, suggesting that metabolic saturation had occurred at that 
dosage. At less than 1.0 mg/kg, the predominant route of elimination was urinary excretion of polar 
metabolites. 
Exhalation of unchanged vinyl chloride was generally complete within 3–4 hours, but excretion of 
metabolites continued for days (Green and Hathway 1975).  Pulmonary excretion of vinyl chloride 
appeared to be monophasic at less than 1.0 mg/kg, with a half-life of about 55–58 minutes (Watanabe et 
al. 1976a). At 100 mg/kg, pulmonary excretion of vinyl chloride was biphasic, with half-lives of 14.4 and 
40.8 minutes for the rapid and slower phases, respectively.  Urinary excretion of radioactivity was 
biphasic, with the rapid phase accounting for more than 97% of total urinary radioactivity and having 
half-lives of 4.5–4.6 hours for dosages of 0.05–100 mg/kg. 
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Metabolites identified in the urine of orally treated rats were consistent with the formation of 
2-chloroethylene oxide and 2-chloroacetaldehyde (Green and Hathway 1977; Watanabe et al. 1976a), as 
postulated for metabolism following inhalation exposure.  The major metabolites were identified as 
thiodiglycolic acid and N-acetyl-S-(2-hydroxyethyl)cysteine (Watanabe et al. 1976a).  
N-Acetyl-S-(2-chloroethyl)cysteine and S-(2-chloroethyl)cysteine have also been identified as having 
smaller amounts of radiolabelled urea, glutamic acid, and 2-chloroacetic acid (Green and Hathway 1975). 
3.4.4.3 Dermal Exposure  
No studies were located regarding excretion in humans after dermal exposure to vinyl chloride. 
When two rhesus monkeys received whole-body (except head) exposure to vinyl chloride gas (800 and 
7,000 ppm) for 2–2.5 hours, although very little vinyl chloride was absorbed, most was excreted in 
expired air (Hefner et al. 1975a).  The percentages of absorbed vinyl chloride that were exhaled were 
0.028 and 0.014% at 700 and 8,000 ppm, respectively (Hefner et al. 1975a). 
3.4.4.4 Other Routes of Exposure 
The elimination of radioactivity following intraperitoneal administration of 14C-vinyl chloride to rats 
resembles the pattern observed following inhalation or oral administration.  Following an intraperitoneal 
dose of 0.25 mg/kg, exhalation of unchanged vinyl chloride, exhalation of carbon dioxide, and urinary 
and fecal excretion of radioactivity accounted for 43.2, 11.0, 43.1, and 1.8% of the administered dose, 
respectively (Green and Hathway 1975).  At 450 mg/kg, exhaled vinyl chloride increased to 96.2% of the 
administered dose, carbon dioxide decreased to 0.7%, urinary radioactivity decreased to 2.6%, and fecal 
radioactivity decreased to 0.1%. 
Doses administered intravenously were eliminated very rapidly and almost entirely by exhalation of 
unchanged vinyl chloride.  Green and Hathway (1975) administered a 0.25-mg/kg intravenous dose of 
14C-vinyl chloride to rats and recovered 80% of the dose within 2 minutes and 99% within 1 hour as 
unchanged compound in expired air. 
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3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models  
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and 
disposition of chemical substances to quantitatively describe the relationships among critical biological 
processes (Krishnan et al. 1994).  PBPK models are also called biologically based tissue dosimetry 
models.  PBPK models are increasingly used in risk assessments, primarily to predict the concentration of 
potentially toxic moieties of a chemical that will be delivered to any given target tissue following various 
combinations of route, dose level, and test species (Clewell and Andersen 1985).  Physiologically based 
pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to 
quantitatively describe the relationship between target tissue dose and toxic end points.   
PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to 
delineate and characterize the relationships between: (1) the external/exposure concentration and target 
tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen and 
Krishnan 1994; Andersen et al. 1987). These models are biologically and mechanistically based and can 
be used to extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from 
route to route, between species, and between subpopulations within a species.  The biological basis of 
PBPK models results in more meaningful extrapolations than those generated with the more conventional 
use of uncertainty factors. 
The PBPK model for a chemical substance is developed in four interconnected steps: (1) model 
representation, (2) model parameterization, (3) model simulation, and (4) model validation (Krishnan and 
Andersen 1994).  In the early 1990s, validated PBPK models were developed for a number of 
toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 
1994; Leung 1993).  PBPK models for a particular substance require estimates of the chemical substance-
specific physicochemical parameters, and species-specific physiological and biological parameters.  The 
numerical estimates of these model parameters are incorporated within a set of differential and algebraic 
equations that describe the pharmacokinetic processes.  Solving these differential and algebraic equations 
provides the predictions of tissue dose.  Computers then provide process simulations based on these 
solutions. 
The structure and mathematical expressions used in PBPK models significantly simplify the true 
complexities of biological systems.  If the uptake and disposition of the chemical substance(s) are 
adequately described, however, this simplification is desirable because data are often unavailable for 
111 VINYL CHLORIDE 
3. HEALTH EFFECTS 
many biological processes.  A simplified scheme reduces the magnitude of cumulative uncertainty.  The 
adequacy of the model is, therefore, of great importance, and model validation is essential to the use of 
PBPK models in risk assessment. 
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the 
maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994).  
PBPK models provide a scientifically sound means to predict the target tissue dose of chemicals in 
humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste 
sites) based on the results of studies where doses were higher or were administered in different species.  
Figure 3-4 shows a conceptualized representation of a PBPK model. 
If PBPK models for vinyl chloride exist, the overall results and individual models are discussed in this 
section in terms of their use in risk assessment, tissue dosimetry, and dose, route, and species 
extrapolations. 
PBPK models are available for vinyl chloride.  The overall results and individual models are discussed in 
this section in terms of their use in risk assessment, tissue dosimetry, and dose, route, and species 
extrapolations. 
Summary of PBPK/PD Models   
Models have been developed to predict the metabolism and distribution of vinyl chloride.  EPA (1987g) 
developed a PBPK model to estimate the metabolized dose of vinyl chloride coupled to a multistage 
model to estimate cancer risk in animals.  This PBPK model consists of four compartments, the liver, fat, 
highly perfused tissue, and poorly perfused tissue.  All metabolism was assumed to occur in the liver by 
one saturable pathway (Michaelis-Menten kinetics) and by a first-order metabolism pathway.  The 
physiologic parameters used were values from an EPA draft "Reference Physiologic Parameters in 
Pharmacokinetic Modeling" by Dr. Curtis Travis of the Oak Ridge National Laboratory. 
The dose delivery of the vinyl chloride model developed by EPA (1987g) was further validated by the Air 
Force (1990b) study with additional vinyl chloride metabolism studies in rats.  At low concentrations, this 
model fit in vivo data in rats by Gehring et al. (1978) well, but at concentrations above 25 ppm, the model 
predicted a greater amount of vinyl chloride metabolism than observed.  The Air Force (1990b) then 
made modifications in the model to improve the fit with actual data.  In the first modification, both vinyl 
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Figure 3-4. Conceptual Representation of a Physiologically Based 
 
Pharmacokinetic (PBPK) Model for a  
 












































 Chemicals in air 
contacting skin 
Source: adapted from Krishnan et al. 1994 
Note: This is a conceptual representation of a physiologically based pharmacokinetic (PBPK) model for a 
hypothetical chemical substance.  The chemical substance is shown to be absorbed via the skin, by inhalation, or by 
ingestion, metabolized in the liver, and excreted in the urine or by exhalation. 
113 VINYL CHLORIDE 
3. HEALTH EFFECTS 
chloride and the epoxide metabolite were assumed to react with glutathione.  This model had difficulty 
predicting glutathione depletion at high doses; for example, it predicted glutathione depletions higher than 
observed at 4,600–5,800 ppm vinyl chloride.  The second alternative model, in which only the product of 
the first-order metabolism was assumed to react with glutathione, also predicted glutathione depletions 
higher than observed at high concentrations.  To improve the model, the investigators suggested the 
addition of a low-affinity glutathione pathway. 
Using data obtained from Wright-Patterson Air Force Base, the Air Force (1990b) extended the first 
glutathione conjugation model, developed in rats, to different strains of rats, mice, and hamsters.  Vinyl 
chloride gas uptake experiments were completed in which animals were exposed to various 
concentrations of vinyl chloride in closed chambers for up to 6 hours, and the disappearance of vinyl 
chloride was monitored.  The glutathione content of the animals was also measured immediately after 
exposure. Using data from these studies and the physiologic parameters shown in Table 3-6, the 
investigators estimated metabolic parameters for vinyl chloride and the rate constant for the conjugation 
of vinyl chloride with glutathione (Table 3-7).  Using the metabolic parameters determined from the gas 
uptake experiments, the model predictions showed good agreement with the actual data for all the strains 
tested. It does not appear that the investigators further validated the model with data from studies other 
than those used to determine the metabolic parameters.  This model was not used to estimate metabolized 
doses for humans because the investigators indicated that human data to estimate all the required 
parameters were not available.  They suggested that allometry may have to be used to estimate some of 
the parameters for humans. 
Clewell et al. (1995) used PBPK modeling coupled with a linearized multistage model to predict human 
cancer risk. The model again had four compartments as described for the EPA (1987g) study, and the 
same EPA physiologic parameters were used.  Partition coefficients were from in vitro experiments and 
are shown in Table 3-4. Metabolism was modeled by two saturable pathways:  one high affinity, low 
capacity (P450 2E1), and one low affinity, high capacity (2C11/6 and 1A1/2).  The metabolic parameters 
used were not provided, but they were estimated from the Air Force (1990b) model.  This model assumed 
that the metabolites (chloroethylene oxide and chloroacetaldehyde) were further degraded to carbon 
dioxide, or reacted with glutathione, or reacted with DNA.  The parameters (not stated) for reactions of 
the metabolites were estimated from vinylidene chloride data (D'Souza and Andersen 1988) using 
appropriate allometric scaling.  Based on this PBPK model and a linearized multistage model using liver 
angiosarcoma data from animal studies, the human risk estimates for lifetime exposure to 1 ppb vinyl 
chloride ranged from 1.1 to 15.7/million persons (Clewell et al. 1995).  Based on the incidence of liver  
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Table 3-6. Physiological Parameters Used to Estimate Parameters from Vinyl 
 
Chloride Gas Uptake Experimentsa
 
Parameter Rats Mice Hamsters 
Ventilation rate (L/hour/body weight0.74) 14 23–25b 13 
Total cardiac output (L/hour/body weight0.74) 14 23–25b 13 
Blood flow to the liver (fraction of total cardiac output) 0.25 0.24 0.24 
Blood flow to highly perfused tissue (fraction of total cardiac output) 0.51 0.52 0.52 
Blood flow to fat (fraction of total cardiac output) 0.09c 0.05 0.09 
Blood flow to poorly perfused tissue (fraction of total cardiac output) 0.15c 0.20 0.15 
Volume of tissue (L/body weight) 0.04 0.04 0.04 
Volume of highly perfused tissue (L/body weight) 0.04 0.05 0.05 
Volume of fat tissue (L/body weight) 0.07–0.1d 0.04 0.07 
Volume of poorly perfused tissue (L/body weight) 0.72–0.75d 0.78 0.75 
aAir Force 1990b; units of body weight were not provided. 
 
bVentilation rates and total cardiac outputs were 23 for male B6C3F1 mice, 25 for female B6C3F1 mice, 28 for female 
 
CD-1 mice, and 35 for male CD-1 mice. 
 
cMale Wistar rats blood flow to fat = 0.08 and blood flow to slowly perfused tissue = 0.16. 
 
dFemale F-344 and female Wistar rats had volume of fat tissue = 0.07 and volume of slowly perfused tissue = 0.75; 
 
male F-344 and female Wistar rats had volume of fat tissue = 0.08 and volume of slowly perfused tissue = 0.74; 
 
male Wistar rats and male CDBR rats had volume of fat tissue = 0.1 and volume of slowly perfused tissue = 0.72. 
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Rat CDBR M 2.5 0.63 ND 
F 2.47 1.0 0.000241 
 F-344 M 3.17 1.08 0.000249 
F 2.95 1.03 0.000227 
 Wistar M 3.11 0.45 0.000093 
F 2.97 1.55 0.00040 
Mouse B6C3F1 M 5.89 5.5 0.000827 
F 5.53 8.93 0.00167 
CD-1 M 6.99 5.1 0.000563 
F 5.54 6.62 0.000809 
Hamster Golden M 4.94 1.67 ND 
Syrian 
F 4.76 2.06 0.000330 
Source: Air Force 1990b 
F = female; GSH = glutathione; Kfc = first order of epoxide formation; Kgsc = rate constant for conjugation of vinyl 
chloride with glutathione; M = male; ND = not determined; Vmax = maximum velocity of reaction 
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angiosarcoma in human epidemiological studies, the risk estimates for lifetime exposure to 1 ppb vinyl 
chloride were 0.4–4.22/million persons.  Clewell et al. (1995) indicated that the risk estimates in the 
occupational exposure range using PBPK modeling are about 30–50 times lower than estimates using 
external dose calculations based on the linearized multistage model. 
Reitz et al. (1996) also developed a PBPK model that coupled measures of delivered dose in rats to a 
linearized multistage model to predict the incidence of hepatic angiosarcoma in mice and humans.  The 
model incorporated four compartments—fat, muscle, rapidly perfused tissues, and liver.  Physiological 
parameters in the model were based on similar ones used in an earlier multispecies PBPK model 
developed for methylene chloride.  Partition coefficients were estimated by vial equilibration techniques 
similar to those described in the Air Force (1990b) study.  Metabolic rate constants were obtained from in 
vivo gas uptake experiments performed at Wright-Patterson Air Force Base. 
Based on the PBPK-based procedure utilized by Reitz et al. (1996), the predicted human risk estimates 
ranged from about 200 cases/100,000 (for workers employed 10 years at a plant where the TWA was 
50 ppm) to almost 4,000 cases/100,000 in workers employed for 20 years in a plant where the TWA was 
2,000 ppm.  The predictions of human risk were compared with the data reported by Simonato et al. 
(1991).  The predictions of angiosarcoma incidence in humans were almost an order of magnitude higher 
than actually observed in exposed human populations, and were more than two orders of magnitude lower 
than risk estimations that did not utilize pharmacokinetic data. 
Clewell et al. (2001) futher refined the PBPK model for vinyl chloride and this model was applied by the 
EPA to develop quantitative toxicity values for vinyl chloride (i.e., reference dose [RfD], reference 
concentration [RfC], inhalation unit risk, oral slope factor) (EPA 2000).  The model had four 
compartments and metabolism was modeled by two saturable pathways:  one high affinity, low capacity 
(P450 2E1), and one low affinity, high capacity (2C11/6 and 1A1/2).  A description of glutathione 
kinetics was also included in the model.  Cancer risk estimates in the occupational exposure range 
calculated using the PBPK model were consistent with risk estimates from epidemiological studies and 
were approximately 80-fold lower than cancer risk estimates from animal studies without PBPK 
modeling.  The inhalation portion of the PBPK model is well documented with experimental inhalation 
data sufficient to ensure a high degree of confidence in the derived dose metrics. Less confidence is 
associated with the oral dose metrics due to the limited experimental data available (EPA 2000). 
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The Clewell et al. (2001) model was also recently applied to evaluate the potential impact of age- and 
gender-specific pharmacokinetic differences on the dosimetry of vinyl chloride (Clewell et al. 2004).  The 
rate of metabolite production per volume of liver was estimated to rise rapidly from birth until about 
age 16, after which it remains relatively constant before rising again late in life.  Other factors that may 
affect vinyl chloride toxicity at early life stages include the presence of fetal P450s and the level of 
glutathione transferase. 
The PBPK model described in Clewell et al. (2001) and EPA (2000) was used to derive the chronic-
duration oral MRL.  The chronic oral MRL for vinyl chloride is based on the same critical effect as that 
used by EPA (2000) to derive the RfD for vinyl chloride (i.e., the NOAEL for liver cell polymorphism in 
the oral rat study of Til et al. 1983, 1991).  Source code and parameter values for running the rat and 
human models in Advance Continuous Simulation Language (ACSL) were transcribed from Appendix C 
of EPA (2000).  Exposures in the Til et al. (1983, 1991) rat dietary study were simulated as 4-hour oral 
exposures with the NOAEL dose for liver effects of 0.17 mg/kg/day.  A 4-hour feeding period was used 
in the study due to the rapid evaporative loss of vinyl chloride from the food.  The total amount of vinyl 
chloride metabolized in 24 hours per liter of liver volume was the rat internal dose metric that was used in 
determining the human dose that would result in an equivalent human dose metric.  One kilogram of liver 
was assumed to have an approximate volume of 1 L.  Dose metrics reflect the cumulative amount of vinyl 
chloride metabolized over the 24-hour period.  The human model was run iteratively, until the model 
converged with the internal dose estimate for the rat (3.16 mg/L liver).  The human dose was assumed to 
be uniformly distributed over a 24-hour period with the resulting human equivalent dose of 
0.09 mg/kg/day.  Therefore, the human equivalent dose of 0.09 mg/kg/day, associated with the rat 
NOAEL of 0.17 mg/kg/day (Til et al. 1983, 1991), served as the basis for the chronic-duration oral MRL 
for vinyl chloride.  A total uncertainty factor of 30 (3 for extrapolating from animals to humans using a 
dose metric conversion and 10 for human variability) was applied to yield the chronic-duration oral MRL 
of 0.003 mg/kg/day (see Appendix A for more detailed information regarding the application of the PBPK 
modeling in deriving the chronic-duration oral MRL for vinyl chloride). 
3.5 MECHANISMS OF ACTION  
3.5.1 Pharmacokinetic Mechanisms 
Absorption.    Vinyl chloride appears to be rapidly and completely absorbed following inhalation and 
oral exposure (Bolt et al. 1977; Krajewski et al. 1980; Watanabe et al. 1976a; Withey 1976).   
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Distribution.    Distribution of vinyl chloride in the body is rapid and widespread.  Storage is limited by 
rapid metabolism and excretion (Bolt et al. 1976a).   
Metabolism.    Vinyl chloride is metabolized by mixed function oxidases (MFO) to form an epoxide 
intermediate, 2-chloroethylene oxide, which spontaneously rearranges to form 2-chloroacetaldehyde.  
Reactive metabolites of vinyl chloride are detoxified by a reaction with glutathione.  The glutamic acid 
and glycine moieties of the tripeptide are cleaved, and the cysteine conjugate of the reactive metabolite is 
either acetylated or further oxidized and excreted. 
Excretion. The primary route of excretion of metabolites of vinyl chloride is through urine.  Urinary 
metabolites that have been identified include N-acetyl-S-(2-hydroxyethyl)cysteine, thiodiglycolic acid, 
and possibly S-(2-hydroxyethyl)cysteine (Watanabe et al. 1976b).  Exhalation of unmetabolized vinyl 
chloride is not an important pathway of elimination by humans after exposure to low concentrations.  The 
importance of exhalation of vinyl chloride varies with the exposure concentration.  At low exposure 
concentrations, little vinyl chloride is excreted unchanged in exhaled air.  However, vinyl chloride can be 
excreted unchanged in exhaled air if metabolic pathways become saturated at high exposure 
concentrations (Green and Hathway 1975; Watanabe and Gehring 1976; Watanabe et al. 1976a, 1978a). 
3.5.2 Mechanisms of Toxicity 
The mechanisms of toxicity for noncancer effects of vinyl chloride have not been completely elucidated.  
Vinyl chloride disease exhibits many of the characteristics of autoimmune diseases (Raynaud's 
phenomenon and scleroderma).  B-cell proliferation, hyperimmunoglobulinemia, and complement 
activation, as well as increased circulating immune complexes or cryoglobulinemia, have been noted in 
affected workers, indicating stimulation of immune response (Bogdanikowa and Zawilska 1984; Grainger 
et al. 1980; Ward 1976).  Mechanisms for the vascular changes, such as those occurring with Raynaud's 
phenomenon, have been proposed by Grainger et al. (1980) and Ward (1976).  According to these 
mechanisms, a reactive vinyl chloride intermediate metabolite, such as 2-chloroethylene oxide or 
2-chloroacetaldehyde, binds to a protein such as IgG.  The altered protein initiates an immune response, 
with deposition of immune products along the vascular endothelium.  Circulating immune complexes are 
proposed to precipitate in response to exposure to the cold, and these precipitates are proposed to produce 
blockage of the small vessels.  Resorptive bone changes in the fingers, also characteristic of vinyl chloride 
disease, may be due to activation of osteoclast secondary to vascular insufficiency in the finger tips, but 
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this mechanism has not been conclusively demonstrated.  Scleroderma is an autoimmune disease of 
unknown etiology.  It is characterized clinically by cutaneous and visceral fibrosis and can range from 
limited skin involvement to extensive cutaneous sclerosis with internal organ changes.  It has been 
proposed that fetal cells may be involved in the pathogenesis of scleroderma.  An increase in the number 
of microchimeric cells of fetal origin was reportedly associated with dermal fibrosis in mice injected with 
vinyl chloride (Christner et al. 2001).   
It has been hypothesized that cardiac arrhythmia reported after vinyl chloride exposure may result from 
sensitization of the heart to circulatory catecholamines, as occurs with other halogenated hydrocarbons.  
This was demonstrated in a dog study where the EC50 for cardiac sensitization was determined to be 
50,000 ppm (Clark and Tinston 1973).  Cardiac sensitization by halogenated hydrocarbons generally 
occurs at very high air concentrations (0.5–90%) (Brock et al. 2003).  Therefore, it appears unlikely that 
persons exposed to low levels of vinyl chloride will experience these effects.    
Peripheral nervous system symptoms such as paresthesia, numbness, weakness, warmth in the 
extremities, and pain in the fingers have been reported after vinyl chloride exposure (Langauer-
Lewowicka et al. 1983; NIOSH 1977; Suciu et al. 1963, 1975).  It is not known whether these effects 
represent direct adverse effects of vinyl chloride on peripheral nerves or whether they are associated with 
tissue anoxia due to vascular insufficiency. 
Vinyl chloride is a known human and animal carcinogen.  It has been associated with both an increased 
incidence of hepatic angiosarcomas and hepatotoxicity.  The mechanism for these liver effects has been 
studied to some extent. Vinyl chloride is metabolized by MFO to form an epoxide intermediate, 
2-chloroethylene oxide, which spontaneously rearranges to form 2-chloroacetaldehyde.  Reactive 
metabolites of vinyl chloride can be transported intercellularly from parenchymal cells to the 
nonparenchymal cells (Kuchenmeister et al. 1996).  Many studies have characterized the mutation profile 
associated with DNA adducts formed by the reactive metabolites of vinyl chloride (Akasaka et al. 1997; 
Chiang et al. 1997; Dosanjh et al. 1994; Guichard et al. 1996; Matsuda et al. 1995; Pandya and Moriya 
1996; Zhang et al. 1995; Zielinski and Hergenhahn 2000).  Four primary DNA adducts are formed by the 
reactive metabolites of vinyl chloride.  These are cyclic etheno-adducts that include 1,N6-ethenoadenine, 
3,N4-ethenocytosine, N2,3-ethenoguanine, and 1,N2-ethenoguanine.  These adducts can produce base-pair 
(i.e., purine-to-purine or pyrimidine-to-pyrimidine exchange) transitions during transcription (Cullinan et 
al. 1997; Pandya and Moriya 1996; Singer et al. 1987, 1996).  DNA crosslinks can also be formed 
because chloracetaldehyde is bifunctional (Singer 1994).  
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The role of etheno-adducts in the carcinogenesis of vinyl chloride has been recently reviewed (Albertini 
et al. 2003, Barbin 1998, 2000; Kielhorn et al. 2000; Laib 1986; Whysner et al. 1996).  2-Chloroethylene 
oxide and 2-chloroacetaldehyde can both react with DNA nucleotide bases; however, 2-chloroethylene 
oxide is a more potent mutagen and may be the ultimate carcinogenic metabolite of vinyl chloride 
(Chiang et al. 1997). Etheno-adducts generate mainly base pair substitiution mutations.  Mutations in 
specific genes (i.e., ras oncogenes, p53 tumor suppressor gene) have been identified in vinyl chloride-
induced liver tumors in rats and humans and are discussed in further detail in Section 3.3. 
The mechanisms for clastogenic effects of vinyl chloride exposure were examined by Fucic et al. (1990). 
Since chromatid and bichromatid breaks most frequently occurred in the terminal A, B, and C group 
chromosomes, these investigators suggested that vinyl chloride or its metabolites might interact with 
specific sites along the chromosome.  This implies that the carcinogenicity induced by vinyl chloride can 
be explained in part by its nonrandom interaction with particular genes. 
Liver toxicity has been demonstrated in workers exposed vinyl chloride (Berk et al. 1975; Falk et al. 
1974; Gedigke et al. 1975; Ho et al. 1991; Jones and Smith 1982; Lilis et al. 1975; Liss et al. 1985; 
Marsteller et al. 1975; NIOSH 1977; Popper and Thomas 1975; Suciu et al. 1975; Tamburro et al. 1984; 
Vihko et al. 1984). The mechanism for liver toxicity is thought to be related to the production of reactive 
metabolites that covalently bind to liver proteins, resulting in cellular toxicity (Kappas et al. 1975).  The 
intermediary metabolites, 2-chloroethylene oxide and 2-chloroacetaldehyde, bind to macromolecules in 
the body. 2-Chloroethylene oxide is believed to bind primarily to DNA and RNA, whereas 
2-chloroacetaldehyde binds primarily to proteins (Bolt 1986; Guengerich and Watanabe 1979; 
Guengerich et al. 1979, 1981; Kappus et al. 1976; Watanabe et al. 1978a, 1978b). 
3.5.3 Animal-to-Human Extrapolations 
Limited information is available regarding the toxicokinetic differences between species.  Toxicokinetic 
data in humans are limited (Krajewski et al. 1980; Sabadie et al. 1980), but a primate study suggested that 
metabolism may saturate at lower concentrations in primates than in rats (Buchter et al. 1980), which is 
suggestive of a lower saturation point in humans.  Exposure concentrations greater than about 300– 
400 ppm in the primate study showed saturation characteristics (Buchter et al. 1980).  PBPK models have 
been developed to predict the metabolism and distribution of vinyl chloride in laboratory animals and 
humans (see Section 3.4.5).  The most recent PBPK model for vinyl chloride (Clewell et al. 2001) was 
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applied by the EPA to develop quantitative toxicity values for vinyl chloride (i.e., RfD, RfC, inhalation 
unit risk, oral slope factor) (EPA 2000). The model had four compartments and metabolism was modeled 
by two saturable pathways:  one high affinity, low capacity (P450 2E1), and one low affinity, high 
capacity (2C11/6 and 1A1/2).  A description of glutathione kinetics was also included in the model.  
Cancer risk estimates calculated using the PBPK model were consistent with risk estimates from 
epidemiological studies. 
Correlation of toxic effects between humans and animals with regard to respiratory, cardiovascular, 
hematological, hepatic, dermal, immunological, neurological, reproductive, and cancer effects has been 
noted. Renal effects, including increased relative kidney weight and an increase in severity of tubular 
nephrosis, have been reported in several rat studies (Bi et al. 1985; Feron and Kroes 1979; Feron et al. 
1979a), but no evidence of renal effects has been shown in humans.  Thus, it is unclear whether the renal 
effects reported in rats represent a lesion that can be attributed to vinyl chloride exposure that is unique to 
rats or whether the effects represent an increase in severity of a naturally occurring lesion.  From the 
limited data available, however, it does not appear that the rat is the most appropriate species for use in 
studies of renal toxicity. 
3.6 TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS 
Recently, attention has focused on the potential hazardous effects of certain chemicals on the endocrine 
system because of the ability of these chemicals to mimic or block endogenous hormones.  Chemicals 
with this type of activity are most commonly referred to as endocrine disruptors.  However, appropriate 
terminology to describe such effects remains controversial.  The terminology endocrine disruptors, 
initially used by Thomas and Colborn (1992), was also used in 1996 when Congress mandated the EPA to 
develop a screening program for “...certain substances [which] may have an effect produced by a 
naturally occurring estrogen, or other such endocrine effect[s]...”.  To meet this mandate, EPA convened a 
panel called the Endocrine Disruptors Screening and Testing Advisory Committee (EDSTAC), and in 
1998, the EDSTAC completed its deliberations and made recommendations to EPA concerning endocrine 
disruptors.  In 1999, the National Academy of Sciences released a report that referred to these same types 
of chemicals as hormonally active agents. The terminology endocrine modulators has also been used to 
convey the fact that effects produced by such chemicals may not necessarily be adverse.  Many scientists 
agree that chemicals with the ability to disrupt or modulate the endocrine system are a potential threat to 
the health of humans, aquatic animals, and wildlife.  However, others think that endocrine-active 
chemicals do not pose a significant health risk, particularly in view of the fact that hormone mimics exist 
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in the natural environment.  Examples of natural hormone mimics are the isoflavinoid phytoestrogens 
(Adlercreutz 1995; Livingston 1978; Mayr et al. 1992).  These chemicals are derived from plants and are 
similar in structure and action to endogenous estrogen.  Although the public health significance and 
descriptive terminology of substances capable of affecting the endocrine system remains controversial, 
scientists agree that these chemicals may affect the synthesis, secretion, transport, binding, action, or 
elimination of natural hormones in the body responsible for maintaining homeostasis, reproduction, 
development, and/or behavior (EPA 1997).  Stated differently, such compounds may produce toxicities 
that are mediated through the neuroendocrine axis.  As a result, these chemicals may play a role in 
altering, for example, metabolic, sexual, immune, and neurobehavioral functions.  Such chemicals are 
also thought to be involved in inducing breast, testicular, and prostate cancers, as well as endometriosis 
(Berger 1994; Giwercman et al. 1993; Hoel et al. 1992). 
Vinyl chloride has not been classified as an endocrine modulator; however, adverse reproductive and 
developmental effects have been reported in human and laboratory animal studies.  Effects on the thyroid 
gland have also been reported.   
A number of case studies of male workers occupationally exposed to vinyl chloride report sexual 
impotence, loss of libido, and decreased androgen secretion (Suciu et al. 1975; Veltman et al. 1975; 
Walker 1976).  Preeclampsia (i.e., elevated blood pressure and edema during pregnancy) was reported in 
female workers exposed to vinyl chloride (Bao et al. 1988).  Animal studies indicate that exposure to 
vinyl chloride can result in a decrease in testicular function (Bi et al. 1985; Sokal et al. 1980); however, 
these effect appears to be due to direct toxicity at the target organ and are not related to a hormone-
mediated mechanism of action.    
Reproductive capability was not affected in a 2-generation inhalation reproductive toxicity study in rats 
(Thornton et al. 2002).  No effects were seen in body weight, feed consumption, ability to reproduce, 
gestation index or length, or pre- and postweaning developmental landmarks.  Sperm counts, motility, and 
morphology were also unaffected by vinyl chloride exposure.  Changes were observed in liver weights 
and/or histopathological alterations in the liver of F0 and F1 generation male and female rats.  No effect 
was observed on male fertility or pre- or postimplantation loss in mice following an acute exposure to 
vinyl chloride (i.e., 30,000 ppm, 6 hours/day, 5 days/week) (Anderson et al. 1976).  In contrast, exposure 
of male rats to concentrations as low as 250 ppm for 6 hours/day, 5 days/week for 11 weeks produced a 
decrease in the ratio of pregnant to mated females, indicating a decrease in male fertility; this effect was 
not observed at 50 ppm (Short et al. 1977).  
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Although evidence has been presented indicating that members of communities with nearby vinyl 
chloride polymerization facilities have significantly greater incidences of some forms of developmental 
toxicity, these studies failed to demonstrate a statistically significant correlation between the 
developmental toxicity and either parental occupation or proximity to the facility (Edmonds et al. 1978; 
Infante et al. 1976b; Rosenman et al. 1989; Theriault et al. 1983). Vinyl chloride did not correlate with 
changes in gender ratio, birth weight or height, perinatal mortality, or the incidence of congenital 
abnormalities in mothers occupationally exposed to vinyl chloride for more than 1 year (Bao et al. 1988).   
There are inconsistencies in the developmental toxicity database for the vinyl chloride.  In general, vinyl 
chloride produced minor developmental effects in laboratory animals (i.e., delayed ossification) only at 
concentrations that were significantly toxic to maternal animals.  Maternal toxicity was evident in mice, 
rats, and rabbits exposed throughout the period of organogenesis.  Adverse fetal effects included delayed 
ossification (all species), increased crown-rump length (mice and rats), and vertebral lumbar spurs (rats).  
Mice were the most sensitive species investigated (John et al. 1977, 1981).  Ungvary et al. (1978) 
reported a significant increase in resorptions in rats exposed to vinyl chloride during the first trimester of 
pregnancy.  Increased liver-to-body weight ratios were observed in maternal animals exposed during the 
first and second trimesters, but no histopathologic alterations were found.  Continuous exposure of rats to 
vinyl chloride throughout gestation resulted in decreased fetal weight and increased early 
postimplantation loss, hematomas, and hydrocephaly with intracerebral hematoma.  Weanling rats 
displayed hepatotoxic effects including decreased bile enzyme activity, decreased bile secretion, 
decreased cholic acid content, and increased hexobarbital sleep time.  No histological data on the livers of 
pups, or information regarding maternal health were presented (Mirkova et al. 1978). 
In contrast with previous studies, no adverse effects were reported in an embryo-fetal developmental 
toxicity study conducted in rats exposed to similar concentrations of vinyl chloride via inhalation 
(Thornton et al. 2002).  Embryo-fetal developmental parameters including uterine implantation, fetal 
gender distribution, fetal body weight, and fetal malformations and variations were not affected by vinyl 
chloride exposure. Vinyl chloride produced a slight decrease in maternal body weight gain at all 
exposure levels; however, no changes were observed in feed consumption, clinical signs, or postmortem 
gross findings.  Maternal liver and kidney weights were increased relative to total body weight. 
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The developmental toxicity of vinyl chloride was examined using an in vitro whole embryo culture 
system (Zhao et al. 1996).  Vinyl chloride induced embryo growth retardation, but was not shown to be 
teratogenic in the rat in vitro whole embryo culture system. 
A study of workers exposed to vinyl chloride in PVC manufacturing plants reported that most workers 
who presented with scleroderma were shown to have thyroid insufficiency (Suciu et al. 1963).  No 
histopathological effects on the adrenals were reported in guinea pigs exposed to 400,000 ppm for 
30 minutes (Mastromatteo et al. 1960).  Rats exposed to 30,000 ppm vinyl chloride 5 days/week, 
4 hours/day for 12 months, were found to have colloid goiter and markedly increased numbers of 
perifollicular cells (Viola 1970). 
3.7 CHILDREN’S SUSCEPTIBILITY  
This section discusses potential adverse health effects from exposures during the period from conception 
to maturity at 18 years of age in humans, when all biological systems will have fully developed.  Potential 
effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect 
effects on the fetus and neonate resulting from maternal exposure during gestation and lactation.  
Relevant animal and in vitro models are also discussed. 
Children are not small adults.  They differ from adults in their exposures and may differ in their 
susceptibility to hazardous chemicals.  Children’s unique physiology and behavior can influence the 
extent of their exposure and the nature of their response to toxicants.  Exposures of children are discussed 
in Section 6.6, Exposures of Children. 
Children sometimes differ from adults in their susceptibility to hazardous chemicals, but whether there is 
a difference depends on the chemical (Guzelian et al. 1992; NRC 1993).  Children may be more or less 
susceptible than adults to adverse health effects, and the relationship may change with developmental age 
(Guzelian et al. 1992; NRC 1993).  Vulnerability often depends on developmental stage.  There are 
critical periods of structural and functional development during both prenatal and postnatal life and a 
particular structure or function will be most sensitive to disruption during its critical period(s).  Damage 
may not be evident until a later stage of development.  There are often differences in pharmacokinetics 
and metabolism between children and adults.  For example, absorption may be different in neonates 
because of the immaturity of their gastrointestinal tract and their larger skin surface area in proportion to 
body weight (Morselli et al. 1980; NRC 1993); the gastrointestinal absorption of lead is greatest in infants 
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and young children (Ziegler et al. 1978).  Distribution of xenobiotics may be different; for example, 
infants have a larger proportion of their bodies as extracellular water and their brains and livers are 
proportionately larger (Altman and Dittmer 1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek 
1966; Widdowson and Dickerson 1964).  The infant also has an immature blood-brain barrier (Adinolfi 
1985; Johanson 1980) and probably an immature blood-testis barrier (Setchell and Waites 1975).  Many 
xenobiotic metabolizing enzymes have distinctive developmental patterns.  At various stages of growth 
and development, levels of particular enzymes may be higher or lower than those of adults, and 
sometimes unique enzymes may exist at particular developmental stages (Komori et al. 1990; Leeder and 
Kearns 1997; NRC 1993; Vieira et al. 1996).  Whether differences in xenobiotic metabolism make the 
child more or less susceptible also depends on whether the relevant enzymes are involved in activation of 
the parent compound to its toxic form or in detoxification.  There may also be differences in excretion, 
particularly in newborns who all have a low glomerular filtration rate and have not developed efficient 
tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948).  
Children and adults may differ in their capacity to repair damage from chemical insults.  Children also 
have a longer remaining lifetime in which to express damage from chemicals; this potential is particularly 
relevant to cancer. 
Certain characteristics of the developing human may increase exposure or susceptibility, whereas others 
may decrease susceptibility to the same chemical.  For example, although infants breathe more air per 
kilogram of body weight than adults breathe, this difference might be somewhat counterbalanced by their 
alveoli being less developed, which results in a disproportionately smaller surface area for alveolar 
absorption (NRC 1993). 
No studies were located that specifically address the effects of vinyl chloride in children.  The effects that 
have been reported to occur in humans come almost exclusively from studies of workers exposed to high 
concentrations of vinyl chloride by inhalation.  Although the effects observed in human adults could also 
be observed in children, it is important to note that occupational exposure concentrations are likely to be 
much greater than environmental levels to which children might be exposed.  The toxicological effects 
reported in adult vinyl chloride workers include cardiovascular, gastric, hematologic, musculoskeletal, 
hepatic, endocrine, dermal, ocular, immunologic, neurologic, and reproductive effects as well as cancer 
and death. 
Some epidemiologic studies (Infante 1976; Infante et al. 1976a, 1976b; NIOSH 1977) have suggested an 
association between birth defects and vinyl chloride exposure of the parents of affected children.  
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However, the design and analysis of these studies has been criticized (Hatch et al. 1981; Stallones 1987).  
Some inhalation studies with animals have suggested that vinyl chloride is a developmental toxicant (i.e., 
produces delayed ossification) at doses that also produce maternal toxicity (John et al. 1977, 1981; 
Mirkova et al. 1978; Sal'nikova and Kotsovskaya 1980; Ungvary et al. 1978).  However, no adverse 
effects on embryo-fetal development were noted in a recent inhalation study in rats conducted using 
similar concentrations of vinyl chloride (Thornton et al. 2002).   
Carcinogenicity studies with animals indicate that some of the adverse health effects of vinyl chloride are 
dependent on the age of the animal at the time of the exposure.  Thus, higher death rates were observed 
when 2-month-old female hamsters, mice, and rats (equivalent to adolescent humans) were exposed to 
vinyl chloride in the air for 12 months than when 8- or 14-month-old animals were exposed (Drew et al. 
1983).  Lifetime cancer risk was also dependent on the age of the animals at the time of exposure to vinyl 
chloride. The incidence of hemangiosarcoma of the liver, skin, and spleen, and angiosarcoma of the 
stomach was greater in animals exposed by inhalation for 12 months starting immediately after weaning 
than in animals that were 1 year older at the time of exposure (Drew et al. 1983).  The incidence of 
mammary gland carcinoma was higher in 2- or 8-month-old hamsters exposed to 200 ppm vinyl chloride 
for 6 months than in 14- or 20-month-old hamsters exposed to the same concentration and for the same 
duration (Drew et al. 1983).  These results demonstrate the importance of the latency period for vinyl 
chloride-induced carcinogenesis.  Animals that were exposed at a younger age had a longer post-exposure 
period for the development of tumors.  It is difficult to assess the sensitivity of younger animals to cancer 
in this study because the same exposure concentrations were used for each age group.  Exposures were 
most effective in producing cancer when started early in life (Drew et al. 1983). 
Maltoni et al. (1981) evaluated the effect of vinyl chloride dosing on liver carcinogenicity in Sprague-
Dawley rats.  Rats were exposed to 0, 6,000, or 10,000 ppm vinyl chloride for 100 hours, beginning either 
at 1 day or at 13 weeks of age.  The incidence of angiosarcoma of the liver in newborn rats exposed for 
only 5 weeks was higher than the incidence observed in rats exposed for 52 weeks beginning at 13 weeks.  
Hepatoma incidence was approximately 50% in newborn rats exposed for 5 weeks, but did not occur in 
rats exposed for 52 weeks after maturity.  The increased tumor incidence combined with the production 
additional tumor types (i.e., angiosarcomas and hepatomas) suggest that newborn rats may be more 
sensitive to vinyl-chloride induced carcinogenicity. 
An age-related increase in DNA adduct formation was noted in an inhalation study of lactating rats and 
their 10-day-old pups exposed to 600 ppm of vinyl chloride, 4 hours/day for 5 days (Fedtke et al. 1990).  
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Concentrations of two adducts found in liver of pups were 4-fold higher than those found in liver of 
dams; however, pups were exposed to contaminated breast milk in addition to air concentrations vinyl 
chloride. In another study, immature rats exposed to vinyl chloride formed 6 times more etheno­
nucleosides compared with adults (Ciroussel et al. 1990).  The concentration of ethenoguanine adducts 
was 2–3-fold greater in weanling rats as compared to adult rats exposed at the same dose for the time 
period (0, 10, 100, or 1,100 ppm, 6 hours/day for 5 days) (Morinello et al. 2002a).   
Vinyl chloride induced preneoplastic foci in newborn rats, but not in mature rats (Laib et al. 1985).  A 
study with newborn male or female Wistar rats exposed to 2,000 ppm vinyl chloride indicated that the 
induction of preneoplastic hepatocellular lesions in rats by vinyl chloride is restricted to an early stage in 
the life of the animals.  The early-life stage sensitivity to the induction of tumors in animals exposed to 
vinyl chloride appears to be related to the induction by vinyl chloride of hepatic adenosine-5’-triphos­
phatase (ATPase) deficient enzyme altered foci, which are putative precursors of hepatocellular 
carcinoma. 
Taken together, the studies cited above suggest an early life stage sensitivity to vinyl chloride 
carcinogenicity (Cogliano et al. 1996). EPA has recommended an adjustment of the cancer risk estimates 
to account for early life-stage sensitivity to vinyl chloride (EPA 2000; Ginsberg 2003). 
No studies were located that specifically address the toxicokinetics of vinyl chloride in children; however, 
the toxicokinetic behavior of vinyl chloride in children is expected to be similar to that in adults.  An 
evaluation of pharmacokinetic differences across life stages suggests that the largest difference in 
pharmacokinetics occurs during the perinatal period (Gentry et al. 2003).  The most important factor 
appears to be the potential for decreased clearance due to immature metabolic enzymes systems; however, 
an analysis of CYP2E1 levels during development suggests that protein levels and enzyme activity in 
children between 1 and 10 years old are comparable to adults (EPA 2001).  This enzyme is not expressed 
in the embryonic liver, but rapidly increases during the first 24 hours after birth.  Young children appear 
capable of metabolizing vinyl chloride to reactive intermediates that form DNA adducts that lead to 
cancer. A PBPK model was also recently applied to evaluate the potential impact of age- and gender-
specific pharmacokinetic differences on the dosimetry of vinyl chloride (Clewell et al. 2004).  The rate of 
metabolite production per volume of liver was estimated to rise rapidly from birth until about age 16, after 
which it remains relatively constant before rising again late in life.  The data on CYP2E1 levels in the 
developing organism suggests that early life stage sensitivity to vinyl chloride-induced cancer is not 
solely due to an increase in the production of reactive intermediates via this isozyme.  Fetal CYP isoforms 
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may play a role in metabolism of vinyl chloride to reactive intermediates in the fetus and neonate.  
Glutathione conjugation may also differ in the developing organism.  DNA repair capacity and other 
pharmacodynamic factors may also be associated with an early life stage susceptibility to cancer.   
3.8 BIOMARKERS OF EXPOSURE AND EFFECT 
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC 
1989). 
Due to a nascent understanding of the use and interpretation of biomarkers, implementation of biomarkers 
as tools of exposure in the general population is very limited.  A biomarker of exposure is a xenobiotic 
substance or its metabolite(s) or the product of an interaction between a xenobiotic agent and some target 
molecule(s) or cell(s) that is measured within a compartment of an organism (NAS/NRC 1989).  The 
preferred biomarkers of exposure are generally the substance itself or substance-specific metabolites in 
readily obtainable body fluid(s) or excreta.  However, several factors can confound the use and 
interpretation of biomarkers of exposure.  The body burden of a substance may be the result of exposures 
from more than one source.  The substance being measured may be a metabolite of another xenobiotic 
substance (e.g., high urinary levels of phenol can result from exposure to several different aromatic 
compounds).  Depending on the properties of the substance (e.g., biologic half-life) and environmental 
conditions (e.g., duration and route of exposure), the substance and all of its metabolites may have left the 
body by the time samples can be taken.  It may be difficult to identify individuals exposed to hazardous 
substances that are commonly found in body tissues and fluids (e.g., essential mineral nutrients such as 
copper, zinc, and selenium).  Biomarkers of exposure to vinyl chloride are discussed in Section 3.8.1. 
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an 
organism that, depending on magnitude, can be recognized as an established or potential health 
impairment or disease (NAS/NRC 1989).  This definition encompasses biochemical or cellular signals of 
tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial 
cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung 
capacity.  Note that these markers are not often substance specific.  They also may not be directly 
adverse, but can indicate potential health impairment (e.g., DNA adducts).  Biomarkers of effects 
produced by vinyl chloride are discussed in Section 3.8.2. 
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A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability 
to respond to the challenge of exposure to a specific xenobiotic substance.  It can be an intrinsic genetic or 
other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the 
biologically effective dose, or a target tissue response.  If biomarkers of susceptibility exist, they are 
discussed in Section 3.10, “Populations That Are Unusually Susceptible”. 
3.8.1 Biomarkers Used to Identify or Quantify Exposure to Vinyl Chloride  
Exposure to vinyl chloride may be monitored to some extent by the identification and quantitation of a 
number of parameters.  For example, following acute exposure to moderate-to-high levels, vinyl chloride 
can be measured in expired air.  The expiration of vinyl chloride follows first-order kinetics; therefore, 
this parameter may be directly correlated with exposure levels (Baretta et al. 1969).  This measure may 
provide the most direct evidence of vinyl chloride exposure.  However, measurement of exposure by this 
technique is limited by the rapidity of excretion of vinyl chloride in expired air.  The half-life of vinyl 
chloride in expired air has been determined to be between 20 and 30 minutes following an inhalation 
exposure and to be approximately 60 minutes following oral dosing (Watanabe and Gehring 1976; 
Watanabe et al. 1976b, 1978a, 1978b). Thus, testing must be initiated as soon as possible following 
termination of exposure.  Furthermore, measurement of vinyl chloride in expired air has limited utility for 
low-level exposures (<50 ppm) because of competition with absorption and rapid metabolic processes 
(Baretta et al. 1969).  In addition, it provides no information on the duration of exposure. 
Thiodiglycolic acid is a major metabolite of vinyl chloride that is excreted in the urine.  Measurement of 
thiodiglycolic acid in urine has been used to monitor workers occupationally exposed to vinyl chloride 
(Cheng et al. 2001; Müller et al. 1979). However, although this metabolite is used to estimate levels of 
exposure, the amount of thiodiglycolic acid in the urine varies according to individual metabolic 
idiosyncracies.  Also, metabolism of vinyl chloride to thiodiglycolic acid is a saturable process. 
Therefore, when exposure exceeds a certain level, the excretion of vinyl chloride as thiodiglycolic acid 
will plateau (Watanabe and Gehring 1976).  Furthermore, the rate of metabolism of vinyl chloride to 
thiodiglycolic acid may be influenced by the presence of liver disease, ethanol, or certain other substances 
such as barbiturates (Hefner et al. 1975b) (also see Section 3.4).  Similar to the measurement of vinyl 
chloride in expired air, the measurement of thiodiglycolic acid must take place shortly after exposure 
because of the rapidity of its excretion.  The half-life for excretion of thiodiglycolic acid following an 
acute exposure is between 4 and 5 hours (Watanabe and Gehring 1976; Watanabe et al. 1978a, 1978b).  
Cheng et al. (2001) suggests that urinary thiodiglycolic acid levels should not be measured at the end of a 
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work shift, but are best detected at the beginning of the following work day.  Finally, excretion of 
thiodiglycolic acid is not unique to exposure to vinyl chloride.  For example, thiodiglycolic acid may be 
excreted in the urine as the result of exposure to vinylidene chloride, ethylene oxide, or 2,2-dichloro­
ethylether (Norpoth et al. 1986; Pettit 1986).  Also, infants delivered prematurely have been found to have 
high levels of urinary thiodiglycolic acid.  A correlation was observed between the thiodiglycolic acid 
levels and the number of weeks that the infant was born prematurely.  The origin of this thiodiglycolic 
acid is unknown, but is not believed to be associated with vinyl chloride exposure (Pettit 1986). 
The intermediary metabolites, 2-chloroethylene oxide and 2-chloroacetaldehyde, bind to macromolecules 
in the body. 2-Chloroethylene oxide is believed to bind primarily to DNA and RNA, whereas 
2-chloroacetaldehyde binds primarily to proteins (Bolt 1986; Guengerich and Watanabe 1979; 
Guengerich et al. 1979, 1981; Kappus et al. 1976; Watanabe et al. 1978a, 1978b).  Two of the DNA 
adducts that are formed are 1,N6-etheno-adenosine and 3,N4-ethenocytidine.  Monoclonal antibodies for 
these DNA adducts have been isolated and used in enzyme-linked immunosorbent assays (ELISA) to 
quantify these ethenoderivatives in biological samples (Eberle et al. 1989; Young and Santella 1988). 
Measurement of DNA adducts may be useful in estimating vinyl chloride exposure.  However, this 
technique is of limited value for quantifying levels of exposure because formation of these products will 
be influenced by variability in vinyl chloride metabolism.  Also, their persistence in tissues will be 
influenced by the rate of DNA metabolism and repair.  Furthermore, the DNA adducts, for which 
monoclonal antibodies have been isolated, are also formed as a result of exposure to vinyl bromide, ethyl 
carbamate, acrylonitrile, 2-cyanoethylene, and 1,2-dichloroethane (Bolt et al. 1986; Svensson and 
Osterman-Golkar 1986).  See Section 3.4 for additional information on the kinetics of vinyl chloride. 
Ethenoguanine adducts have been quantified in human urine using high performance liquid 
chromatography and tandem mass spectrometry (Gonzalez-Reche et al. 2002).  Etheno-adducts are 
removed from DNA through base excision repair and excreted in the urine where they can be measured 
using this technique.  This method would also include the measurement of endogenously formed etheno­
adducts; thus, it is critical to determine the background level of urinary adducts in a control population. 
Vinyl chloride-induced genetic alterations have been identified in the Ki-ras oncogene and the p53 tumor 
suppressor gene, and oncoproteins and p53 antibodies have been detected in the serum of cancer patients 
with angiosarcoma (see Section 3.3).  Immunological techniques have been used to detect the presence of 
Asp13p21 (oncoprotein for mutation of the Ki-ras gene), p53 mutant protein, and p53 antibodies in the 
serum of exposed workers (Brandt-Rauf et al. 2000a, 2000b; Marion 1998).  Statistical analyses suggest a 
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relationship between vinyl chloride exposure and the presence of these serum biomarkers; however, the 
predictive value of these biomarkers for development of cancer is not known. 
The micronucleus assay, performed using peripheral lymphocytes of 32 vinyl chloride workers, was used 
to indicate the time elapsed since the last vinyl chloride exposure occurred (Fucic et al. 1994, 1997).  The 
study showed a decrease in the frequency of micronuclei and mitotic activity in proportion to the length 
of the interval after the last vinyl chloride exposure.  For the group with 10 years of employment, the 
percentage of micronuclei decreased from 12.82 when exposure occurred on the day of blood sampling to 
3.16 when the last exposure occurred 90 days before blood sampling (Fucic et al. 1994).  Similar changes 
were noted when the mean duration of employment was 5 years.  However, this use of the micronucleus 
assay must take into account the total duration of exposure.  Micronucleus frequency was shown to be 
several times higher in binucleated lymphocytes as compared to mononuclear lymphocytes in 25 workers 
exposed to vinyl chloride for an average of 10 years (Fucic et al. 2004).  
Exposure to vinyl chloride may also be estimated to some extent by the presence of certain symptoms 
known to be closely associated with vinyl chloride exposure.  The exposure may have occurred even if 
the symptoms were not found upon examination, but their presence could be indicative of exposure.  For 
example, a syndrome known as vinyl chloride disease has been identified in workers occupationally 
exposed to vinyl chloride.  This syndrome includes Raynaud's phenomenon, acroosteolysis of the distal 
phalanges of the fingers, and scleroderma-like changes in the hands and forearms (also see Section 3.2). 
Although this syndrome resembles systemic sclerosis, a differential diagnosis may be made based on the 
absence of antinuclear antibodies from the blood of those afflicted with vinyl chloride disease (Black et 
al. 1983, 1986). The occurrence of vinyl chloride disease in highly exposed worker populations is about 
3%, and susceptibility appears to be genetically related (Black et al. 1983, 1986).  Symptoms of vinyl 
chloride disease are unlikely to occur in hazardous waste site conditions because of predicted low levels 
of exposure. Absence of these symptoms would not eliminate the possibility of exposure, but their 
presence may be a good indicator of exposure.  
Angiosarcoma of the liver has been identified in workers occupationally exposed to vinyl chloride.  This 
type of tumor is extremely rare in the general population (Heath et al. 1975); therefore, its diagnosis may 
indicate vinyl chloride exposure.  However, other causes of angiosarcoma such as exposure to arsenicals 
and Thorotrast (thorium dioxide; formerly used in arteriography) should be considered as possible 
causative factors, if present, before correlating hepatic angiosarcoma with vinyl chloride exposure 
(Gedigke et al. 1975; Marsteller et al. 1975).  Their elimination may depend upon such factors as the 
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magnitude of the vinyl chloride exposure and the frequency of the other causes of angiosarcoma in the 
population. 
3.8.2 Biomarkers Used to Characterize Effects Caused by Vinyl Chloride  
The realization that angiosarcoma of the liver is associated with vinyl chloride exposure prompted several 
investigators to try to identify assays that could be used to monitor those individuals considered to be at 
risk. Standard serum assays designed to detect the presence of hepatic enzymes in the blood were found 
to be of limited value in monitoring the progression of vinyl chloride-induced hepatic changes (Berk et al. 
1975; Liss et al. 1985; Vihko et al. 1984).  This may be because of the extent of hepatic damage produced 
by vinyl chloride and the late development of necrotic areas in the disease process (Popper et al. 1981).  
In contrast, studies indicate that clearance type assays, which measure liver function, are more sensitive 
indicators of the hepatic damage resulting from vinyl chloride exposure.  These assays include the 
indocyanine clearance test, measurement of serum bile acids, and measurement of serum hyaluronic acid 
concentration (Berk et al. 1975; Liss et al. 1985; McClain et al. 2002; Vihko et al. 1984). 
Liver biopsy may provide the most accurate identification of vinyl chloride-associated liver damage (Liss 
et al. 1985). This is because of the characteristic pattern of hepatic histopathology associated with vinyl 
chloride-induced damage (Popper et al. 1981).  However, liver biopsy is an invasive procedure with 
attendant risks and, therefore, may not be justified. 
Individual exposure to vinyl chloride has been linked to angiosarcoma and benign angiomatous lesions 
based on the monitoring of serum found to be positive for the presence of the mutant protein 
Asp 13 c-Ki-ras p21, which was not present in control individuals (DeVivo et al. 1994).  Additionally, 
this protein was found in the serum of 49% of exposed workers who had no apparent liver lesions.  It may 
be possible to utilize the presence of this mutant protein for the early detection of angiosarcoma of the 
liver. 
Use of enzyme-linked immunoassay (EIA) to detect anti-p53 antibodies in serum of individuals exposed 
to vinyl chloride may provide an early method of screening for angiosarcoma of the liver (Trivers et al. 
1995).  Detection of serum anti-p53 antibodies has occurred in some, but not all, individuals exposed to 
vinyl chloride who later developed angiosarcoma of the liver (Trivers et al. 1995).  However, not all 
individuals who developed angiosarcoma of the liver tested positive for anti-p53 antibodies.  Also, anti­
p53 antibodies are not specific to angiosarcoma of the liver but can be detected in the sera of patients with 
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other types of cancers such as leukemia; childhood lymphoma; breast, lung, and colon cancer; and 
hepatocellular carcinoma. 
The symptoms and signs associated with vinyl chloride disease (Raynaud's phenomenon, scleroderma-
like skin changes, and acroosteolysis) are similar to those observed in systemic sclerosis.  Vinyl chloride 
disease may be differentiated from systemic sclerosis by the absence of antinuclear antibodies in the 
blood and association of vinyl chloride disease with vinyl chloride exposure (Black et al. 1983, 1986).  
Raynaud's phenomenon is an early symptom of vinyl chloride disease.  However, cyanosis and blanching 
of fingers with exposure to cold may be the result of a number of other conditions such as connective 
tissue disorders, mechanical arterial obstruction, hyperviscosity of the blood, or exposure to drugs, 
chemicals, or vibrating tools (Freudiger et al. 1988).  Thus, other potential causes must be eliminated 
before this syndrome can be used to identify vinyl chloride disease.  The symptoms associated with vinyl 
chloride disease have been attributed to vinyl chloride-induced changes in the microvasculature (Grainger 
et al. 1980). Capillary abnormalities in the hands may be detected using wide-field capillary microscopy 
and have been proposed to represent an early manifestation of the effects of vinyl chloride (Maricq et al. 
1976). Also, immunofluorescent examination of biopsy material from the skin may be used to identify 
circulating immune complexes and their deposition on the vascular endothelium (Ward 1976). 
Chromosomal aberrations found in lymphocytes may be indicative of the genotoxic effects of vinyl 
chloride (Anderson 2000; Anderson et al. 1980; Ducatman et al. 1975; Fucic et al. 1990a, 1990b, 1992; 
Funes-Cravioto et al. 1975; Garaj-Vrhovac et al. 1990; Hansteen et al. 1978; Hrivnak et al. 1990; 
Kucerova et al. 1979; Purchase et al. 1978; Sinues et al. 1991).  However, any of a number of genotoxic 
substances can produce chromosomal aberrations.  Also, de Jong et al. (1988) have found that variability 
in the control population may obscure the observation of chromosomal aberrations in persons exposed to 
low levels of vinyl chloride.  G-banding analysis appeared to provide a more sensitive indication of 
chromosomal alteration than sister chromatid exchanges (Zhao et al. 1996).  DNA damage in 
lymphocytes can be directly assessed using a single-cell gel electrophoresis technique.  The severity of 
the damage may correlate with the duration of exposure (Awara et al. 1998).  The DNA adducts produced 
by the reactive intermediary metabolites of vinyl chloride, including 1,N6-ethenoadenosine and 
3,N4-ethenocytidine, may be more specific indicators of vinyl chloride's genotoxic potential. 
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3.9 INTERACTIONS WITH OTHER CHEMICALS  
A number of studies have been performed that examine the effect of agents intended to alter the 
metabolism of vinyl chloride on its toxicity.  For example, the effects of phenobarbital pretreatment on 
vinyl chloride-induced hepatotoxicity have been examined by Jaeger et al. (1974, 1977), Jedrychowski et 
al. (1985), and Reynolds et al. (1975a, 1975b).  Pretreatment of rats with phenobarbital for 7 days prior to 
a 4-hour vinyl chloride exposure produced an increase in microsomal cytochrome P-450 activity 
(Reynolds et al. 1975b) and enhanced hepatotoxicity (Jaeger et al. 1974, 1977; Jedrychowski et al. 1985; 
Reynolds et al. 1975a, 1975b).  In these studies, in the absence of the phenobarbital pretreatment, a single 
exposure to approximately 50,000 ppm had no detectable adverse effect on the livers of exposed rats.  
However, following phenobarbital pretreatment, 50,000 ppm of vinyl chloride produced increased serum 
activity of hepatic enzymes (Jaeger et al. 1977; Jedrychowski et al. 1985), areas of hepatic necrosis 
(Reynolds et al. 1975a), or both (Jaeger et al. 1974; Reynolds et al. 1975b). 
Another agent known to increase MFO activity, Aroclor 1254, was also tested for its ability to enhance 
vinyl chloride-induced hepatotoxicity (Conolly and Jaeger 1979; Conolly et al. 1978; Jaeger et al. 1977; 
Reynolds et al. 1975b).  Pretreatment of rats with Aroclor 1254 for several days prior to exposure to vinyl 
chloride resulted in an increase in serum activity of hepatic enzymes (Conolly and Jaeger 1979; Conolly 
et al. 1978; Jaeger et al. 1977; Reynolds et al. 1975b) and areas of hepatic necrosis (Conolly et al. 1978; 
Reynolds et al. 1975b). 
Additional support for a role for MFO in the enhanced toxicity of vinyl chloride was obtained using 
SKF525A, an MFO inhibitor.  If SKF525A was administered following phenobarbital pretreatment and 
before vinyl chloride exposure, it blocked the ability of phenobarbital pretreatment to enhance vinyl 
chloride-induced hepatotoxicity (Jaeger et al. 1977). 
The role of glutathione conjugation in vinyl chloride-induced toxicity was also examined (Conolly and 
Jaeger 1979; Jaeger et al. 1977).  The investigators hypothesized that depletion of glutathione might 
enhance the toxicity of vinyl chloride by preventing the excretion of toxic intermediary metabolites.  
However, diethylmaleate, an agent known to deplete hepatic glutathione levels, had no effect on the 
toxicity produced by vinyl chloride following pretreatment with either phenobarbital (Jaeger et al. 1977) 
or Aroclor 1254 (Conolly and Jaeger 1979).  Trichloropropene oxide (TCPO), another agent known to 
deplete hepatic glutathione, produced enhancement of the hepatic toxicity produced by Aroclor 1254 
pretreatment and vinyl chloride exposure but only when the animals had been fasted prior to vinyl 
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chloride exposure (Conolly and Jaeger 1979).  The study authors hypothesized that the enhancement of 
vinyl chloride toxicity was a result of the ability of TCPO to inhibit epoxide hydrase rather than its ability 
to deplete glutathione levels.  The lack of the effect of glutathione depletion indicates that the glutathione 
pathway is not very important at normal levels of exposure. 
Although the depletion of cellular glutathione levels did not appear to enhance vinyl chloride toxicity, 
treatment with cysteine, the rate-limiting precursor in hepatic glutathione synthesis, increased hepatic 
glutathione levels and provided partial protection against the toxic effects produced by Aroclor 1254 and 
vinyl chloride (Conolly and Jaeger 1979). 
The effects of the interaction of ethanol with vinyl chloride on development were tested by John et al. 
(1977). In this study, animals were exposed to vinyl chloride in the presence and absence of 15% ethanol 
in the drinking water during pregnancy.  Ethanol produced a decrease in maternal food consumption and 
maternal weight gain in mice, rats, and rabbits and enhanced incidence of skeletal abnormalities in mice, 
and to a lesser extent, in rats.  Interpretation of these results is clouded by the absence of an ethanol-
exposed control group and the current recognition of the adverse effects of ethanol on pregnancy 
outcome. 
In the experiment by Radike et al. (1981), ethanol-consuming rats exposed to vinyl chloride for a year had 
an enhanced incidence of hepatic angiosarcomas, hepatomas, and lymphosarcomas, earlier onset of the 
tumors, and an enhanced death rate.  The incidence of vinyl chloride-induced angiosarcomas was 
potentiated by ethanol, whereas the increased incidences of hepatoma and lymphosarcomas by ethanol 
were additive in nature. 
The effects of smoking on chromosomal aberrations in vinyl chloride-exposed workers was examined by 
Hrivnak et al. (1990), who found no effect of smoking in 43 workers exposed for an average of 11.2 years 
to levels of vinyl chloride ranging from 0.8 to 16 ppm.  Most cytogenetic studies of the effects of smoking 
in humans have reported no effect on chromosomal aberrations, although the sister chromatid exchange 
frequency is usually elevated (Wong et al. 1998). 
A study that examined the interaction between vinyl chloride and trichloroethylene using both inhalation 
exposures of rats and pharmacokinetic modeling found that trichloroethylene exposure inhibited vinyl 
chloride in a competitive manner (Barton et al. 1995).  This interaction was observed only at high 
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concentrations (both chemicals >10 ppm), and the study authors concluded that the interaction is not 
likely to be important for environmental exposures. 
3.10 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 
A susceptible population will exhibit a different or enhanced response to vinyl chloride than will most 
persons exposed to the same level of vinyl chloride in the environment.  Reasons may include genetic 
makeup, age, gender, health and nutritional status, physiological status (e.g., pregnancy), and exposure to 
other toxic substances (e.g., cigarette smoke).  These parameters result in reduced detoxification or 
excretion of vinyl chloride or compromised function of organs affected by vinyl chloride.  Populations 
who are at greater risk due to their unusually high exposure to vinyl chloride are discussed in Section 6.7, 
Populations With Potentially High Exposures. 
Data suggest that the following subsets of the human population may be unusually susceptible to the toxic 
effects of vinyl chloride:  fetuses; infants; young children; people with liver disease, irregular heart 
rhythms, impaired peripheral circulation, or systemic sclerosis; people with exposure to organochlorine 
pesticides; and people consuming ethanol or barbiturates or taking Antabuse for alcoholism. Also, 
persons who possess the HLA-DR5, HLA-DR3, and B8 alleles may be at increased risk. 
Vinyl chloride can cross the placenta and enter the blood of the fetus (Ungvary et al. 1978).  Studies by 
Drew et al. (1983), John et al. (1977, 1981), and Maltoni et al. (1981) have shown that animals exposed 
by inhalation prior to adolescence or during pregnancy may have a greater death rate and increased 
likelihood of developing cancer than adult animals exposed for similar periods.  This may relate to the 
length of the induction period of hepatic angiosarcoma rather than to an increased susceptibility of the 
young, per se. It is also possible that there are explanations for these findings.  Cogliano and Parker 
(1992) suggested that in the multistage model of carcinogenesis, carcinogens that induce an initial 
transition early in the life of an animal would be more effective since there would be a longer period of 
time remaining in the lifespan for completion of the remaining transitions.  Their empirical model of the 
effect of age at exposure on the development of cancer suggests that there is an age-sensitive period of 
exposure to vinyl chloride. 
Vinyl chloride is metabolized in the liver in a multistep process.  The intermediary metabolites of vinyl 
chloride, 2-chloroethylene oxide and 2-chloroacetaldehyde, have been suggested to be responsible for 
some of the adverse effects produced by vinyl chloride.  Thus, activation of the enzyme system 
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responsible for production of these toxic metabolites would be expected to increase the toxicity of vinyl 
chloride exposures. 2-Chloroethylene oxide is formed by action of the MFO system associated with 
cytochrome P-450.  The barbiturate, phenobarbital, and the pesticide extender, Aroclor 1254, increased 
MFO activity and have been shown to greatly increase the hepatotoxicity of vinyl chloride (Conolly and 
Jaeger 1979; Conolly et al. 1978; Jaeger et al. 1974, 1977; Jedrychowski et al. 1985; Reynolds et al. 
1975a, 1975b).  Thus, persons taking barbiturates or who might be exposed to organochlorine pesticides 
that are known to induce microsomal enzymes (such as Aroclor 1254) would be expected to be at 
increased risk for developing vinyl chloride-induced hepatotoxicity. 
Genetic polymorphisms related to vinyl chloride metabolism and DNA repair may increase the 
susceptibility of individuals to liver toxicity and cancer.  CYP2E1 and glutathione S-transferase genotypes 
were associated with abnormal liver function, “vinyl chloride disease”, and the incidence of angiosarcoma 
in exposed workers (El Ghissassi et al. 1995; Green et al. 2000; Huang et al. 1997).  Genotypes for 
CYP2E1, the DNA repair gene, x-ray repair cross-complementing group 1 (XRCC1), and aldehyde 
dehydrogenase 2 (ALDH2) have been associated with increased sister chromatid exchange frequency and 
increased expression of p53 mutant protein and anti-p53 antibody in exposed workers (Li et al. 2003; 
Wong et al. 1998, 2002b, 2003b).  The risk of developing liver cancer also appears elevated in those with 
a history of Hepatitis B viral infection (Du and Wang 1998; Wong et al. 2003b). 
Radike et al. (1981) demonstrated that ethanol-consuming rats exposed to vinyl chloride had an increased 
incidence of cancer and an earlier death rate than animals exposed to vinyl chloride in the absence of 
ethanol. 
Some persons consume the agent, Antabuse, to curb the desire for alcohol.  In its role as a therapeutic 
agent, Antabuse blocks aldehyde dehydrogenase and causes a build-up of acetaldehyde, which is emetic, 
in the body when alcohol is consumed.  If persons taking Antabuse are exposed to vinyl chloride, the 
alternative metabolic pathway for vinyl chloride metabolism will be blocked, causing more vinyl chloride 
to be metabolized to the toxic metabolite, 2-chloroethylene oxide.  Thus, these persons may be at 
increased risk for hepatotoxicity, cancer, and death at an early age. 
Very high levels of vinyl chloride have been demonstrated to cause cardiac arrhythmias in dogs (Carr et 
al. 1949; Oster et al. 1947).  Persons with a propensity to develop cardiac arrhythmias because of heart 
disease or damage may be at an increased risk of having heart beat irregularities when exposed to high 
concentrations of vinyl chloride. 
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Vinyl chloride has been shown to produce decreased circulation in the hands and fingers of some people.  
Persons with impaired circulation due to some other cause such as connective tissue disorders, systemic 
sclerosis, hyperviscosity of the blood, or use of vibrating tools, may experience more severe impairment 
of the circulation. 
Work by Black et al. (1983, 1986) has shown that persons with the HLA allele HLA-DR5 may have an 
increased likelihood of developing vinyl chloride disease, and those with the alleles HLA-DR3 and B8 
may have an increased severity of the disease. 
3.11 METHODS FOR REDUCING TOXIC EFFECTS 
This section will describe clinical practice and research concerning methods for reducing toxic effects of 
exposure to vinyl chloride.  However, because some of the treatments discussed may be experimental and 
unproven, this section should not be used as a guide for treatment of exposures to vinyl chloride.  When 
specific exposures have occurred, poison control centers and medical toxicologists should be consulted 
for medical advice. The following texts provide specific information about treatment following exposures 
to vinyl chloride:   
Bronstein AC, Currance PL, eds. 1988. Emergency care for hazardous materials exposure.  St. Louis, 
MO: CV Mosby Company, 143-144. 
Haddad LM, Winchester JF, eds. 1990.  Clinical management of poisoning and overdose.  Philadelphia, 
PA: W.B. Saunders Company, 516, 1209, 1214, 1224, 1227-1229. 
Stutz DR, Ulin S, eds. 1992. Hazardous materials injuries.  A handbook for pre-hospital care.  3rd ed. 
Beltsville, MD: Bradford Communications Corporation, 286-287. 
3.11.1 Reducing Peak Absorption Following Exposure  
Limited information from humans and results from animal studies indicate that vinyl chloride is rapidly 
and virtually completely absorbed following inhalation and oral exposure, but animal studies suggest that 
dermal absorption of vinyl chloride gas is not likely to be significant (see Section 3.3.1).  Efforts to 
reduce absorption following acute exposure to vinyl chloride should focus on removing the individual 
from the site of exposure and decontaminating exposed areas of the body.  Vinyl chloride gas is relatively 
dense and accumulates at ground level.  Therefore, the subject should be moved from low-lying areas.  
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Contaminated skin may be washed with soap and water; however, this will most likely not prevent tissue 
damage produced by frostbite from the cooling caused by the rapid evaporation of vinyl chloride from the 
skin. It is suggested that eyes exposed to vinyl chloride be copiously irrigated with water or normal saline 
(Bronstein and Currance 1988; Haddad and Winchester 1990; Stutz and Ulin 1992).  Because of its 
volatility, it is unlikely that vinyl chloride would be ingested unless it had been dissolved in a solvent.  If 
such ingestion of vinyl chloride occurs, it is suggested that water or milk be administered for dilution if 
the patient can swallow, has a good gag reflex, and is not drooling (Bronstein and Currance 1988; Stutz 
and Ulin 1992). In addition, gastric lavage and administration of activated charcoal have been suggested 
as a means to reduce absorption of vinyl chloride.  Induction of emesis is contraindicated (Bronstein and 
Currance 1988; Haddad and Winchester 1990; Stutz and Ulin 1992). 
3.11.2 Reducing Body Burden  
Because of its rapid metabolism and excretion, vinyl chloride does not tend to accumulate in the body.  
As discussed in Section 3.4.3, the metabolism of vinyl chloride is a dose-dependent, saturable process.  
Vinyl chloride is oxidized primarily by the microsomal MFO system (cytochrome P-450) to a reactive 
epoxide intermediate (2-chloroethylene oxide), which can rearrange to 2-chloroacetaldehyde or conjugate 
with glutathione to form S-formylmethyl glutathione.  At exposure concentrations below about 1,000 ppm 
in air, very little vinyl chloride is excreted unchanged in the exhaled air.  However, when metabolic 
saturation occurs at high exposure concentrations (approximately 1,000 ppm following inhalation 
exposure in rats [Watanabe and Gehring 1976; Watanabe et al. 1976b] and approximately 20 mg/kg 
following oral administration to rats [Green and Hathway 1975; Watanabe and Gehring 1976; Watanabe 
et al. 1976a]), vinyl chloride is excreted unchanged in expired air.  Therefore, a possible means to 
enhance the elimination of vinyl chloride without allowing its biotransformation to toxic intermediates is 
to saturate this oxidative pathway by administration of substances known to be metabolized via this route. 
Saturation of the P-450 system may occur with drugs such as phenytoin or dicumerol (Goodman and 
Gilman 1980).  However, the effectiveness of these agents in blocking the P-450 metabolism of vinyl 
chloride has not been tested, and it is unclear whether toxic doses would be necessary to overcome the 
relative affinities of the enzymes for vinyl chloride versus these agents.  In addition, the potential toxicity 
of any side products of these substances would need to be considered in any protocol.  Several agents 
induce activity of the microsomal enzymes and could potentially increase the toxicity of vinyl chloride.  
Administration of such substances would be contraindicated. 
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3.11.3 Interfering with the Mechanism of Action for Toxic Effects  
Following acute, high-level exposure, vinyl chloride behaves as an anesthetic and produces central 
nervous system and respiratory depression (see Sections 3.2.1.4).  Therefore, basic life support measures, 
such as supplemental oxygen and cardiopulmonary resuscitation, are suggested in such instances 
(Bronstein and Currance 1988; Haddad and Winchester 1990; Stutz and Ulin 1992).  In addition, like 
other halogenated hydrocarbons, vinyl chloride may sensitize the heart to the effects of circulating 
catecholamines. Therefore, the patient's cardiac rhythm should be monitored, and the use of 
isoproterenol, epinephrine, or other sympathomimetic drugs should be avoided (Haddad and Winchester 
1990). 
Vinyl chloride is a known human and animal carcinogen; long-term exposure to this compound is 
associated with an increased incidence of hepatic angiosarcomas (see Section 3.2.1.7).  Vinyl chloride is 
also hepatotoxic.  The mechanism by which vinyl chloride induces its carcinogenic and toxic effect on the 
liver has been well studied. A reactive epoxide intermediate of vinyl chloride, 2-chloroethylene oxide, 
interacts directly with DNA and RNA producing cyclic etheno-adducts that include 1,N6-ethenoadenine, 
3,N4-ethenocytosine, N2,3-ethenoguanine, and 1,N2-ethenoguanine.  This alkylation results in highly 
efficient base-pair substitution, leading to neoplastic transformation (see Section 3.5.2).  As discussed 
above, this epoxide intermediate is formed when vinyl chloride is oxidized by the P-450 isoenzymes.  
Interference with this metabolic pathway, therefore, could reduce the toxic and carcinogenic effects of 
vinyl chloride by reducing the amount of epoxide produced.  A number of drugs, such a cobaltous 
chloride, SKF-535-A, and 6-nitro-1,2,3-benzothioadiazole, have been reported to inhibit P-450 enzymes.  
Pretreatment with 6-nitro-1,2,3-benzothioadiazole completely blocked the metabolism of vinyl chloride in 
rats exposed to 0.45 ppm in a closed system for 5 hours (Bolt et al. 1977).  P-450 metabolism also results 
in products that can be more readily eliminated than can the parent compound.  Hence, any side products 
of the drugs and their potential to increase the biological half-life of vinyl chloride would also need to be 
considered in any protocol.  In fact, a study by Buchter et al. (1977) showed that substantial 
unmetabolized vinyl chloride accumulated in fatty tissue when 6-nitro-1,2,3-benzothioadiazole was used 
to block P-450 metabolism.  The study did not examine the fate of vinyl chloride in fatty tissue after 
P-450 metabolism was reactivated, but it is likely that vinyl chloride would leave the fat slowly and be 
metabolized.  Thus, while P-450 metabolism would probably reduce the generation of toxic metabolites in 
the short term, it is unclear whether the generation of toxic metabolites could be completely avoided.  
Further research to determine which isozymes are involved in the metabolism to the reactive 
intermediates, as well as which isozymes are involved in enhancing the elimination of vinyl chloride, 
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could lead to the development of strategies to selectively inhibit specific isozymes and thus reduce the 
toxic effects of vinyl chloride. 
Because vinyl chloride is detoxified by conjugation with glutathione and/or cysteine (see discussion 
above and Section 3.4.3), ensuring sufficient glutathione stores in the body (e.g., by treatment with 
N-acetyl cysteine) may reduce the possibility of toxic effects following acute exposure to vinyl chloride. 
Vinyl chloride disease has been reported in a small percentage of workers exposed to this compound.  
One of the symptoms of this condition is Raynaud's phenomenon (blanching, numbness, and discomfort 
of the fingers upon exposure to cold).  Studies of these individuals demonstrated that vinyl chloride may 
produce blockage of the blood vessels supplying the hand, hypervascularity, and a thickening of the blood 
vessel walls (Harris and Adams 1967; Preston et al. 1976; Veltman et al. 1975; Walker 1976).  Several 
investigators have suggested that the mechanism for vinyl chloride disease may be an autoimmune 
response similar to systemic sclerosis.  Grainger et al. (1980) and Ward (1976) proposed that a reactive 
vinyl chloride intermediate metabolite, such as 2-chloroethylene oxide or 2-chloroacetaldehyde, binds to a 
protein such as IgG.  The altered protein initiates an immune response, with deposition of immune 
products along the vascular endothelium.  Cold temperatures could produce the precipitation of these 
immune complexes resulting in blockage of the blood vessels.  Another characteristic of vinyl chloride 
disease is acroosteolysis, in which the terminal phalanges of the fingers are resorbed.  This condition has 
been noted predominantly in workers who first had Raynaud's phenomenon (Dinman et al. 1971; 
Freudiger et al. 1988; Harris and Adams 1967; Magnavita et al. 1986; Markowitz et al. 1972; Preston et 
al. 1976; Sakabe 1975; Veltman et al. 1975; Wilson et al. 1967). The resorptive bone changes may be 
due to activation of osteoclasts secondary to vascular insufficiency in the finger tips, but this remains to 
be demonstrated conclusively.  Other manifestations of vinyl chloride disease include joint and muscle 
pain, enhanced collagen deposition, stiffness of the hands, and scleroderma-like skin changes.  Increased 
levels of circulating immune complexes and immunoglobulins have been observed in vinyl chloride 
workers, suggesting a stimulatory effect of vinyl chloride on the immune system (Bogdanikowa and 
Zawilska 1984). A correlation between the severity of the symptoms of vinyl chloride disease and the 
magnitude of the immune response was observed (Grainger et al. 1980; Langauer-Lewowicka et al. 1976; 
Ward 1976).  Research on the genetic characteristics of workers with this disease has demonstrated that 
the susceptibility to vinyl chloride disease was increased in the presence of the HLA-DR5 allele or a gene 
in linkage disequilibrium with it, and progression of the disease to its more severe forms was favored by 
HLA-DR3 and B8 (Black et al. 1983, 1986).  If vinyl chloride disease is mediated by an immune 
mechanism in individuals with a genetic predisposition, then the effects of this disease may be mitigated 
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by administration of drugs used to treat other similar autoimmune diseases (e.g., azathioprine, 
cyclophosphamide, and prednisone).  However, the toxicity associated with the use of these drugs must 
also be considered. 
3.12 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the adverse health effects of vinyl chloride is available.  Where adequate 
information is not available, ATSDR, in conjunction with the National Toxicology Program (NTP), is 
required to ensure the initiation of a program of research designed to determine the adverse health effects 
(and techniques for developing methods to determine such adverse health effects) of vinyl chloride. 
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
3.12.1 Existing Information on Adverse Health Effects of Vinyl Chloride  
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to 
vinyl chloride are summarized in Figure 3-5.  The purpose of this figure is to illustrate the existing 
information concerning the adverse health effects of vinyl chloride.  Each dot in the figure indicates that 
one or more studies provide information associated with that particular effect.  The dot does not 
necessarily imply anything about the quality of the study or studies, nor should missing information in 
this figure be interpreted as a “data need”.  A data need, as defined in ATSDR’s Decision Guide for 
Identifying Substance-Specific Data Needs Related to Toxicological Profiles (Agency for Toxic 
Substances and Disease Registry 1989), is substance-specific information necessary to conduct 
comprehensive public health assessments.  Generally, ATSDR defines a data gap more broadly as any 
substance-specific information missing from the scientific literature. 
143 VINYL CHLORIDE 
3. HEALTH EFFECTS 




































































































144 VINYL CHLORIDE 
3. HEALTH EFFECTS 
Virtually all of the literature regarding adverse health effects in humans comes from studies of workers 
exposed to vinyl chloride during the production of PVC.  Case reports and cohort studies describe some 
acute health effects and a wide range of long-term health effects.  The predominant mode of exposure in 
these studies is via inhalation.  These studies are limited by the lack of reliable data on individual 
exposure levels. No studies were found regarding the adverse health effects of oral exposure.  One case 
report examined the effects of dermal exposure to liquid vinyl chloride, but exposure by this route is not 
expected to contribute significantly to producing adverse health effects because of the limited absorption 
of vinyl chloride through the skin. 
A large number of studies examining the adverse health effects of inhaled vinyl chloride in animals were 
reviewed. As can be seen in Figure 3-5, no information is available on acute adverse systemic effects, 
immunologic, neurologic, reproductive, developmental, or genotoxic effects of exposure of animals by 
the oral route. One study examined the effects of dermal/ocular exposure to vinyl chloride gas, but 
toxicokinetic studies indicate that this route is not an important means of exposure. 
3.12.2 Identification of Data Needs 
Acute-Duration Exposure.    Populations in areas that contain hazardous waste sites may be exposed 
to vinyl chloride for brief periods.  Exposure most likely would occur by inhalation, but relatively brief 
oral and dermal exposures are also possible. There are acute inhalation exposure data in humans and 
animals that indicate that the central nervous system is a major target organ of vinyl chloride toxicity.   
Symptoms of central nervous system depression ranging from dizziness and drowsiness to loss of 
consciousness have been observed in humans and animals as a result of brief exposure to very high levels 
of vinyl chloride (Hehir et al. 1981; Jaeger et al. 1974; Lester et al. 1963; Mastromatteo et al. 1960; Patty 
et al. 1930). A threshold for central nervous system effects appears to be approximately 8,000 ppm 
(Lester et al. 1963).  Extremely high concentrations of vinyl chloride produce respiratory irritation and 
death in humans and animals by the inhalation route (Danziger 1960; Lester et al. 1963; Mastromatteo et 
al. 1960; Patty et al. 1930).  Based on studies in animals, the threshold for these effects appears to be in 
the range of 100,000–400,000 ppm (Lester et al. 1963; Mastromatteo et al. 1960; Patty et al. 1930).  
However, increased rate of death was noted in pregnant mice at 500 ppm (John et al. 1977, 1981).  
Extremely high concentrations of vinyl chloride produced cardiac arrhythmias in dogs exposed by the 
inhalation route (Carr et al. 1949; Oster et al. 1947).  Although no threshold was reported for these 
effects, concentrations of this magnitude would not likely be encountered by humans.  Pharmacokinetic 
data indicate that similar end points might be expected if sufficiently high doses could be consumed by 
145 VINYL CHLORIDE 
3. HEALTH EFFECTS 
the oral route.  However, the solubility characteristics of vinyl chloride in aqueous media (1,100– 
2,763 mg/L at 25 °C) (Cowfer and Magistro 1983; EPA 1985b) indicate that achieving concentrations of 
vinyl chloride in excess of 5,000 ppm may be extremely difficult.  Animal studies indicate that acute 
inhalation exposures to vinyl chloride can produce developmental effects at concentrations that also cause 
significant maternal toxicity (John et al. 1977, 1981; Ungvary et al. 1978).  Concentrations of 500 ppm 
were observed to produce delayed ossification in the fetus and decreased food consumption, body weight 
gain, and increased rate of mortality in maternal mice (John et al. 1977, 1981).  The NOAEL (50 ppm) in 
this study was used to derive an acute-duration inhalation MRL.  Animal studies examining the 
developmental, neurological, and systemic effects of the highest doses achievable in drinking water 
would be helpful for determining whether any effects would occur when vinyl chloride-contaminated 
groundwater or food products are consumed.  One report described severe frostbite with second degree 
burns on the hands of a man resulting from the rapid evaporation of spilled liquid vinyl chloride (Harris 
1953).  A toxicokinetic study using two monkeys indicates that absorption of vinyl chloride by the dermal 
route is exceedingly small (Hefner et al. 1975a); thus, studies examining the effects of acute-duration 
dermal exposure do not seem warranted.  However, if further toxicokinetics studies contradict these 
findings, acute-duration dermal exposure studies in animals may be valuable. 
A report was located regarding adverse hepatic and respiratory effects observed 18 months following a 
single 1-hour inhalation exposure to vinyl chloride (Hehir et al. 1981).  However, limitations in the study 
diminished its reliability. Because of the implications of adverse chronic effects from acute exposure, 
confirmation of these results in another study would be valuable. 
Intermediate-Duration Exposure.    No studies in humans specifically address intermediate-duration 
effects by any route.  Most epidemiological studies of occupationally exposed persons have concentrated 
on persons who have been employed over several years.  A study with reliable quantification of exposure 
levels that examined the effects experienced by vinyl chloride workers in their first year of exposure 
would be helpful for predicting the effects that might be observed in populations exposed to hazardous 
waste sites for similar periods of time.  However, at current low levels of exposure in the workplace, it 
may be difficult to demonstrate effects.  There is a large database describing the effects of intermediate-
duration inhalation exposures in animals (Adkins et al. 1986; Bi et al. 1985; Drew et al. 1983; Du et al. 
1979; Feron et al. 1979a, 1979b; Hong et al. 1981; Lee et al. 1978; Lester et al. 1963; Maltoni et al. 1981; 
Mirkova et al. 1978; Sal'nikova and Kotsovskaya 1980; Schaffner 1978; Sharma and Gehring 1979; Short 
et al. 1977; Sokal et al. 1980; Suzuki 1978, 1981; Thornton et al. 2002; Torkelson et al. 1961; 
Wisniewska-Knypl et al. 1980).  Animals exposed to vinyl chloride for more than 2 weeks and less than a 
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year have experienced effects on the liver, kidneys, lungs, and blood (Bi et al. 1985; Du et al. 1979; Feron 
et al. 1979a, 1979b; Lester et al. 1963; Sal'nikova and Kotsovskaya 1980; Schaffner 1978; Sokal et al. 
1980; Torkelson et al. 1961; Wisniewska-Knypl et al. 1980).  Data were sufficient to determine an 
intermediate-duration inhalation MRL based on adverse liver effects in rats.  The MRL was based on a 
NOAEL of 15 ppm for hepatic centrilobular hypertrophy (Thornton et al. 2002).  Extremely limited 
information was available regarding oral intermediate-duration effects.  One chronic study presented 
interim sacrifice data that identified relative weight and histopathological changes in the liver (Feron et al. 
1981).  However, only a single-dose group was compared to controls, precluding determination of the 
dose-response of the effects observed. Thus, no MRL for oral intermediate-duration exposures could be 
determined.  Additional studies examining the effects of oral exposure to vinyl chloride would be helpful 
for evaluating relevant biomarkers of exposure and effects in humans consuming contaminated drinking 
water or foods (see Section 3.8). As noted above, absorption of vinyl chloride through the skin is not 
expected to be significant (Hefner et al. 1975a); thus, additional dermal exposure studies do not seem 
warranted. However, if further toxicokinetics studies contradict these findings, other intermediate-
duration dermal exposure studies may be valuable. 
Chronic-Duration Exposure and Cancer.    A large number of studies of workers exposed to vinyl 
chloride have identified a wide range of target organs that may be affected by chronic-duration inhalation 
of vinyl chloride (Bao et al. 1988; Bencko et al. 1988; Berk et al. 1975; Black et al. 1983, 1986; 
Bogdanikowa and Zawilska 1984; Brugnami et al. 1988; Byren et al. 1976; Creech and Johnson 1974; 
Dinman et al. 1971; Falk et al. 1974; Freudiger et al. 1988; Fucic et al. 1995; Gedigke et al. 1975; 
Grainger et al. 1980; Harris and Adams 1967; Jayson et al. 1976; Jones and Smith 1982; Langauer-
Lewowicka et al. 1976; Laplanche et al. 1987; Lee et al. 1977b; Lilis et al. 1975; Liss et al. 1985; Lloyd et 
al. 1984; Magnavita et al. 1986; Maricq et al. 1976; Markowitz et al. 1972; Marsteller et al. 1975; Micu et 
al. 1985; Miller 1975; NIOSH 1977; Perticoni et al. 1986; Popper and Thomas 1975; Popper et al. 1981; 
Preston et al. 1976; Sakabe 1975; Spirtas et al. 1975; Suciu et al. 1963, 1975; Tamburro et al. 1984; 
Veltman et al. 1975; Vihko et al. 1984; Walker 1976; Ward 1976; Wilson et al. 1967; Wong et al. 1991). 
The target organs include the liver, lungs, blood, immune system, cardiovascular system, skin, bones, 
nervous system, and the reproductive organs.  These studies are severely limited in that individual 
exposure levels have not been documented.  In general, studies in animals provide supportive evidence 
for these effects and give indications of the exposure levels that may be associated with them (Bi et al. 
1985; Feron and Kroes 1979; Feron et al. 1979a, 1979b; Lee et al. 1981; Thornton et al. 2002; Viola 
1970; Viola et al. 1971). 
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No information was available regarding chronic-duration oral exposure in humans.  However, studies in 
animals indicate that the liver, blood, and skin are target organs for oral exposure to vinyl chloride (Feron 
et al. 1981; Knight and Gibbons 1987; Til et al. 1983, 1991).  A chronic-duration oral MRL of 
0.003 mg/kg/day was derived from a human equivalent NOAEL of 0.09 mg/kg/day based on liver cell 
polymorphism in rats (Til et al. 1983, 1991). 
No information was available regarding effects of chronic-duration dermal exposure in humans or 
animals, but absorption of vinyl chloride gas through the skin was not significant in an acute-duration 
exposure study in monkeys (Hefner et al. 1975a).  However, only two animals were used, and this was the 
only study located that examined toxicokinetics after dermal exposure.  No information is available 
regarding dermal absorption of vinyl chloride from liquid or solid media (i.e., water, soil).  Dermal 
exposure from these media is expected to be minimal; however, a study confirming this assumption 
would be useful.  If further toxicokinetic studies demonstrate significant dermal absorption of vinyl 
chloride, then other intermediate-duration dermal exposure studies may be needed. 
There is sufficient evidence to indicate that vinyl chloride is carcinogenic to humans (Belli et al. 1987; 
Boffetta et al. 2003; Brugnami et al. 1988; Byren et al. 1976; Cheng et al. 1999; Chung and Keh 1987; 
Cooper 1981; Creech and Johnson 1974; Davies et al. 1990; Du and Wang 1998; Fitzgerald and Griffiths 
1987; Fox and Collier 1977; Gelin et al. 1989; Geryk and Zudova 1986; Hagmar et al. 1990; Heldass et 
al. 1987; Infante et al. 1976b; Jones et al. 1988; Lelbach 1996; Lewis 2001; Lewis and Rempala 2003; 
Lewis et al. 2003; Monson et al. 1975; Mundt et al. 2000; Ojajarvi et al. 2001; Pirastu et al. 1990; 
Rhomberg 1998; Rinsky et al. 1988; Saurin et al. 1997; Simonato et al. 1991; Smulevich et al. 1988; Teta 
et al. 1990; Ward et al. 2001; Waxweiler et al. 1981; Weber et al. 1981; Weihrauch et al. 2000; 
Williamson and Ramsden 1988; Wong et al. 1991, 2002a, 2002b, 2003a, 2003b; Wu et al. 1989) and 
animals (Bi et al. 1985; Drew et al. 1983; Feron and Kroes 1979; Feron et al. 1979a; Froment et al. 1994; 
Lee et al. 1978; Maltoni et al. 1981; Viola et al. 1971) exposed via inhalation, and in animals exposed via 
the oral route (Feron et al. 1979a; Maltoni et al. 1981; Til et al. 1983, 1991).  The mechanism for 
carcinogenicity appears to be associated with the formation of reactive intermediates that bind to DNA. 
Genotoxicity.    There are substantial data on clastogenesis in humans exposed to vinyl chloride that 
indicate that this chemical acts as a potent genotoxicant (Anderson 2000; Anderson et al. 1980; Awara et 
al. 1998; Becker et al. 2001; Ducatman et al. 1975; Fucic et al. 1990a, 1990b, 1992, 1995; Funes-Cravioto 
et al. 1975; Hansteen et al. 1978; Hrivnak et al. 1990; Huttner and Nikolova 1998; Huttner et al. 1998, 
1999; Kucerova et al. 1979; Marion et al. 1991; Purchase et al. 1978; Sinues et al. 1991; Wong et al. 
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1998; Zhao et al. 1996).  The reversibility of chromosome damage has been reported for several 
populations of workers following a cessation or reduction of exposure to vinyl chloride (Anderson et al. 
1980; Fucic et al. 1996a, 1996b; Hansteen et al. 1978).  Findings in humans are supported by both animal 
studies and in vitro studies that show positive genotoxicity in a variety of microbial organisms, cultured 
cell lines, and isolated nucleic acid assays (Anderson and Richardson 1981; Andrews et al. 1976; Bartsch 
1976; Bartsch et al. 1976; Bolt et al. 1986; Ciroussel et al. 1990; de Meester et al. 1980; Eberle et al. 
1989; Froment et al. 1994; Green and Hathway 1978; Gwinner et al. 1983; Hansteen et al. 1978; 
Huberman et al. 1975; Jacobsen et al. 1989; Kandala et al. 1990; Laib and Bolt 1977; Laib et al. 1989; 
Loprieno et al. 1977; McCann et al. 1975; Osterman-Golkar et al. 1977; Poncelet et al. 1980; Rannug et 
al. 1974, 1976; Simmon et al. 1977; Singer et al. 1987; Victorin and Stahlberg 1988a; Walles et al. 1988). 
The role of etheno-adducts in the carcinogenesis of vinyl chloride has been extensively studied (Albertini 
et al. 2003, Barbin 1998, 1999, 2000; Kielhorn et al. 2000; Nivard and Vogel 1999; Whysner et al. 1996).  
Both 2-chloroethylene oxide and 2-chloroacetaldehyde can react with DNA nucleotide bases; however, 
2-chloroethylene oxide is a more potent mutagen and may be the ultimate carcinogenic metabolite of 
vinyl chloride (Chiang et al. 1997).  Etheno-adducts generate mainly base pair substitution mutations.  
Mutations in specific genes (i.e., ras oncogenes, p53 tumor suppressor gene) have been identified in vinyl 
chloride-induced liver tumors in rats and humans (Barbin et al. 1997; Brandt-Rauf et al. 1995; Hollstein et 
al. 1994; Marion and Boivin-Angele 1999; Marion et al. 1991; Trivers et al. 1995; Weihrauch et al. 2002). 
Immunological techniques have been used to detect the presence of Asp13p21 (oncoprotein for mutation 
of the Ki-ras gene), p53 mutant protein, and p53 antibodies in the serum of exposed workers (Brandt-
Rauf et al. 2000a, 2000b; Marion 1998).  Statistical analyses suggest a relationship between vinyl 
chloride exposure and the presence of these serum biomarkers; however, the predictive value of these 
biomarkers for development of cancer is not known.  Further mechanistic research would be helpful in 
identifying the specific gene mutations responsible for vinyl chloride-induced liver cancer. 
Reproductive Toxicity. Data from a number of epidemiological studies provide suggestive evidence 
of adverse effects on male and female reproductive function.  Sexual impotence and decreased androgen 
levels were found in men exposed occupationally to vinyl chloride (Suciu et al. 1975; Veltman et al. 
1975; Walker 1976).  In women exposed to vinyl chloride, menstrual disturbances and an increased 
incidence of elevated blood pressure and edema during pregnancy (preeclampsia) were observed (Bao et 
al. 1988).  Animal studies indicate that exposure to vinyl chloride can result in a decrease in testicular 
weight, damage to the seminiferous tubules, and depletion of spermatocytes (Bi et al. 1985).  A 
significant increase in damage to the spermatogenic epithelium and disorders of spermatogenesis were 
also observed (Sokal et al. 1980).  Reproductive capability was not affected in a 2-generation inhalation 
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reproductive toxicity study in rats (Thornton et al. 2002).  No effects were seen in body weight, feed 
consumption, ability to reproduce, gestation index or length, or pre- and postweaning developmental 
landmarks. Sperm counts, motility, and morphology were also unaffected by vinyl chloride exposure.  
Animal models of preeclampsia could be tested to determine the mechanism by which vinyl chloride 
might produce this effect.  Well-designed and well-conducted epidemiological studies examining such 
changes would also be helpful. No data are available on the possible reproductive toxicity resulting from 
oral exposure to vinyl chloride.  Oral studies that use drinking water as the vehicle of administration 
would be particularly useful because contaminated groundwater is a potentially significant source of 
human exposure.  However, such studies would be technically difficult to perform due to the volatility of 
vinyl chloride and its low solubility in water.  The PBPK model would be useful for assessing 
reproductive toxicity resulting from oral exposure to vinyl chloride. 
Developmental Toxicity.    The epidemiological studies that have addressed developmental toxicity in 
offspring of humans who have been exposed to vinyl chloride are controversial.  Although some of these 
purport to show a significant association between birth defects and vinyl chloride exposure (Infante 1976; 
Infante et al. 1976a, 1976b; NIOSH 1977), their design and analysis have been severely criticized (Hatch 
et al. 1981; Stallones 1987).  At this time, there are insufficient human data to provide a definitive answer 
to this question.  A well-designed and well-conducted epidemiological study examining potential 
developmental end points would be helpful.  There are also inconsistencies in the developmental toxicity 
data for vinyl chloride in laboratory animals.  In general, vinyl chloride produced minor adverse 
developmental effects only at concentrations that were significantly toxic to maternal animals. 
Concentrations of 500 ppm were observed to produce delayed ossification in the fetus and decreased food 
consumption, body weight gain, and mortality in maternal mice (John et al. 1977, 1981).  In contrast, no 
adverse effects were reported in an embryo-fetal developmental toxicity study conducted in rats exposed 
to vinyl chloride via inhalation (Thornton et al. 2002).  Embryo-fetal developmental parameters including 
uterine implantation, fetal gender distribution, fetal body weight, and fetal malformations and variations 
were not affected by vinyl chloride exposure.  Vinyl chloride produced a decrease in maternal body 
weight gain at all exposure levels; however, no changes were observed in feed consumption, clinical 
signs, or postmortem gross findings.  Maternal liver and kidney weights were increased relative to total 
body weight.  It would be helpful to determine whether pregnancy increases the susceptibility to vinyl 
chloride in the mother.  There are no data for oral exposures.  Because of this deficiency, oral studies 
examining a range of developmental end points would be useful in assessing the possibility of these 
effects in humans. However, such studies would be technically difficult to perform due to the volatility of 
150 VINYL CHLORIDE 
3. HEALTH EFFECTS 
vinyl chloride and its low solubility in water.  The PBPK model would be a useful tool in such risk 
assessment. 
Immunotoxicity.    Studies of workers occupationally exposed to vinyl chloride suggest that the 
immune system may be activated by vinyl chloride (Bogdanikowa and Zawilska 1984).  Some data 
suggest that reactive intermediates may bind to proteins in the body, sufficiently altering them so that they 
become antigenic (Grainger et al. 1980).  In some instances, an autoimmune-like syndrome develops.  
The likelihood of this may be associated with the possession by individuals of specific genetic 
determinants (HLA alleles) (Black et al. 1983, 1986).  Because of the low incidence of the autoimmune 
response in humans, the immunotoxicity may be best further studied in one of the strains of mice known 
to have a propensity for developing autoimmune diseases.  Also, additional epidemiological studies 
examining the immune response of exposed populations may be helpful.  
Neurotoxicity.    A number of studies in humans (Lester et al. 1963; Patty et al. 1930) and animals 
(Hehir et al. 1981; Jaeger et al. 1974; Lester et al. 1963; Mastromatteo et al. 1960; Patty et al. 1930) 
demonstrate that vinyl chloride is a central nervous system depressant following brief high-level 
inhalation exposures.  Two studies in animals have also found degenerative effects in central nervous 
system tissue following chronic inhalation exposure to high levels of vinyl chloride (Viola 1970; Viola et 
al. 1971).  It is unknown whether these degenerative changes might also occur at lower doses; thus, a 
study examining the effects of a range of lower doses would be informative.  In addition, relatively recent 
studies present suggestive evidence that vinyl chloride may also produce peripheral nerve damage in 
humans exposed chronically via inhalation (Langauer-Lewowicka et al. 1976; Magnavita et al. 1986; 
Perticoni et al. 1986; Sakabe 1975; Walker 1976).  Animal studies examining histopathological and 
electrophysiological end points in peripheral nerves would be helpful for assessing what doses may be 
associated with this effect.  Epidemiological studies examining exposed populations for subclinical 
peripheral nerve damage would also be helpful.   
Epidemiological and Human Dosimetry Studies.    Virtually all of the data on effects in humans 
following inhalation exposure to vinyl chloride come from epidemiological studies of workers exposed 
during the production of PVC (Belli et al. 1987; Boffetta et al. 2003; Brugnami et al. 1988; Byren et al. 
1976; Cheng et al. 1999; Chung and Keh 1987; Cooper 1981; Creech and Johnson 1974; Davies et al. 
1990; Du and Wang 1998; Fitzgerald and Griffiths 1987; Fox and Collier 1977; Gelin et al. 1989; Geryk 
and Zudova 1986; Hagmar et al. 1990; Heldass et al. 1987; Infante et al. 1976b; Jones et al. 1988; 
Lelbach 1996; Lewis 2001; Lewis and Rempala 2003; Lewis et al. 2003; Monson et al. 1975; Mundt et al. 
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2000; Ojajarvi et al. 2001; Pirastu et al. 1990; Rhomberg 1998; Rinsky et al. 1988; Saurin et al. 1997; 
Simonato et al. 1991; Smulevich et al. 1988; Teta et al. 1990; Ward et al. 2001; Waxweiler et al. 1981; 
Weber et al. 1981; Weihrauch et al. 2000; Williamson and Ramsden 1988; Wong et al. 2002a, 2002b, 
2003a, 2003b, 1991; Wu et al. 1989).  These studies are limited by the absence of information on 
individual exposure levels.  Also, in North America and Western Europe, only limited numbers of 
females have been studied. 
For the most part, studies examining the carcinogenic potential of vinyl chloride have been adequate to 
distinguish an increased incidence of the rare cancer, angiosarcoma (Byren et al. 1976; Creech and 
Johnson 1974; Fox and Collier 1977; Infante et al. 1976b; Jones et al. 1988; Monson et al. 1975; Pirastu 
et al. 1990; Rinsky et al. 1988; Teta et al. 1990; Waxweiler et al. 1976; Weber et al. 1981; Wong et al. 
1991; Wu et al. 1989).  However, many studies have used cohorts that are too small to detect smaller 
increases in other types of cancer (respiratory, central nervous system, lymphatic, or hematopoietic).  
Epidemiological studies designed to investigate reproductive and developmental effects of vinyl chloride 
have not been useful, in part because of a poor choice of statistical analysis, inadequate controls, lack of 
effects due to current low levels of exposure, or failure to take into account nutritional status and other 
chemical exposures.  Additional cohort studies of these end points would be useful for examining these 
effects in humans. 
Clastogenic effects have been used as a dosimeter for exposures to radioactive substances, and work has 
been done to use this approach for chemical exposures as well.  More data on quantified exposures and 
well-controlled cytogenetic studies would be useful in developing a method for monitoring populations 
living near hazardous waste sites.  
Biomarkers of Exposure and Effect.    
Exposure. Several potential biomarkers for exposure to vinyl chloride have been identified.  Vinyl 
chloride measured in expired air is an adequate indicator of recent, moderate-to-high-level exposure 
(Baretta et al. 1969).  However, for low-level exposures or exposures that occur over 1–2 hours prior to 
the time of measurement, this biomarker is not useful.  Thiodiglycolic acid, a major urinary metabolite of 
vinyl chloride, has been used to monitor workers occupationally exposed to vinyl chloride (Müller et al. 
1979).  However, this biomarker is rapidly excreted, and therefore, the period of its utility is limited 
(Watanabe and Gehring 1976; Watanabe et al. 1979b).  Also, thiodiglycolic acid is not specific for vinyl 
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chloride; it may also be produced as a result of the metabolism of 1,1-dichloroethene, ethylene oxide, or 
2,2-dichloroethylether (Norpoth et al. 1986; Pettit 1986). 
The DNA adducts 1,N6-ethenoadenosine and 3,N4-ethenocytidine may be used to indicate vinyl chloride 
exposure, although studies correlating the levels of these adducts with exposure levels are still lacking.  
These products remain in the body longer than free vinyl chloride or thiodiglycolic acid, thereby 
increasing the period after exposure that a potential exposure may be detected (Bolt 1986; Guengerich 
and Watanabe 1979; Guengerich et al. 1979, 1981; Kappus et al. 1976; Watanabe et al. 1987a, 1987b).  
However, the presence of these adducts cannot indicate how long it has been since exposure occurred.  In 
addition, these adducts are formed as the result of binding of the intermediary metabolites with nucleic 
acids, and other compounds producing the same intermediary metabolites will also produce these adducts.  
For example, these adducts have been identified as a result of exposure to vinyl bromide, ethyl carbamate, 
acrylonitrile, 2-cyanoethylene, and 1,2-dichloroethane (Bolt et al. 1986; Svensson and Osterman-Golkar 
1986).  Studies attempting to identify a metabolite more specific to vinyl chloride may be helpful in 
developing a biomarker that may be used to facilitate future medical surveillance, which can lead to early 
detection and possible treatment. 
Vinyl chloride-induced genetic alterations have been identified in the Ki-ras oncogene and the p53 tumor 
suppressor gene, and oncoproteins and p53 antibodies have been detected in the serum of cancer patients 
with angiosarcoma (see Section 3.3).  Immunological techniques have been used to detect the presence of 
Asp13p21 (oncoprotein for mutation of the Ki-ras gene), p53 mutant protein, and p53 antibodies in the 
serum of exposed workers (Brandt-Rauf et al. 2000a, 2000b; Marion 1998).  Statistical analyses suggest a 
relationship between vinyl chloride exposure and the presence of these serum biomarkers; however, the 
predictive value of these biomarkers for development of cancer is not known. 
Effect. With regard to biomarkers of effect of vinyl chloride exposure, numerous indicators have been 
examined.  The central nervous system depression associated with brief high-level exposures is easily 
determined by observation.  The hepatic changes that may develop during longer term exposures are 
difficult to detect by standard biochemical liver function tests (Berk et al. 1975; Du et al. 1995; Liss et al. 
1985; Vihko et al. 1984). In contrast, tests of clearance such as the indocyanine clearance test or 
measurement of serum bile acid levels are more specific and sensitive indicators of vinyl chloride-induced 
liver damage (Berk et al. 1975; Liss et al. 1985; Vihko et al. 1984).  Angiosarcoma of the liver is a rare 
tumor type that has been shown to result from vinyl chloride exposure.  However, other agents are known 
to produce angiosarcoma of the liver, such as arsenic and Thorotrast® (Gedigke et al. 1975; Marsteller et 
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al. 1975).  Enzyme-linked immunoassay (EIA) has been used to detect anti-p53 antibodies in the serum of 
some individuals with angiosarcoma of the liver before clinical diagnosis of this lesion was made (Trivers 
et al. 1995). However, not all individuals who develop angiosarcoma of the liver test positive for anti-p53 
antibodies; in addition, anti-p53 bodies are not specific only to angiosarcoma of the liver.  Further 
investigation into the ability of this assay to predict individuals at increased risk for developing 
angiosarcoma of the liver would be useful.  Measurement of chromosomal aberrations may indicate the 
genotoxic effects of vinyl chloride (Anderson et al. 1980; Ducatman et al. 1975; Fucic et al. 1990a, 
1990b). However, these aberrations do not specifically indicate vinyl chloride-induced damage.  Also, 
DNA adducts may signal the potential to develop genotoxic effects.  Further work identifying the 
correlation between specific adducts and genotoxic effects would be useful.  The cyanosis and blanching 
of the fingers in response to exposure to the cold may be an early indicator for the development of vinyl 
chloride disease. However, other conditions also known to produce these symptoms include connective 
tissue disorders, mechanical arterial obstruction, hyperviscosity of the blood, and exposure to drugs, 
chemicals, or vibrating tools (Black et al. 1983, 1986; Freudiger et al. 1988).  The presence of basophilic 
stippled erythrocytes has been reported after inhalation exposure of mice to vinyl chloride (Kudo et al. 
1990). Further study would be necessary to determine whether this parameter could be used as a 
biomarker of effect in humans.   
Absorption, Distribution, Metabolism, and Excretion.    There are few data on humans for all 
toxicokinetic parameters across all exposure routes (Krajewski et al. 1980; Sabadie et al. 1980).  There 
are a number of animal studies describing the absorption, distribution, metabolism, and excretion of vinyl 
chloride administered via the oral route (Feron et al. 1981; Green and Hathway 1978; Watanabe and 
Gehring 1976; Watanabe et al. 1987a, 1987b; Withey 1976) and the inhalation route (Bolt et al. 1976a, 
1977; Buchter et al. 1977, 1980; Filser and Bolt 1979; Guengerich and Watanabe 1979; Hefner et al. 
1975b; Jedrychowski et al. 1984, 1985; Ungvary et al. 1978; Watanabe and Gehring 1976; Watanabe et 
al. 1978a, 1978b; Withey 1976) but few describing the toxicokinetics of vinyl chloride administered via 
the dermal route. One study in monkeys found an extremely limited absorption of vinyl chloride across 
the skin (Hefner et al. 1975a).  However, only two animals were used, and this was the only study located 
that examined toxicokinetics after dermal exposure. No information is available regarding dermal 
absorption of vinyl chloride from liquid or solid media (i.e., water, soil).  Dermal exposure from these 
media is expected to be minimal; however, a study confirming this assumption would be useful.  
Furthermore, the intermediary metabolites of vinyl chloride appear to be responsible for many of the toxic 
effects observed.  Therefore, information regarding differences in the metabolic pattern according to 
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gender, age, nutritional status, and species and correlations to differences in health effects would also be 
useful. 
Comparative Toxicokinetics.    The absorption, distribution, metabolism, and excretion of vinyl 
chloride have been studied in animals (Bolt et al. 1976a, 1977; Buchter et al. 1977, 1980; Feron et al. 
1981; Filser and Bolt 1979; Green and Hathway 1975; Guengerich and Watanabe 1979; Hefner et al. 
1975b; Jedrychowski et al. 1984, 1985; Ungvary et al. 1978; Watanabe and Gehring 1976; Watanabe et 
al. 1976a, 1976b, 1978a, 1978b; Withey 1976), but information on toxicokinetics in humans is extremely 
limited (Krajewski et al. 1980; Sabadie et al. 1980). Human and animal data indicate that similar target 
organs (liver, central nervous system) for the toxic effects of vinyl chloride exist, suggesting some 
similarities of kinetics.  Limited information is available regarding interspecies differences in kinetics.  
Most toxicokinetic studies have been conducted using rats (Bolt et al. 1976a, 1977; Buchter et al. 1977; 
Feron et al. 1981; Filser and Bolt 1979; Green and Hathway 1975; Guengerich and Watanabe 1979; 
Hefner et al. 1975b; Jedrychowski et al. 1984, 1985; Ungvary et al. 1978; Watanabe and Gehring 1976; 
Watanabe et al. 1976a, 1976b, 1978a, 1978b; Withey 1976), but one study in primates indicates that 
metabolism may saturate at lower concentrations in primates than rats (Buchter et al. 1980).  This may 
suggest a lower saturation point in humans also.  Modeling studies might continue to provide information 
on the toxicokinetics of vinyl chloride in humans. 
Methods for Reducing Toxic Effects.    Vinyl chloride appears to be rapidly and completely 
absorbed following inhalation and oral exposure (Bolt et al. 1977; Krajewski et al. 1980; Watanabe et al. 
1976a; Withey 1976).  Methods used to reduce absorption immediately after exposure include removal 
from the source of exposure, cleansing contaminated body parts, and in cases of ingestion, speeding the 
removal of unabsorbed material from the gastrointestinal tract (Bronstein and Currance 1988; Haddad and 
Winchester 1990; Stutz and Ulin 1992).  No information was located regarding the mechanism of 
absorption. Additional experiments examining the mechanism of absorption and potential means of 
interfering with that mechanism would be useful.  Distribution of vinyl chloride in the body is rapid and 
widespread, but storage is limited by rapid metabolism and excretion (Bolt et al. 1976a; Buchter et al. 
1977; Watanabe et al. 1976a, 1976b, 1978a).  The toxicity of vinyl chloride has been attributed to the 
formation of reactive epoxide metabolites.  No information was located regarding removal of these toxic 
metabolites from the body once they have been formed, but information from toxicokinetic studies 
suggest that vinyl chloride metabolism to toxic metabolites may be reduced.  Saturation of the metabolic 
pathways for vinyl chloride can result in the clearance of unmetabolized vinyl chloride in exhaled air 
(Green and Hathway 1975; Watanabe and Gehring 1976; Watanabe et al. 1976a, 1976b, 1978a).  Studies 
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examining the effectiveness and endogenous toxicity of the agents used to block the metabolic pathways 
(cobaltous chloride, SKF-535-A, 6-nitro-1,2,3-benzothiadiazole) would provide useful information.  
Another strategy for reducing the formation of toxic metabolites includes increasing the pool of 
glutathione for use in metabolism to nontoxic metabolites.  Studies examining the effectiveness of this 
procedure would also be helpful.  Vinyl chloride disease may be mediated by an autoimmune mechanism 
(Grainger et al. 1980; Ward 1976).  Further studies continuing to examine the role of autoimmune 
responses in vinyl chloride disease, the genetic factors resulting in greater susceptibility to the disease, 
and the effectiveness of drugs that block immune responses in reducing the symptoms of vinyl chloride 
disease would also provide valuable information. 
Children’s Susceptibility.    Data needs relating to both prenatal and childhood exposures, and 
developmental effects expressed either prenatally or during childhood, are discussed in detail in the 
Developmental Toxicity subsection above. 
No studies were located that specifically address the effects of vinyl chloride in children.  Some 
epidemiologic studies (Infante 1976; Infante et al. 1976a, 1976b; NIOSH 1977) have suggested an 
association between birth defects and vinyl chloride exposure of the parents of affected children.  
However, the design and analysis of these studies has been criticized (Hatch et al. 1981; Stallones 1987).  
Some inhalation studies with animals have suggested that vinyl chloride is a developmental toxicant (i.e., 
produces delayed ossification), but only at doses that produce significant maternal toxicity (John et al. 
1977, 1981; Mirkova et al. 1978; Sal'nikova and Kotsovskaya 1980; Ungvary et al. 1978).  No adverse 
effects on embryo-fetal development were noted in a recent inhalation study in rats conducted using 
similar concentrations of vinyl chloride (Thornton et al. 2002).  There is no evidence that vinyl chloride 
has hormone-like effects.  However, a developmental neurotoxicity study in rats in which pups are tested 
at various ages after being exposed in utero would be informative. 
Carcinogenicity studies with animals suggest that younger animals may be more sensitive to the toxicity 
and carcinogenicity of vinyl chloride (Laib et al. 1985; Maltoni et al. 1981).  An age-related sensitivity to 
DNA adduct formation was noted in rats (Ciroussel et al. 1990; Fedtke et al. 1990; Morinello et al. 
2002a). Further mechanistic research may be useful in establishing the mechanism of early life stage 
sensitivity in laboratory animals and determining whether it is anticipated to be relevant to humans. 
No studies were located that specifically address the toxicokinetics of vinyl chloride in children; however, 
the toxicokinetic behavior of vinyl chloride in children is expected to be similar to that in adults.  Young 
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children appear capable of metabolizing vinyl chloride to reactive intermediates that form DNA adducts 
that lead to cancer. The data on CYP2E1 levels in the developing organism suggest that early life stage 
sensitivity to vinyl chloride-induced cancer is not solely due to an increase in the production of reactive 
intermediates via this isozyme.  Fetal CYP isoforms may play a role in metabolism of vinyl chloride to 
reactive intermediates in the fetus and neonate. Glutathione conjugation may also differ in the developing 
organism.  DNA repair capacity and other pharmacodynamic factors may also be associated with an early 
life stage susceptibility to cancer.  Further information on the toxicokinetics and toxicodynamics of vinyl 
chloride and metabolites during pregnancy, lactation, and early childhood would be useful.  The 
biomarkers of exposure and effects used in occupational worker populations should be evaluated for their 
relevance to human exposure at all age levels following acute or chronic exposure to vinyl chloride.  
There are no data on the interaction of vinyl chloride with other chemicals in children.  The information 
available indicates that methods to reduce peak absorption of vinyl chloride are applicable to children. 
Child health data needs relating to exposure are discussed in Section 6.8.1, Identification of Data Needs:  
Exposures of Children. 
3.12.3 Ongoing Studies 
The following ongoing studies concerning the adverse health effects associated with vinyl chloride have 
been identified in the Federal Research in Progress (FEDRIP 2005) database. 
Dr. P.W. Brandt-Rauf at Columbia University proposes to investigate whether genetic polymorphisms in 
vinyl chloride-metabolizing enzymes are also related to the more specific biomarkers of mutagenic 
damage (mutant ras-p21 and/or mutant p53) in vinyl chloride-exposed workers.  Restriction fragment 
length polymorphism techniques will be used to analyze DNA from sub-groups of vinyl chloride-exposed 
workers. It is anticipated that workers with genetic polymorphisms will be more likely to have the 
biomarkers of mutagenic damage than similarly exposed workers without the polymorphisms and thus 
will be more likely to suffer from the subsequent carcinogenic and other health effects of vinyl chloride 
exposure. If this proves to be correct, then such special populations at risk could be targeted for more 
stringent interventions to help prevent the occurrence of vinyl chloride-related occupational diseases.  
This research is sponsored by the National Institute for Occupational Safety and Health. 
Dr. W.K. Kaufman at the University of North Carolina at Chapel Hill will investigate the role of DNA 
repair in the formation of hprt mutations in vinyl chloride-exposed workers.  A subfraction of people 
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exposed to vinyl chloride in the workplace expressed high frequencies of hprt mutations in blood 
lymphocytes.  The possible existence of a DNA repair defect in sensitive workers will be evaluated by 
studying chlorethylene oxide-induced genotoxicity in lymphoblastoid lines derived from sensitive and 
resistant people. This project will employ a functional assay for DNA repair capacity in peripheral 
lymphocytes that measures rejoining of radiation-induced chromatid breaks.  This research is supported 
by the National Institute of Environmental Health Sciences (NIEHS). 
Dr. G.E. Kisby at the Oregon Health Sciences University proposes experiments to examine the 
relationship between the formation of etheno base DNA adducts of chloroacetaldehyde and neurotoxicity 
or mutations.  Neuronal and astrocyte cell cultures will be developed from different brain regions (e.g., 
cortex, hippocampus, midbrain, cerebellum) of DNA repair proficient and deficient mice (i.e., 
k N-methylpurine DNA glycosylase Aag).  These cell lines will be examined for acute and delayed 
chloroacetaldehyde-induced neurotoxicity.  Separate sets of astrocyte cell cultures will be developed from 
hprt heterozygous-deficient mice and examined to determine the spectrum of chloroacetaldehyde-induced 
mutations.  Findings from these studies are expected to provide important information about the 
neurotoxic and mutagenic mechanisms of vinyl chloride.  This research is sponsored by the NIEHS. 
Dr. K.D. Thrall at the Oregon Health Sciences University will investigate the influence of route of 
exposure on the total body burden and internal target tissue dosimetry of vinyl chloride and other 
chemicals.  Exposure assessment studies will be conducted with human volunteers using a novel real-time 
breath analysis system to determine the uptake of contaminants from tap water by each of three routes:  
inhalation, ingestion, and dermal contact.  These data will be coupled with PBPK modeling to determine 
uptake kinetics and brain dosimetry.  This research is sponsored by the NIEHS. 
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4.1 CHEMICAL IDENTITY  
Information regarding the chemical identity of vinyl chloride is located in Table 4-1.  This information 
includes synonyms, chemical formula and structure, and identification numbers. 
4.2 PHYSICAL AND CHEMICAL PROPERTIES  
Information regarding the physical and chemical properties of vinyl chloride is located in Table 4-2. 
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Table 4-1. Chemical Identity of Vinyl Chloride 
Characteristic Information Reference 
Chemical name Vinyl chloride HSDB 2005 
Synonym(s) Chloroethene; chloroethylene; 1-chloroethylene; 
ethylene monochloride; monovinyl chloride; 
monochloroethene; monochloroethylene; 
MVCs; Trovidur; VC; VCM; vinyl chloride 
monomer 
Fire 1986; HSDB 2005 
Registered trade name(s) No data 
Chemical formula C2H3Cl HSDB 2005 
Chemical structure H H HSDB 2005 




CAS registry 75-01-4 HSDB 2005 
 NIOSH/RTECS KU9625000 HSDB 2005 
EPA hazardous waste U043 HSDB 2005 
 OHM/TADS 7216947 HSDB 2005 
 DOT/UN/NA/IMCO 1086 HSDB 2005 
shipping 
HSDB 169 HSDB 2005 
NCI No data HSDB 2005 
CAS = Chemical Abstract Services; DOT/UN/NA/IMCO = Department of Transportation/United Nations/North 
America/International Maritime Dangerous Goods Code; EPA = Environmental Protection Agency; 
HSDB = Hazardous Substance Data Bank; NCI = National Cancer Institute; NIOSH = National Institute for 
Occupational Safety and Health; OHM/TADS = Oil and Hazardous Materials/Technical Assistance Data System; 
RTECS = Registry of Toxic Effects of Chemical Substances 
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Table 4-2. Physical and Chemical Properties of Vinyl Chloride 
Property Information Reference 
Molecular weight 62.5 Lewis 1996 
Color Colorless Budavari 1989 
Physical state Gas Budavari 1989 
Melting point -153.8 °C Budavari 1989 
Boiling point -13.37 °C Budavari 1989 
Density: 
at -14.2 °C 0.969 g/cm3 Cowfer and Magistro 1983 
at 15 °C 0.9195 g/cm3 Lewis 1996 
at 20 °C 0.9106 g/cm3 NIOSH 1986 
Vapor density 2.16 Fire 1986 
Odor Sweet HSDB 1996 
Odor threshold: 
Water 3.4 ppm Amoore and Hautala 1983 
Air 3,000 ppm Amoore and Hautala 1983 
Solubility: 
Water at 25 °C 2,763 mg/L EPA 1985b 
1,100 mg/L Cowfer and Magistro 1983 
Organic solvent(s) Soluble in hydrocarbons, oil, alcohol, Cowfer and Magistro 1983 
chlorinated solvents, and most common 
organic liquids 
Partition coefficients: 
 Log Kow 1.36 NIOSH 1986
 Log Koc 1.99 Lyman et al. 1982 
Vapor pressure: 
at 20 °C 2,530 mmHg Budavari 1989 
at 25 °C 2,600 mmHg Lewis 1996 
Henry’s law constant: 
10.3 °C 0.0147 (atm-m3)/mol Gossett 1987 
17.5 °C 0.0193 (atm-m3)/mol Gossett 1987 
24.8 °C 0.0278 (atm-m3)/mol Gossett 1987 
34.6 °C 0.0358 (atm-m3)/mol Gossett 1987 
Autoignition temperature 472 °C Lewis 1996 
Flashpoint -78 °C (closed cup) Budavari 1989 
Flammability limits 3.6–33 volume % NIOSH 1986 
Conversion factors: 
ppm to mg/m3 in air 1 ppm=2.6 mg/m3 NIOSH 1990
 mg/m3 to ppm in air 1 mg/m3=0.38 ppm NIOSH 1990 
Explosive limits 4–22 volume % Lewis 1996 
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5.1 PRODUCTION 
Vinyl chloride was first produced commercially in the 1930s by reacting hydrogen chloride with 
acetylene.  Currently, vinyl chloride is produced commercially by the chlorination of ethylene through 
one of two processes, direct chlorination or oxychlorination.  Direct chlorination reacts ethylene with 
chlorine to produce 1,2-dichloroethane. Similarly, oxychlorination produces 1,2-dichloroethane, but this 
is accomplished by reacting ethylene with dry hydrogen chloride and oxygen. After both processes, the 
1,2-dichloroethane is subjected to high pressures (2.5–3.0 megapascals) and temperatures (550–550 °C).  
This causes the 1,2-dichloroethane to undergo pyrolysis, or thermal cracking, which forms the vinyl 
chloride monomer and hydrogen chloride.  The vinyl chloride monomer is then isolated (Cowfer and 
Magistro 1985).  The technical-grade product is available in 99.9% purity (HSDB 2005).  Efforts are 
being made to minimize by-product formation (hydrocarbons, chlorinated hydrocarbons, and unreacted 
material) in 1,2-dichloroethane pyrolysis (Cowfer and Magistro 1985). 
Table 5-1 summarizes the facilities in the United States that either manufacture or process vinyl chloride.  
This information was obtained from the Toxic Release Inventory (TRI03 2005), and also lists the 
maximum amounts of vinyl chloride that are present at these sites and the end uses of vinyl chloride.  
Table 5-2 lists the facilities that solely manufacture vinyl chloride for commercial purposes and their 
production capacities. In 2001, the global demand for vinyl chloride was 14.89 billion pounds; in 2002, 
demand was 15.94 billion pounds; and in 2006, it is estimated that demand for vinyl chloride will be 
17.8 billion pounds (CMR 2003).  Demand for vinyl chloride monomer is almost entirely dependent upon 
the consumption of polyvinyl chloride (PVC) materials.  Demand is expected to increase globally at a rate 
of approximately 3.5% annually due to increasing demand in Asia, while demand in the United States is 
expected to increase by about 2.8% annually (CMR 2003).  
5.2 IMPORT/EXPORT 
Imports of vinyl chloride totaled 29 million pounds (13.17 million kilograms) in 1994 and 164 million 
pounds in 1991 (CPS 1993; NTD 1995). Imports have been steadily declining from a high of 302 million 
pounds in 1989, prior to which they had been increasing (CPS 1993).  Currently, the amounts of vinyl  
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Table 5-1. Facilities that Produce, Process, or Use Vinyl Chloride 
Number Minimum Maximum 
of amount on site amount on site 
Statea facilities in poundsb in poundsb Activities and usesc 
AL 2 1,000 999,999 2, 3, 6, 7 
AR 3 1,000 999,999 6, 12 
CA 8 100 9,999,999 2, 3, 6, 7, 8, 9, 10, 12 
DE 6 10,000 99,999,999 2, 3, 6, 11, 12 
FL 2 100,000 9,999,999 6 
GA 3 1,000 999,999 6, 7, 8 
IL 5 1,000 49,999,999 6, 8, 11 
IN 4 0 99,999 1, 7, 8, 13 
KS 8 100 99,999 1, 2, 3, 5, 6, 10, 12, 13 
KY 10 1,000 49,999,999 1, 2, 3, 4, 6, 12, 14 
LA 37 100 10,000,000,000 1, 2, 3, 4, 5, 6, 11, 12, 13 
MI 8 1,000 9,999,999 2, 3, 6, 12 
MO 5 1,000 9,999,999 1, 2, 3, 5, 6, 8, 11 
MS 4 1,000,000 999,999,999 6 
NC 7 0 999,999 1, 5, 6, 8, 11 
NE 1 10,000 99,999 12 
NJ 11 1,000 49,999,999 6, 7, 8, 12 
NY 2 10,000 999,999 6, 8 
OH 10 0 9,999,999 2, 3, 6, 7, 8, 11, 12 
OK 1 1,000,000 9,999,999 6 
PA 2 1,000,000 9,999,999 3, 6, 8 
SC 2 10,000 9,999,999 8, 12 
TX 43 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14 
UT 1 1,000 9,999 12 
VA 4 1,000 999,999 1, 7, 12, 13 
WI 1 10,000 99,999 7 
aPost office state abbreviations used 









8. Formulation Component 
9. Article Component 
10. Repackaging 
11. Chemical Processing Aid 
12. Manufacturing Aid  
13. Ancillary/Other Uses 
14. Process Impurity 
Source: TRI03 2005 (Data are from 2003) 
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Table 5-2. U.S. Production Capacity of Vinyl Chloride 
U.S. Producer Location Capacity (millions pounds per year) 
Dow Chemicals Oyster Creek, Texas; Freeport, Texas 2,700 
Dow Chemicals Plaquemine, Louisiana  1,500 
Formosa Plastics Baton Rouge, Louisiana 980 
Formosa Plastics Point Comfort, Texas 1,235 
Geismar Vinyls Geismar, Louisiana 650 
Georgia Gulf Lake Charles, Louisiana 1,000 
Georgia Gulf Plaquemine, Louisiana  1,600 
Oxy Mar Ingleside, Texas 2,300 
Oxy Vinyls Deer Park, Texas 1,300 
Oxy Vinyls La Porte, Texas 2,400 
PHH Monomers Lake Charles, Louisiana 1,300 
Westlake Monomers Calvert City, Kentucky 1,200 
U.S. total capacity:  18,165 million pounds 
Source: CMR 2003 
166 VINYL CHLORIDE 
5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL 
chloride imported into the United States are negligible (CMR 2003).  Exports of vinyl chloride were 
1.65 billion pounds (0.75 billion kilograms) in 1992 and 2.10 billion pounds (0.95 billion kilograms) in 
1994 (NTD 1995). Recent estimates have shown a slight decrease in U.S. export volumes.  In 2001, 
exports of vinyl chloride totaled 1.89 billion pounds and in 2002, exports were 1.43 billion pounds (CMR 
2003). 
5.3 USE 
Vinyl chloride is an important industrial chemical because of its wide variety of end-use products and the 
low cost of producing polymers from it.  Approximately 98% of all vinyl chloride produced is used to 
manufacture PVC materials (CMR 2003).  These PVC materials are widely used in automotive parts, 
packaging products, pipes, construction materials, furniture, and a variety of other products (Cowfer and 
Magistro 1985).  Other miscellaneous uses, which account for about 2% of the vinyl chloride that is 
produced annually, include the production of 1,1,1-trichloroethane and copolymers with vinyl acetate, 
vinyl sterate, and vinylidene chloride (CMR 2003). 
Vinyl chloride has been used in the past as a refrigerant, as an extraction solvent for heat-sensitive 
materials, and in the production of chloroacetaldehyde and methyl chloroform (IARC 1979).  In the 
United States, limited quantities of vinyl chloride were used as an aerosol propellant and as an ingredient 
of drug and cosmetic products; however, these practices were banned by the EPA in 1974 (HSDB 2005; 
IARC 1979). 
5.4 DISPOSAL 
Since vinyl chloride has been identified by EPA as a hazardous material, its disposal is regulated under 
the Federal Resource Conservation and Recovery Act (RCRA) (EPA 1993d).  The transportation of 
hazardous materials for disposal is regulated by the Department of Transportation in compliance with this 
act (DOT 1993). The recommended method of disposal is total destruction by incineration.  The 
temperature of the incinerator must be sufficient to ensure the complete combustion of the vinyl chloride 
in order to prevent the formation of phosgene.  The recommended temperature range for incineration is 
450–1,600 °C, with residence times of seconds for gases and liquids, and hours for solids (HSDB 2005).  
If in solution, the vinyl chloride product may need to be adsorbed onto a combustible material prior to 
incineration. Recommended materials include vermiculite, sawdust, or a sand-soda ash mixture (90/10) 
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covered with wood and paper (OHM/TADS 1985).  The vinyl chloride can also be dissolved in a 
flammable solvent prior to incineration.  An acid scrubber should be used in conjunction with the 
incinerator in order to remove any hydrogen chloride that is produced by the combustion process (HSDB 
2005; OHM/TADS 1985).  Alternatively, chemical destruction may be used, especially with small 
quantities. From 1 to 2 days is generally sufficient for complete destruction (HSDB 2005). 
Aqueous byproduct solutions from the production of vinyl chloride are usually steam-stripped to remove 
volatile organic compounds, neutralized, and then treated in an activated sludge system to remove 
nonvolatile organic compounds remaining in the waste water (Cowfer and Magistro 1983). 
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6.1 OVERVIEW 
Vinyl chloride has been identified in at least 622 of the 1,662 hazardous waste sites that have been 
proposed for inclusion on the EPA National Priorities List (NPL) (HazDat 2005).  However, the number 
of sites evaluated for vinyl chloride is not known.  The frequency of these sites can be seen in Figure 6-1. 
Of these sites, all are located within the continental United States with the exception of one site located in 
the Virgin Islands and one site in the Commonwealth of Puerto Rico (not shown).   
Vinyl chloride is used almost exclusively in the United States by the plastics industry for the production 
of polyvinyl chloride (PVC) and several copolymers.  Much of the vinyl chloride produced at 
manufacturing facilities gets converted to PVC and vinyl chloride derived copolymers on-site.  Nearly all 
vinyl chloride shipped to facilities off-site is also converted to PVC or PVC copolymers.  In many cases, 
vinyl chloride is transported by pipeline directly to the plant producing the polymer.  The physical form of 
vinyl chloride is a neat liquid (99.9% minimum purity) stored or transported under pressure (OECD 
2001). 
Anthropogenic sources are responsible for all of the vinyl chloride found in the environment.  Most of the 
vinyl chloride released to the environment eventually escapes to the atmosphere.  Lesser amounts are 
released to groundwater.  Vinyl chloride has been detected in the ambient air in the vicinity of vinyl 
chloride and PVC manufacturing plants and hazardous waste sites.  The compound has also leached into 
groundwater from spills, landfills, and industrial sources; it can also enter groundwater after being 
produced by the bacterial degradation of trichloroethylene, tetrachloroethylene, and 1,1,1-trichloroethane 
(Smith and Dragun 1984). 
Effluents and emissions from vinyl chloride and PVC manufacturers are responsible for most of the vinyl 
chloride released to the environment.  In the vicinity of hazardous waste sites, a significant source of 
vinyl chloride may originate from the bacterial degradation of chlorinated solvents such as 
trichloroethylene, tetrachloroethylene, and 1,1,1-trichloroethane, rather than industrial sources.  When 
released to the atmosphere, vinyl chloride is expected to be removed by reaction with photochemically 
generated hydroxyl radicals (half-life=1–2 days).  Reaction products include hydrochloric acid,  
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formaldehyde, formyl chloride, acetylene, chloroacetaldehyde, chloroacetylchloranil, and chloroethylene 
epoxide. In photochemical smog, the half-life of vinyl chloride is reduced to a few hours.  When released 
to water, volatilization is expected to be the primary environmental fate process.  In waters containing 
photosensitizers, such as humic materials, sensitized photodegradation may also be important.  Sensitized 
photodegradation may occur when a molecule other than the compound of interest absorbs light, 
promoting it to an excited state; a transfer of energy occurs between the excited state of the photo­
sensitizer and the compound of interest, which involves no direct absorption of photons by that particular 
compound. When released to soil, vinyl chloride either volatilizes rapidly from soil surfaces or leaches 
readily through soil, ultimately entering groundwater. 
Segments of the general population living in the vicinity of emission sources are exposed to vinyl 
chloride by inhalation of contaminated air.  Average daily intake of vinyl chloride by inhalation for these 
people ranges from trace amounts to 2,100 μg/day.  The average daily intake of vinyl chloride by 
inhalation is expected to be very low for the remainder of the population.  The majority of the general 
population is not expected to be exposed to vinyl chloride through ingestion of drinking water.  The 
average daily intake of vinyl chloride through the diet is essentially zero.  Workers, particularly those 
employees at vinyl chloride and PVC manufacturing facilities, are exposed to vinyl chloride mainly by 
inhalation, although minor absorption through the skin possible.  Workers involved in the handling and 
and processing of PVC resins are exposed to lower levels of vinyl chloride than employees at vinyl 
chloride and PVC manufacturing facilities since fabricated products contain only minute quantities of 
vinyl chloride present as residual monomer.  The National Occupational Exposure Survey (NOES), 
conducted by NIOSH from 1981 to 1983, estimated that 81,314 workers (28,398 of these are females) 
employed at 3,711 plant sites were potentially exposed to vinyl chloride (NOES 1990).  This survey does 
not differentiate between exposures to persons working in vinyl chloride and PVC manufacturing 
facilities and those persons employed in trades that fabricate end products where the level of exposure is 
expected to be lower. Since the early 1970s, improvements in manufacturing facilities, engineering 
controls, and workplace practices have substantially reduced workplace exposures in the United States 
and most other industrialized countries that manufacture vinyl chloride and produce or fabricate PVC 
products. 
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6.2 RELEASES TO THE ENVIRONMENT 
The Toxics Release Inventory (TRI) data should be used with caution because only certain types of 
facilities are required to report (EPA 2005).  This is not an exhaustive list.  Manufacturing and processing 
facilities are required to report information to the TRI only if they employ 10 or more full-time 
employees; if their facility is included in Standard Industrial Classification (SIC) Codes 10 (except 1011, 
1081, and 1094), 12 (except 1241), 20–39, 4911 (limited to facilities that combust coal and/or oil for the 
purpose of generating electricity for distribution in commerce), 4931 (limited to facilities that combust 
coal and/or oil for the purpose of generating electricity for distribution in commerce), 4939 (limited to 
facilities that combust coal and/or oil for the purpose of generating electricity for distribution in 
commerce), 4953 (limited to facilities regulated under RCRA Subtitle C, 42 U.S.C. section 6921 et seq.), 
5169, 5171, and 7389 (limited S.C. section 6921 et seq.), 5169, 5171, and 7389 (limited to facilities 
primarily engaged in solvents recovery services on a contract or fee basis); and if their facility produces, 
imports, or processes ≥25,000 pounds of any TRI chemical or otherwise uses >10,000 pounds of a TRI 
chemical in a calendar year (EPA 2005). 
6.2.1 Air 
Estimated releases of 587,677 pounds of vinyl chloride to the atmosphere from 52 domestic 
manufacturing and processing facilities in 2003, accounted for about 85% of the estimated total 
environmental releases from facilities required to report to the TRI (TRI03 2005).  These releases are 
summarized in Table 6-1. 
The major source of vinyl chloride releases to the environment is believed to be emissions and effluents 
from plastic industries, primarily vinyl chloride and PVC manufacturers.  Worldwide emissions of vinyl 
chloride into the atmosphere during 1982 totaled approximately 400 million pounds (Hartmans et al. 
1985). Another emission source is tobacco smoke, which has been found to contain 5.6–28 ng vinyl 
chloride per cigarette (Hoffman et al. 1976). The combustion of coal and the incineration of municipal 
waste may also release small quantities of vinyl chloride to the atmosphere (Dempsey 1993; Miller et al. 
1994). 
The EPA National Toxics Inventory (NTI) estimated that in 1996, 1,650 tons of vinyl chloride 
(3.3 million pounds) were released to the atmosphere in the contiguous United States (plus Puerto Rico 
and the Virgin Islands) (EPA 2005).  The NTI includes more facilities than the TRI because of TRI 
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Reported amounts released in pounds per yearb 
Total release 
Statec RFd Aire Waterf UIg Landh Otheri On-sitej Off-sitek 
On- and off-
site 
AL 1 2,427 No data 0 0 0 2,427 0 2,427 
AR 2 109 No data 0 0 0 109 0 109 
DE 2 84,092 1 0 5 0 84,093 5 84,098 
IL 2 57,025 5 0 5 0 57,030 5 57,035 
IN 1 0 No data 0 0 0 0 0 0 
KS 1 0 No data 38 0 0 38 0 38 
KY 6 44,481 7 0 7 28 44,488 35 44,523 
LA 10 140,614 3 80,116 18 45 220,735 61 220,796 
MI 2 3,534 0 0 0 0 3,534 0 3,534 
MO 1 100 0 0 0 0 100 0 100 
MS 1 30,272 No data 0 0 0 30,272 0 30,272 
NC 1 17 No data 0 0 0 17 0 17 
NJ 3 32,484 64 0 71 0 32,548 71 32,619 
OH 4 267 5 0 24,250 1,260 272 25,510 25,782 
OK 1 4,235 No data 0 0 0 4,235 0 4,235 
PA 1 73,241 0 0 0 0 73,241 0 73,241 
TX 11 114,629 267 0 8 87 114,904 87 114,991 
UT 1 1 No data 0 0 0 1 0 1 
VA 1 149 No data 0 0 0 149 0 149 
Total 52 587,677 352 80,154 24,364 1,420 668,193 25,775 693,967 
aThe TRI data should be used with caution since only certain types of facilities are required to report.  This is not an 
 
exhaustive list.  Data are rounded to nearest whole number.
 
bData in TRI are maximum amounts released by each facility.
 
cPost office state abbreviations are used. 
 
dNumber of reporting facilities.
 
eThe sum of fugitive and point source releases are included in releases to air by a given facility. 
 
fSurface water discharges, waste water treatment-(metals only), and publicly owned treatment works (POTWs)
 
(metal and metal compounds).
 
gClass I wells, Class II-V wells, and underground injection. 
 
hResource Conservation and Recovery Act (RCRA) subtitle C landfills; other on-site landfills, land treatment, surface 
 
impoundments, other land disposal, other landfills. 
 




jThe sum of all releases of the chemical to air, land, water, and underground injection wells. 
 
kTotal amount of chemical transferred off-site, including to POTWs. 
 
RF = reporting facilities; UI = underground injection 
Source: TRI03 2005 (Data are from 2003) 
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reporting thresholds and the limitations in the types of facilities required to report to TRI.  The NTI is 
compiled primarily using state and local agency and tribal toxic air pollutant emission inventories.  The 
emissions organized by state are summarized in Table 6-2.  Vinyl chloride was detected in the air at 63 of 
the 1,662 current or former EPA NPL hazardous waste sites (HazDat 2005).  Vinyl chloride detected at 
these hazardous waste sites may not necessarily arise from industrial sources.  The bacterial degradation 
of chlorinated solvents such as trichloroethylene, tetrachloroethylene, and 1,1,1-trichloroethane can 
produce vinyl chloride as a degradation product, and this may be the origin of vinyl chloride at these sites 
(Smith and Dragun 1984). 
6.2.2 Water 
Estimated releases of 352 pounds of vinyl chloride to surface water from 52 domestic manufacturing and 
processing facilities in 2003, accounted for <1% of the estimated total environmental releases from 
facilities required to report to the TRI (TRI03 2005).  These releases are summarized in Table 6-1. 
Vinyl chloride released in waste water from the plastics industries is expected to volatilize fairly rapidly 
(on the order of hours to days) into the atmosphere.  Anaerobic reductive dehalogenation of trichloro­
ethylene, tetrachloroethylene, and 1,1,1-trichloroethane also releases vinyl chloride into groundwater at 
hazardous waste sites (Smith and Dragun 1984) or other locations where the proper conditions are found 
in the subterranean strata.  Vinyl chloride was detected in groundwater at 538 of the 1,662 current or 
former EPA NPL hazardous waste sites, and in surface water at 110 of the 1,662 current or former EPA 
NPL hazardous waste sites (HazDat 2005).  Since vinyl chloride possesses high mobility in soils, it 
leaches into groundwater from spills, landfills, and industrial sources that may release it to soil (TRI03 
2005). According to data collected from the analysis of leachates and monitoring wells at sites where 
groundwater was contaminated by municipal solid waste landfill leachate, vinyl chloride was present in 
both the leachates and the groundwater samples (Sabel and Clark 1984).  Vinyl chloride has been found in 
groundwater at other landfills also (Agency for Toxic Substances and Disease Registry 1995a, 1995b).   
6.2.3 Soil 
Estimated releases of 24,364 pounds of vinyl chloride to soils from 52 domestic manufacturing and 
processing facilities in 2003, accounted for about 3.5% of the estimated total environmental releases from 
facilities required to report to the TRI (TRI03 2005). In addition, 80,154 pounds of vinyl chloride,  
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Table 6-2. Emissions of Vinyl Chloride Organized by State in 1996 
State Emissions (pounds/year) Emission density (pounds/year/square mile) 
Alabama 19,300 0.38 
Arizona 26,200 0.23 
Arkansas 7,220 0.14 
California 568,000 3.64 
Colorado 70,200 0.67 
Connecticut 3,080 0.63 
Delaware 155,800 78.40 
Washington, DC 2 0.03 
Florida 31,400 0.57 
Georgia 26,400 0.45 
Idaho 3,460 0.04 
Illinois 176,400 3.16 
Indiana 26,000 0.72 
Iowa 7,120 0.13 
Kansas 7,860 0.10 
Kentucky 80,200 2.00 
Louisiana 158,600 3.54 
Maine 480 0.02 
Maryland 8,100 0.84 
Massachusetts 86,000 10.78 
Michigan 124,000 2.20 
Mississippi 36,600 0.77 
Missouri 14,540 0.21 
Montana 1,768 0.01 
Nebraska 4,120 0.05 
Nevada 7,260 0.07 
New Hampshire 3,080 0.34 
New Jersey 63,200 8.36 
New Mexico 10,680 0.09 
New York 248,000 5.20 
North Carolina 26,800 0.55 
North Dakota 2,760 0.04 
Ohio 43,000 1.04 
Oklahoma 6,640 0.10 
Oregon 12,000 0.13 
Pennsylvania 246,000 5.46 
Rhode Island 2,820 3.14 
South Carolina 11,160 0.37 
South Dakota 1,280 0.02 
Tennessee 19,940 0.48 
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Table 6-2. Emissions of Vinyl Chloride Organized by State in 1996 
State Emissions (pounds/year) Emission density (pounds/year/square mile) 
Texas 846,000 3.22 
Utah 6,060 0.07 
Vermont 1,038 0.11 
Virginia 23,400 0.59 
Washington 11,460 0.17 
West Virginia 13,600 0.56 
Wisconsin 9,320 0.17 
Wyoming 1,292 0.01 
Puerto Rico 2,480 0.72 
Virgin Islands 1 0.01 
Source: National Toxics Inventory (NTI) 
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amounting to about 11.5% of the total released was injected underground.  These releases are summarized 
in Table 6-1. 
Vinyl chloride can either enter the soil from leachates at hazardous waste sites or enter the ground via 
underground injection.  Release through either of these mechanisms is, however, only a small fraction of 
the total environmental discharge (TRI03 2005).  Vinyl chloride was detected in soil at 160 of the 
1,662 current or former EPA NPL hazardous waste sites, and in sediment at 47 of the 1,662 current or 
former EPA NPL hazardous waste sites (HazDat 2005).  The bacterial degradation of chlorinated solvents 
such as trichloroethylene, tetrachloroethylene, and 1,1,1-trichloroethane can produce vinyl chloride as a 
degradation product, and this may be a significant source of vinyl chloride at these sites (Smith and 
Dragun 1984). 
6.3 ENVIRONMENTAL FATE 
6.3.1 Transport and Partitioning 
Based on a vapor pressure of 2,660 mmHg at 25 °C, essentially all vinyl chloride in the atmosphere is 
expected to exist solely as a gas (Eisenreich et al. 1981; Verschueren 1983).  Consequently, removal from 
the atmosphere by dry deposition is not expected to be an important fate process. 
The primary transport process for vinyl chloride from natural water systems is volatilization into the 
atmosphere.  The Henry's law constant of vinyl chloride has been measured as 0.0278 atm-m3/mol at 
24.8 °C (Gossett 1987), which suggests that vinyl chloride should partition rapidly to the atmosphere.  
The half-life for vinyl chloride volatilization from a typical pond, river, and lake has been estimated to be 
43.3, 8.7, and 34.7 hours, respectively. These values are based on an experimentally determined 
reaeration rate ratio of approximately 2 and assumed oxygen reaeration rates of 0.008, 0.04, and 0.01 per 
hour for a typical pond, river, and lake, respectively (EPA 1982a).  Predicted half-lives should be 
considered rough estimates since the presence of various salts in natural water systems may affect the 
volatility of vinyl chloride significantly (EPA 1979d).  Many salts have the ability to form complexes 
with vinyl chloride and can increase its water solubility; therefore, the presence of salts in natural waters 
may significantly influence the amount of vinyl chloride remaining in the water (EPA 1979d). The half-
life of vinyl chloride in bodies of water is also affected by depth and turbidity. 
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The relatively high vapor pressure of vinyl chloride indicates that the compound volatilizes quite rapidly 
from dry soil surfaces (Verschueren 1983).  The effective half-life (due to volatilization and degradation) 
of vinyl chloride incorporated 10 cm deep in dry soil is predicted to be 12 hours (Jury et al. 1984).  Vinyl 
chloride is soluble in water and thus can leach through the soil and enter groundwater before evaporation 
can occur (Cowfer and Magistro 1983). 
Experimental data regarding adsorption of vinyl chloride to soil were not located.  Based on the 
regression equations given by Lyman et al. (1982), Sabljic (1984), and Kenaga and Goring (1980), the 
soil organic carbon adsorption coefficient (Koc) for vinyl chloride was estimated to range from 14 to 131.  
These Koc values suggest a very low sorption tendency, meaning that this compound would be highly 
mobile in soil.  Thus, vinyl chloride has the potential to leach into groundwater. 
Vinyl chloride is soluble in most common organic solvents (Cowfer and Magistro 1983).  In situations 
where organic solvents exist in relatively high concentrations (e.g., landfills, hazardous waste sites), 
cosolvation of vinyl chloride could have the effect of reducing its volatility, thus causing it to have even 
greater mobility than indicated by estimated Koc values. 
Vinyl chloride's small octanol/water partition coefficient (log Kow=1.23) indicates that the potential for 
bioconcentration in aquatic organisms is low (EPA 1982a).  Using a log Kow of 1.23 and a regression 
derived equation (Meylan et al. 1999), the bioconcentration factor (BCF) for vinyl chloride is estimated 
as 3. Freitag et al. (1985) measured BCFs in algae, fish, and activated sludge.  The BCFs for algae, fish, 
and activated sludge were 40, <10, and 1,100, respectively.  The very low value for fish, in comparison to 
the algae and activated sludge, may suggest a detoxification process in more highly developed organisms 
such as fish. Lu et al. (1977) examined the bioaccumulation of 14C-vinyl chloride in a closed model 
aquatic ecosystem over a 3-day period. The high volatility of vinyl chloride minimized any potential 
bioaccumulation.  Relatively low tissue concentrations found in fish suggested that vinyl chloride is not 
biomagnified in aquatic food chains to any substantial degree. 
6.3.2 Transformation and Degradation  
6.3.2.1 Air 
Reaction of gaseous vinyl chloride with photochemically generated hydroxyl radicals is predicted to be 
the primary degradation mechanism for this compound in the atmosphere (Cox et al. 1974; Howard 1976; 
179 VINYL CHLORIDE 
6. POTENTIAL FOR HUMAN EXPOSURE 
Perry et al. 1977).  The rate constant for this reaction has been measured as 6.96x10-12 cm3/molec-second 
(Kwok and Atkinson 1994).  This rate constant corresponds to an atmospheric half-life of about 18 hours 
assuming a hydroxyl radical concentration of 1.5x106 molecules/cm3. Products of this reaction are 
hydrochloric acid, formaldehyde, formyl chloride, carbon monoxide, carbon dioxide, chloroacetaldehyde, 
acetylene, chloroethylene epoxide, chloroacetylchloranil, and water (Müller and Korte 1977; Woldbaek 
and Klaboe 1978). Under conditions of photochemical smog, the half-life of vinyl chloride would be 
reduced to a few hours (Carassiti et al. 1977).  Reaction with ozone, nitrate radicals and direct photolysis 
are less important degradation mechanisms of vinyl chloride in the atmosphere (EPA 1976a, 1985c; 
Zhang et al. 1983). Vinyl chloride in the gas phase does not absorb light of wavelengths above 220 nm 
(EPA 1976a).  Since atmospheric ozone blocks almost all sunlight with wavelengths <295 nm, direct 
photolysis is likely to occur very slowly, if at all, in the atmosphere (EPA 1976a). 
6.3.2.2 Water 
The primary removal process for vinyl chloride from surface waters is volatilization into the atmosphere.  
Vinyl chloride in water does not absorb ultraviolet radiation above 218 nm; therefore, direct photolysis in 
the aquatic environment is expected to occur very slowly, if at all (EPA 1976a).  In sunlit surface waters 
containing photosensitizers, such as humic materials, photodegradation may be more rapid.  If so, in some 
waters, sensitized photodegradation may be an important removal mechanism (EPA 1976a).  Vinyl 
chloride decomposed rapidly when irradiated with ultraviolet light in the presence of acetone, a high 
energy triplet sensitizer, or hydrogen peroxide, a free radical source (EPA 1976a). 
The hydrolytic half-life of vinyl chloride has been estimated to be <10 years at 25 °C (EPA 1976a).  Since 
the volatilization rate of vinyl chloride is much more rapid than the predicted rate of hydrolysis, 
hydrolysis is not a significant aquatic fate (EPA 1976a, 1979d).  Vinyl chloride is not oxidized chemically 
by reaction with photochemically generated molecular oxygen in natural water systems (EPA 1976a).  
Experiments carried out at 20 mg/L vinyl chloride in water saturated with molecular oxygen at elevated 
temperatures showed that, after 12 hours at 85 °C, no degradation of vinyl chloride was observed.  At 
temperatures and oxygen concentrations in natural waters, therefore, vinyl chloride is not expected to 
degrade by molecular oxygen at a significant rate (EPA 1976a). 
EPA (1977) observed no change in the biochemical oxygen demand in raw sewage seed (used as a 
microbial inoculum) and raw sewage seed plus vinyl chloride at 20 °C over a 25-day period. The study 
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authors interpreted this to mean that no biodegradation of vinyl chloride occurred.  However, more recent 
data has shown that vinyl chloride can undergo microbial degradation under aerobic conditions.  
Rhodococcus sp. strains SM-1 and Wrink, which were isolated from a trichloroethylene-degrading 
bacterial mixture, and Rhodococcus rhodochrous ATCC 21197 were shown to degrade >99.9% of vinyl 
chloride within 7 days (Malachowsky et al. 1994).  No significant differences in the amount of vinyl 
chloride degraded were found among the three organisms.  The majority (66–83%) of the labeled carbon 
was metabolized to carbon dioxide (CO2). 
Vinyl chloride (1 ppm) was rapidly degraded under aerobic conditions in a laboratory study that used soil-
water microcosms from aquifer material without the addition of other nutrients, such as nitrogen and 
phosphorus (Davis and Carpenter 1990).  About 25% of the vinyl chloride was degraded after 1 week and 
more than 99% was degraded after 108 days.  Sixty-five percent of labeled vinyl chloride was recovered 
as 14CO2 after 108 days, demonstrating the extent of the mineralization. 
Rhodococcus sp. Strain SM-1, a member of the order Actinomycetales, obtained from a trichloroethylene-
degrading consortium was found to mineralize vinyl chloride to CO2 by using propane as an energy 
source during growth experiments or cell suspension experiments (Phelps et al. 1991).  Vinyl chloride 
concentrations decreased by more than 90%; growth cultures and cell suspensions incorporated about 
10% of the transformed vinyl chloride into biomass (Phelps et al. 1991). Mycobacterium vaccae JOB5 
degraded 100% of vinyl chloride in a 2-hour incubation (Wackett et al. 1989). 
Degradation of vinyl chloride generally occurs slowly in anaerobic groundwater and sediment; however, 
under methanogenic or Fe(III) reducing conditions anaerobic degradation occurs more rapidly.  Vinyl 
chloride was mineralized approximately 34% in 84 hours in anaerobic aquifer microcosms supplemented 
with Fe(III) and held under Fe(III) reducing conditions (Bradley and Chapelle 1996). 
6.3.2.3 Sediment and Soil 
Most vinyl chloride present on soil surfaces will volatilize to the atmosphere.  Vinyl chloride is also 
mobile in soil and susceptible to leaching (Lyman et al. 1982).  The presence of other organic solvents, 
such as those found at hazardous waste sites, may affect the mobility of the substance in the soil (Cowfer 
and Magistro 1983).  Photodegradation on the surface of soils is possible since sensitized 
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photodegradation in water occurs; however, this is not expected to be an important environmental fate 
process for vinyl chloride in most soils and sediment. 
Several laboratory studies have indicated that both aerobic and anaerobic biodegradation of vinyl chloride 
can occur in soils and aquifer materials via a number of mechanisms (Barrio-Lage et al. 1990; Castro et 
al. 1992a, 1992b; Davis and Carpenter 1990), although these degradation processes were generally slow.  
More recently, Nelson et al. (1993) investigated methanotrophic degradation of vinyl chloride using a 
laboratory-scale, methanotrophic, attached-film, expanded-bed bioreactor.  They found that this technique 
is an efficient way to degrade vinyl chloride, with the removal efficiency >90%.  Under methanotrophic 
conditions, vinyl chloride was mineralized between 5 and 44% over 37 days using creek bed sediment 
microcosms obtained from a naval station near Jacksonville, Florida (Bradley and Chapelle 1997).  
Slightly higher mineralization rates were observed under Fe(III) reducing conditions. 
6.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT  
Reliable evaluation of the potential for human exposure to vinyl chloride depends in part on the reliability 
of supporting analytical data from environmental samples and biological specimens.  Concentrations of 
vinyl chloride in unpolluted atmospheres and in pristine surface waters are often so low as to be near the 
limits of current analytical methods.  In reviewing data on vinyl chloride levels monitored or estimated in 
the environment, it should also be noted that the amount of chemical identified analytically is not 
necessarily equivalent to the amount that is bioavailable.  The analytical methods available for monitoring 
vinyl chloride in a variety of environmental media are detailed in Chapter 7. 
6.4.1 Air 
Air in rural/remote and urban/suburban areas of the United States typically contains very low or no 
detectable amounts of vinyl chloride (EPA 1982f; Grimsrud and Rasmussen 1975a, 1975b; Harkov et al. 
1984; Pratt et al. 2000; Stephens et al. 1986; Wallace et al. 1984).  The mean concentration of vinyl 
chloride from 3,650 samples monitored in the state of Minnesota over an 8-year study period (1991– 
1998) was 0.01 μg/m3 (0.0038 ppb), with a maximum observed value of 1.77 μg/m3 (0.672 ppb) (Pratt et 
al. 2000).  Sampling was performed at 25 different sites across the state with sampling sites chosen to 
measure concentrations of pollutants near specific point sources, or to collect baseline data near the 
Minneapolis-St. Paul area. Vinyl chloride levels in urban air were summarized in the EPA 1997 Urban 
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Air Toxics Monitoring Program, a study designed to characterize the magnitude and composition of 
potentially toxic air pollution in, or near, urban areas (EPA 1999). These data are summarized in 
Table 6-3. In general, few detections of vinyl chloride were observed in most of the cities sampled, and 
when positive detections were measured, the levels were below 1 ppb (EPA 1999).   
Limited monitoring data indicate that in areas near vinyl chloride and PVC manufacturing facilities, the 
concentration of vinyl chloride in air typically ranges from trace levels to 105 μg/m3 (40 ppb) (EPA 
1979a, 1982f; Gordon and Meeks 1977) but have been shown to exceed 2,600 μg/m3 (1,000 ppb) 
(Fishbein 1979). More recent monitoring data sampled at the fenceline of vinyl chloride production 
facilities suggest that levels around these sites are in the low ppb range.  Vinyl chloride levels ranged 
from below the detection limits of 0.16 μg/m3 (0.06 ppb) to approximately 90 μg/m3 (34 ppb) at one site, 
and were <0.16 μg/m3 (0.06 ppb) to 26 μg/m3 (10 ppb) at a second facility (OECD 2001).   
Elevated levels of vinyl chloride may also be found in the vicinity of hazardous waste sites and municipal 
landfills. Concentrations ranging from below detection limits to 5–8 μg/m3 (2–3 ppb) have been 
measured in the air above some landfills (Baker and Mackay 1985; Stephens et al. 1986).  Homes near 
one hazardous waste site in southern California were found to contain levels as high as 1,040 μg/m3 
(400 ppb) (Stephens et al. 1986) and homes near another site contained between 1 and 9 ppb (Miller and 
Beizer 1985). Gaseous emissions from 20 Class II (nontoxic) landfills in southern California were 
analyzed for vinyl chloride (Wood and Porter 1987).  Vinyl chloride was found in emissions from 85% of 
the landfills tested, and concentrations >2,600 μg/m3 (1 ppm) were detected in more than half of the 
landfill emissions.  The concentrations of vinyl chloride measured in this study ranged from 0.624 to 
114.4 mg/m3 (240–44,100 ppb).  Based on their observations, the study authors concluded that the 
presence of vinyl chloride at these landfills was due to either illegal disposal or in situ generation by the 
degradation of chlorinated solvents by bacteria and other microbes (Wood and Porter 1987).  Ambient air 
monitoring data downwind from the Eastview Road Landfill located in Guelph, Ontario indicated the 
presence of vinyl chloride at low levels.  Concentrations ranging from 0.0023 to 0.042 μg/m3 (0.0009– 
0.016 ppb) were observed downwind from this facility during sampling conducted in May and June 1993 
(Chadder 1994).   
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Table 6-3. Vinyl Chloride Levels in Ambient Urban Air 
Prevalence of vinyl Range of concentrations Central tendency and variability of 
chloride in air (ppb) measured concentrations 
Number Percent of 
of non- positive Arithmetic Geometric 
detects detections Lowest Highest Median mean mean SD CV 
Baton Rouge, Louisiana 
20 33 ND 0.52 0.03 0.07 0.05 0.10 1.39 
Garyville, Louisiana 
 
































30 0 ND ND – – – – – 
 
North Little Rock, Arkansas
 




30 0 ND ND – – – – – 
 
CV = coefficient of variance; ND = not detected; SD = standard deviation 
Source: EPA 1999 
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6.4.2 Water 
Vinyl chloride has been detected at varying concentrations in surface water, groundwater, and drinking 
water throughout the United States.  Concentrations of vinyl chloride in drinking water wells and surface 
water in New York State were found to be 50 μg/L (0.05 ppm) and 10 μg/L (0.01 ppm), respectively 
(Burmaster 1982).  Monitoring studies in nine states have identified concentrations as high as 380 μg/L 
(0.38 ppm) in groundwater (Dyksen and Hess 1982). Vinyl chloride levels ranged from below the 
detection limit (0.64 μg/L) to 55.6 μg/L (3.35 μg/L mean value) in river water sampled near vinyl chloride 
and PVC manufacturing facilities in Osaka, Japan (Yamamoto et al. 2001).    
Levels of vinyl chloride in groundwater in the United States were determined during the 1982 EPA 
Groundwater Supply Survey (Westrick et al. 1984).  Water supplies from 945 sites throughout the United 
States were studied. Vinyl chloride was positively identified in only 0.74% of the 945 groundwater 
supplies (detection limit 0.001 ppm).  It was reported that 0.5% of 186 random sample sites and 3.8% of 
158 nonrandom sample sites contained detectable levels of vinyl chloride.  The maximum concentrations 
at the random and nonrandom sites were 1.1 μg/L (0.0011 ppm) and 8.4 μg/L (0.0084 ppm), respectively 
(Westrick et al. 1984).  Approximately half of the samples were taken from a random list of water 
systems, which were subdivided into two sets of systems—those serving fewer than 10,000 people and 
those serving more than 10,000 people.  The nonrandom samples were taken from systems selected by the 
states, using groundwater sources that were likely to include volatile organic compounds in drinking 
water (Westrick et al. 1984).  Other studies have reported the occurrence of vinyl chloride in groundwater 
samples collected throughout the United States at levels at or below 380 μg/L (0.38 ppm) (Cotruvo 1985; 
EPA 1982f; Goodenkauf and Atkinson 1986; Stuart 1983).  In a study of three landfills located in Orange 
County, Florida, vinyl chloride was detected in water samples obtained at four out of nine wells with 
average concentrations ranging from 2.0 to 26.5 μg/L (Hallbourg et al. 1992).  In a survey of 30 industrial 
sites located in Taiwan, vinyl chloride was detected in six groundwater wells at concentrations of 
100,000 (1993 sampling period) and 22,000 μg/L (1994 sampling period) (Kuo et al. 2000). 
6.4.3 Sediment and Soil 
Monitoring data for vinyl chloride in soil were not located in the available literature. 
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6.4.4 Other Environmental Media 
In the past, vinyl chloride had been detected in various foods and bottled drinking water as a result of 
migration from PVC food wrappings and containers (Benfenati et al. 1991; Gilbert et al. 1980).  Vinyl 
chloride has been found in vinegar at levels up to 98,000 μg/L (98 ppm), in edible oils at 300–1,800 μg/L 
(0.3–1.8 ppm), and in alcoholic beverages at 0.0–8,400 μg/L (0.0–8.4 ppm) when these foods were 
packaged and stored in PVC containers (Williams 1976; Williams and Miles 1975).  At present, the Food 
and Drug Administration (FDA) regulates the use of PVC polymers in food packaging materials and the 
amount of residual monomer in polymers and as a result, significant reduction in the levels of vinyl 
chloride in food samples has been achieved since the early 1970s (WHO 1999).  In 1986, FDA 
determined that thick-walled PVC food packaging (i.e., bottles and blister packages) was safe provided 
that the polymer contained <10 ppb vinyl chloride (McNeal et al. 2003).  Since the late 1970s, 
modifications to the vinyl chloride and PVC manufacturing and production processes have greatly 
reduced the amount of residual vinyl chloride monomer in food packaging and other PVC related items.  
To determine whether the residual vinyl chloride levels in PVC containing food packages in current use 
are <10 ppb, a survey and analysis of PVC containing food packages was recently conducted (McNeal et 
al. 2003).  The results showed that vinyl chloride levels found in the packages ranged from none detected 
(<1 ppb) to about 275 ppb.  The package containing 275 ppb residual vinyl chloride was not a food 
contact material (McNeal et al. 2003).  Data regarding the residual vinyl chloride monomer levels in food 
packaging items was summarized by Borrelli et al. (2004) and are presented in Tables 6-4 and 6-5. In 
general, most food packaging items contain nondetectable or minute quantities of residual vinyl chloride 
and most food products do not contain levels above the analytical detection limits.  Dietary exposure to 
vinyl chloride from PVC packages used for food has been calculated by several agencies, and based upon 
estimated average intakes in the United Kingdom and the United States, an exposure of 
<0.0004 μg/kg/day was estimated for the late 1970s and early 1980s (WHO 1999). 
In a modeling study using liquid chromatography to simulate migration conditions of vinyl chloride from 
PVC in actual food packaging and storage, it was shown that at the very low concentrations (<1 ppm) of 
residual vinyl chloride monomer in PVC packaging material, "essentially zero" migration of the vinyl 
chloride monomer into foods occurs (Kontominas et al. 1985).  Vinyl chloride levels were determined in 
Italian drinking water bottled in PVC; levels ranged from 13 to 83 parts per trillion (ppt) (mean, 48 ppt) 
(Benfenati et al. 1991).  It was also determined that there was a progressive migration of vinyl chloride 
from the bottle to the water, which occurred at a rate of 1 ng/L/day (Benfenati et al. 1991).  Vinyl chloride  
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Table 6-4. Residual Vinyl Chloride Monomer in Food and Nonfood 
 
Packaging Items from Store Shelves 
 
Package item Residual vinyl chloride monomer (ppb) 
Food packaging 
1-Gallon water jug A 4.7 
1-Gallon water jug B 5 
Mouthwash bottle 3.3 
Non-dairy creamer jar <2 
PVC meat wrap A <2 
PVC meat wrap B <2 
Saran® wrap <2 
Canola oil jug 1.7 
Vegetable oil jug 2.9 
Olive oil jug 2.4 
Olive oil bottles (n=3) 28.3 
Nonfood packaging 
PVC plumbing blister 135.4 
PVC cell phone blister 3.9 
Source: Borrelli et al. 2004 
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Table 6-5. Residual Vinyl Chloride Monomer in Food Products 
Food item Residual vinyl chloride monomer (ppb) 
Olive oil A ND 
Turkish olive oil B 0.6 
Vegetable oil A ND 
Vegetable oil B ND 
Mouth wash ND 
Source: Borrelli et al. 2004 
188 VINYL CHLORIDE 
6. POTENTIAL FOR HUMAN EXPOSURE 
was also detected in bottled water from Saudi Arabia packaged in PVC bottles; however, the levels were 
≤0.6 ppb (Fayad et al. 1997). 
Vinyl chloride has been detected in municipal drinking water supplies.  A study by EPA (1982f) 
estimated that 12 of 11,202 public water supplies that used surface water as their primary source had 
levels of vinyl chloride between 1.0 μg/L (0.001 ppm) and 5.0 μg/L (0.005 ppm); none had levels above 
5 μg/L (0.005 ppm).  Another study found that drinking water that ran through PVC pipes contained vinyl 
chloride at 1.4 μg/L (0.0014 ppm), whereas water that ran through a PVC system 9 years older contained 
0.03–0.06 μg/L (0.03–0.06 ppb) (Dressman and McFarren 1978).  The amount of vinyl chloride migrating 
from rigid PVC water pipes into drinking water was directly proportional to the residual level of vinyl 
chloride in the pipe itself.  In 2000, the National Sanitation Foundation (NSF), at the request of the Vinyl 
Institute, conducted a study on the levels of residual vinyl chloride monomer found in PVC pipe and 
fittings (Borelli et al. 2004). This report concluded that 86% of the PVC pipes and 88% of the fittings 
had no detectable levels (detection limit of 0.1 mg/kg) of residual vinyl chloride monomer.  The average 
residual vinyl chloride monomer level for all samples (non-detects were counted as zero) were 
0.007 mg/kg for PVC pipes, and 0.03 mg/kg for fittings (Borelli et al. 2004).  Under certain test 
conditions, vinyl chloride in drinking water reacts with chlorine and is converted to chloroacetaldehyde 
and chloroacetic acid (Ando and Sayato 1984).  Information concerning the effect of this reaction on 
drinking water supplies that are treated with chlorine and the extent of this reaction was not stated.  
During an EPA study, detectable levels of vinyl chloride were found in indoor air samples taken from two 
of seven new 1975 model cars.  Levels of vinyl chloride in indoor air in the two cars ranged from 0.4 to 
1.2 ppm (EPA 1976b).  Ventilation of the car interiors led to the dissipation of vinyl chloride.  The cars 
involved in the study had a high ratio of plastic to interior volume and were expected to provide worst-
case concentrations for vinyl chloride in interior car air (EPA 1976b).  Because of the limited nature of 
these data and the fact that this study is somewhat dated, no conclusions can be drawn regarding levels of 
vinyl chloride monomer in interior air of cars currently being produced. 
Vinyl chloride has been detected in tobacco smoke.  Cigarette smoke and smoke from small cigars has 
been found to contain 5.6–27 ng vinyl chloride per cigarette (Hoffman et al. 1976).  The study authors 
suggested that the inorganic chloride concentrations in the tobacco determine the amount of vinyl chloride 
formed upon combustion of tobacco and released into the smoke (Hoffman et al. 1976). 
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6.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE  
Inhalation of ambient or workplace air containing vinyl chloride is the most likely route of exposure for 
the general population.  Typical values for the average daily intake of vinyl chloride by inhalation in 
urban/suburban and rural/remote areas not near emission sources are very small, since only trace levels of 
vinyl chloride are usually found in ambient air.  Assuming that the average adult intake of air is 
20 m3/day, the average daily intake of vinyl chloride by people living in the vicinity of emission sources 
has been estimated to range from trace amounts to 2,100 μg (EPA 1979a, 1982f; Gordon and Meeks 
1977).  The majority of drinking water supplies in the United States do not contain detectable levels of 
vinyl chloride (EPA 1982f; Westrik et al. 1984).  Based on this conclusion, it is estimated that the average 
daily intake of vinyl chloride by ingestion of drinking water for most people in the United States is 
essentially zero (at or below 0.028 μg/kg/day [EPA 1982f]).  Estimates provided by EPA (1985b) indicate 
that 0.9% of the U.S. population is exposed to levels of vinyl chloride in drinking water ≥1 μg/L, and 
0.3% of the population is exposed to levels >5 μg/L. 
NOES conducted by NIOSH from 1981 to 1983 estimated that 81,314 workers employed at 3,711 plant 
sites were potentially exposed to vinyl chloride in the United States (NOES 1990).  The NOES database 
does not contain information on the frequency, concentration, or duration of exposure; the survey 
provides only estimates of workers potentially exposed to chemicals in the workplace.  Employees 
involved in the handling and and processing of PVC resins are exposed to lower levels of vinyl chloride 
than employees at vinyl chloride and PVC manufacturing facilities since finished products contain only 
minute quantities of vinyl chloride present as residual monomer.  Exposure is believed to occur primarily 
through inhalation with some minor absorption through the skin (Hefner et al. 1975a).  Upon exposure to 
800 or 7,000 ppm of vinyl chloride vapor over a 2–2.5-hour period, 0.023–0.031% was absorbed 
dermally by monkeys (Hefner et al. 1975a).  The authors concluded that significant percutaneous 
absorption is not likely to occur at relatively low concentrations (1–5 ppm) that might be encountered in 
the workplace. Workers who are involved in welding applications that use PVC pipes or other PVC 
materials may be exposed to higher levels of vinyl chloride from subsequent fumes.  Airborne vinyl 
chloride levels of less than the detection limit of 0.05 ppm (0.13 mg/m3) to 0.1 ppm (0.26 mg/m3) were 
observed during the thermal welding of PVC pipes (Williamson and Kavanaugh 1987).  Table 6-6 
summarizes the level of vinyl chloride observed in five PVC manufacturing facilities located in Taiwan, 
and Table 6-7 provides the time-weighted average (TWA) exposure to workers performing various job 
tasks (Du et al. 1996).  Tank suppliers, cleaners, and PVC relievers were observed to have the highest 
TWA exposure since they more often came into direct contact with vinyl chloride in these job functions.   
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Table 6-6. Vinyl Chloride Levels in Five Polyvinyl Chloride  
 
Manufacturing Facilities Located in Taiwan 
 
Number of Mean Median 
Sample site samples (mg/m3) (mg/m3) Range (mg/m3) 
Outside reaction tank 4 296.30 86.25 6.19–1009.32 
Reaction tank farm 18 13.60 9.97 0.18–110.59 
Vinyl chloride recovery 9 9.25 5.46 0.85–33.39 
Vinyl chloride shipping 3 5.98 7.38 0.85–9.71 
Vinyl chloride storage tanks 6 4.97 3.03 0.60–14.25 
Stripper 12 3.86 1.68 <LOD–18.62 
Waste water treatment 7 3.37 3.32 0.83–6.73 
Drier 11 2.62 1.55 <LOD–7.17 
Control room (inside) 6 2.15 1.48 0.57–5.13 
Control room (inside) 7 1.71 0.91 0.18–4.07 
Polyvinyl chloride warehouse 17 1.66 1.79 <LOD–5.96 
Factory perimeter 3 1.66 0.85 <LOD–3.34 
Additive preparation 6 1.61 0.78 0.57–4.07 
Administrative office 4 0.65 0.67 <LOD–1.27 
Plastic pallet making area 1 <LOD <LOD <LOD 
LOD = limit of detection (0.1259 mg/m3) 
Source: Du et al. 1996 
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Table 6-7. Time-Weighted Average Exposure to Workers in Polyvinyl 
 
Chloride Manufacturing Facilities Located in Taiwan
 
Number of Mean Median 
Job description samples (mg/m3) (mg/m3) Range (mg/m3) 
Tank supplier 9 659.67 23.70 5.70–3,677.8 
Polyvinyl chloride reliever 10 153.07 47.92 1.04–825.69 
Tank cleanera 14 95.57 69.15 0.36–341.88 
Vinyl chloride unloading 2 12.56 12.56 10.23–14.97 
Safety/health specialist 4 12.04 1.74 1.19–22.87 
Foreman 4 9.04 6.89 1.84–20.59 
Stripper operator 3 4.51 3.37 2.33–7.82 
Vinyl chloride recovery 5 4.38 4.48 0.88–5.93 
Control room operator 8 4.01 3.47 1.04–10.02 
Field supervisor 6 3.42 3.47 1.19–7.95 
General office personnel 4 3.34 2.56 <LOD–8.18 
Maintenance 3 2.69 1.76 0.85–5.49 
Dryer operator 6 1.84 1.48 <LOD–4.25 
Bagger and trucker 5 0.93 1.09 <LOD–1.58 
Gatekeeper 2 0.93 0.93 <LOD–1.86 
aTank cleaner exposure measured on a short term task lasting 15–40 minutes. 
 
LOD = limit of detection (0.1259 mg/m3) 
 
Source: Du et al. 1996 
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These workplace levels likely exceed current levels observed in the United States due to strict regulations 
imposed governing workplace exposure to vinyl chloride over the past 30 years.  In the United States, 
vinyl chloride is an Occupational Safety and Health Administration (OSHA) regulated substance.  Current 
OSHA regulations impose a permissible exposure limit (PEL) of 1.0 ppm (2.6 mg/m3) averaged over an 
8-hour period or a short-term exposure of no more than 5 ppm over a 15-minute period (Cowfer and 
Gorensek 1997). Where concentrations cannot be lowered below the PEL of 1.0 ppm, employers must 
create an area with controlled access and a respirator program conforming to OSHA standards. 
6.6 EXPOSURES OF CHILDREN  
This section focuses on exposures from conception to maturity at 18 years in humans.  Differences from 
adults in susceptibility to hazardous substances are discussed in Section 3.7, Children’s Susceptibility. 
Children are not small adults.  A child’s exposure may differ from an adult’s exposure in many ways. 
Children drink more fluids, eat more food, breathe more air per kilogram of body weight, and have a 
larger skin surface in proportion to their body volume.  A child’s diet often differs from that of adults.  
The developing human’s source of nutrition changes with age:  from placental nourishment to breast milk 
or formula to the diet of older children who eat more of certain types of foods than adults.  A child’s 
behavior and lifestyle also influence exposure.  Children crawl on the floor, put things in their mouths, 
sometimes eat inappropriate things (such as dirt or paint chips), and spend more time outdoors.  Children 
also are closer to the ground, and they do not use the judgment of adults to avoid hazards (NRC 1993). 
Children are likely to be exposed to vinyl chloride via the same pathways that affect non-occupationally 
exposed adults; namely inhalation of ambient air and ingestion of food items or drinking water that may 
contain low levels of vinyl chloride.  Children’s plastic products such as bath toys, squeeze toys, and dolls 
are often made from PVC.  Chewing or sucking on these toys has the potential to release any 
unpolymerized vinyl chloride from the object; however, no quantitative data exists regarding this 
potential exposure route and it is unlikely that there are significant levels of vinyl chloride in PVC-based 
toys.  Vinyl chloride has not been detected in samples of human maternal adipose tissue, maternal blood, 
cord blood, or breast milk.  No body burden studies that quantitatively or qualitatively identified vinyl 
chloride in children were located. 
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6.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES  
Individuals located near or downwind of production facilities, hazardous waste disposal sites, and 
landfills may be exposed to atmospheric levels of vinyl chloride higher than ambient background levels.  
Concentrations around 5–8 μg/m3 (0.002–0.003 ppm) have been measured in the air above some landfills 
(Baker and Mackay 1985; Stephens et al. 1986).  Homes near one hazardous waste site in southern 
California were found to contain levels as high as 1,040 μg/m3 (0.4 ppm) of vinyl chloride (Stephens et al. 
1986) and homes near another site contained levels between 2.6 and 23.4 μg/m3 (0.001–0.009 ppm) 
(Miller and Beizer 1985). These concentrations are several times greater than ambient air levels that are 
generally <1 μg/m3 (Pratt et al. 2000).  For specific levels associated with health effects, see Section 3.4. 
Individuals living near hazardous waste sites and landfills may also be exposed to vinyl chloride in their 
drinking water.  Workers involved in the production or use of vinyl chloride are likely to be exposed to 
levels greater than the levels that the general public is exposed to (see Section 6.5).   
Cigarette smoke and smoke from small cigars have been found to contain vinyl chloride at levels of 5.6– 
27 ng per cigarette (Hoffman et al. 1976).  Therefore, people who smoke heavily may be potentially 
exposed to higher levels of vinyl chloride than nonsmokers. 
6.8 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the adverse health effects of vinyl chloride is available.  Where adequate 
information is not available, ATSDR, in conjunction with NTP, is required to ensure the initiation of a 
program of research designed to determine the adverse health effects (and techniques for developing 
methods to determine such health effects) of vinyl chloride.  
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.  
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6.8.1 Identification of Data Needs 
Physical and Chemical Properties.    The physical and chemical properties of vinyl chloride are 
sufficiently well characterized to permit estimation of its environmental fate (Amoore and Hautala 1983; 
Cowfer and Magistro 1983; EPA 1985b; Fire 1986; HSDB 2005; IARC 1979; Lewis 1996; Lyman et al. 
1982). 
Production, Import/Export, Use, Release, and Disposal. According to the Emergency Planning 
and Community Right-to-Know Act of 1986, 42 U.S.C. Section 11023, industries are required to submit 
substance release and off-site transfer information to the EPA.  The Toxics Release Inventory (TRI03 
2005), which contains this information for 2003, became available in May of 2005.  This database will be 
updated yearly and should provide a list of industrial production facilities and emissions. 
Vinyl chloride is released primarily to the atmosphere via emissions from vinyl chloride and PVC 
manufacturing facilities (Hartmans et al. 1985; SRI 1990a, 1990b, 1993, 1994; TRI03 2005).  The risk of 
exposure to vinyl chloride is highest for workers in the plastics industry and populations living near 
industrial areas or hazardous waste sites.  Current production, use, and manufacturing methods are well 
described in the literature (Cowfer and Magistro 1985; HSDB 1996; IARC 1979; SRI 1990a, 1990b, 
1993, 1994; TRI03 2005; USITC 1994).  More current information on releases and disposal methods 
might assist in estimating potential exposures to vinyl chloride, particularly for populations living near 
hazardous waste sites. 
Environmental Fate. Vinyl chloride primarily partitions to the air where it is degraded relatively 
quickly by photochemically produced hydroxyl radicals (Kwok and Atkinson 1994).  It is removed from 
surface water and soils mainly by volatilization and photodegradation (EPA 1976a).  Biodegradation and 
hydrolysis also occur (Barrio-Lage et al. 1990; Castro et al. 1992a, 1992b; Davis and Carpenter 1990; 
EPA 1976a), but these reactions are generally slow as compared to the volatilization rate.  More 
information regarding the transformation and degradation in soil and water would be helpful in defining 
the potential pathways for human exposure. 
Bioavailability from Environmental Media.    Vinyl chloride can be absorbed following inhalation 
(Bolt et al. 1977; Krajewski et al. 1980; Withey 1976), oral (Feron et al. 1981; Watanabe et al. 1976a; 
Withey 1976), and to a much lesser extent, dermal exposure (Hefner et al. 1975a).  These routes of 
exposure may be of concern to humans because of the potential of vinyl chloride to contaminate air 
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(Baker and MacKay 1985; EPA 1979a; Fishbein 1979; Gordon and Meeks 1977; Stephens et al. 1986; 
Wood and Porter 1987), water (Burmaster 1982; Cotruvo 1985; Dyksen and Hess 1982; Goodenkauf and 
Atkinson 1986; Stuart 1983; Westrick et al. 1984), and food (Gilbert et al. 1980; Williams 1976; Williams 
and Miles 1975). Information regarding the bioavailability from ingestion and dermal contact of 
contaminated soils would be helpful, particularly for populations living near hazardous waste sites, 
although vinyl chloride is not believed to be considerably absorbed through skin. 
Food Chain Bioaccumulation.    Vinyl chloride can bioconcentrate to a limited extent in aquatic 
organisms (EPA 1982a; Freitag et al. 1985).  Biomagnification of vinyl chloride in terrestrial and aquatic 
food chains does not appear to be important because of its high volatility and the fact that it is readily 
metabolized by higher-trophic-level organisms (Freitag et al. 1985; Lu et al. 1977).  No data were located 
regarding biomagnification in terrestrial foodchains. 
Exposure Levels in Environmental Media.    Reliable monitoring data for the levels of vinyl 
chloride in contaminated media at hazardous waste sites are needed so that the information obtained on 
levels of vinyl chloride in the environment can be used in combination with the known body burden of 
vinyl chloride to assess the potential risk of adverse health effects in populations living in the vicinity of 
hazardous waste sites. 
Vinyl chloride has been detected in air (Baker and Mackay 1985; EPA 1979a; Fishbein 1979; Gordon and 
Meeks 1977; Stephens et al. 1986; Wood and Porter 1987), water (Burmaster 1982; Cotruvo 1985; 
Dyksen and Hess 1982; Goodenkauf and Atkinson 1986; Stuart 1983; Westrick et al. 1984), sediment 
(Wang et al. 1985), and food (Gilbert et al. 1980; Williams 1976; Williams and Miles 1975).  Intake data 
for the general population from the various media are available (EPA 1979a, 1985b; Gordon and Meeks 
1977; Westrick et al. 1984).  Data on levels of vinyl chloride in soils are needed.  Site-specific data on 
concentrations of vinyl chloride in air, soil, and water would be helpful in estimating the risk of exposure 
for populations living in the vicinity of hazardous waste sites.  Also, current data on the extent of release 
(if any) of vinyl chloride from PVC pipes and from car interiors are needed to estimate the risk of 
exposure of the general population. 
Exposure Levels in Humans.    Vinyl chloride has been detected in exhaled breath of humans 
(Baretta et al. 1969; Conkle et al. 1975), but no other body burden studies are available.  More 
information on exposure levels for populations living in the vicinity of hazardous waste sites would be 
helpful. This information is necessary for assessing the need to conduct health studies on these 
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populations.  It is noted that it is difficult to directly analyze for vinyl chloride in humans, which may 
limit the practicality of conducting these tests. 
This information is necessary for assessing the need to conduct health studies on these populations. 
Exposures of Children.    No data exist regarding the levels of vinyl chloride in children.  Children 
are exposed to vinyl chloride by the same pathways that affect adults; inhalation of ambient air and the 
ingestion of foods or drinking water.  It would be useful to determine if there exists any free 
unpolymerized vinyl chloride that can be extracted from PVC children’s toys.  Child health data needs 
relating to susceptibility are discussed in Section 3.12.2, Identification of Data Needs: Children’s 
Susceptibility. 
Exposure Registries. No exposure registries for vinyl chloride were located.  This substance is not 
currently one of the compounds for which a subregistry has been established in the National Exposure 
Registry.  The substance will be considered in the future when chemical selection is made for 
subregistries to be established. The information that is amassed in the National Exposure Registry 
facilitates the epidemiological research needed to assess adverse health outcomes that may be related to 
exposure to this substance. 
6.8.2 Ongoing Studies 
The Federal Research in Progress (FEDRIP 2005) database provides additional information obtainable 
from a few ongoing studies that may fill in some of the data needs identified in Section 6.8.1.  
Josse Fabien and Zhou Rongnong of the University of Marquette (Milwaukee, Wisconsin) are attempting 
to characterize and design polymer-coated chemical sensors for the direct, rapid, in-situ monitoring of 
vinyl chloride and other hazardous constituents in water.  Karla Thrall (Oregon Health and Science 
University) is studying the potential for human exposure to vinyl chloride and other VOC near Superfund 
sites. Exposure assessment studies will be conducted with volunteers using a novel real-time breath 
analysis system to determine the uptake of any of the nine potential contaminants of study from tap water 
by each of three routes:  inhalation, ingestion, and dermal contact. 
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The purpose of this chapter is to describe the analytical methods that are available for detecting, 
measuring, and/or monitoring vinyl chloride, its metabolites, and other biomarkers of exposure and effect 
to vinyl chloride.  The intent is not to provide an exhaustive list of analytical methods.  Rather, the 
intention is to identify well-established methods that are used as the standard methods of analysis.  Many 
of the analytical methods used for environmental samples are the methods approved by federal agencies 
and organizations such as EPA and the National Institute for Occupational Safety and Health (NIOSH).  
Other methods presented in this chapter are those that are approved by groups such as the Association of 
Official Analytical Chemists (AOAC) and the American Public Health Association (APHA).  
Additionally, analytical methods are included that modify previously used methods to obtain lower 
detection limits and/or to improve accuracy and precision. 
7.1 BIOLOGICAL MATERIALS  
The analytical method used to analyze for the presence of vinyl chloride in biological samples is 
separation by gas chromatography (GC) combined with detection by mass spectrometry (MS), flame 
ionization detector (FID), or electron capture detector (ECD).  Vinyl chloride and/or its metabolite, 
thiodiglycolic acid, have been detected in breath, urine, blood, and tissues.  Breath samples can be 
concentrated by cryogenic trapping.  The two methods most commonly used to prepare liquid and solid 
samples are concentration by a purge-and-trap technique or headspace analysis.  Concentration not only 
increases the sensitivity but, also in certain instances, may decrease the sample separation time prior to 
quantitation. Details of commonly used analytical methods for several types of biological samples are 
presented in Table 7-1. 
Vinyl chloride was determined in exhaled air by concentration with a multistage cryogenic trapping 
system followed by thermal desorption using GC/FID, GC/ECD, and GC/MS (Conkle et al. 1975). 
Sensitivity is in the low-ppb range.  The authors of this study noted that the reproducibility of the 
subject/sampling system was inconclusive; a larger experimental population is needed for its 
demonstration.  The quantitative data reflected considerable scatter, apparently indicating the variability 
of the biological system and the trace amounts of the compound.  The additional requirement for long-
term coupling (30–60 minutes) of the sampling system to the subject probably limits the method to 
industrial health applications, with relatively robust subjects (Conkle et al. 1975).  Baretta et al. (1969)  
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Sample Analytical detection Percent 
matrix Preparation method method limit recovery Reference 
Breath Breath collected in pipets 
lined with Saran® film; 
GC/FID NR NR Baretta et al. 1969 
direct injection into gas 
chromatograph 
Breath Cyrogenic trapping of GC/FID, NR NR Conkle et al. 1975 
expired air; thermal GC/ECD, and 
desorption into gas GC/MS 
chromatograph 
Urine Acidified and desiccated GC/MS 50 ng/mL NR Müller et al. 1979 




Urine Internal standard added to GC/FID, GC/MS 10 mg/L NR Draminski and 
urine; acidification and Trojanowska 1981 
ethyl acetate extraction; 
evaporation of solvent; 
addition of 
N-trimethylsilyldiethyl­
amine in pyridine (1:1); 
injection into gas 
chromatograph 
Blood and Extraction in ethanol-water GC/FID 5 ng/mL 75–79% Zuccato et al. 1979 
tissues mixture; incubation, blood 
injection into gas 
chromatograph 
Tissue preparation also  30 ng/g 76–92%  
includes freezing and tissue 
homogenization before the 
extraction procedure 
GC/ECD = gas chromatography/electron capture detector; GC/FID = gas chromatography/flame ionization detector; 
GC/MS = gas chromatography/mass spectrometry; NR = not reported 
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monitored exposure to vinyl chloride by breath analysis.  The breath samples were collected in pipets 
with plastic caps lined with six layers of Saran film identical to that used for the construction of Saran air 
sampling bags.  Aliquots were drawn from the pipets and injected directly into a gas chromatograph 
equipped with FID.  One limitation of this method is its reduced ability to detect vinyl chloride when air 
concentrations in the workplace are below 50 ppm.  
Vinyl chloride has been measured in rat blood and tissues using headspace GC/FID (Zuccato et al. 1979).  
In headspace analysis, the gaseous layer above the sample is injected into the gas chromatograph.  Sample 
preparation steps for rat blood and tissues involve extraction in an ethanol-water mixture, incubation, and 
direct injection into the gas chromatograph.  Sample preparation for tissues includes an extra step 
involving freezing and homogenization before the extraction procedure.  The recovery ranged from about 
75 to 92%.  The method is sensitive to 5 ng/mL vinyl chloride in blood and 30 ng/g in tissues. 
Müller et al. (1979) employed GC/MS as a selective biomonitoring method for the quantitative 
measurement of thiodiglycolic acid, a urinary metabolite of vinyl chloride.  They reported a sensitivity of 
50 ng/mL.  Precision was generally good.  These investigators noted that some thiodiglycolic acid has 
been found in supposedly unexposed subjects.  Therefore, exposure to low levels of vinyl chloride could 
be masked by background metabolic levels within normal limits.  This may limit the application of 
biological monitoring for the measurement of vinyl chloride following low-level exposure (Müller et al. 
1979; van Sittert and de Jong 1985).  In a study by Jedrychowski et al. (1984), urinary excretion of 
thiodiglycolic acid was determined using GC/FID.  The urine was extracted twice with ethyl acetate prior 
to analysis.  No recovery data were given for this method. 
7.2 ENVIRONMENTAL SAMPLES 
Analysis of environmental samples is similar to that of biological samples.  The most common methods 
used to detect vinyl chloride in environmental samples are GC/MS, GC/ECD, and GC/FID.  
Concentration of samples is usually done by sorption on solid sorbent for air and by the purge-and-trap 
method for liquid and solid matrices.  Alternatively, headspace above liquid and solid samples may be 
analyzed without preconcentration.  Details of commonly used analytical methods for several types of 
environmental samples are presented in Table 7-2. 
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Analytical detection Percent 
Sample matrix Preparation method method limit recovery Reference 
Occupational air Vinyl chloride in air 
adsorbed in activated 
GC/FID 0.04 μg per 94% at 1– 
sample 64 mg/m3 
NIOSH 1994a 
carbon trap and desorbed (0.00039– 
by carbon disulfide 0.025 ppb) 
Ambient indoor Air containing vinyl chloride GC/FID 5 ppb NR 	 IARC 1978 
and outdoor air passed through activated 
carbon trap and desorbed 
by dichloromethane or 
carbon 
Air Adsorption onTenax®-GC 
or SKC® Carbon, then 
GC/MS 0.33 ppb NR 	 Krost et al. 
1982 
thermal desorption 
Air Air prefiltered by Na2S2O3­ GC/FID, 0.005 ppb NR Harkov et al. 
treated glass fiber filter was GC/MS, 1983, 1984 
passed through spherocarb GC/ECF 
adsorbent cartridge and 
thermally desorbed 
Automobile Exhaust samples contained GC/FID 0.02 ppm NR 	 Hasanen et al. 
exhaust in aluminized plastic bags 1979 
Air Trapped in cold Tenax®-GC GC/FID NR 	89.6% at Ives 1975 
trap; thermal desorption 6 ppb; 100% 
at 60 ppb 
Air Sample collected in GC/ECD 0.01 ppb NR 	 Harsch et al. 
pressurized canister is 1979; 
passed through a freezeout Rasmussen et 
loop and subsequently al. 1977 
heated 
Air Sample collected in GC/FID 0.4 ppb NR 	 McMurray and 
polyester-coated plastic Tarr 1978 
bags concentrated by 
freezeout and subsequently 
heated 
Drinking water Samples collected in serum GC/HSD, NR NR Dressman and 
reaction bottles; purge and GC/MS McFarren 1978 
trap technique 
Tenax®-GC; thermal 
Drinking water Purge and trap in 









desorption Methods 601 
and 624) 
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Analytical detection Percent 
Sample matrix Preparation method method limit recovery Reference 
Groundwater, Purge at 45 °C and trap in 
liquid and solid Tenax®-GC; thermal 
matrices desorption  
Water 	Purge into CarbosieveTM S 
III; desorption with CS2 and 
bromine derivation 
Drinking water 	 Purge and trap in 
Tenax®-GC; thermal 
desorption 
Migration of 	 Small section put in water 
monomer into	 in sealed serum vial for a 
drinking water 	 number of days at 20 °C; 
from PVC pipes	 solution directly injected 
into gas chromatograph 
Water 	 Sample ins sealed vial is 
equilibrated at constant 
temperature; headspace 
gas injected into gas 
chromatograph 
Landfill gas 	 Gas from landfill sites 
sampled by PTFE tubing 
inside drive-in piezometers 
was adsorbed in Tenax®­
GC or Porapak®, a sorbent; 
trapped sample desorbed 
and concentrated in liquid 
N2-cooled loop and flash 
desorbed 
Sediment and 	 Homogeneous sample 
oyster 	 mixed with water and vinyl 
chloride purged into a 
closed loop injected into 
gas chromatograph 
Landfill gas 	 Sample collected in 2-L 
evacuated glass bulb; gas 















0.18 ppb 	 102% at EPA 1982e 
0.82– 
32.3 ppb 
0.0004 ppb 98.9% at 	 Wittsiepe et al. 
0.00625– 1993 
62.5 ppb 
0.04 ppb 100–119% at Reding 1987 




NR NR 	 Ando and 
Sayato 1984 
<1 ppb 	 NR 	 IARC 1978 
0.04–	 NR 	Young and 
0.8 ppm 	 Parker 1984 








NR NR 	 Wood and 
Porter 1987 
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Analytical detection Percent 
Sample matrix Preparation method method limit recovery Reference 
Food (orange Sample sealed in vials and GC/FID NR NR Chudy and 
drink, wine, olive equilibrated at 40 °C for Crosby 1977 
oil) 2 hours; injected into gas 
chromatograph 
Foodstuffs 	 Sample sealed in vials and GC/FID 1–5 ppb NR IARC 1978 
equilibrated at 40 °C for a 
minimum of 2 hours; 
headspace gas injected 
into gas chromatograph 
CS2 = carbon disulfide; EPA = Environmental Protection Agency; GC/ECD = gas chromatography/electron capture 
detector; GC/FID = gas chromatography/flame ionization detector; GC/HSD = gas chromatography/halogen specific 
detector; GC/MS = gas chromatography/mass spectrometry; GC/PID = gas chromatography/photoionization 
detector; HSD = halogen specific detector; N2 = nitrogen; Na2S2O3 = sodium thiosulfate; NR = not reported; 
PID = photoionization detector; PTFE = polytetrafluorethylene; PVC = polyvinyl chloride 
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The primary method of analyzing vinyl chloride in air is GC combined with either MS, ECD, or FID.  Air 
samples are usually pumped through a sample collection column with Tenax-GC, coconut activated 
charcoal, or spherocarb (a carbon molecular sieve material) as the most common adsorbents. Several 
authors have noted that Tenax-GC displays poor retention for vinyl chloride when the compound is 
present in the very low-ppb range (Bozzelli and Kebbekus 1979; Krost et al. 1982; McMurry and Tarr 
1978).  Vinyl chloride is thermally desorbed from the collection column and concentrated on a cryogenic 
trapping column located on the gas chromatograph.  Vapors are heat-released from the trapping column 
directly to the gas chromatograph (Bozzelli and Kabbekus 1979; Krost et al. 1982).  Grab samples of air 
can also be obtained and preconcentrated on a cryogenic column (Rasmussen et al. 1977).  The limit of 
detection for GC/MS and GC/ECD is in the sub-ppb range (Bozzelli and Kebbekus 1979; Harsch et al. 
1979; Krost et al. 1982; Rasmussen et al. 1977).  Accuracy is generally good (Bozzelli and Kebbekus 
1979). With careful technique, precision is adequate, ranging from 5 to 20% (Bozzelli and Kebbekus 
1979; McMurray and Tarr 1978). 
Trace amounts of vinyl chloride in air and water were detected employing GC/ECD after derivatization to 
1,2-dibromochloroethane (Wittisiepe et al. 1990, 1993).  Air samples were taken by drawing a known 
volume directly through an ice-cooled adsorption tube.  Water samples were purged with an inert gas 
before being drawn through the adsorption tube.  The tubes were eluted with carbon disulfide, and the 
vinyl chloride was derivatized with bromine water to form 1,2-dibromochloroethane.  This derivatization 
technique is used for enhancement of sensitivity with GC/ECD.  The derivative was determined by 
capillary GC with ECD.  The detection limits for air and water samples are 50 ng/m3 and 0.4 ng/L 
(0.4 parts per trillion), respectively.  Results from recovery experiments with dosed water indicated that 
accuracy was good. 
Vinyl chloride can be detected in drinking water, groundwater, waste water, and leachate from solid 
waste. Analysis of vinyl chloride is done by purge-and-trap or headspace GC.  The primary analytical 
method is separation by GC combined with MS, ECD, FID, Hall's electrolytic conductivity detector 
(HECD), or another type of halogen specific detector (HSD).  In most methods, vinyl chloride is liberated 
from the liquid matrix by purging with an inert gas and concentrated by trapping on a suitable solid 
sorbent. Vinyl chloride is thermally desorbed and backflushed onto the column of the gas chromatograph 
with an inert gas.  Detection of vinyl chloride is generally achieved using HECD, HSD, or MS (APHA 
1985; EPA 1982d, 1982e; IARC 1978; Reding 1987).  The limit of detection is in the sub-ppb range for 
halogen specific detectors (APHA 1985; EPA 1982d, 1982e) and in the low-ppb range for MS (EPA 
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1982d).  Accuracy is >98% and precision ranges from 11 to 25% for GC/HECD and GC/MS (EPA 
1982d). 
EPA has made improvements in methods for measuring volatile organic chemicals.  The major change is 
the use of smaller sample volumes allowed by increased use of capillary gas chromatographic columns.  
Capillary columns provide better resolution, minimum detection limits, and less column bleed than 
packed columns (Reding 1987). 
Vinyl chloride has been measured in sediment using GC/ECD with sensitivity in the low-ppb range.  
Accuracy and precision data were not provided in the report (Wang et al. 1985).  No information on 
analysis of vinyl chloride in soil was located.  GC/HSD of headspace gases is the EPA-recommended 
method for solid matrices with sensitivity in the sub-ppb range.  Accuracy (101.9%) is good and precision 
(11.4%) is adequate (EPA 1982d).  Vinyl chloride levels in food have been determined using GC/FID.  
GC analysis by headspaces gases is a common method for testing foods, with sensitivity in the low-ppb 
range (IARC 1978). 
7.3 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the adverse health effects of vinyl chloride is available.  Where adequate 
information is not available, ATSDR, in conjunction with NTP, is required to ensure the initiation of a 
program of research designed to determine the adverse health effects (and techniques for developing 
methods to determine such adverse health effects) of vinyl chloride. 
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.  
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7.3.1 Identification of Data Needs 
Methods for Determining Biomarkers of Exposure and Effect.     
Exposure. Methods are available for measuring vinyl chloride and/or its metabolite, thiodiglycolic acid, 
in breath, urine, blood, and tissue (Baretta et al. 1969; Conkle et al. 1975; Draminski and Trojanowska 
1981; Müller et al. 1979; Zuccato et al. 1979).  These methods are sensitive for measuring levels at which 
adverse health effects might occur, and for measuring higher background levels that might be found in 
specific populations known to be exposed to elevated levels of vinyl chloride (e.g., workers in the plastics 
industry and individuals living in the vicinity of hazardous waste sites).  Measurement of urinary 
thiodiglycolic acid can be used as an indicator of vinyl chloride intake as long as individual variability in 
metabolism (due to such factors as liver disease, use of drugs, and alcohol intake) can be accounted for 
(Hefner et al. 1975b; Müller et al. 1979).  Exposure to vinyl chloride at concentrations below 1–5 ppm 
could be masked by background metabolic levels of thiodiglycolic acid within normal limits (Müller et al. 
1979).  Also, the formation of thiodiglycolic acid is not unique to vinyl chloride exposure (Norpoth et al. 
1986; Pettit 1986).  The methods are generally reliable, although increased precision for most methods 
would increase reliability. Background levels for the general population are ill defined (EPA 1985b).  
Further research on the relationship between low-level exposure and levels of vinyl chloride in biological 
media would be helpful in assessing the risks and adverse health effects of chronic, low-level exposure. 
Effect. Existing methods are sensitive for measuring levels of vinyl chloride and its metabolite, 
thiodiglycolic acid, in individuals affected by exposure to very high levels of vinyl chloride (Baretta et al. 
1969; Conkle et al. 1975; Draminski and Trojanowska 1981; Müller et al. 1979; Zuccato et al. 1979).  
Also, methods are available to detect DNA adducts produced by the reaction of vinyl chloride metabolites 
with DNA (Eberle et al. 1989; Young and Santella 1988).  These DNA adducts are specific indicators of 
vinyl chloride's genotoxic potential.  These methods, however, are not sufficiently sensitive to determine 
the genotoxic effects resulting from low-level exposure.  Correlations between levels detected in 
biological tissues and fluids and specific observed effects for lower levels of exposure have not been 
established. Additional research in this area would allow better assessment of existing methods and 
would help in defining areas in which improvements are needed. 
Methods for Determining Parent Compounds and Degradation Products in Environmental 
Media.    Existing methods for determining vinyl chloride in air (Harkov et al. 1983, 1984; Harsch et al. 
1979; Hasanen et al. 1979; IARC 1978; Ives 1975; Krost et al. 1982; McMurry and Tarr 1978; NIOSH 
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1994a; Rasmussen et al. 1977) and water (Ando and Sayato 1984; APHA 1985; Dressman and McFarren 
1978; EPA 1982d, 1982e; IARC 1978; Reding 1987), the media of most concern for human exposure, are 
sensitive, reproducible, and reliable for measuring background levels in the environment.  Research 
investigating the relationship between levels measured in air and water and observed adverse health 
effects could increase our confidence in existing methods and/or indicate where improvements are 
needed. Methods specifically relating to the analysis of vinyl chloride in soils were not located.  EPA 
does, however, have sensitive and reliable methods for determining the concentration of vinyl chloride in 
soil matrices (EPA 1982e), which include contaminated soils. 
7.3.2 Ongoing Studies 
Eltron Research Incorporated (Principal Investigator, Thomas Ross) is developing a direct-reading 
personal monitor for detecting vinyl chloride in workplace air (FEDRIP 2005). 
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The international, national, and state regulations and guidelines regarding vinyl chloride in air, water, and 
other media are summarized in Table 8-1. 
ATSDR has derived three MRL values for vinyl chloride.  An acute-duration inhalation MRL of 0.5 ppm 
was derived for vinyl chloride based on a NOAEL for developmental effects for mice (John et al. 1977, 
1981). An intermediate-duration inhalation MRL of 0.03 ppm was derived for vinyl chloride based on a 
LOAEL of 10 ppm for increased incidences of hepatic centrilobular hypertrophy in rats (Thornton et al. 
2002). A chronic-duration oral MRL of 0.003 mg/kg/day was derived for vinyl chloride based on a 
human equivalent NOAEL of 0.09 mg/kg/day for liver cell polymorphism in rats (Til et al. 1983, 1991).   
EPA (IRIS 2004) has derived an RfD of 0.003 mg/kg/day for vinyl chloride, based on a NOAEL for liver 
cell polymorphism in rats administered vinyl chloride in the diet for a lifetime (Til et al. 1983, 1991). 
EPA (IRIS 2004) has derived an RfC of 0.1 mg/m3 (0.04 ppm) for vinyl chloride, based on route-to-route 
extrapolation (using PBPK modeling) from a NOAEL for liver cell polymorphism in rats administered 
vinyl chloride in the diet for a lifetime (Til et al. 1983, 1991). 
The FDA is responsible for regulating vinyl chloride as an indirect food additive.  With regard to 
components of coatings, paper, and paperboard, the FDA states that when vinyl chloride is copolymerized 
with certain other substances, it is a safe food-contact surface.  The amount of vinyl chloride content 
permitted varies depending on the nature of the polymer and its use (FDA 1994). 
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Table 8-1. Regulations and Guidelines Applicable to Vinyl Chloride 
Agency Description Information Reference 
INTERNATIONAL 
Guidelines: 
IARC Carcinogenicity classification Group 1a IARC 1987 
WHO Drinking water guideline 0.3 µg/Lb WHO 2000 
Air quality guideline (10-6 cancer risk) 1 μg/m3 WHO 2000 
NATIONAL 
Regulations and Guidelines: 
a. Air 
ACGIH TLV (8-hour TWA) 1 ppm ACGIH 2003 
EPA Hazardous air pollutant EPA 2004k 
42USC7412 
Regulated toxic substances pursuant to 10,000 poundsc EPA 2004a 
Section 112(r) of the Clean Air Act and 40CFR68.130 
threshold quantities for accidental release 
prevention 
NIOSH REL (10-hour TWA) Potential occupational NIOSH 2004 
carcinogen 
IDLH No data 
OSHA PEL for general industry OSHA 2004a 
8-hour TWA 1 ppm 29CFR1910.1017 
15-minute TWA 5 ppm 
PEL for construction industry OSHA 2004c 
8-hour TWA 1 ppm 29CFR1926.1117 
15-minute TWA 5 ppm 
PEL for shipyard industry OSHA 2004b 
8-hour TWA 1 ppm 29CFR1915.1017 
15-minute TWA 5 ppm 
b. Water 
Drinking water standards 0.002 mg/L EPA 2004j 
40CFR141.32 
Drinking water standards and health EPA 2004c 
advisories 
1-Day HA for a 10-kg child 3.0 mg/L 
10-Day HA for a 10-kg child 3.0 mg/L 
DWEL 
10-4 Cancer risk 
0.1 mg/L 
0.002 mg/L 
MCL 0.002 mg/L EPA 2004i 
40CFR141.61 
MCLG Zero EPA 2004g 
40CFR141.50 
c. Food 
FDA Bottled water 0.002 mg/L FDA 2003a 
21CFR165.110 
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Table 8-1. Regulations and Guidelines Applicable to Vinyl Chloride 
Agency Description 	 Information Reference 
NATIONAL (cont.) 
FDA Drug products withdrawn or removed from 
the market for reasons of safety or 
effectiveness 
Indirect food additive for use only as a 
component of adhesives 
d. 	Other 
 ACGIH Carcinogenicity classification 
EPA Carcinogenicity classification 
Oral slope factor 
Continuous lifetime exposure during 
adulthood 
Continuous lifetime exposure from 
birth 
Drinking water unit risk 
Continuous lifetime exposure during 
adulthood 
Continuous lifetime exposure from 
birth 
Inhalation unit risk 
Continuous lifetime exposure during 
adulthood 
Continuous lifetime exposure from 
birth 
Hazardous waste identification 
RfC 
RfD 
Superfund; community right-to-know; toxic 
chemical release reporting; effective date 
Superfund; designated as a hazardous 
substance pursuant to Section 307(a) of the 
Clean Water Act, Section 112 of the Clean 
Air Act, and Section 3001 of RCRA 
Reportable quantity 
Unlisted hazardous waste; characteristic 
of toxicity; RCRA waste number 
NTP Carcinogenicity classification 
STATE 
a. 	Air 


























 FDA 2003b 
21CFR175.105 
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Table 8-1. Regulations and Guidelines Applicable to Vinyl Chloride 
Agency Description 	 Information Reference 
STATE (cont.) 
b. 	Water 
California Public health goal 0.05 µg/L CalEPA 2000 
Drinking water guidelines and standards HSDB 2005 
 Arizona 0.015 μg/L 
California 0.5 μg/L 
 Connecticut 2.0 μg/L 
 Florida 1.0 μg/L 
Maine 0.2 μg/L 
 Minnesota 0.2 μg/L 
 New Jersey 2.0 μg/L 





aGroup 1: Carcinogenic to humans. 
bFor substances that are considered to be carcinogenic, the guideline value is the concentration in drinking water 
associated with an upper-bound excess lifetime cancer risk of 10-5 (one additional cancer per 100,000 of the 
population ingesting drinking-water containing the substance at the guideline value for 70 years).  Concentrations 
associated with upper-bound estimated excess lifetime cancer risks of 10-4 and 10-6 can be calculated by multiplying 
and dividing, respectively, the guideline value by 10. 
cVinyl chloride: Mandated for listing by Congress and it is a flammable gas. 
dGroup A1: Confirmed human carcinogen. 
eGroup A: Human carcinogen; according to EPA Risk Assessment Guidelines (EPA 1986). 
fVinyl chloride is a known human carcinogen by the inhalation route of exposure, based on human epidemiological 
data, and by analogy the oral route because of positive animal bioassay data as well as pharmacokinetic data 
allowing dose extrapolation across routes.  Vinyl chloride is also considered highly likely to be carcinogenic by the 
dermal route because it is well absorbed and acts systemically (EPA 1996). 
gThe Air Resources Board has identified vinyl chloride as 'toxic air contaminants' with no threshold level of exposure 
for adverse health effects determined. These actions allow for the implementation of control measures at levels below 
the ambient concentrations specified for these pollutants. 
ACGIH = American Conference of Governmental Industrial Hygienists; CFR = Code of Federal Regulations; 
DWEL = drinking water equivalent level; EPA = Environmental Protection Agency; FDA = Food and Drug 
Administration; HA = Health Advisory; HSDB = Hazardous Substances Data Bank; IARC = International Agency for 
Research on Cancer; IDLH = immediately dangerous to life or health; IRIS = Integrated Risk Information System; 
MCL = maximum contaminant level; MCLG = maximum contaminant level goal; NIOSH = National Institute for 
Occupational Safety and Health; NTP = National Toxicology Program; OSHA = Occupational Safety and Health 
Administration; PEL = permissible exposure limit; RCRA = Resource Conservation and Recovery Act; 
RfC = reference concentration; RfD = reference dose; STEL = short-term exposure limit; TLV = threshold limit values; 
TWA = time-weighted average; USC = United States Codes; WHO = World Health Organization 
_______________________ 
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Absorption—The taking up of liquids by solids, or of gases by solids or liquids. 
Acute Exposure—Exposure to a chemical for a duration of 14 days or less, as specified in the 
Toxicological Profiles. 
Adsorption—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the 
surfaces of solid bodies or liquids with which they are in contact. 
Adsorption Coefficient (Koc)—The ratio of the amount of a chemical adsorbed per unit weight of 
organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium. 
Adsorption Ratio (Kd)—The amount of a chemical adsorbed by sediment or soil (i.e., the solid phase) 
divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a 
fixed solid/solution ratio. It is generally expressed in micrograms of chemical sorbed per gram of soil or 
sediment. 
Benchmark Dose (BMD)—Usually defined as the lower confidence limit on the dose that produces a 
specified magnitude of changes in a specified adverse response.  For example, a BMD10 would be the 
dose at the 95% lower confidence limit on a 10% response, and the benchmark response (BMR) would be 
10%.  The BMD is determined by modeling the dose response curve in the region of the dose response 
relationship where biologically observable data are feasible.    
Benchmark Dose Model—A statistical dose-response model applied to either experimental toxicological 
or epidemiological data to calculate a BMD. 
Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms 
at a specific time or during a discrete time period of exposure divided by the concentration in the 
surrounding water at the same time or during the same period. 
Biomarkers—Broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility. 
Cancer Effect Level (CEL)—The lowest dose of chemical in a study, or group of studies, that produces 
significant increases in the incidence of cancer (or tumors) between the exposed population and its 
appropriate control. 
Carcinogen—A chemical capable of inducing cancer. 
Case-Control Study—A type of epidemiological study that examines the relationship between a 
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic 
chemicals).  In a case-controlled study, a group of people with a specified and well-defined outcome is 
identified and compared to a similar group of people without outcome. 
Case Report—Describes a single individual with a particular disease or exposure.  These may suggest 
some potential topics for scientific research, but are not actual research studies. 
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Case Series—Describes the experience of a small number of individuals with the same disease or 
exposure. These may suggest potential topics for scientific research, but are not actual research studies. 
Ceiling Value—A concentration of a substance that should not be exceeded, even instantaneously. 
Chronic Exposure—Exposure to a chemical for 365 days or more, as specified in the Toxicological 
Profiles. 
Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a 
common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are 
followed forward from exposure to outcome.  At least one exposed group is compared to one unexposed 
group. 
Cross-sectional Study—A type of epidemiological study of a group or groups of people that examines 
the relationship between exposure and outcome to a chemical or to chemicals at one point in time. 
Data Needs—Substance-specific informational needs that if met would reduce the uncertainties of human 
health assessment. 
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result 
from exposure to a chemical prior to conception (either parent), during prenatal development, or 
postnatally to the time of sexual maturation.  Adverse developmental effects may be detected at any point 
in the life span of the organism. 
Dose-Response Relationship—The quantitative relationship between the amount of exposure to a 
toxicant and the incidence of the adverse effects. 
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to 
a chemical; the distinguishing feature between the two terms is the stage of development during which the 
insult occurs.  The terms, as used here, include malformations and variations, altered growth, and in utero 
death. 
Environmental Protection Agency (EPA) Health Advisory—An estimate of acceptable drinking water 
levels for a chemical substance based on health effects information.  A health advisory is not a legally 
enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials. 
Epidemiology—Refers to the investigation of factors that determine the frequency and distribution of 
disease or other health-related conditions within a defined human population during a specified period.   
Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of 
affected cells, can be expressed as a mutagenic, clastogenic, or carcinogenic event because of specific 
alteration of the molecular structure of the genome. 
Half-life—A measure of rate for the time required to eliminate one half of a quantity of a chemical from 
the body or environmental media. 
Immediately Dangerous to Life or Health (IDLH)—The maximum environmental concentration of a 
contaminant from which one could escape within 30 minutes without any escape-impairing symptoms or 
irreversible health effects. 
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Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from 
exposure to environmental agents such as chemicals. 
Immunological Effects—Functional changes in the immune response. 
Incidence—The ratio of individuals in a population who develop a specified condition to the total 
number of individuals in that population who could have developed that condition in a specified time 
period. 
Intermediate Exposure—Exposure to a chemical for a duration of 15–364 days, as specified in the 
Toxicological Profiles. 
In Vitro—Isolated from the living organism and artificially maintained, as in a test tube. 
In Vivo—Occurring within the living organism. 
Lethal Concentration(LO) (LCLO)—The lowest concentration of a chemical in air that has been reported 
to have caused death in humans or animals. 
Lethal Concentration(50) (LC50)—A calculated concentration of a chemical in air to which exposure for 
a specific length of time is expected to cause death in 50% of a defined experimental animal population. 
Lethal Dose(LO) (LDLo)—The lowest dose of a chemical introduced by a route other than inhalation that 
has been reported to have caused death in humans or animals. 
Lethal Dose(50) (LD50)—The dose of a chemical that has been calculated to cause death in 50% of a 
defined experimental animal population. 
Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a chemical 
is expected to cause death in 50% of a defined experimental animal population. 
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study, 
or group of studies, that produces statistically or biologically significant increases in frequency or severity 
of adverse effects between the exposed population and its appropriate control. 
Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the 
lymph nodes, spleen, and thymus. 
Malformations—Permanent structural changes that may adversely affect survival, development, or 
function. 
Minimal Risk Level (MRL)—An estimate of daily human exposure to a hazardous substance that is 
likely to be without an appreciable risk of adverse noncancer health effects over a specified route and 
duration of exposure. 
Modifying Factor (MF)—A value (greater than zero) that is applied to the derivation of a Minimal Risk 
Level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty 
factors. The default value for a MF is 1. 
Morbidity—State of being diseased; morbidity rate is the incidence or prevalence of disease in a specific 
population. 
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Mortality—Death; mortality rate is a measure of the number of deaths in a population during a specified 
interval of time. 
Mutagen—A substance that causes mutations.  A mutation is a change in the DNA sequence of a cell’s 
DNA. Mutations can lead to birth defects, miscarriages, or cancer. 
Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of 
death or pathological conditions. 
Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a 
chemical. 
No-Observed-Adverse-Effect Level (NOAEL)—The dose of a chemical at which there were no 
statistically or biologically significant increases in frequency or severity of adverse effects seen between 
the exposed population and its appropriate control.  Effects may be produced at this dose, but they are not 
considered to be adverse. 
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical 
in n-octanol and water, in dilute solution. 
Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances 
and a disease or condition) that represents the best estimate of relative risk (risk as a ratio of the incidence 
among subjects exposed to a particular risk factor divided by the incidence among subjects who were not 
exposed to the risk factor). An OR of greater than 1 is considered to indicate greater risk of disease in the 
exposed group compared to the unexposed group. 
Organophosphate or Organophosphorus Compound—A phosphorus-containing organic compound 
and especially a pesticide that acts by inhibiting cholinesterase. 
Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA) 
allowable exposure level in workplace air averaged over an 8-hour shift of a 40-hour workweek. 
Pesticide—General classification of chemicals specifically developed and produced for use in the control 
of agricultural and public health pests. 
Pharmacokinetics—The dynamic behavior of a material in the body, used to predict the fate 
(disposition) of an exogenous substance in an organism.  Utilizing computational techniques, it provides 
the means of studying the absorption, distribution, metabolism, and excretion of chemicals by the body. 
Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent 
chemical or metabolite in an animal system.  There are two types of pharmacokinetic models:  data-based 
and physiologically-based.  A data-based model divides the animal system into a series of compartments, 
which, in general, do not represent real, identifiable anatomic regions of the body, whereas the 
physiologically-based model compartments represent real anatomic regions of the body. 
Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically based dose-
response model that quantitatively describes the relationship between target tissue dose and toxic end 
points. These models advance the importance of physiologically based models in that they clearly 
describe the biological effect (response) produced by the system following exposure to an exogenous 
substance. 
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Physiologically Based Pharmacokinetic (PBPK) Model—Comprised of a series of compartments 
representing organs or tissue groups with realistic weights and blood flows.  These models require a 
variety of physiological information:  tissue volumes, blood flow rates to tissues, cardiac output, alveolar 
ventilation rates, and possibly membrane permeabilities.  The models also utilize biochemical 
information, such as air/blood partition coefficients, and metabolic parameters.  PBPK models are also 
called biologically based tissue dosimetry models. 
Prevalence—The number of cases of a disease or condition in a population at one point in time.  
Prospective Study—A type of cohort study in which the pertinent observations are made on events 
occurring after the start of the study.  A group is followed over time. 
q1*—The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the 
multistage procedure.  The q1* can be used to calculate an estimate of carcinogenic potency, the 
incremental excess cancer risk per unit of exposure (usually μg/L for water, mg/kg/day for food, and 
μg/m3 for air). 
Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health 
(NIOSH) time-weighted average (TWA) concentration for up to a 10-hour workday during a 40-hour 
workweek. 
Reference Concentration (RfC)—An estimate (with uncertainty spanning perhaps an order of 
magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups) 
that is likely to be without an appreciable risk of deleterious noncancer health effects during a lifetime.  
The inhalation reference concentration is for continuous inhalation exposures and is appropriately 
expressed in units of mg/m3 or ppm. 
Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of the 
daily exposure of the human population to a potential hazard that is likely to be without risk of deleterious 
effects during a lifetime.  The RfD is operationally derived from the no-observed-adverse-effect level 
(NOAEL, from animal and human studies) by a consistent application of uncertainty factors that reflect 
various types of data used to estimate RfDs and an additional modifying factor, which is based on a 
professional judgment of the entire database on the chemical.  The RfDs are not applicable to 
nonthreshold effects such as cancer. 
Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under 
the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA).  Reportable 
quantities are (1) 1 pound or greater or (2) for selected substances, an amount established by regulation 
either under CERCLA or under Section 311 of the Clean Water Act.  Quantities are measured over a 
24-hour period. 
Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result 
from exposure to a chemical.  The toxicity may be directed to the reproductive organs and/or the related 
endocrine system.  The manifestation of such toxicity may be noted as alterations in sexual behavior, 
fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of 
this system. 
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Retrospective Study—A type of cohort study based on a group of persons known to have been exposed 
at some time in the past.  Data are collected from routinely recorded events, up to the time the study is 
undertaken. Retrospective studies are limited to causal factors that can be ascertained from existing 
records and/or examining survivors of the cohort. 
Risk—The possibility or chance that some adverse effect will result from a given exposure to a chemical. 
Risk Factor—An aspect of personal behavior or lifestyle, an environmental exposure, or an inborn or 
inherited characteristic that is associated with an increased occurrence of disease or other health-related 
event or condition. 
Risk Ratio—The ratio of the risk among persons with specific risk factors compared to the risk among 
persons without risk factors. A risk ratio greater than 1 indicates greater risk of disease in the exposed 
group compared to the unexposed group. 
Short-Term Exposure Limit (STEL)—The American Conference of Governmental Industrial 
Hygienists (ACGIH) maximum concentration to which workers can be exposed for up to 15 minutes 
continually. No more than four excursions are allowed per day, and there must be at least 60 minutes 
between exposure periods. The daily Threshold Limit Value-Time Weighted Average (TLV-TWA) may 
not be exceeded. 
Standardized Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected 
number of deaths in a specific standard population. 
Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or 
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime of exposure to a chemical. 
Teratogen—A chemical that causes structural defects that affect the development of an organism. 
Threshold Limit Value (TLV)—An American Conference of Governmental Industrial Hygienists 
(ACGIH) concentration of a substance to which most workers can be exposed without adverse effect.  
The TLV may be expressed as a Time Weighted Average (TWA), as a Short-Term Exposure Limit 
(STEL), or as a ceiling limit (CL). 
Time-Weighted Average (TWA)—An allowable exposure concentration averaged over a normal 8-hour 
workday or 40-hour workweek. 
Toxic Dose(50) (TD50)—A calculated dose of a chemical, introduced by a route other than inhalation, 
which is expected to cause a specific toxic effect in 50% of a defined experimental animal population. 
Toxicokinetic—The absorption, distribution, and elimination of toxic compounds in the living organism. 
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Uncertainty Factor (UF)—A factor used in operationally deriving the Minimal Risk Level (MRL) or 
Reference Dose (RfD) or Reference Concentration (RfC) from experimental data.  UFs are intended to 
account for (1) the variation in sensitivity among the members of the human population, (2) the 
uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from 
data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using lowest-
observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data. 
A default for each individual UF is 10; if complete certainty in data exists, a value of 1 can be used; 
however, a reduced UF of 3 may be used on a case-by-case basis, 3 being the approximate logarithmic 
average of 10 and 1. 
Xenobiotic—Any chemical that is foreign to the biological system. 
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APPENDIX A.  ATSDR MINIMAL RISK LEVELS AND WORKSHEETS 
The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 
9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99– 
499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with 
the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most 
commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological 
profiles for each substance included on the priority list of hazardous substances; and assure the initiation 
of a research program to fill identified data needs associated with the substances. 
The toxicological profiles include an examination, summary, and interpretation of available toxicological 
information and epidemiologic evaluations of a hazardous substance.  During the development of 
toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to 
identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a 
given route of exposure. An MRL is an estimate of the daily human exposure to a hazardous substance 
that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration 
of exposure. MRLs are based on noncancer health effects only and are not based on a consideration of 
cancer effects.  These substance-specific estimates, which are intended to serve as screening levels, are 
used by ATSDR health assessors to identify contaminants and potential health effects that may be of 
concern at hazardous waste sites.  It is important to note that MRLs are not intended to define clean-up or 
action levels. 
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor 
approach. They are below levels that might cause adverse health effects in the people most sensitive to 
such chemical-induced effects.  MRLs are derived for acute (1–14 days), intermediate (15–364 days), and 
chronic (365 days and longer) durations and for the oral and inhalation routes of exposure.  Currently, 
MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method 
suitable for this route of exposure. MRLs are generally based on the most sensitive chemical-induced end 
point considered to be of relevance to humans.  Serious health effects (such as irreparable damage to the 
liver or kidneys, or birth defects) are not used as a basis for establishing MRLs.  Exposure to a level 
above the MRL does not mean that adverse health effects will occur. 
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MRLs are intended only to serve as a screening tool to help public health professionals decide where to 
look more closely.  They may also be viewed as a mechanism to identify those hazardous waste sites that 
are not expected to cause adverse health effects.  Most MRLs contain a degree of uncertainty because of 
the lack of precise toxicological information on the people who might be most sensitive (e.g., infants, 
elderly, nutritionally or immunologically compromised) to the effects of hazardous substances.  ATSDR 
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health 
principle of prevention. Although human data are preferred, MRLs often must be based on animal studies 
because relevant human studies are lacking.  In the absence of evidence to the contrary, ATSDR assumes 
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons 
may be particularly sensitive.  Thus, the resulting MRL may be as much as 100-fold below levels that 
have been shown to be nontoxic in laboratory animals. 
Proposed MRLs undergo a rigorous review process:  Health Effects/MRL Workgroup reviews within the 
Division of Toxicology and Environmental Medicine, expert panel peer reviews, and agency-wide MRL 
Workgroup reviews, with participation from other federal agencies and comments from the public.  They 
are subject to change as new information becomes available concomitant with updating the toxicological 
profiles. Thus, MRLs in the most recent toxicological profiles supersede previously published levels.  
For additional information regarding MRLs, please contact the Division of Toxicology and 
Environmental Medicine, Agency for Toxic Substances and Disease Registry, 1600 Clifton Road NE, 
Mailstop F-32, Atlanta, Georgia 30333. 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: Vinyl Chloride 
CAS Number: 75-01-4 
Date:   March 2006 
Profile Status: Final Draft Post-Public Comment 
Route: [X] Inhalation [ ] Oral 
Duration: [X] Acute   [ ] Intermediate  [ ] Chronic 
Graph Key: 33 
Species: Mouse 
Minimal Risk Level: 0.5 [ ] mg/kg/day   [X] ppm 
References: 
John JA, Smith FA, Leong BKJ, et al.  1977.  The effects of maternally inhaled vinyl chloride on 
embryonal and fetal development in mice, rats, and rabbits.  Toxicol Appl Pharmacol 39:497-513. 
John JA, Smith FA, Schwetz BA.  1981.  Vinyl chloride:  Inhalation teratology study in mice, rats, and 
rabbits. Environ Health Perspect 41:171-177. 
Experimental design: CF-1 mice were exposed to vinyl chloride at concentrations of 0, 50, or 500 ppm 
for 7 hours/day on gestational days 6–15 (John et al. 1977, 1981).  Concurrent control groups were used, 
one for each dose level. Control groups were sham-exposed to filtered room air.  Exposure was 
conducted in chambers of 3.7 m3 volume under dynamic conditions.  Animals were observed daily for 
clinical signs, and maternal body weights were determined several times during gestation.  Animals were 
euthanized on gestational day 18 by carbon dioxide inhalation.  Maternal liver weight was determined and 
uterine horns were examined.  Fetuses were weighed, measured (crown-rump length), sexed, and 
subjected to gross and histopathological examinations. 
Effects noted in study and corresponding doses: No adverse maternal or fetal effects were noted at 
50 ppm, with the exception of a slight increase (p<0.05) in crown-rump length that was not observed at 
500 ppm.  The 50-ppm exposure level is considered to be a NOAEL for maternal and developmental 
toxicity.  At the LOAEL of 500 ppm, delayed ossification (p<0.05) was observed.  An increase in 
resorptions at 500 ppm was considered to have been within historical control limits.  Significant changes 
in percentage resorption, litter size, and fetal body weight would not have been observed at 500 ppm if 
comparison had been made to the other control group.  There was frank maternal toxicity at 500 ppm 
(17% death).  The limited number and spacing of dose group precludes the use of benchmark dose 
modeling for determination of the point-of-departure for the MRL. 
Dose and end point used for MRL derivation: 
[X] NOAEL  [ ] LOAEL [  ] benchmark dose 
Uncertainty Factors used in MRL derivation: 
[ ]  10 for use of a LOAEL 
[X]  3 for extrapolation from animals to humans with dosimetric adjustment 
[X]  10 for human variability 
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Was a conversion used from ppm in food or water to a mg/body weight dose? No. 
If so, explain: 
If an inhalation study in animals, list the conversion factors used in determining human equivalent dose: 
The intermittent exposure duration of 7 hours/day was duration-adjusted (NOAELADJ) to continuous 
exposure according to the following equation: 
NOAELADJ = NOAEL (50 ppm) x 7 hours/24 hours per day = 15 ppm. 
Following EPA (1994g) methodology, the human equivalent concentration (NOAELHEC) for an 
extrarespiratory effect produced by a category 3 gas, such as vinyl chloride, is calculated by multiplying 
the duration-adjusted animal NOAEL by the ratio of the blood:gas partition coefficients in animals and 
humans ([Hb/g]A / [Hb/g]H). Since the partition coefficient in mice is greater than that in humans, as seen in 
Table 3-3, a default value of 1 is used for the ratio resulting in a NOAELHEC of 15 ppm.  The acute-
duration inhalation MRL of 0.5 ppm was derived by dividing the NOAELHEC of 15 ppm for 
developmental effects in female CF-1 mice by a factor of 30 (3 for species extrapolation using a 
dosimetric conversion and 10 for human variability). 
Other additional studies or pertinent information which lend support to this MRL: Delayed ossification 
(500 ppm, the lowest concentration tested) was the only developmental effect observed in a rabbit 
developmental study (John et al. 1977/ 1981). 
Agency Contact (Chemical Manager): G. Daniel Todd, Ph.D. 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: Vinyl Chloride 
CAS Number: 75-01-4 
Date:   March 2006 
Profile Status: Final Draft Post-Public Comment 
Route: [X] Inhalation [ ] Oral 
Duration: [ ] Acute   [X] Intermediate  [ ] Chronic 
Graph Key: 44 
Species: Rat 
Minimal Risk Level: 0.03 [ ] mg/kg/day  [X] ppm 
Reference: Thornton SR, Schroeder RE, Robison RL, et al.  2002.  Embryo-fetal developmental and 
reproductive toxicology of vinyl chloride in rats.  Toxicol Sci 68:207-219. 
Experimental design: Groups of male and female Sprague-Dawley rats (30/sex/group) were exposed to 
vinyl chloride vapor concentrations of 0, 10, 100, or 1,100 ppm, 6 hours/day for 10 weeks prior to mating 
and during a 3-week mating period.  F0 males were exposed during the gestational period and sacrificed 
following the completion of parturition. F0 females were exposed during gestation and lactation (with the 
exception of a break in exposure from gestation day 21 through postnatal day 4 to allow for delivery of 
litters). All F0 rats were observed twice daily for clinical signs.  Body weights and food consumption 
were monitored.  F1 litters were examined for live and dead pups and on lactation day 4, litters were 
culled to eight pups (equal numbers of male and female pups where possible).  All F0 female rats 
(including those that did not produce offspring) were sacrificed after the F1 rats had been weaned. 
Reproductive tissues, adrenal glands, brain, kidneys, liver, lungs, spleen, thymus, mammary glands, nasal 
tissues, pituitary, and trachea from each of the F0 rats were individually weighed and subjected to 
histopathologic examinations.  At weaning, 15 male and female F1 rats/group were selected for gross and 
microscopic examinations.  Other F1 rats were randomly selected to form groups of 30/sex/group, and 
these F1 rats were subjected to the same treatment as the F0 rats during the production of an F2 generation. 
At weaning, 15 male and female F2 rats/group were subjected to gross and microscopic examinations.  
Sperm parameters were assessed in 15 F0 and 15 F1 male rats of each exposure group. 
Effects noted in study and corresponding doses: Absolute and relative mean liver weights were 
significantly increased at all exposure levels in F0 males and in 100- and 1,100-ppm F1 males.  Slight 
centrilobular hypertrophy, considered to be a minimal adverse effect, was noted in the livers of all 
1,100-ppm male and female F0 and F1 rats, most 100-ppm male and female F0 and F1 rats, and in 2/30 and 
6/30 of the 10-ppm F0 and F1 female rats, respectively (see Table A-1).  No incidences of centrilobular 
hypertrophy were found in any of the control rats.  Compared to an incidence of 0/30 for this lesion in 
controls, the incidence of 6/30 in the 10-ppm F1 female rats exceeded the level of statistical significance 
(p<0.05 according to Fisher’s Exact Test performed by ATSDR). 
Dose and end point used for MRL derivation: 
[ ] NOAEL  [ ] LOAEL  [X]  LEC10 from benchmark dose modeling 
Uncertainty Factors used in MRL derivation: 
[ ]  10 for use of a LOAEL 
[X]  3 for extrapolation from animals to humans with dosimetric adjustment 
[X]  10 for human variability 
A-6 VINYL CHLORIDE 
APPENDIX A 
Was a conversion used from ppm in food or water to a mg/body weight dose? No. 
If so, explain: 
If an inhalation study in animals, list the conversion factors used in determining human equivalent dose: 
The incidence data for centrilobular hypertrophy in the male and female F0 and F1 rats exposed to vinyl 
chloride by inhalation, 6 hours/day for 10 weeks prior to mating and during mating, gestation, and 
lactation (Thornton et al. 2002) are shown in Table A-1. 
Table A-1. Incidences of F0 And F1 Male and Female With Centrilobular 
 
Hypertrophy in the Liver Following Inhalation Exposure to Vinyl  
 
Chloride Vapors for 6 Hours/Day for 10 Weeks Prior to Mating  
 




Exposure concentration (ppm) 
0 10 100 1,100 
F0 males 0/30 0/30 15/30* 30/30* 
F0 females 0/30 2/30 26/30* 30/30* 
F1 males 0/30 0/30 19/30* 30/30* 
F1 females 0/30 6/30* 30/30* 30/30* 
*Statistically significantly (p<0.05) different from controls according to Fisher’s Exact Test performed by ATSDR. 
Source: Thornton et al. (2002) 
All dichotomous models in the Benchmark Dose Software (BMDS version 1.3.2) were fit to the incidence 
data for centrilobular hypertrophy in the liver of the F1 female rats, which had also been exposed via their 
mothers during pre- and post-natal development.  The lower 95% confidence limit (LEC10) of a 10% extra 
risk (EC10) for hepatic centrilobular hypertrophy was selected as the benchmark response for the point of 
departure. The Quantal Quadratic model provided the best fit as assessed by a chi-square goodness-of-fit 
test and the Aikake’s Information Criteria (AIC) (Table A-2).  Therefore, the LEC10 value of 5 ppm, 
derived from the Quantal Quadratic model, was selected as the point of departure for calculating an 
intermediate-duration inhalation MRL (see Table A-2 and Figure A-1). 
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Table A-2. Modeling Results for the Incidence of F1 Female Rats with 
 
Centrilobular Hypertrophy in the Liver Following Inhalation  
 
Exposure to Vinyl Chloride Vapors for 6 Hours/Day for  
 
10 Weeks Prior to Mating and During Mating, 
 
Gestation, and Lactation, and Exposed via  
 





Model (ppm) (ppm) χ2 p-value AIC 
Gammaa 7.78 3.15 1.00 34.02 
Logistic 8.75 6.15 1.00 32.05 
Log-logisticb 9.12 5.22 1.00 34.02 
Multi-stagec 6.35 3.44 undefined 36.02 
Probit 9.11 5.69 1.00 34.02 
Log-probitb 8.56 5.09 1.00 34.02 
Quantal linear 3.03 2.05 0.53 35.28 
Quantal quadratic 6.87 5.08 1.00 32.02 
Weibulla 6.68 3.03 1.00 34.02 
aRestrict power >=1 
bSlope restricted to >1 
cRestrict betas >=0; Degree of polynomial=3 
Source: Thornton et al. (2002) 
Figure A-1. Benchmark Dose Model Results for the Incidence of Female F1 Rats 
 
with Centrilobular Hypertrophy Following Exposure to Vinyl Chloride  
 
by Inhalation, 6 Hours/Day for 10 Weeks Prior to Mating and During  
 
Mating, Gestation, and Lactation, and Exposed Via their Mothers  
 
During Pre- and Postnatal Development 
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The intermittent exposure duration of 6 hours/day was duration-adjusted (LEC10ADJ) to continuous 
exposure according to the following equation: 
LEC10ADJ = LEC10 (5 ppm) x 6 hours/24 hours per day = 1.25 ppm; (rounded to 1.0 ppm). 
Following EPA (1994g) methodology, the human equivalent concentration (LEC10HEC) for an 
extrarespiratory effect produced by a category 3 gas, such as vinyl chloride, is calculated by multiplying 
the animal LEC10ADJ by the ratio of the blood:gas partition coefficients in animals and humans [(Hb/g)A / 
Hb/g)H].  Since the partition coefficient in mice is greater than that in humans, as seen in Table 3-3, a 
default value of 1 is used for the ratio and the animal LEC10ADJ is equivalent to the LEC10HEC. Several 
physiologically-based pharmacokinetic (PBPK) models are available for vinyl chloride; however, none of 
these models included an evaluation of exposure during mating, gestation, or lactation.  Therefore, PBPK 
models could not be used to calculate a LEC10HEC from the Thornton et al. (2002) study.  The 
intermediate-duration inhalation MRL of 0.03 ppm was derived by dividing the LEC10HEC of 1.0 ppm for 
centrilobular hypertrophy in female Sprague-Dawley rats by a factor of 30 (3 for species extrapolation 
using a dosimetric conversion and 10 for human variability). 
Other additional studies or pertinent information which lend support to this MRL: Liver enlargement 
and/or histopathological changes have been noted in a number of intermediate-duration inhalation studies 
in animals (Bi et al. 1985; Lester et al. 1963; Schaffner 1978; Sokal et al. 1980; Torkelson et al. 1961; 
Wisniewska-Knypl et al. 1980).  The studies by Thornton et al. (2002) and Bi et al. (1985) show these 
effects at a somewhat lower dosage.  Additional support comes from a study citing immunostimulation in 
mice at 10 ppm (Sharma and Gehring 1979).   
Agency Contact (Chemical Manager): G. Daniel Todd, Ph.D. 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: Vinyl Chloride 
CAS Number: 75-01-4 
Date:   March 2006 
Profile Status: Final Draft Post-Public Comment 
Route: [ ] Inhalation [X] Oral 
Duration: [ ] Acute   [ ] Intermediate   [X] Chronic 
Graph Key: 5 
Species: Rat 
Minimal Risk Level: 0.003 [X] mg/kg/day  [ ] ppm 
References: 
Til HP, Immel HR, Feron VJ. 1983.  Lifespan oral carcinogenicity study of vinyl chloride in rats.  Final 
report. Civo Institutes, TNO.  Report No. V 93.285/291099. 
Til HP, Feron VJ, Immel HR.  1991.  Lifetime (149-week) oral carcinogenicity study of vinyl chloride in 
rats. Food Chem Toxicol 29:713-718. 
Experimental design:  Groups of Wistar rats (100/sex/group in controls and the two lowest exposure 
groups; 50/sex at the highest exposure level) were administered vinyl chloride in the daily diet at intended 
initial dietary concentrations of 0, 0.46, 4.6, or 46 ppm for 149 weeks.  Due to rapid evaporative loss of 
vinyl chloride from the food, liquid vinyl chloride was mixed with polyvinyl chloride granules to produce 
a mixture in which vinyl chloride was effectively encapsulated in polyvinyl chloride granules (Feron et al. 
1975).  The study authors trained the rats to a feeding schedule of 4 hours/day prior to the initiation of 
exposure to vinyl chloride in the diet.  The authors noted that food consumption per hour was fairly 
constant during the 4-hour feeding period.  Loss of vinyl chloride from food during the first hour, the 
second hour, and the final 2 hours was calculated.  Periodic food intake measurements were made for the 
first hour, the second hour, and the final 2 hours.  Based on these measurements, the study authors 
calculated the average oral intake of the combined sexes during the daily 4-hour feeding periods to be 0, 
0.018, 0.17, and 1.7 mg/kg/day for the 0-, 0.49-, 4.49-, and 44.1-ppm groups, respectively (see 
Table A-3). Measurements of vinyl chloride in the feces were made periodically at 1 hour prior to the 
feeding period, the end of the 4-hour feeding period, and 4 and 9 hours later.  The study authors 
considered the vinyl chloride content in the feces to have remained encapsulated in the polyvinyl chloride 
granules and thus not to have been available for absorption from the gastrointestinal tract.  The amount of 
vinyl chloride in the feces was subtracted from the calculated daily oral intake of vinyl chloride to arrive 
at what the study authors termed “actual oral exposure levels” of 0, 0.014, 0.13, and 1.3 mg/kg/day for the 
0-, 0.49-, 4.49-, and 44.1-ppm groups, respectively (see Table A-3).  Results of toxicokinetic assessments 
for vinyl chloride indicate that, following absorption, vinyl chloride and its metabolites are not excreted in 
appreciable amounts in the feces.  Types and incidences of neoplastic and nonneoplastic liver lesions 
were determined at the end of the study. 




Table A-3. Exposure Levels and Oral Intake Values for Rats Exposed to Vinyl 
 
Chloride in the Diet for 149 Weeks 
 








0 0 0 0 
0.49 0.022 0.018 0.014 
4.49 0.21 0.17 0.13 
44.1 2.1 1.7 1.3 
aAssuming no loss of vinyl chloride by evaporation from the diet. 
 
bOral intake, adjusted for evaporative loss from the diet during the daily 4-hour feeding periods. 
 
cOral intake of vinyl chloride (adjusted for evaporative loss and the amount excreted in the feces, which was 
 




Source: Til et al. (1983, 1991) 
Effects noted in study and corresponding doses:  The critical nonneoplastic effect was determined to be 
liver cell polymorphism, which was classified by severity (slight, moderate, severe).  The incidences of 
this lesion are listed in Table A-4. 
Table A-4. Incidences of Male and Female Wistar Rats Exhibiting Slight, 
 
Moderate, or Severe Liver Cell Polymorphism Following Daily Oral  
 
Exposure to Vinyl Chloride in the Diet for 149 Weeks 
 
Oral intake (mg/kg/day) 
Males Females 
0 0.018 0.17 1.7 0 0.018 0.17 1.7 




















Severe 1 1 1 3 2 3 4 9c 
aSignificantly different from controls according to Fisher’s exact test (p<0.001). 
bSignificantly different from controls according to Fisher’s exact test (p<0.05). 
cSignificantly different from controls according to Fisher’s exact test (p<0.0001). 
Source: Til et al. (1983, 1991) 
A LOAEL of 1.7 mg/kg/day was identified for statistically significantly increased incidences of liver cell 
polymorphism in male and female rats.  The NOAEL for nonneoplastic liver effects is 0.17 mg/kg/day. 
An increase in the incidence of female rats with many hepatic cysts was also observed at the highest dose 
(1.7 mg/kg/day).  Other histopathologic lesions, described as hepatic foci of cellular alteration, were 
observed at all dose levels in female rats and in high-dose male rats, but were not used to derive an MRL 
because they are considered to be preneoplastic lesions.  MRLs are protective only for non-neoplastic 
effects and do not reflect cancer risk. 
The liver cell polymorphism incidences reported by Til et al. (1983, 1991) were also used as the basis of 
the RfD of 0.003 mg/kg/day for vinyl chloride derived by the U.S. EPA (EPA 2000).  However, EPA 
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used the estimated absorbed dose of 0.13 mg/kg/day as the NOAEL, rather than the adjusted oral intake 
NOAEL of 0.17 mg/kg/day used by ATSDR.  EPA (2000) applied the Clewell et al. (1995) PBPK model 
for vinyl chloride to the low-, mid-, and high-dose groups (estimated absorbed doses of 0.014, 0.13, and 
1.3 mg/kg/day, respectively) to generate dose metrics of 0.3, 3, and 30 mg vinyl chloride metabolites/L 
liver, respectively. The EPA (2000) rationale for using the total amount of metabolite generated divided 
by the volume of liver tissue as the dose metric for liver toxicity included evidence that vinyl chloride-
induced liver toxicity is related to the production of reactive intermediates and that binding to liver 
macromolecules correlates well with total metabolism (Watanabe et al. 1978).  In EPA’s derivation of the 
RfD, it was assumed that all of the metabolism of vinyl chloride occurred in the liver.  EPA (2000) 
simulated a continuous human exposure scenario (ingestion of 1 ppm of vinyl chloride in water or 
0.286 mg/kg/day, assuming consumption of 2 L water/day for a 70-kg person) using the Clewell et al. 
(1995) model, which resulted in a human internal dose metric of 1.01 mg metabolite/L liver.  The ratio of 
the value for the human internal dose metric 1.01 mg metabolite/L liver) to the vinyl chloride intake of 
0.286 mg/kg/day in the simulated human exposure scenario (1.01 ÷ 0.286 = 35.31) was used by EPA 
(2000) to convert from the rat dose metric (3 mg metabolite/L liver) at the NOAEL (0.13 mg/kg/day 
estimated absorbed dose) to a human equivalent dose (i.e., the rat NOAEL of 0.13 mg/kg/day divided by 
35.31 equals a human equivalent dose of 0.09 mg/kg/day).  EPA considered this approach to be adequate 
because vinyl chloride metabolism is linear in the dose range that includes the NOAEL of 0.13 mg/kg/day 
identified in the rat study of Til et al. (1983, 1991). 
EPA (2000) assessed the feasibility of using Benchmark Dose Modeling on incidence data for liver cell 
polymorphism in the study of Til et al. (1983, 1991).  Incidence data for moderate and severe grades of 
liver cell polymorphism were combined for both sexes and summed to produce one control group and 
three exposure groups (moderate + severe incidences of liver cell polymorphism divided by the number of 
treated male and female rats at each dose level; 21/197 controls, 21/199 low-dose, 20/196 mid-dose, and 
37/98 high-dose rats). The resulting incidence data for each dose metric (0.3, 3, and 30 mg metabolite/L 
liver) were subjected to Benchmark Dose modeling in order to statistically identify a threshold response 
for vinyl chloride-induced effects.  The resulting dose metric values are shown in Table A-5. 
Table A-5. LED10 Values Generated from Various Models to Liver Cell 
 
Polymorphism Incidence Data from Oral Exposure of Male and 
 
Female Rats to Vinyl Chloride in the Diet for 149 Weeks in the 
 
Study of Til et al. 1991 
 
Model LED10 (mg/L liver)a p-value 
Weibull (power≥1) 24.0 0.88 
Gammahit 21.4 0.88 
Quantal quadratic 13.8 0.96 
Logistic 12.9 0.47 
Multistage 11.8 0.79 
Probit 11.6 0.44 
Quantal linear 6.5 0.46 
NOAEL 3.00 (0.13 mg/kg/day) 
LOAEL 29.9 (1.3 mg/kg/day) 
aLED10 is the lower 95% confidence limit of a 10% change in numbers exhibiting polymorphism evaluated as 
either moderate or severe.  The NOAEL and LOAEL are shown for comparison. 
Source: EPA (2000) 
EPA (2000) noted that although all models provided adequate fit to the data, the liver cell polymorphism 
appeared to be only a high-dose phenomenon, the LED10 values ranged from 6.5 to 24.01 mg/L liver 
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(nearly a 4-fold range), and all modeled LED10 values were higher than the NOAEL of the study.  EPA 
(2000) argued that there was no biological reason to choose the results of one model over another and that 
the dose-response characteristics present additional uncertainty due to the large gaps between dose levels.  
For these reasons, EPA (2000) chose to use the internal dose metric of 3 mg/L liver, corresponding to the 
rat NOAEL, rather than a benchmark LED10 value, to derive the RfD for vinyl chloride.  EPA (2000) 
applied an uncertainty factor of 30 (3 for extrapolating from animals to humans using a dosimetric 
adjustment and 10 for intrahuman variability) to the HED of 0.09 mg/kg/day. 
Therefore, the RfD = 0.09 mg/kg/day ÷ 30 = 0.003 mg/kg/day.  The chronic-duration oral MRL for vinyl 
chloride is based on the same critical effect as that used by EPA (2000) to derive the RfD for vinyl 
chloride (i.e., the NOAEL for liver cell polymorphism in the oral rat study of Til et al. 1983, 1991).  
However, the point of departure for the chronic-duration oral MRL was the NOAEL of 0.17 mg/kg/day 
(average ingested dose), rather than the estimated absorbed dose of 0.13 mg/kg/day used by EPA (2000), 
based on the assumption that all of the vinyl chloride that remained in the diet (after volatilization) was 
available for absorption. 
In deriving the MRL, the rat NOAEL of 0.17 mg/kg/day was converted to a human equivalent dose using 
the PBPK models described in Clewell et al. (2001) and EPA (2000) to extrapolate from rats to humans.  
Source code and parameter values for running the rat and human models in Advance Continuous 
Simulation Language (ACSL) were transcribed from Appendix C of EPA (2000).  Parameter values used 
in the interspecies extrapolation are presented in Table A-6.  Accuracy of the implementation of the 
model in ACSL (v. 11.8.4) was checked against observations reported in Gehring et al. (1978), also 
reported in Clewell et al. (2001) (results shown in Figure A-2).  The total amount of vinyl chloride 
metabolized in 24 hours per L of liver volume was the rat internal dose metric that was used in 
determining the human dose that would result in an equivalent human dose metric.  One kilogram of liver 
was assumed to have an approximate volume of 1 L.  Exposures in the Til et al. (1983, 1991) rat dietary 
study were simulated as 4-hour oral exposures, for which, the average daily dose was equivalent to the 
NOAEL dose for liver effects (ADD, 0.17 mg/kg/day).  This dose was uniformly distributed over a 
4-hour period (i.e., 0.0425 mg/kg/hour for 4 hours, followed by 16 hours at 0 mg/kg/hour).  Dose metrics 
reflect the cumulative amount of vinyl chloride metabolized over the 24-hour period.  
Table A-6. Parameter Values for Rat and Human Models  
Model 
Parameter Definition Rat Human 
BW Body weight (kg) 0.377 (m) 70 
0.204 (f) 
VLC Liver volume (fraction of body) 0.05 0.026 
VFC Fat volume (fraction of body) 0.12 0.19 
VSC Slowly-perfused  tissue volume (fraction of body) 0.75 0.63 
VRC Rapidly-perfused tissue volume (fraction of body) 0.05 0.064 
QCC Cardiac output (L/hr-kg body weight) 18.0 16.5 
QPC Alveolar ventilation rate (L/hr-kg body weight) 21.0 24.0 
QLC Liver blood flow (fraction of cardiac output) 0.25 0.26 
QFC Fat blood flow (fraction of cardiac output) 0.09 0.05 
QSC Slowly-perfused blood flow (fraction of cardiac output) 0.15 0.19 
QRC Rapidly-perfused blood flow (fraction of cardiac output) 0.51 0.5 
PB Blood:air partition coefficient 2.4 1.16 
PL Liver:blood partition coefficient 0.7 1.45 
PF Fat:blood partition coefficient 10.0 20.7 
PS Slowly-perfused partition coefficient 4.0 0.83 
PR Rapidly-perfused partition coefficient 0.7 1.45 
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Table A-6. Parameter Values for Rat and Human Models  
Model 
Parameter Definition Rat Human 
VMAX1C Maximum rate of oxidative metabolism  4.0 4.0 
(mg/hr-kg body weight) 
VMAX2C Maximum rate of oxidative metabolism  2.0 0.1 
(mg/hour-kg body weight) 
KM1 Michaelis-Menten coefficient for oxidative metabolism 0.1 0.1 
(mg/L) 
KM2 Michaelis-Menten coefficient for oxidative metabolism 10.0 10.0 
(mg/L) 
KCO2C Rate constant for formation of CO2 from oxidative 1.6 1.6 
metabolite (hour-1) 
KGSMC Rate constant for conjugation with GSH (hour-1) 0.13 0.13 
KFEEC Rate constant for conjugation, not with GSH (hour-1) 35.0 35.0 
CGSZ Initial GSH concentration in liver (µmol/L) 5,800 5,800 
KBC Rate constant for GSH catabolism (hour-1) 0.12 0.12 
KS Coefficient controlling resynthesis of GSH (µmol/L) 2,000 2,000 
KZC Zero-order rate constant for resynthesis of GSH (µmol/hour) 28.5 28.5 
Ka Gastrointestinal absorption rate constant (hour-1) 3.0 
Figure A-2. Predicted and Observed Relationship Between Air Exposure 
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Gehring et al. 1978 
Model (BW=0.200) 
*Measurements of metabolites (non-volatile 14C in carcass) were made immediately following a 6-hour exposure to 
[14C]vinyl chloride in air.  Circles represent observations (±SD); the line shows the corresponding simulations. 
VINYL CHLORIDE A-14 
APPENDIX A 
The human model was run iteratively, varying the ADD, until the model converged with the internal dose 
estimate shown in row 1 in Table A-7 (rat, male).  The value for the Km1 for oxidative metabolism in 
humans was assumed to be equal to the Km1 value for rats (0.1 mg/L) (EPA 2000).  The human ADD 
was assumed to be uniformly distributed over a 24-hour period.  The resulting HED was 0.09 mg/kg/day 
(see Table A-7).  Additional simulations were performed assuming that the ADD was distributed over a 
12-hour period (to simulate exposure from drinking water or food during the day only). The resulting 
dose metrics were very similar to the 24-hour estimates (data not shown). 
Table A-7. Summary of Internal Dose Predictions and Corresponding Human 
and Rat Equivalent Doses 
BW Km1 ED EF1 EF2 ADD DM 
Species (kg) mg/L (week) (day/week) (hour/day) (mg/kg/day) (mg/L) 
Wistar rat 
Male 0.377 0.1 149 7 4 0.17 3.16 
Female 0.204 0.1 149 7 4 0.17 3.16 
Human 70 0.1 3,640 7 24 0.09 3.16 
ADD = average daily administered dose; BW = body weight; DM = dose metric equals the total amount of 
metabolite formed in 24 hours per L of liver; ED = exposure duration; EF = exposure frequency; Km1 = Michaelis-
Menten constant for oxidative metabolism 
ATSDR accepted the rationale used by EPA (2000) for not using Benchmark Dose modeling results for 
incidences of the critical effect (liver cell polymorphism in the oral rat study of Til et al. 1983, 1991) in 
the risk assessment.  Therefore, the HED of 0.09 mg/kg/day, associated with the rat NOAEL of 
0.17 mg/kg/day (Til et al. 1983, 1991), served as the basis for the chronic-duration oral MRL for vinyl 
chloride. The chronic-duration oral MRL of 0.003 mg/kg/day was derived by dividing the PBPK-
modeled equivalent human NOAEL of 0.09 mg/kg/day for liver cell polymorphisms by a factor of 
30 (3 for species extrapolation using a dosimetric conversion and 10 for human variability). 
Dose and end point used for MRL derivation: 
[X] NOAEL  [ ] LOAEL 
Uncertainty Factors used in MRL derivation: 
[ ]  10 for use of a LOAEL 
[X]    3 for extrapolation from animals to humans using a dose metric conversion 
[X]  10 for human variability 
Was a conversion used from ppm in food or water to a mg/body weight dose? No. 
If so, explain: 
If an inhalation study in animals, list the conversion factors used in determining human equivalent dose: 
N/A 
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Other additional studies or pertinent information which lend support to this MRL: This MRL is 
reinforced by a study by Feron et al. (1981) in which rats were fed diets containing PVC powder.  
Increased areas of cellular alteration (consisting of clear foci, basophilic foci, and eosinophilic foci) were 
observed in the liver of rats at an oral intake of vinyl chloride monomer of 1.8 mg/kg/day. 
Agency Contact (Chemical Manager):  G. Daniel Todd, Ph.D. 
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APPENDIX B.  USER'S GUIDE 
Chapter 1 
Public Health Statement 
This chapter of the profile is a health effects summary written in non-technical language.  Its intended 
audience is the general public, especially people living in the vicinity of a hazardous waste site or 
chemical release.  If the Public Health Statement were removed from the rest of the document, it would 
still communicate to the lay public essential information about the chemical. 
The major headings in the Public Health Statement are useful to find specific topics of concern.  The 
topics are written in a question and answer format.  The answer to each question includes a sentence that 
will direct the reader to chapters in the profile that will provide more information on the given topic. 
Chapter 2 
Relevance to Public Health 
This chapter provides a health effects summary based on evaluations of existing toxicologic, 
epidemiologic, and toxicokinetic information.  This summary is designed to present interpretive, weight-
of-evidence discussions for human health end points by addressing the following questions: 
1.	 What effects are known to occur in humans? 
2. 	 What effects observed in animals are likely to be of concern to humans? 
3. 	 What exposure conditions are likely to be of concern to humans, especially around hazardous 
waste sites? 
The chapter covers end points in the same order that they appear within the Discussion of Health Effects 
by Route of Exposure section, by route (inhalation, oral, and dermal) and within route by effect.  Human 
data are presented first, then animal data.  Both are organized by duration (acute, intermediate, chronic).  
In vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also 
considered in this chapter. 
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using 
existing toxicokinetic, genotoxic, and carcinogenic data.  ATSDR does not currently assess cancer 
potency or perform cancer risk assessments.  Minimal Risk Levels (MRLs) for noncancer end points (if 
derived) and the end points from which they were derived are indicated and discussed. 
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public 
health are identified in the Chapter 3 Data Needs section. 
Interpretation of Minimal Risk Levels 
Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral 
routes of entry at each duration of exposure (acute, intermediate, and chronic).  These MRLs are not 
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meant to support regulatory action, but to acquaint health professionals with exposure levels at which 
adverse health effects are not expected to occur in humans. 
MRLs should help physicians and public health officials determine the safety of a community living near 
a chemical emission, given the concentration of a contaminant in air or the estimated daily dose in water.  
MRLs are based largely on toxicological studies in animals and on reports of human occupational 
exposure. 
MRL users should be familiar with the toxicologic information on which the number is based.  Chapter 2, 
"Relevance to Public Health," contains basic information known about the substance.  Other sections such 
as Chapter 3 Section 3.9, "Interactions with Other Substances,” and Section 3.10, "Populations that are 
Unusually Susceptible" provide important supplemental information. 
MRL users should also understand the MRL derivation methodology.  MRLs are derived using a 
modified version of the risk assessment methodology that the Environmental Protection Agency (EPA) 
provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.   
To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement, 
represents the most sensitive human health effect for a given exposure route and duration.  ATSDR 
cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available 
for all potential systemic, neurological, and developmental effects.  If this information and reliable 
quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive 
species (when information from multiple species is available) with the highest no-observed-adverse-effect 
level (NOAEL) that does not exceed any adverse effect levels.  When a NOAEL is not available, a 
lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor 
(UF) of 10 must be employed.  Additional uncertainty factors of 10 must be used both for human 
variability to protect sensitive subpopulations (people who are most susceptible to the health effects 
caused by the substance) and for interspecies variability (extrapolation from animals to humans).  In 
deriving an MRL, these individual uncertainty factors are multiplied together.  The product is then 
divided into the inhalation concentration or oral dosage selected from the study. Uncertainty factors used 




Tables and Figures for Levels of Significant Exposure (LSE) 
Tables and figures are used to summarize health effects and illustrate graphically levels of exposure 
associated with those effects.  These levels cover health effects observed at increasing dose 
concentrations and durations, differences in response by species, MRLs to humans for noncancer end 
points, and EPA's estimated range associated with an upper- bound individual lifetime cancer risk of 1 in 
10,000 to 1 in 10,000,000. Use the LSE tables and figures for a quick review of the health effects and to 
locate data for a specific exposure scenario.  The LSE tables and figures should always be used in 
conjunction with the text.  All entries in these tables and figures represent studies that provide reliable, 
quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs). 
The legends presented below demonstrate the application of these tables and figures.  Representative 
examples of LSE Table 3-1 and Figure 3-1 are shown.  The numbers in the left column of the legends 
correspond to the numbers in the example table and figure. 
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LEGEND 
See Sample LSE Table 3-1 (page B-6) 
(1) 	 Route of Exposure. One of the first considerations when reviewing the toxicity of a substance 
using these tables and figures should be the relevant and appropriate route of exposure.  Typically 
when sufficient data exist, three LSE tables and two LSE figures are presented in the document.  
The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, 
and dermal (LSE Tables 3-1, 3-2, and 3-3, respectively).  LSE figures are limited to the inhalation 
(LSE Figure 3-1) and oral (LSE Figure 3-2) routes.  Not all substances will have data on each 
route of exposure and will not, therefore, have all five of the tables and figures. 
(2) 	 Three exposure periods—acute (less than 15 days), intermediate (15– Exposure Period. 

364 days), and chronic (365 days or more)—are presented within each relevant route of exposure.  

In this example, an inhalation study of intermediate exposure duration is reported.  For quick 

reference to health effects occurring from a known length of exposure, locate the applicable 

exposure period within the LSE table and figure. 

(3) 	 The major categories of health effects included in LSE tables and figures are Health Effect. 

death, systemic, immunological, neurological, developmental, reproductive, and cancer.  

NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer.  





(4) 	 Key to Figure. Each key number in the LSE table links study information to one or more data 
points using the same key number in the corresponding LSE figure.  In this example, the study 
represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL 
(also see the two "18r" data points in sample Figure 3-1). 
(5) 	 The test species, whether animal or human, are identified in this column.  Chapter 2,Species. 

"Relevance to Public Health," covers the relevance of animal data to human toxicity and 

Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics.  

Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent 

human doses to derive an MRL. 

(6) 	 The duration of the study and the weekly and daily exposure Exposure Frequency/Duration. 

regimens are provided in this column.  This permits comparison of NOAELs and LOAELs from 

different studies. In this case (key number 18), rats were exposed to “Chemical x” via inhalation 

for 6 hours/day, 5 days/week, for 13 weeks.  For a more complete review of the dosing regimen, 





(7) 	 This column further defines the systemic effects.  These systems include respiratory, System. 
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and 
dermal/ocular.  "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered 
in these systems.  In the example of key number 18, one systemic effect (respiratory) was 
investigated. 
(8) 	 A NOAEL is the highest exposure level at which no harmful effects were seen in the NOAEL. 

organ system studied.  Key number 18 reports a NOAEL of 3 ppm for the respiratory system, 
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which was used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see 
footnote "b"). 
(9) 	 A LOAEL is the lowest dose used in the study that caused a harmful health effect. LOAEL. 
LOAELs have been classified into "Less Serious" and "Serious" effects.  These distinctions help 
readers identify the levels of exposure at which adverse health effects first appear and the 
gradation of effects with increasing dose.  A brief description of the specific end point used to 
quantify the adverse effect accompanies the LOAEL.  The respiratory effect reported in key 
number 18 (hyperplasia) is a Less Serious LOAEL of 10 ppm.  MRLs are not derived from 
Serious LOAELs. 
(10)	 Reference. The complete reference citation is given in Chapter 9 of the profile. 
(11)	 CEL. A CEL is the lowest exposure level associated with the onset of carcinogenesis in 
experimental or epidemiologic studies.  CELs are always considered serious effects.  The LSE 
tables and figures do not contain NOAELs for cancer, but the text may report doses not causing 
measurable cancer increases. 
(12)	 Footnotes. Explanations of abbreviations or reference notes for data in the LSE tables are found 
in the footnotes.  Footnote "b" indicates that the NOAEL of 3 ppm in key number 18 was used to 
derive an MRL of 0.005 ppm. 
LEGEND 
See Sample Figure 3-1 (page B-7) 
LSE figures graphically illustrate the data presented in the corresponding LSE tables.  Figures help the 
reader quickly compare health effects according to exposure concentrations for particular exposure 
periods. 
(13)	 Exposure Period. The same exposure periods appear as in the LSE table.  In this example, health 
effects observed within the acute and intermediate exposure periods are illustrated. 
(14) 	 These are the categories of health effects for which reliable quantitative data Health Effect. 

exists. The same health effects appear in the LSE table. 

(15)	 Levels of Exposure. Concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures.  Exposure concentration or dose is measured on the log 
scale "y" axis.  Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in 
mg/kg/day. 
(16) 	 In this example, the open circle designated 18r identifies a NOAEL critical end point in NOAEL. 
the rat upon which an intermediate inhalation exposure MRL is based.  The key number 18 
corresponds to the entry in the LSE table.  The dashed descending arrow indicates the 
extrapolation from the exposure level of 3 ppm (see entry 18 in the table) to the MRL of 
0.005 ppm (see footnote "b" in the LSE table). 
(17)	 CEL. Key number 38m is one of three studies for which CELs were derived.  The diamond 
symbol refers to a CEL for the test species-mouse.  The number 38 corresponds to the entry in the 
LSE table. 
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(18)	 Estimated Upper-Bound Human Cancer Risk Levels. This is the range associated with the upper-
bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000.  These risk levels are derived 
from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the 
cancer dose response curve at low dose levels (q1*). 





















→ Systemic ↓	 ↓ ↓ ↓ ↓ ↓ 
18 Rat 13 wk Resp 3b 10 (hyperplasia) 





38 Rat 18 mo 
5 d/wk 
7 hr/d 
20 (CEL, multiple 
organs) 
Wong et al. 1982 
39 Rat 89–104 wk 
5 d/wk 
6 hr/d 
10 (CEL, lung tumors, 
nasal tumors) 
NTP 1982 
40 Mouse 79–103 wk 
5 d/wk 
6 hr/d 
10 (CEL, lung tumors, 
hemangiosarcomas) 
NTP 1982 
12 →	 a The number corresponds to entries in Figure 3-1. 
b Used to derive an intermediate inhalation Minimal Risk Level (MRL) of  5x10-3 ppm; dose adjusted for intermittent exposure and divided 
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APPENDIX C.  ACRONYMS, ABBREVIATIONS, AND SYMBOLS 
ACGIH American Conference of Governmental Industrial Hygienists 
ACOEM American College of Occupational and Environmental Medicine 
ADI acceptable daily intake 
ADME absorption, distribution, metabolism, and excretion 
AED atomic emission detection 
AFID alkali flame ionization detector 
AFOSH Air Force Office of Safety and Health 
ALT alanine aminotransferase 
AML acute myeloid leukemia 
AOAC Association of Official Analytical Chemists 
AOEC Association of Occupational and Environmental Clinics 
AP alkaline phosphatase 
APHA American Public Health Association 
AST aspartate aminotransferase 
atm atmosphere 
ATSDR Agency for Toxic Substances and Disease Registry 
AWQC Ambient Water Quality Criteria 
BAT best available technology 
BCF bioconcentration factor 
BEI Biological Exposure Index 
BMD benchmark dose 
BMR benchmark response 
BSC Board of Scientific Counselors 
C centigrade 
CAA Clean Air Act 
CAG Cancer Assessment Group of the U.S. Environmental Protection Agency 
CAS Chemical Abstract Services 
CDC Centers for Disease Control and Prevention 
CEL cancer effect level 
CELDS Computer-Environmental Legislative Data System 
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act 
CFR Code of Federal Regulations 
Ci curie 
CI confidence interval 
CL ceiling limit value 
CLP Contract Laboratory Program 
cm centimeter 
CML chronic myeloid leukemia 
CPSC Consumer Products Safety Commission 
CWA Clean Water Act 
DHEW Department of Health, Education, and Welfare 
DHHS Department of Health and Human Services 
DNA deoxyribonucleic acid 
DOD Department of Defense 
DOE Department of Energy 
DOL Department of Labor 
DOT Department of Transportation 
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DOT/UN/ Department of Transportation/United Nations/ 
NA/IMCO     North America/International Maritime Dangerous Goods Code 
DWEL drinking water exposure level 
ECD electron capture detection 
ECG/EKG electrocardiogram 
EEG electroencephalogram 
EEGL Emergency Exposure Guidance Level 
EPA Environmental Protection Agency 
F Fahrenheit 
F1 first-filial generation 
FAO Food and Agricultural Organization of the United Nations 
FDA Food and Drug Administration 
FEMA Federal Emergency Management Agency 
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act 
FPD flame photometric detection 
fpm feet per minute 
FR Federal Register 
FSH follicle stimulating hormone 
g gram 
GC gas chromatography 
gd gestational day 
GLC gas liquid chromatography 
GPC gel permeation chromatography 
HPLC high-performance liquid chromatography 
HRGC high resolution gas chromatography 
HSDB Hazardous Substance Data Bank  
IARC International Agency for Research on Cancer 
IDLH immediately dangerous to life and health 
ILO International Labor Organization 
IRIS Integrated Risk Information System 
Kd adsorption ratio 
kg kilogram 
kkg metric ton 
Koc organic carbon partition coefficient 
Kow octanol-water partition coefficient 
L liter 
LC liquid chromatography 
LC50 lethal concentration, 50% kill 
LCLo lethal concentration, low 
LD50 lethal dose, 50% kill 
LDLo lethal dose, low 
LDH lactic dehydrogenase 
LH luteinizing hormone 
LOAEL lowest-observed-adverse-effect level 
LSE Levels of Significant Exposure 
LT50 lethal time, 50% kill 
m meter 
MA trans,trans-muconic acid 
MAL maximum allowable level 
mCi millicurie 
MCL maximum contaminant level 
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MCLG maximum contaminant level goal 
MF modifying factor 




mmHg millimeters of mercury 
mmol millimole 
mppcf millions of particles per cubic foot 
MRL Minimal Risk Level 
MS mass spectrometry 
NAAQS National Ambient Air Quality Standard 
NAS National Academy of Science 
NATICH National Air Toxics Information Clearinghouse 
NATO North Atlantic Treaty Organization 
NCE normochromatic erythrocytes 
NCEH National Center for Environmental Health 
NCI National Cancer Institute 
ND not detected 
NFPA National Fire Protection Association 
ng nanogram 
NHANES National Health and Nutrition Examination Survey 
NIEHS National Institute of Environmental Health Sciences 
NIOSH National Institute for Occupational Safety and Health 
NIOSHTIC NIOSH's Computerized Information Retrieval System 
NLM National Library of Medicine 
nm nanometer 
nmol nanomole 
NOAEL no-observed-adverse-effect level 
NOES National Occupational Exposure Survey 
NOHS National Occupational Hazard Survey 
NPD nitrogen phosphorus detection 
NPDES National Pollutant Discharge Elimination System 
NPL National Priorities List 
NR not reported 
NRC National Research Council 
NS not specified 
NSPS New Source Performance Standards 
NTIS National Technical Information Service 
NTP National Toxicology Program 
ODW Office of Drinking Water, EPA 
OERR Office of Emergency and Remedial Response, EPA 
OHM/TADS Oil and Hazardous Materials/Technical Assistance Data System 
OPP Office of Pesticide Programs, EPA 
OPPT Office of Pollution Prevention and Toxics, EPA 
OPPTS Office of Prevention, Pesticides and Toxic Substances, EPA 
OR odds ratio 
OSHA Occupational Safety and Health Administration 
OSW Office of Solid Waste, EPA 
OTS Office of Toxic Substances 
OW Office of Water 
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OWRS Office of Water Regulations and Standards, EPA 
PAH polycyclic aromatic hydrocarbon 
PBPD physiologically based pharmacodynamic  
PBPK physiologically based pharmacokinetic 
PCE polychromatic erythrocytes 
PEL permissible exposure limit 
pg picogram 
PHS Public Health Service 
PID photo ionization detector 
pmol picomole 
PMR proportionate mortality ratio 
ppb parts per billion 
ppm parts per million 
ppt parts per trillion 
PSNS pretreatment standards for new sources 
RBC red blood cell 
REL recommended exposure level/limit 
RfC reference concentration 
RfD reference dose 
RNA ribonucleic acid 
RQ reportable quantity 
RTECS Registry of Toxic Effects of Chemical Substances 
SARA Superfund Amendments and Reauthorization Act 
SCE sister chromatid exchange 
SGOT serum glutamic oxaloacetic transaminase 
SGPT serum glutamic pyruvic transaminase 
SIC standard industrial classification 
SIM selected ion monitoring 
SMCL secondary maximum contaminant level 
SMR standardized mortality ratio 
SNARL suggested no adverse response level 
SPEGL Short-Term Public Emergency Guidance Level 
STEL short term exposure limit 
STORET Storage and Retrieval 
TD50 toxic dose, 50% specific toxic effect 
TLV threshold limit value 
TOC total organic carbon 
TPQ threshold planning quantity 
TRI Toxics Release Inventory 
TSCA Toxic Substances Control Act 
TWA time-weighted average 
UF uncertainty factor 
U.S. United States 
USDA United States Department of Agriculture 
USGS United States Geological Survey 
VOC volatile organic compound 
WBC white blood cell 
WHO World Health Organization 
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> greater than 
≥ greater than or equal to 
= equal to 
< less than 








* q1 cancer slope factor 
– negative 
+ positive 
(+) weakly positive result 
(–) weakly negative result 
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aerobic ...............................................................................................................................................................192, 193 
 
alanine aminotransferase .............................................................................................................................................55 
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blanching .............................................................................................................................................14, 140, 148, 161 
 
blood cell counts..........................................................................................................................................................21 
 
body weight effects..........................................................................................................................................60, 79, 84 
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cancer.....................................5, 6, 7, 14, 17, 18, 19, 26, 28, 70, 71, 72, 73, 74, 75, 76, 77, 84, 86, 115, 118, 123, 127,
 
................................................................................... 131, 132, 134, 137, 140, 143, 144, 157, 159, 160, 164, 223, 225 
 
carcinogen...................................................................................................... 6, 15, 71, 77, 85, 125, 147, 223, 224, 225
 
carcinogenic..........................................6, 16, 18, 19, 20, 25, 26, 70, 74, 77, 85, 96, 126, 147, 155, 156, 159, 165, 225
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